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Abstract
The glycosylation features o f  CSF oligoclonal IgG, and possible changes in 
N-glycans o f  CSF IgG in multiple sclerosis (MS) were studied.
After isoelectric focusing (IEF) o f  CSF, bands were detected using biotinylated 
lectins and avidin-horseradish peroxidase. Concanavalin A (Con A) binding showed that 
mannose exists throughout the pH range o f  oligoclonal IgG. Sambucus nigra antigen 
(SNA) bound acidic and neutral oligoclonal IgG only, suggesting that alkaline oligoclonal 
IgG is deficient in sialic acid. Deglycosylatton o f  CSF IgG using peptide-IV-glycosidase F 
suggested that the range o f  isoelectric points o f  oligoclonal IgG bands is not due to 
carbohydrate differences alone.
Lectin immunoassays, whereby protein A  purified IgG was captured by anti-IgG 
coated tubes and probed using a range o f  biotinylated lectins, were used to compare 13 
CSF samples from MS patients with 14 control samples. With Con A  binding, a 
significantly higher mean and larger variance was found for the MS group (t-test: P<0.05). 
Con A binding correlated with CSF PgG]/ [total protein]% (r=0.390; P=0.0443).
Using HPLC to separate oligosaccharides released from IgG by hydrazinolysis and 
labelled with 2-aminobenzamide, glycans were determined in 7 CSF samples with 
oligoclonal IgG, and 6 CSF samples without. The ratio o f  the peak for biantennary 
fucosylated agalactosyl glycans to total monogalactosylated glycan peaks was lower for the 
oligoclonal IgG samples (t-test: P=0,0141).
The overall results suggested that glycosylation changes occur in CSF IgG in MS, 
and that oligoclonal IgG contains less sialic acid but more galactose than polyclonal IgG.
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HCG human chorionic gonadotropin
HEMPAS hereditary erythroblastic anaemia with 
multinuclearity and a positive serum lysis test
HIV human immunodeficiency virus
HLA leucocyte histocompatibility antigens
HPLC high performance liquid chromatography
HRP horseradish peroxidase
HSA human serum albumin
Hyl hydroxylysine
Hyp hydroxyproline
ICAM immunoglobulin-like cell adhesion molecule
IEC ion-exchange chromatography
IFF isoelectric focusing
IFN interferon
IgA immunoglobulin A
IgD immunoglobulin D
IgE immunoglobulin E
IgG immunoglobulin G
IgM immunoglobulin M
IT immuno turbidimetry
kDa kiloDalton
L light (immunoglobulin chain)
LacNAc N-acetyUactosamine
LCA Lens culinaris agglutinin
Le Lewis antigen
X
LEL JLycopmicon esculentum lectin
LH luteinizing hormone
LIA luminescence immunoassay
MAG myelin-associated glycoprotein
MALDI matrix assisted laser desorption ionisation
Man mannose
MBP myelin basic protein
MHz megahertz
min minute
M OG myelin oligodendrocyte glycoprotein
MRI magnetic resonance imaging
MS mass spectrometry
MS multiple sclerosis
NADH reduced nicotinamide adenine dinucleotide
NAL IV-acetyllactosamine
NB-DNj IV-butyldeoxynojirimycin
N-CAM neural cell adhesion molecule
NeuAc N-acetylneuraminic acid
IV-linked, IV-Glycans linkage through amide nitrogen o f  asparagine
NMR nuclear magnetic resonance
NOE nuclear Overhauser effect
OID other inflammatory diseases
O-linked, O-Glycans linkage through hydroxyl group o f  an amino acid
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PBS-G phosphate buffered saline with gelatine
PBS-T phosphate buffered saline with Tween 20
PHA Phaseolus vulgaris agglutinin
Pi isoelectric point
PLP proteolipid protein
PNA peanut agglutinin
PNGase F peptide-IV-glycosidase (Flavobacterium)
PNS peripheral nervous system
PP primary-progressive
PR progressive-relapsing
PSA Pisum sativum agglutinin
PSA polysialic acid
PUFA polyunsaturated fatty acids
PVDF polyvinylidene fluoride
r correlation coefficient
RA rheumatoid arthritis
RAAM reagent analysis array method
RCA Pdcimis communis agglutinin
REGA remnant epitopes generate autoimmunity
RF rheumatoid factor
RIA radioimmunoassay
RID radial immunodiffusion
RLU relative luminescence units
RNA ribose nucleic acid
RR relapsing-remitting
RT room temperature
xi
s second
SBA soybean agglutinin
SD standard deviation
SDS sodium dodecyl sulphate
SEM standard error o f  the mean
Ser serine
SiaLe sialyl Lewis antigen
SNA Sambucus nigra agglutinin
SP secondary-progressive
SpA protein A
STL Solatium tuberosum lectin
TBS tris buffered saline
TFA trifluoroacetic acid
TFMS trifluoromethanesulphonic acid
Thr threonine
TOF time o f  flight
TSH thyroid stimulating hormone
Tyr tyrosine
UDP uridine diphosphate
UEA Ulex europaeus agglutinin
V variable (of domain in immunoglobulins)
V Volt
W L Vida villosa lectin
W GA wheat germ agglutinin
Xaa any amino acid except proline
Xyl xylose
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Chap te r  One
In t r o d u c t io n
1.1. The Dawning of Glycobiology
In the last thirty years there has been soaring interest in the relatively small, but 
highly variable, carbohydrate components o f  glycoproteins and other glycoconjugates. 
These oligosaccharide chains are fundamental to the function and structure o f proteins 
and variations modify a protein’s behavior. Moreover, changes in oligosaccharides are 
associated with disease states, and from this has arisen the concepts that manipulation and 
modification o f  sugar structures might result in therapeutic benefits, or that they might 
make useful diagnostic tools (Dwek, 1995a).
1.1.1. Early History
The recent development o f  sensitive methods to elucidate the chain structures has 
opened up the road o f glycobiology research. Previously, during the long history o f 
protein biochemistry, die functional aspect o f  the sugar moieties was largely ignored, 
mainly because o f  the difficulty in assaying the small sugar chains associated witii die large 
protein structures (Kobata, 1998). For many years, carbohydrates were ill-defined 
components o f  glycoproteins, and were even thought to be contaminants. The agglutin­
ation properties o f lectins had been known for many years (StiUmark, 1888; Sumner and 
Howell, 1936) as was their ability to distinguish different blood groups (Boyd and 
Sharpleigh, 1954). By the early nineteenth century, carbohydrates were being isolated 
from mucins and odier proteins and in the 1930s mannose, galactose and glucosamine 
were characterized (Gottschalk, 1972). One o f  die first glycoproteins to be investigated 
was ovalbumin, from hen’s egg white. It was shown in 1965 to have a carbohydrate
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moiety which was attached at a given position o f  the polypeptide chain, and which was 
often variable in structure from one ovalbumin molecule to another (Cunningham et al, 
1965). Thus the concept o f ‘microheterogeneity’ was born.
1.1.2. Glycoproteins and Disease
It was realized that carbohydrate composition could vary with different diseases. 
Assays measuring serum sialic acid (Svennerholm, 1958) were developed, which was 
found to be increased in cancer, and sialic acid-deficient ai-acid glycoprotein was shown 
to be produced in certain pathological states (Schmid, 1964). Wheat germ agglutinin was 
found to agglutinate malignant cells, but not normal ones (Aub, 1965) and histological 
stains based on lectins were developed which could distinguish pathological tissue from 
normal (Riley and Elhay, 1996).
Various chemical methods were developed to analyze glycosylation, such as hydra- 
zinolysis to release N-linked chains from glycoproteins (Yosizawa et al, 1966) and 
periodate oxidation to sequence the oligosaccharides determined (Neuberger and 
Marshall, 1972). By the 1970s the structures o f many o f the carbohydrate groups o f 
glycoproteins had been determined, though their function was somewhat a mystery. 
Nevertheless, numerous papers were published describing variations in carbohydrate 
composition o f  glycoproteins related to specific diseases, such as IgG in rheumatoid 
arthritis (Mullinax, 1975), fucosylated alpha-fetoprotein in liver disease (Aoyagi, 1985), and 
acute-phase proteins in cancer (Turner et al, 1985). Abnormal heterogeneity o f  serum 
transferrin was found in alcoholics (Stibler, 1980). Microheterogeneity was also 
demonstrated in glycoprotein hormones (Kerckaert et al, 1979) using lectin affinity 
chromatography or lectin affino-electrophoresis (B0g-Hansen, 1973). Lectins were still 
very important tools in the characterization o f glycoproteins (Sharon and Lis, 1972; 
Goldstein and Poretz, 1986). As analysis became more and more sophisticated, and new 
techniques, such as X-ray crystallography, high pressure liquid chromatography (HPLC),
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mass spectrometry (GC-MS), and nuclear magnetic resonance (NMR) came to be 
developed, different glycoproteins and different diseases were looked at. But none has 
been as extensively researched as IgG in rheumatoid arthritis, which is described below.
1.1.3. Galactose-Deficient IgG
For some years it had been known that the serum o f  rheumatoid arthritis (RA) 
patients contained rheumatoid factor (RF), consisting o f  IgM and IgG molecules which 
bound to human IgG. It was known that the reaction with IgG took place only if the 
IgGs were immobilized by adsorption to red blood cells (Waaler, 1940; Rose et al, 1948), 
to latex particles (Singer et al, 1962), or if  the IgGs themselves were aggregated by heat 
(Normansell, 1971). The adsorption or heating o f  IgG was necessary, causing a change in 
the configuration o f  the IgG molecule to reveal reactive determinants, present in a cryptic 
state on native IgG. These determinants were identified as carbohydrate residues on the 
Fc fragment (Clamp and Putnam, 1964; Fhmneyball and Stanworth, 1976). Later it was 
realized that carbohydrate was necessary for the formation o f  an IgG-IgG complex 
(Hymes et al., 1978) and that carbohydrate residues influence the secondary structure o f  
IgG (Due Dodon and Quash, 1981).
In 1975 it was reported that there was a decrease in the galactose content o f  IgG 
in patients with rheumatoid arthritis (Mullinax, 1975). In 1985, scientists collaborating in 
Oxford, Birmingham and Tokyo presented a fundamental paper in Nature based on the 
analysis o f  the primary sequences o f  about 1400 oligosaccharides chains from 46 IgG 
samples (Parekh et al, 1985). They used various techniques: controlled hydrazinolysis to 
release the intact chains; reduction o f  the terminal N-acetylglucosamine (GlcNAc) 
residues using NaB3H4 to radioactively label each chain; neuraminidase digestion to 
analyze the distribution o f  neutral structures, then fractionation o f  the resulting ‘asialo’ 
oligosaccharide mixtures by gel filtration chromatography. Later it was shown that there 
was reduced galactosyltransferase activity in the Golgi bodies o f  B-cells in rheumatoid
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arthritis giving rise to the galactose deficient glycans o f  IgG (Axford et al, 1987). It was 
also found that die observed remission o f  the disease in pregnancy corresponded to 
increased activity o f  this enzyme (Pekelliaring et al, 1988). Agalactosyl IgG was associated 
with juvenile onset, as well as adult, rheumatoid artiiritis, and its prevalence correlated 
widi disease activity (Pareldi et al, 1988). Further work on IgG showed that the galacto- 
sylation o f  IgG N-linked oligosaccharides decreased as a parabolic function o f  age, and a 
parallel was seen with the decrease o f  immunological competence with age (Pareldi et al, 
1988).
1.1.4. Further Glycoprotein Studies.
Abnormal lectin binding to IgG was demonstrated in die sera (Malaise, 1987; 
Parkkinen, 1989; Sumar, 1990) and synovial fluid (Casburn-Budd, 1990) o f  rheumatoid 
arthritis patients. IgG and other proteins were shown to be abnormally glycosylated in 
other inflammatory diseases such as osteoarthritis (Carter et al, 1989), systemic lupus 
erythematosus and Crohn’s disease (Tomana et al, 1988), Sjogren’s syndrome, 
sclerodermic disorders and mixed connective tissue diseases (Silvestrini et al, 1989). The 
glycosylation o f  IgA has been studied in relation to various diseases, notably nephropathy 
(Baharaki et al, 1996). Various acute-phase proteins have been investigated: for example 
ai-acid glycoprotein glycoforms in relation to inflammation (De Graaf et al, 1993; Lacki 
et al, 1994; van Dijk et al, 1994), cancer (Macldewicz and Macldewicz, 1995) and 
tuberculosis (Fassbander et al, 1995); haptoglobin witii respect to cancer (Katnik et al, 
1992) and rheumatoid arthritis (Thompson et al, 1993), and ai-antichymotrypsin with 
liver diseases (Hachulla et al, 1992). Transferrin has been particularly studied in relation to 
Ever disease (Matsumoto et al, 1994), alcohol abuse (Stibler et al, 1980) and carbohydrate- 
deficient glycoprotein syndromes (Stibler and Jaeken, 1990). The different glycoforms o f 
alkaline phosphatase have provided a means o f  distinguishing between liver and bone 
isoforms (Chamberlain et al, 1992; Crofton, 1992). Glycosylation changes in various
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proteins in cancer have been extensively investigated, notably alpha-feto protein (Marrink 
et al, 1990; Aoyagi et al, 1990) and chorionic gonadotropin (Kobata, 1998). Other 
hormones such as thyroid stimulating hormone (TSH) (Papandreou et al, 1993), 
luteinizing hormone (LH), follicle-stimulating hormone (FSH) and erythropoietin (EPO) 
(Storting, 1992) have been shown to differ in their activities in vivo and in vitro, according 
to their carbohydrate moieties.
1.1.5. Glycobiology.
The glycosylation aspects o f  some diseases will be looked at in more detail in 
Section 3. The above examples are a small part o f  the whole picture o f  glycoconjugates 
and glycosystems that has been uncovered in the last thirty years. The ability to accurately 
sequence the oligosaccharide units o f  glycoconjugates has revealed the remarkable 
complexity and diversity o f  these molecules which can affect every aspect o f  biological 
function (Varki, 1993).
In addition to glycoproteins there are a number o f  other types o f  glycoconjugates 
whose oligosaccharides are not always the discrete, specific and conserved structures 
which are found in proteins and glycopeptides (Kobata, 1994). Many lipids, such as the 
phosphoglycerides and the glycosphingolipids, contain carbohydrates. These have mainly 
a structural or organizational function in the cell, such as the glycosylphosphatidylinositol 
(GPI) membrane anchors which are interposed through the lipid bilayer affording a stable 
association o f  the membrane and a protein (Ferguson, 1991). Another large group o f  
glycoconjugates is the proteoglycans, containing a larger fraction o f  carbohydrate than 
glycoproteins in the form o f  glycosaminoglycan chains covalently linked to a protein core. 
These have roles o f  lubricants and support elements in the body, but also exist as heparin 
and other anti-coagulation agents (Yanagishita and Hascall, 1992). Lectins exist in plants, 
animals and bacteria, as defence mechanisms, as mediators in cell to cell interactions or as 
receptors within or outside cells. For instance, the selectins mediate interactions between
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circulating leukocytes and endothelial cells at sites o f  inflammation and in lymph nodes, 
causing the leukocyte to roll along the surface o f  the epithelium (Lasky, 1992; Springer, 
1991). Galectins bind (3-galactosides within the cell, possibly regulating RNA 
transcription, and at the cell surface are involved in cellular differentiation during growth 
(Barondes et al, 1994). Collectins and mannose receptors in animals recognize exogenous 
sugars present on potential microbial pathogens (Drickamer and Taylor, 1993; Weis and 
Drickamer, 1994), and carbohydrate-binding properties have been detected in cytokines 
such as interleukin 1 and 2 (Brody and Durum, 1989). With respect to neurology, 
mamiose-binding cerebellar soluble lectin (CSL) on cell surfaces is important both for cell 
adhesion and signaling between cells (Zanetta et al. 1987). Antibodies to CSL cause 
demyelination and have been implicated in multiple sclerosis (Zanetta et al. 1990). Neural 
cell adhesion molecule (N-CAM) which belongs to the immunoglobulin-superfamily, 
carries long chains o f  polysialic acid (PSA) which allow binding between cells. (Seld and 
Arai, 1993) Other members o f  this family, which actually bind sialic acids, are 
sialoadhesin, CD22, CD33 and myelin associated glycoprotein (MAG) (Powell and Varki, 
1995).
1.1.6. This Project.
It can be seen diat the field o f  glycobiology extends across a range o f  disciplines 
in biological sciences, and a review o f  the whole area is beyond the scope o f  this thesis. 
Attention will be focused on glycosylation with relevance to diseases and diagnosis and, 
more specifically, to the IV-glycosylation o f  human IgG and changes that may be found in 
multiple sclerosis.
1.2. Structures and Functions of the Sugar Chains.
There follows a brief description o f  the sugar chains o f  glycoproteins. The 
aspects which relate most to this project, i.e. the glycosylation o f  IgG, will be covered in
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greatest depth. N-linked glycans will be described in more detail than O-linked, even 
though O-linked are just as widespread and biologically important.
1.2.1. Prevalence,
Glycoproteins vary considerably in their carbohydrate content: less than 1% in 
some o f  the collagens, more than 99% in glycogen. They also differ in the number o f  
their monosaccharide units, which ranges from one up to two hundred for most 
glycoproteins, although some, such as glycogen, contain many thousands. These mono­
saccharides are usually in the form o f  oligosaccharide or polysaccharide chains, linear or 
branched, and often referred to as glycans. Branches are very seldom crosslinked (Sharon 
and Lis, 1997).
A  feature o f  glycans is their heterogeneity. Individual molecules o f  a given 
glycoprotein may carry different saccharides at the same attachment site o f  the 
polypeptide chain. This contrasts to the uniformity o f  the polypeptide chains to which 
they are attached. For example, IgG contains an average o f 3 glycans per molecule, with 
more than 30 different glycan structures possible (Dwek, 1995). However the ratio o f  the 
different structures for the sum o f  all molecules in a sample is relatively constant. 
Moreover, a similar heterogeneity is found upon analysis o f  monoclonal IgG, showing 
that the large number o f different structures found with IgG is not due to polyclonicity. 
Heterogeneity results from major or minor changes in glycan structure, such as increased 
branching, loss o f  one or more arms, or deletion or addition o f  one or more carbohydrate 
units, producing discrete molecular subsets o f  a glycoprotein, often called glycoforms. In 
IgG the number o f  glycoforms could be 900. Different forms o f  glycan chains produce 
different effects on a protein, altering strengths or positions o f  charges and so causing a 
different confirmation o f  the tertiary structure o f  the protein. So various glycoforms o f a 
protein may have different physical and biochemical properties, which might produce a 
functional diversity.
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Carbohydrates, through their unique multi-linkages o f  both monomer and 
branching structures, contain potentially more information, in a short sequence, than any 
odier biological oligomer (Laine 1994). Other biopolymers such as nucleic acids and 
proteins are composed o f  covalently linked units. For example, a pair o f  amino acids will 
combine to make two structures, at most. But, taking a pair o f  monosaccharides such as 
iV-acetylglucosamine (GlcNAc) and mannose: GlcNAc can bind to any one o f  4 hydroxyl 
groups on mannose; two anomeric linkages exist for die GlcNAc link, making 8 
possibilities; furthermore, die GlcNAc might exist in the furanose or pyranose form, 
making 16 possibilities. Table 1.1 shows the number o f combinations o f units found in 
similar lengths o f  DNA, proteins and oligosaccharides.
1.2.2. Carbohydrate Complexity
Table 1.1. Number of linear oligomers of length N (Kobata, 1994)
N
DNA Proteins Oligosaccharides
0 = 4* 0 II 00 *
1 4 20 4 8
2 16 400 128 800
3 64 8000 4096 6.40 x 104
6 4096 6.40 x 107 1.34 x lO 8 3.27 x 1010
10 1.04 x lO 6 1.28 x lO 13 1.40 x lO 14 1.34 x 1018
* —Number of monosaccharide types
Another important distinction between these biopolymers is that, while nucleic 
acids and proteins are direct gene products i.e. arise from a DNA template, 
oligosaccharide sequence is determined at the time o f  synthesis and allows for 
considerable variation, with possible influence from die environment.
1.2.3. Monosaccharides
The commonly occurring monosaccharides found in glycoproteins are shown in Table
1.2. O f these, galactose, mannose and IV-acetylglucosamine are very common in most 
organisms. Glucose is largely confined to a small number o f animal glycoproteins (mainly 
collagens).
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Table 1.2. Common monosaccharide constituents of glycoproteins (Sharon and Lis, 1997).
Class Compound3 Abbreviation Comments
Hexoses D-Galactose
D-Glucose
D-Mannose
Gal
Glc
Man
Mainly in collagens
Deoxyhexoses L-Fucose Fuc
Pentoses L-Arabinose
D-Xylose
Ara
Xyl
In plant glycoproteins 
In proteoglycans and 
plant glycoproteins
Hexosamines N-Acetyl-D-galactosamine 
N-Acetyl-D-glucosamine
GalNAc
GlcNAc
Uronic acids D-Glucuronic acid 
L-Iduronic acid
GlcA
IdoA
In proteoglycans 
In proteoglycans
Sialic acids N-Acetylneuraminic acidb Neu5Ac In vertebrates and 
higher invertebrates
a The ring form is usually pjranose, although furanose forms do occur. 
b Other sialic acids are also found in glycoproteins.
IV-acetylgalactosamine and uronic acids exist mainly in animals, rarely in plants. Fucose is 
common to plants and animals. Xylose is in plant glycoproteins, but animal 
proteoglycans. Arabinose is confined to plants. Sialic acids are found in most abundance 
in higher invertebrates and vertebrates. While IV-acetylneuraminic acid occurs widely, 
other sialic acids have a limited distribution. Figure 1.1 shows the structures o f  the main 
monosaccharides in eukaryotes. D-glucose most frequently serves as the starter molecule 
for the biosynthesis o f  all monosaccharides and amino sugars.
1.2.4. Carbohydrate-peptide linkage
There are three main types o f  linkage between glycans and polypeptides. It is only 
the IV-glycosidic type which has been found to date in human IgG, and will be dealt with 
here in more depth than other linkages. The more common N  and 0  types are 
summarized in Table 1.3.
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Figure 1.1. Structures of monosaccharides commonly found in eukaryotic glyco­
proteins (Oxford GlycoSystems, 1994a).
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Table 1.3. Carbohydrate-peptide linking groups (Sharon and Lis, 1997).
Type Monosaccharide Amino acid Occurrence
N-glycosidic [3-GalNAc Asn Archaebacteria
P-Glc Asn Animals®
P-Glc Asn Archaebacteria
P-GlcNAc Asn Common
Rhamnose Asn Eubacteria
O-glycosidic Ara Hyp Plants
a-Fuc Ser, Thr Animals
a-Gal Flyp Plants, eubacteria
ot-Gal Ser Plants, eubacteria
p-Gal Hyl Animalsb
(3-Gal Tyr Eubacteria
a-GalNAc Ser, Thr Common
a-Glc Tyr Animalsc
P-Glc Ser, Thr Eubacteria, animals
P-GlcNAc Ser, Thr Animals
a-Man Ser, Thr Yeasts, animals
P-Xyl Ser Animalsd
a To date found only in laminin 
b Found only in collagens 
c Only in glycogen 
d Confined to proteoglycans
1. N -G Ivcosidic. This occurs between the reducing terminal sugar and the amide group 
o f  asparagine, producing iV-glycans. The most common linking group is IV-acetyl- 
glucosamine-asparagine (GlcNAc-Asn). The asparagine is part o f  the consensus 
sequence (sequon) Asn-X-Ser/Thr, where X  may be any amino acid except proline. 
Not all such residues however are glycosylated. During the last decade new 
carbohydrate-asparagine linking groups have been discovered, mainly in bacterial 
glycoproteins, where GlcNAc is replaced by other monosaccharides, as shown in Table
1.3.
2. O-Glycosidic. This will occur between the terminal sugar and a hydroxyl group o f  an 
amino acid, most commonly serine or threonine. A large variety o f  O-glycosidic 
linkages exist (Table 1.3), including the well-known GalNAc-Ser/Thr linking group 
found in numerous animal glycoproteins.
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3. Other. A  linkage in which a-mannose is attached C-glycosidically to the indole ring o f 
a tryptophan has been discovered in human RNase Us (Hofsteenge et al, 1994). Also, a 
covalent linkage o f  the 3-hydroxyl o f  ribose with glutamic (or aspartic) acid, arginine 
or cysteine is involved in ADP-ribosylation (Burnette, 1994).
1.2.5, Oligosaccharide Linkages
I.2.5.I. N-Linked
The asparagine-linked oligosaccharides, notwithstanding all their heterogeneity, 
have a common core:
Man(al-6)
^  Man({31 -4) GlcNAc([31 -4) GlcNAc(P 1 -4) [ASN]
Man(al-3)
This structure is often referred to as the ‘pentasaccharide core’ (Sharon and Lis, 1997) or 
the ‘trimannosyl core’ (Brockhausen, 1993). IV-linked glycans are usually classified into 
three groups: oligomannose, complex and hybrid, to which a fourth, xylose containing, 
has recently been added (Vliegenthart and Montreuil, 1995) (Table 1.4). Oligomannose 
glycans usually contain 2 to 6 a-mannose residues in these branches, although some yeasts 
produce chains with up to 200 mannose units. Complex glycans contain up to five units 
o f  the disaccharide Gal(pl-4)GlcNAc (sometimes referred to as XLacetyllactosamine, 
LacNAc or NAL in brief), p-linked to the two a-mannoses o f  the trimannosyl core. 
These often have terminal sialic acids. Further variations occur with possible additions o f  
fucose to the core or to outer branches, o f  a ‘bisecting’ GlcNAc linked P1-4 to the p- 
mannose o f  the trimannosyl core, or o f  Gala(l-3) to the galactose o f  XT- 
acetyUactosamine. Hybrid glycans have features o f  both oligomannose and complex 
types. One or two a-mannose units are linked to the Manal-6 arm o f  the core, with a 
complex chain attached to the Manal-3 arm.
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Table 1.4. Representative structures of the different types of AMinked glycans (Sharon and 
Lis. 1997)_____________________________________________________________________
Olmmannose 
Man(al -2)Man(al -6)
yVtan(al-6)N^
Man(al -2)Man(al -3) ^  Man(p 1 -4) GlcNAc((31 -4) GlcNAcP
Man(al -2)Man(al -2)Man(al -3)
Complex
Fuc(al-6)o,i
Neu5Ac(a2-6)Gal(pl-4)GlcNAc(P 1 -2)Man(al-6) x  |
[GlcNAc(P 1 -4)o,iMan(p 1 -4)GlcNAc(p 1 -4) GlcNAcp 
Neu5Ac(a2-6)Gal(P 1 -4)GlcNAc({31 -2)Man(al -3) /
Hybrid
Man(al-6)x
Man(al-6)
Man(al-3)/ \
[GlcNAc(pi-4)]0>iMan(pl-4)GlcNAc(pl-4)GlcNAcp
Gal(pi-4)GlcNAc(pi-2)M an(al-3)/
Xylose-containing
Fuc(al-3)o,i 
M an(al-6)\ |
Man (P1 -4) GlcNAc (p 1 -4) GlcNAcp 
Man (a 13)y  I
Xyl(Pl-2)o,i
The subscript ’ indicates residue may be present or absent.
The branches o f  many N-glycans contain poly-N-acetyllactosamine, [Gaip4GlcNAcP3]n, 
where n may be as high as 50. Due to the branch specificity o f  the enzyme that forms 
these - pi,3-N-acetylglucosaminyltransferase — these chains predominate on the a(l-6) 
linked mannose o f the trimannosyl core. With substitution o f  galactose, a large number 
o f  different structures are formed and they serve as backbones for the ABH(O), I /i  and 
Lewis (Lea and Leb) blood group determinants on human erythrocyte membrane glyco-
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conjugates, as well as the Lex and sialyl Lex (SiaLex) determinants on granulocytes and 
other cells.
1.2.5.2. O-Linked
The O-linked glycans, bound to proteins via the GalNAc-Ser or GalNAc-Thr 
linkage, are a large heterogeneous group, divided into subgroups according to the 
structure o f  the core region, as shown in Table 1.5.
The O-Glycans vary in size from monomers to polymers, typically up to 20 
monosaccharides. However, mucins, common constituents o f  membranes and o f 
epithelial secretions, are very large molecules with extensive heterogeneity. Their main 
constituent is IV-acetylgalactosamine, along with galactose, IV-acetylglucosamine, fucose, 
various sialic acids or sulphate.
Table 1.5. Core structures of O-glycans (Sharon and Lis, 1997)
Core Structure Occutrence
1. Gal(P 1-3) GalNAca- Mucins and other glycoproteins
2. GlcNAc(pl-6) Mucins and other glycoproteins
Gal(P 1 -3) GalNAca-
3. GlcNAc(P 1 -3) GalNAca- Mucins
4. GlcNAc(pl-6) Mucins
GlcNAc(P 1-3) GalNAca-
5. GalNAc(al -3)GalNAca- Glycoproteins
6 GlcNAc (p 1 -6) GalNAca- Mucins and other glycoproteins
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Whereas nucleic acids and proteins are both linear molecules in which die 
component units are joined by similar bonds (phosphodiester and peptide bonds 
respectively), glycans are usually branched and contain many different linkages. 
Furthermore, whereas nucleic acids and proteins are produced from template molecules 
as essentially invariant copies, the components o f  glycans are put together sequentially, 
with frequent opportunities for variation. This occurs in the endoplasmic reticulum (ER) 
and the Golgi apparatus, where glycosidases and glycosyltransferases, firmly embedded in 
the endoplasmic reticulum with catalytic domains in the lumen, act on the growing 
oligosaccharide as it moves along the lumen o f  the endomembrane system (Brockhausen 
and Schachter, 1997). The form the glycan takes is dependent on the concentrations o f  
these enzymes in the individual cell. This can vary with the pathological or physiological 
state o f  the cell, but may also vary between individual cells in the same state. So a range 
o f  glycan structures is produced, conferring microheterogeneity to that particular protein 
or proteoglycan. The character o f  the microheterogeneity is often species or tissue 
specific and can change with normal development o f  tissues, or with pathological 
changes. Possible reasons for heterogeneity will be discussed in section 1.2.9.
I.2.6.I. N-Glycan Biosynthesis
A  scheme o f  N-glycan biosynthesis is shown in Figure 1.2. It begins in the rough 
ER with the co-translational transfer o f  a large oligosaccharide (Glc3Man9GlcNAc2) from 
dolichol pyrophosphate (Dol-P-P) to an asparagine (Asn) residue in the nascent 
polypeptide chain (Step 1). The Asn residue must be Asn-Xaa-Ser/Thr triplet (known as 
a ‘sequon’), where Xaa is any amino acid except proline. This is followed by removal o f  
three glucose and four mannose residues, within the lumen o f  the ER and Golgi 
apparatus, by specific a-glucosidases (Steps 2 and 3) and a-mannosidases (Steps 4 and 5).
1.2.6. Glycan Biosynthesis
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Figure 1.2. A representative pathway for the formation of a bi-antennary glycan chain 
(adapted from Keir et al, 1999). ■  = glucose; O = mannose; ^  = N-acetylglucosamine; 
•  = galactose; □ = N-acetyl neuraminic acid; Dd-P-P = ddichd pyrophosphate. 
Enzymatic steps shown are as fdlows:
1 Oligosaccharyltransferase
2,3 a-glucosidases
4,5 a2-mannosidases
6 GlcNAo-transferase I
7 oc3 or a6-mannosidase II
8 GlcNAc-transferase II
Core a6-fucosyltransferase
GlcNAc-transferases III, IV, V and VI
9 (33 or (34-Gal-transferases (or (34-Gal NAc transferase)
10 cc2,3 or a2,6-sialyltransferases (or sulpho-transferases)
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The product o f  this processing is the structure [Manal-6(Manal-3)Manal-6](Manal- 
3)Man(3l -4GlcNaAc|31 -4GlcNAcP-Asn, i.e. (Man5GlcNAc2-R), which is the starting core 
for the synthesis o f  all complex and hybrid N-glycans.
The key enzyme for initiating this synthesis is N-acetylglucosaminylttansferase 
(GlcNAc-transferase) I, which adds the first N-acetylglucosamine (GlcNAc) unit to die 
core using uridine diphosphate GlcNAc (UDP-GlcNAc) as donor (Step 6). Then a - 
mannosidase II clips o ff  further mannose units (Step 7), which allows GlcNAc-transferase 
II to begin extending die second antenna, again using UDP-GlcNAc as donor (Step 8). 
Also at this stage, fucose can be added by core a6-fucosyltransferase, and further 
GlcNAcs by GlcNAc-transferases III, IV, V  and VI (GlcNAc-transferase III adding the 
“ bisecting” GlcNAc to the middle mannose o f  die tdmannosyl core). All these enzymes 
in steps 7 and 8 cannot proceed until GlcNAc-transferase I has initiated the sequence.
(33 or 4-galactosyltransferase then adds die galactose residues donated from UDP- 
galactose (or P4-GalNAc transferase adds GalNAc) (Step 9). Finally a(2,3) or a(2,6) 
sialyltransferase adds sialic acid transferred from CMP-N-acetylneuraminic acid (Step 10).
There are many crossroads during biosynthesis at which more than one enzyme 
competes for a common substrate. The route taken by the synthetic pathway at a 
competition point is mainly dictated by the relative activities o f  the competing enzymes 
(Schachter, 1991). Some glycosyl residues act as a ‘stop signal’: for instance the bisecting 
GlcNAc prevents the actions o f  a3/6-mannosidase II, core a6-fucosyltransferase and 
GlcNAc-transferases II, IV and V, so preventing further brandling. However, the 
bisecting GlcNAc does not prevent the glycan chain from moving to the tram Golgi, with 
possible addition to the antenna o f  D-Gal, N-acetyl-D-galactosamine, sialic acid, sulphate, 
L-fucose or other residues. These points help to explain how microheterogeneity arises: 
why it should occur will be considered in later sections.
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The synthesis o f  O-glycans starts in the cis Golgi, and does not involve dolichol 
derivatives. As for N-glycans, the synthetic paths are ordered rather than random i.e. 
certain key glycosyl residues divert the synthetic flux either away from or into a particular 
pathway. Many o f  the enzymes involved are common to both N- and O-glycan pathways. 
However, with O-glycans, no glycosidases are involved, but instead sugars are transferred 
individually from nucleotide sugars. There are eight possible core structures, which may 
be further elongated and terminated in many ways, to produce hundreds o f  possible O- 
glycan chains.
1.2.7. Functions of Glycan Chains
Some o f  the functions o f  glycans have already been alluded to in Section 1.5. 
These broadly fall into two main categories: structural or recognition functions, although 
these two cannot be totally separated. 
jt.2.7.1. Structural Functions
Some oligosaccharides are important in the physical maintenance o f  tissue 
structure, integrity and porosity, as seen in the heparan, dermatan and chondroitin chains 
o f  the proteoglycans in the formation o f  basement membranes and extracellular matrix. 
Related to this are protective or stabilizing roles. For instance, a coating o f 
glycoconjugates around a whole cell can form a protective ‘glycocalyx’, and 
oligosaccharides on many glycoproteins can protect the polypeptide from the action o f  
proteases or antibodies (Varki, 1993).
N- and O-linked glycans contribute overall to the physical properties o f  a protein, 
influencing its solubility, viscosity, hydrogen bonding, overall charge, degradation, stability, 
folding and conformation (Brockhausen, 1993). It is well accepted that the N-linked 
oligosaccharides o f  glycoproteins initiate the correct polypeptide folding in the rough ER, 
and subsequent maintenance o f  protein solubility and conformation. The involvement
I.2.6.2. O -G lycan B iosyn thesis
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begins as the nascent polypeptide is extruded into the ER, and the Glc3Man9GlcNAcAc2 
structure is transferred en bloc from the lipid-linked precursor, to an Asn group in the 
polypeptide, before folding is complete (Paulson, 1989). Many proteins that are 
incorrectly glycosylated fail to fold properly and are degraded. However, treatment with 
tunicamycin, which inhibits N-linked glycosylation, causes some proteins to have merely 
compromised biological activity, while others appear totally unaffected (Kornfeld and 
Kornfeld, 1985).
1.2.7.2. Recognition Functions
The remarkable diversity o f  carbohydrate complexes plays a pivotal role in 
determining the specificity o f  many biological recognition phenomena. Intracellular and 
intercellular trafficking — movement o f  molecules from one receptor to another — is often 
dependent on carbohydrate ligands (Varki, 1993). Cell adhesion molecules, as mentioned 
in Section 1.5, recognize carbohydrate groups. Since all cells are covered with a dense 
coating o f  sugars, oligosaccharides are critical determinants o f  ‘cell-cell’ interactions. 
During cell growth, development and differentiation there are continuous changes o f  
cellular interactions mediated through cell-surface antigens on glycolipids and 
glycoproteins (Feizi, 1985). Fertilization in mammals depends on the binding o f  sperm to 
a-linked Gal residues o f O-glycans on the surface o f  the egg (Miller et al, 1992).
As well as determining cell-cell and cell-molecule interactions within an organism, 
oligosaccharides are used by a variety o f  -(druses, bacteria and other parasites to target host 
cells. Viruses often have carbohydrate-containing membrane lipids or glycoproteins on 
their surface, whose purpose may be to shield the virus from immune attack, or to interact 
with host cells or other viruses. Some o f  the surface proteins may be lectins or 
agglutinins recognizing specific host cell carbohydrates. For instance, the influenza 
viruses bind to residues containing terminal sialic acid (Alford et al, 1994). The falciparum 
malaria merozoite binds to sialic acid containing residues on host erythrocytes (Orlandi et
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al, 1992). Bacteria have been shown to interact with carbohydrates o f  glycolipids 
(Lingwood, 1991) and mucins, and have glycosidases which act on mammalian 
glycoproteins.
Oligosaccharides also have important roles in host protection and immunity. As 
well as coatings to protect them from proteases, mentioned previously, addition o f  
specific monosaccharides or modifications mask the sequences recognized by 
microorganisms, toxins or autoimmune antibodies. For example, the addition o f  a single 
O-acetylester to the 9-position o f  terminal sialic acid residues abrogates binding o f  the 
highly pathogenic influenza A  viruses (Alford et al, 1994). The presence o f  terminal sialic 
acid on glycoproteins and cell surfaces masks recognition o f  (3 Gal and PGalNAc residues 
by pathogens as well as endogenous macrophages. Sialic acid prevents rapid clearance 
from circulation by asialo- and asialogalacto-glycoprotein-specific receptors on 
hepatocytes and macrophages (Paulson, 1989). This could be seen as a form o f defence 
mechanism, since sialic acid is not found in viral or bacterial glycans. The phenomenon 
also means that recombinant glycoproteins, such as tissue plasminogen activator and 
plasminogen, produced commercially for administration to humans or other animals, must 
be produced in mammalian cells or it will be cleared rapidly from the circulation. There 
are several other receptor mechanisms which recognize glycan determinants on circulating 
proteins, such as the hepatic fucose receptor, the mannose-6-phosphate receptors and the 
M an/GlcNAc receptor o f  the reticulo-endothelial system (Dahms et al, 1989; McFarlane, 
1983).
The glycosylation o f  the immunoglobulins, especially IgG, and autoimmune 
mechanisms will be described later. As well as the adaptive immune response, which in 
mammals is based on sophisticated gene rearrangement processes that yield a diversity o f  
antibodies and cellular receptors, the more primitive innate immunity is based on 
recognition by carbohydrates, as a first line o f  defence (Gabius et al, 1997). There are a
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number o f  molecules directed against common constituents o f  pathogenic organisms, 
d isting u ish in g  (hopefully) infectious non-self from harmless self (Janeway, 1992). Lectins, 
including acute-phase reactants such as C-reactive protein, are an important group in this  
class o f  molecules, and will be considered later.
Finally, a number o f  glycoproteins function as hormones. The pituitary hormones 
LLI, FSH, GH and TSH contain N-glycans with differing distributions o f  terminal sialic 
acid and S04-4-GalNAc structures. Neither sialic acid nor sulphate are required for 
hormonal activity or receptor binding. Sialic acid appears to function in the prevention o f  
rapid clearance o f  hormone from the body via the hepatic asialoglycoprotein receptor, 
and in this way may influence hormone potency (Thotakura et al, 1991). Sulphate 
increases hormone clearance by a specific hepatic receptor (Baenziger et al, 1992).
1.2.8. Sialic Acids
Although sialic acids are only one o f  the many monosaccharide components o f 
glycoconjugates, a section is devoted to them because they are important with regards to 
this project for several reasons. They are widespread in nature and abundant constituents 
o f  plasma membranes, gangliosides, most secreted proteins and mucins, (Reutter et al, 
1997). They are often in the peripheral position o f  oligosaccharide chains in 
glycoproteins and glycolipids, which makes them o f  prime importance in recognition and 
targeting roles. Thus they are involved in the modulation o f  many cellular processes, and 
in many aspects o f  cancer, infection and immunology. Moreover, they are the only 
monosaccharide in glycoconjugates to carry a charge, which has implications not only in 
their biological roles, but also in analysis o f  oligosaccharides, where charge differences can 
be exploited as in, for instance, HPLC and IEF.
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Rs R+7,8,9
-CO-CH3 (N-acetylneuraminic acid) 
-CO-CH2OH (N-glycolylneuraminic acid)
-H (neuraminic acid; only stable in glycosidic
bonds)
-H (4,7,8,9) 
-CO-CH3 (4,7,8 ,9) 
-CO-CHOH-CH3 (9) 
-CH3 (8)
-SO3H (8 )
-PO3H2 (9)
Figure 1.3. The chemical structure of neuraminic acids. All natural derivatives of neuraminic 
acid share an elementary 9-carbon carboxylated structure. However several positions (R4,5,7,8,9) 
can be substituted by different chemical residues as indicated in the table. More than 40 
naturally occurring sialic acids have been identified so far (Reutter et al, 1997)
The term sialic acid is given to all acetylated derivatives o f  neuraminic acid, which 
share an elementary 9-carbon carboxylated skeleton (Figure 1.3). With many different 
substituents, the sialic acids are the most varied structurally o f  any group o f  natural 
monosaccharides (Varki, 1992). The most prominent member is N-acetylneuraminic acid 
(Neu5Ac), found in N-linked oligosaccharides including IgG. Sialic acid occurs most 
abundantly in vertebrates, but is found in most other types o f  living organisms except 
certain bacteria. They are derived in the cells from N-acetylglucosamine (GlcNAc) by a 
series o f  enzymatic reactions.
Five major biological functions have been attributed to the sialic acids (Crook, 
1993; Powell and Varki, 1995).
1. Their large electronegative charge, with a pK  value o f about 2, under physiological 
conditions suggests a role in the binding and transport o f  positively charged 
molecules. The charge gives rise to attractive or repulsive forces between different 
cells, and provides an overall electronegative charge on cell surfaces. They are thus
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involved in adhesion, aggregation and agglutination. They also function as 
recognition molecules for various cellular adhesion molecule such as the selectins, the 
sialoadhesins, CD22, myelin-associated glycoprotein (MAG) and neural cell adhesion 
molecule (N-CAM).
2. They are essential components o f  many cell-surface receptors for example the 
receptor for insulin. They are also involved in the modulation o f  amino acid 
transport in certain cells.
3. They are important for glycoprotein conformation, solubility, viscosity and charge. 
The grouping o f  glycoproteins on cell membranes is partiy due to a mutual repulsion 
o f  tiieir sialic acid residues, important for conferring rigidity to the cell.
4. They are an important part o f  many glycoprotein and glycolipid antigenic 
determinants, notably in die blood group antigens.
5. They protect glycoconjugates and cells from degradation, acting as shields to prevent 
recognition by clearing receptors. This is important in the removal from the 
circulation o f  glycoproteins and also cells such as platelets and erythrocytes. The 
removal o f  terminal sialic acid exposes galactose, which can be a recognition site for 
antibodies that bind and remove glycoproteins and cells via the reticulo-endotiielial 
system.
They also protect proteins from degradation by steric hindrance o f  proteolytic 
action (Sjoberg et al, 1994) or by alteration o f  the biophysical environment. Rates o f 
degradation o f  glycoconjugates are strongly influenced by the structure o f  their sialic 
acids: the half-lives o f  C7, Cs, and C9 O-acetylated sialic acids are markedly longer than 
that o f  unmodified NeuSAc because their sialidases are longer acting (Schauer, 1991). 
Gastric mucus, a highly viscous gel containing many O-linked sialylated 
oligosaccharides, protects the stomach from self-digestion by secreted HC1 (Bhaskar et 
al, 1992).
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1.2.9. Evolution and Diversity of Glycans
I.2.9.I. Suggested Evolutionary Stages
Examination o f  the biosynthetic pathways and biological functions o f oligo­
saccharides in different groups o f  organisms has produced a picture o f the way in which 
they may have evolved (Drickamer and Taylor, 1998).
The sugars in mammalian oligosaccharides can be divided into two groups: (1) 
core sugars - e.g. GlcNAc, mannose, glucose - which establish the basic branching pattern, 
complemented by extensions — usually polylactosamine chains i.e. Gal-GlcNAc repeats; 
(2) A  variety o f  terminal elaborations e.g. galactose, GalNAc, L-fucose, sialic acid and 
sulphates. In all eukaryotic cells, the initial N-linked carbohydrate structure that is 
transferred en bloc to proteins as they emerge in the ER consists o f  two GlcNAcs, nine 
mannoses and three glucoses. The core is then modified during passage through various 
luminal compartments, with glucose and some mannoses being removed, and then the 
terminal elaborations being added.
It is suggested that die core could be a primordial structure, since organisms such 
as yeast contain very large high mannose structures lacking mammalian-type elaborations, 
and has a much older role as a cell-wall constituent. The elaborations appear to have 
evolved more recently, extensively within the animal kingdom, and in a slightly different 
way in plants (Driouich et al, 1993). This theory is supported by the intracellular location 
o f  the glycosylation machinery: the circuitous route o f  adding a set o f  nine mannose 
residues and then taking them away suggests the grafting o f  a new pathway onto an old 
one.
O-linked oligosaccharides, with no en bloc transfer during their synthesis, can be 
regarded as comprising mainly terminal extensions, and it is suggested that they developed 
in parallel with the more recent part o f  the N-linked pathway.
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In higher organisms, many o f  the terminal groups operate as recognition 
structures for a number o f different receptors. Hepatic receptors for instance remove 
circulating asialoglycoproteins that bear terminal galactose residues, and glycoprotein 
hormones that bear terminal GalNAc-4-suIphate residues. Selectins and sialoadhesins 
interact with sialylated cell-surface ligands. All o f  these are useful only in multicellular 
organisms.
Recent evidence suggests that in the luminal compartments o f  the ER removal o f 
glucose from the core structure indicates to the sorting mechanism that the synthesized 
protein is successfully folded, mediated by the chaperones calnexin and calreticulin 
(Fieldler and Simons, 1995). Some components o f  the sorting mechanism exist in yeasts 
but not in prokaryotes, suggesting that die structural role was followed first by this sorting 
role and then by the cell/ligand recognition role.
The effects the integral oligosaccharides have on a glycoprotein’s properties, such 
as folding, stability etc., are thought to be a relatively recent development. Once the 
glycosylation machinery was in place, attached oligosaccharides inevitably became an 
essential part o f  the protein. It appears that the core sugars have importance in this role, 
probably due to their proximity to the peptide surface, while the terminal elaborations are 
distally located for interaction with other ligands.
This view helps to explain why sugar residues sometimes perform functions in 
protein structure that one would think could be accomplished by amino acids. The 
evolution o f  the glycosylation machinery gave rise adventitiously to protein modifications, 
which were subsequently selected for.
1.2.9.2. Diversity and Complexity
One o f  the striking things, mentioned already, about oligosaccharide chains is the 
diversity o f  glycosylation that is found at every level o f  biological organization. In many 
instances, this heterogeneity has no obvious function that benefits the organism (Gagneux
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and Varki, 1999). The greatest diversity is found in the terminal elaborations where 
interaction witii other ligands occurs. However, most pathogens have their own 
recognition molecules, such as lectins, which react to tiiese terminal glycans and hence 
gain access to die host’s biological processes. It has been proposed that multi-cellular 
organisms witii long life cycles must constantiy change in order to keep “ a step ahead”  o f  
potential pathogens, which have much shorter life cycles and tiius evolve faster. This has 
been named “The Red Queen Effect”  (Van Valen, 1974), after the Red Queen’s comment 
to Alice in Through the Rooking Glass that “it takes all die running you can do just to stay in 
die same place” .
The vertebrate immune system relies on somatic mechanisms for die generation 
o f  variation i.e. somatic recombination, hypermutation, gene conversion and clonal 
selection, which allows somatic vertebrate defence cells to evolve at rates comparable to 
diose o f microorganisms. However, allowing somatic cells to evolve at this rate, incurs 
die risk o f  uncontrolled proliferation (cancer) and misdirected immune reactions 
(autoimmune diseases) (Gagneux and Varki, 1999).
Other ways that glycans function to ward o ff pathogens have been proposed. 
Endogenous recognition in vertebrates is often through lectins which have poor single­
site affinities (i.e. ‘looseness o f  fit’), and will permit variation in ligand structure, whilst 
maintaining recognition (Weis and Drickamer, 1996). When die vertebrate makes a 
permitted variation pathogens are unable to recognize the modification, and so die 
vertebrate ‘keeps ahead’. Similar processes may occur because o f  the inherent flexibility 
o f  glycosidic linkages in comparison to peptide bonds.
Some molecules have been proposed as ‘decoy’ structures. For example 
glycophorin A  is a very complex membrane glycoprotein in erythrocytes. It does not 
appear essential to host functions, as individuals genetically lacking this protein suffer no 
apparent ill effects, but perhaps is a ‘sink’ for glycan-binding viruses. Viruses could be
26
‘sopped up’ by these non-nucleated cells which cannot serve as hosts for replication 
(Wybenga et al, 1996).
Glycoproteins generally exist as populations o f  glycosylated variants (glycoforms) 
o f  a single polypeptide, but why so many variants should exist is not well understood. 
IgG, for instance, has about 30 glycoforms. One theory is that this confers a ‘herd 
immunity’ to the protein: a pathogen recognizing a specific glycan cannot infect all 
members o f  a heterogeneous population (Gagneux and Varki, 1999). In the case o f  IgG, 
could it be that the IgG is ‘offering’ a variety o f  receptors to actually attract a wide- 
spectrum o f  pathogens with different receptor specificities? Immunoglobulins, o f  course, 
are proteins with capabilities o f  dealing with foreign invaders. More will be said about 
IgG in later sections.
1.3. Glycosylation Changes in Disease
Changes in glycosylation have been observed in many diseases and some aspects 
o f  some the main disease groups, with a few examples, will be looked at here, which may 
help towards understanding the disease mechanism o f MS.
1.3.1. Congenital Disorders
Diseases due to a genetic deficiency o f  an enzyme in the biosynthetic pathway o f 
N-glycans are rare, although more are coming to light as the disease symptoms and 
characteristics become more understood (Krasnewich and Gahl, 1997). Congenital 
dyserythropoietic anaemia type II (previously known as ‘HEMPAS’ — hereditary 
erythroblastic anaemia with multinuclearity and a positive acid serum lysis test) is caused 
by a deficiency o f  Mana:GlcNAc-transferase II (Fukada, 1990). Inclusion body cell 
disease (I-cell disease) is caused by deficiency o f  GlcNAc-1-phosphotransferase 
(Glickman et al, 1996). The carbohydrate-deficient glycoprotein syndromes (CDGS) — o f  
which several types have been identified — manifest as multi-systemic diseases with major
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nervous system involvement. Types la and lb are related to deficiencies o f  
phosphomannomutase and phosphomannose isomerase, respectively, while type II results 
from a deficiency o f  GlcNAc-transferase II (Jaeken et al, 1993). Types III, IV (Stibler et 
al, 1994) and V  (Korner et al, 1998) have also been described. Diagnosis o f  the CDGS is 
often aided by the identification o f  the glycoforms o f transferrin in CSF by isoelectric 
focusing (Keir et al, 1999). CSF is the better sample for the test as it contains a mixture o f  
transferrin glycoforms having between 0 and 6 sialic acids, while transferrin in serum is 
less abundant and the glycoforms possess less than 3 sialic acids.
Another group o f  congenital diseases comprises the lysosomal storage diseases. 
These stem from deficiency o f  the enzymes required for glycosphingolipid catabolism 
within lysosomes, resulting in accumulation o f  undegraded substrate (Platt and Butters, 
1998).
1.3.2. Cancer
The glycosylation o f  cells changes in cancer, with the type o f  change depending 
on the type o f cancer as well as the underlying glycosylation programs o f  the cell type 
(Brockhausen, 1993). With the surface glycosylation o f the tumour cell fundamentally 
altered, the interaction o f  the cell with other tissue cells, leukocytes, or extracellular 
ligands, including lectins, is substantially changed (Kim and Varki, 1997). The cell may 
therefore escape immune surveillance, leading to tumour progression and metastases 
(Yoshida et al, 1995). In general, the surface o f  cancer cells compared with normal cells 
has more branched glycans and is more highly sialylated. There may also be differences in 
fucosylation or galactosylation. The increase in brandling is often at the GlcNAcf3(l-6) 
linkage on the Man(al-6) arm o f  the trimannosyl core, so an increase in GlcNAc- 
transferase V  (GnT V) may be a common feature in tumour progression.
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Table 1.6. Structures of carbohydrate antigens (Kim et al, 1996).
Antigen Structure
Tn GalNAca-Thr/Ser
Sialyl-Tn NeuAc(a2-6)GalNAca-Thr/Ser
T Gai(p1 -3)GalNAca-Thr/Ser
i Gal(pi -4)GlcNAc(pi -3)Gaip-R
Sialyl Lea NeuAc(ot2-3)Gal(pi-3)Fuc(a1-4)GlcNAcp-R
Lex Gal(p1-4)Fuc(a1 -3)GlcNAcp-R
Difucosyl Lex Gal(p1-4)Fuc(a1-3)GlcNAc(p1-3)Gal(p1-4)Fuc(a1-3)GlcNAcp-R
Sialyl Lex NeuAc(a2-3)Gal(pi-4)Fuc(al-3)GlcNAcp-R
Sialyl Lex (extended) NeuAc(a2-3)Gai(pi -4)Fuc(a1 ~3)GlcNAc(pi -3)Gal(pi -4)Fuc(a1 -
3) GlcNAcp-R
Ley (short) Fuc(a1 -2)Ga!(pi -4)Fuc(a1 -3)GlcNAcp-R
Ley (extended) Fuc(a1-2)Gai(p1-4)Fuc(a1-3)GlcNAc(pi-3)Gal(pi-4)GlcNAcp-R
Ley (polymeric) Fuc(a1 -2)Gai(p1 -4)Fuc(a1 -3)GicNAc(p1 -3)Gal(pi -4)Fuc(a1 -3)
GlcNAcp-R
Le: Lewis antigen
In cancer there may be expression o f  cell surface antigens that are not normally 
present in the particular tissue, but may occur elsewhere in the body or occur at a different 
period o f  growtii or differentiation. They are often oncofetal antigens i.e. previously 
expressed in fetal life. A  number o f  these antigens, usually O-linked oligosaccharides, 
have been found to be useful in determining the grade, metastatic potential or prognosis 
o f die tumour (Muramatsu, 1993). These antigens exist in the core region o f  the 
oligosaccharides o f  normal cells, but are usually masked by additional sugar residues. 
Some o f  the commoner antigens are shown in Table 1.6. They tend to be more strongly 
expressed in tumour cells with either a poor prognosis or greater metastatic potential. In 
contrast, cells that normally express die ABH antigens tend to lose this expression when 
they become malignant.
The sialyl Tn antigen has been termed the ‘pan-carcinoma antigen’ and is 
expressed in 94% o f  adenocarcinomas o f  the colon, breast (84%), lung (non-small cell, 
96%) and ovary (100%) (Kim et al, 1996). The Tn antigen in breast carcinoma is 
associated with poor prognosis and may be detected in tissue by H elix pomatia lectin 
binding (Leatiiem and Brooks, 1987). The Lex structure is recognized by the Lotus 
tetragonolobus lectin, and indicates unfavorable prognosis in patients with carcinoma o f  the
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bladder or colon (Nakagoe et al, 1993). Other antigens have been associated with various 
other diseases.
Cancer cells tend to produce increased mucins, which are high molecular weight, 
heavily O-glycosylated glycoproteins. MUC1 is a membrane type mucin highly expressed 
in breast and pancreas cancer cells. Other mucins have been associated with other cancer 
types (Kim et al, 1996).
As well as cell surface antigens, other cancer markers exist in serum or urine. 
These include carcino-embrionic antigen (CEA), CA-125, CA 15.3, CA 19.9, and CA 26 -  
all heavily glycosylated and containing blood group antigen related glyco-epitopes. Serum 
alpha-fetoprotein (AFP) shows differences in fucosylation in liver germ cell tumour 
compared to hepatomas when reacted with Lens culinaris agglutinin (LCA) (Aoyagi et al, 
1998). Human chorionic gonadotropin (HCG) in urine from women with invasive 
hydatidiform mole has additional triantennary chains compared with urine from women in 
normal pregnancy. Abnormal biantennary chains are found in urine HCG from patients 
with choriocarcinoma or non-invasive mole (Kobata and Takeuchi, 1999) and can be 
distinguished by using a Datura stramonium agglutinin (DSA) column.
1.3.3. Infection
Some features o f  the recognition and interaction o f  pathogenic organisms with 
hosts’ cells have already been mentioned in Sections 1.2.7 and 1.2.8. Glycosylation in 
relation to infection can be seen in two ways. Firstly from the point o f  view o f  the 
pathogen as a means o f  invading a host’s cells, and secondly in relation to the host’s 
defence mechanisms.
1.3.3.1. Pathogen Strategies
In this section, for simplicity, the term ‘parasite’ will refer to a non-viral or non- 
bacterial pathogen.
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a. Parasites
As in mammalian cell-cell interactions, tlie parasite-host cell interaction is a 
complex step-wise process, involving multiple receptors and complementary ligands on 
both cell types (Ward, 1997). A  primary step is the attachment o f  the organism. This can 
lead to colonization, as occurs with Giardia /^/^^s-enterocyte interaction, lysis o f  the host
cell, which is characteristic o f  Entamoeba 
histolytica infection, or invasion o f  the host
f  Carbohydrate
y  Carbohydrate-binding protein cell, as with Plasmodium falciparum. These 
X  Carbohydrate-binding enzyme
interactions are mediated by carbohydrate- 
binding proteins, which may be lectins or 
enzymes, on the parasite, and their specific 
carbohydrate ligands on the host cell (Figure 
1.4). Host cell ligands may include 
glycoproteins, glycolipids or proteoglycans.
Carbohydrates targeted by parasites 
include, primarily, sialic acids, GlcNAc, 
galactose, GalNAc, heparin and chondroitin 
sulphate. Sialic acid on host erythrocytes is 
believed to be involved in the adherence and 
invasion o f  erythrocytes by Plasmodium 
falciparum, and sialidase treatment o f  human 
erythrocytes leads to reduction o f  invasion 
(Hadley et al, 1986). In addition, human 
erythrocytes lacking die sialoglycoproteins glycophoiin A and B, or the sialic component 
o f  these are resistant to invasion (Hadley et al, 1987). Trypanosoma cntyi protozoa also 
recognize terminal sialic acids on host glycoconjugates. After binding, they transfer host
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X  Qycoconjugate 
J Proteoglycan 
J Glycoprotein
PARASITE
Figure 1.4. Attachment of parasites to 
host cells is mediated by carbohydrate- 
binding proteins and complementary 
ligands on both cell types. Various 
possibilities are shown (Ward, 1997).
sialic acids to their own surface by the coordinated activity o f  a neuraminidase and a 
sialyltransferase, which then shields the parasite from the host immune response and 
complement system (Tomlinson et al, 1994). A  Gal/GalNAc-specific lectin o f Entamoeba 
histolytica enables the trophozoites to adhere to host colonic cells (Burchard et al, 1993). 
This is followed by invasion leading to lysis o f  host tissue and dissemination o f  the 
parasite to extraintestinal sites.
b. Bacteria
The adherence o f  bacteria to host cells is largely by means o f  various bacterial 
lectins with specificity for particular carbohydrates. The lectins may interact with a range 
o f  receptors, enabling adherence to many tissues in diverse hosts. The presence o f  
several lectin types on the same bacterium may allow adhesion to almost any cell type 
(Gilboa-Garber et al, 1997).
Some bacteria have preferential binding for a particular kind o f  cell. Helicobacter 
pylori, for instance, binds to the surface o f  gastric epithelial ceEs in the stomach using the 
Lewisb antigens (Boren et al, 1993). However an adhesin binding to sialic acid has also 
been found in H. pylori (Evans et al, 1993). Vibrio cholerae bacteria produce the cholera 
toxin o f  which the B-subunit binds the glycosphingolipid GMi, enabling the A-subunit to 
enter the host cell and activate cAMP production (Masco et al, 1991).
c. Viruses
Many viruses bind to glycoconjugates on hosts’ cells by means o f  surface receptor 
proteins, such as haemagglutinin. Terminal sialic acid is often the target molecule (Reutter 
et al, 1997). The influenza A  virus strain binds specifically to Neu-5-Ac a(2-6)Gal 
residues, whereas the B strain o f  the same virus is specific for to Neu-5-Ac ot(2-3)Gal 
residues (Schauer et al, 1985), while the influenza C strain prefers Neu-5-Ac with 9-0- 
acetylation (Zimmer et al, 1994). For effective infection and replication, the virus needs a
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second surface enzyme, sialidase, which attacks die protective mucus layer on mucosal 
cells (Corfield, 1992). Drugs have been developed which inhibit die viral sialidase (Von 
Itzstein et al, 1993).
The human immunodeficiency virus (HIV) has a major envelope glycoprotein (gp 
160) which is unusually highly glycosylated, and much research has been focused on tiiis 
structure (Fenouillet et al, 1994). Imino sugars such as N-biityldeoxynojirimycin (NB- 
DNJ) inhibit the processing enzymes a-glucosidases I and II, resulting in modification o f  
N-glycans in die envelope glycoproteins, and reduction in infectivity o f  the virus (Fischer 
et al, 1995).
1.3.4. Host Defences
The vertebrate immune system can be divided into specific (adaptive) or aspecific 
(innate) means o f  defence, although the two systems are not separated. Most proteins in 
die defence systems are glycosylated, and awareness is growing o f  the importance o f  die 
attached sugars (Rudd at al, 1999).
I.3.4.I. The Adaptive Immune System
The adaptive immune system can be divided into humoral and ceEular 
mechanisms, aldiough the division is artificial, with interaction o f  molecules and cells. 
The adaptive response is based on sophisticated gene rearrangement processes which 
yield an enormous diversity o f  antibodies and ceEular receptors (Gabius et al, 1997). The 
reasons for glycosylation o f  the components are wide-ranging. Some examples are: 
assisting with protein folding through interactions witii calnexin; stabilizing protein 
structure (as in IgG); providing protease protection (as in IgAl); modulating the 
presentation o f  ceE surface glycoproteins (e.g. ceE adhesion molecules, CD2, CD48 and 
CD59), and providing potential recognition epitopes (as in IgG and IgM).
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The immunoglobulins have a common Y-shaped structure, composed o f  two 
identical heavy chains (H) and two identical light chains (L) (Figure 1.5). The heavy chains 
are designated a, p, S, y or p for the different immunoglobulin classes. Each heavy chain 
comprises 4 or 5 domains, while each light chain has 2 domains. The domains each 
consist o f  approximately 100 amino acids and contain, as a basic structural unit, the 
immunoglobulin fold. The tertiary structure o f  this is formed by two P-pleated sheets 
packed face to face and stabilized by disulphide bonds. All the immunoglobulins contain 
variable (V) or constant (C) domains that have many similarities but are ah structurally 
different and vary in their primary sequence. (Rudd et al, 1999). Constant domains on the 
H chains contain conserved N-glycosylation sites. In addition an average o f  30% o f
IgD
igGi
Figure 1.5. Examples of each of the five classes of immunoglobulins, showing regions of 
N-glycosylation (y ) and O-glycosylation (o) (Rudd etal, 1999).
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serum IgAl molecules (Mattu et al, 1998) and 40% o f IgG molecules (Pareldi et al, 1985) 
contain N-glycans in die variable Fab regions (Vr and V l).
The occurrence o f N-glycans is determined by die presence o f  die sequon 
AsnXaaSer/Thr (where Xaa is any amino acid other than Pro). The biosyntiiesis o f  the 
immunoglobulin glycans proceeds in the way described in Section 1.2.6. In the case o f  
IgA or IgM, monomers are glycosylated and trimmed in die ER, and are then assembled 
into dimers or pentamers respectively before transfer to the Golgi. Overall it is not a 
functional requirement for an immunoglobulin domain to contain a glycan at any 
particular site, but the specific location does influence the processing o f  the glycan, and in 
some cases plays a critical role in the structure and function o f  the immunoglobulin (Rudd 
et al, 1999).
Conserved N-glycans in die Fc regions o f  IgG and IgAl protect die peptides 
from pro teases. IgAl and IgD also contain a Ser/Pro/Thr rich hinge region between the 
Fc and Fab components, which is heavily O-glycosylated. This is also thought to protect 
the hinge region from protease attack, as well as extending the peptide chain and 
conferring rigidity to the structure through repulsion between the charged sialic acids. 
Only certain bacteria, using highly specific proteases, are able to cleave IgAl at its 
extended hinge area. These include Neisseria meningitides, Haemophilus influenzae, Streptococcus 
pneumonia and Neisseriagonorrhoeae (Rudd et al,1999).
The quaternary structure o f  the immunoglobulins can restrict the accessibility o f  
some o f  die glycosylation sites. The Fc sugars in IgG are contained in die interior o f  die 
CH2 domains, whereas in IgAl die sugars are orientated away from die Fc surface and are 
fully exposed. Hence IgAl sugars are larger, may be triantennary, and 90% are o f  the 
larger sialylated type, while in IgG only mono- and bi-antennary sugars exist, and only 
15% are sialylated (Wormald et al, 1997). In IgM, N-glycans are contained in the center o f  
die pentamer and are relatively inaccessible to proteins, including the enzymes in the ER
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which process oligomannose structures to complex types. Thus the glycans found are 
oligomannose types. It is suggested these become clustered together when the IgM takes 
up a ‘staple’ conformation during interaction with an antigen, becoming exposed in a 
group above the surface o f  the molecule and available for complement activation 
(Wormald et al, 1991). This is an example o f  ‘multiple presentation’ which ensures that 
single molecules attached to ‘self proteins do not trigger defence mechanisms normally 
initiated only by ‘non-self pathogens.
As well as IgG, which will be discussed further in the next section, IgA 
glycosylation has been shown to change in disease. In IgA nephropathy, it is thought that 
IgAl is over-sialylated in the hinge region, shown by increased binding to Samubus nigra 
agglutinin (SNA), which binds preferentially to NeuAc(a2-6)Gal (Baharaki et al, 1996).
1.3.4.2. The Oligosaccharides o f IgG
a. IgG Structure
In human IgG two conserved bi-antennary oligosaccharide chains are attached to 
Asn 297 amino acids in each conserved Cy2 domain in the Fc region. These normally 
impinge towards the inside o f  the Fc regions, and interact with each other to stabilize the 
whole molecule (Figure 1,6). Non-conserved oligosaccharide chains occur in the Fab 
region, and their frequency and location varies with the presence o f  Asn-X-Ser/Thr sites 
(where X  is any amino acid apart from Pro). An immunoglobulin domain and a fully 
extended N-linked complex oligosaccharide are o f  roughly similar sizes (Keusch et al, 
1996; Parekh et al, 1985). The largest glycan chain that is found in IgG is shown in Figure
1.7. Any o f the residues underlined may be missing, thus conferring heterogeneity to the 
molecule.
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C L
Conserved 
Glycosylation C h2
sites
Non-conserved
Glycosylation
Figure 1.6. The structure of immnoglobulin G showing positions of the conserved and 
non-conserved oligosaccharide chains (Parekh et al, 1985).
b. Modulation of Behavior
Some ways in which glycans modulate die behavior o f  IgG and other 
immunoglobulins have been discussed, and more examples will be given here. The 
carbohydrate components are necessary for some, but not all, functions o f  IgG. If 
carbohydrate is removed from IgG - either by glycosidase digestion or by treating IgG 
secreting cells with tunicamycin, which inhibits glycosylation — die molecule loses its 
ability to bind to Fc receptors on macrophages (Dwek, 1995). It also has three times less
Neu5Ac(a2-6)Gal(pi -4)GlcNAc(pi -2)Man(a1 -6) Fuc(a1-6)
GIcNAc(pi-4)Man(p 1-4)GlcNAc(pi-4)GldNAc 
Neu5Ac(a2-6)Gai(P 1 -4)GlcNAc(p 1 -2)Man(a1 -3)
Figure 1.7. The largest N-linked sugar chain of human IgG. Residues underlined may be 
absent (Kobata, 1994).
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affinity for the complement component C lq (Tsuchiya et al. 1988). But its antigen 
binding properties are not affected, suggesting that the Fab glycans are not involved in 
specific immunity. However the antigen-antibody complexes formed failed to be 
eliminated from the circulation.
As already mentioned, oligosaccharides o f  IgG help stabilize the molecule and 
shield it from protease attack. The Fc glycans are particularly hidden (Figure 1.8). When 
terminal sugars are absent from these, the conformation o f  the IgG molecule may change 
(Rudd et al, 1999) and also the glycans may become less hidden and available for binding 
by lectins or other molecules (Figure 1.9).
In comparison to Fab, Fc glycans have been found to contain: (i) lower levels o f  
bisecting GlcNAc; (ii) lower levels o f  galactose; (iii) higher than expected levels o f  a(l-6)
Figure 1.8. Molecular mode! of lgG1 based on the crystal structures of IgG Fab 
and IgG Fc. Fab glycosylation sites are in the hypervariable region and are 
occupied approximately 40% of the time. Conserved glycosylation sites are in 
the Fc region and are normally shielded by the CH2 domains. (Carbohydrates 
are shown in blue, light chains in green, heavy chains in red and disulphide 
bonds in yellow). From Dwek et al, 1995.
ami galactose compared to that on die a(l-3) arm; (iv) no a(l-6) arm sialylation 
(Wormald et al, 1997). NMR relaxation was measured to compare the mobility o f  die 
glycans. In the Fc region the mobility depends direcdy on the primary sequence o f  the 
giycans: glycans with galactose on the a(l-6) arm have relaxation properties very similar to 
those o f  the unglycosylated protein backbone i.e. they have no independent motion. 
However glycans lacking galactose had relaxation rates 30 times slower than the peptide,
i.e. much greater mobility. This confirms that die glycans lacking galactose do not interact 
with die protein, which would result in exposure o f  the previously covered peptide
Figure 1.9. Refined structures at 2.8 A of rabbit Fc fragment showing the two carbohydrate chains, 
each attached at Asn 297 (Parekh et a!, 1985). A is a maximally glycosylated fragment: the a(1-3) 
arm of the left-hand chain is always devoid of galactose and interacts through its p(1-2) linked 
GlcNAc residue (c) with the Manp(1-4) GlcNAc segment of the opposing oligosaccharide chain. The 
a(1-3) arm of the right chain extends outwards between the domains with no apparent steric 
constraints on its length; a Neu5Ac unit (a1) is shown on one a(1-6) arm only (left). The electron 
density for this unit is weak, and experimentally no disialylated chains occur on the Fc. B is the 
same Fc fragment containing oligosaccharides devoid of galactose and sialic acid on each of the a(1- 
6) arms. Since these residues in normal IgG are in contact with the surface of the protein, their 
absence could make the IgG ‘sticky’ by creating a lectin-like activity.
Key: c: GlcNAc, g: core GlcNAc - on the a(1-3) arm; a’: sialic acid, b’: galactose, c’: GlcNAc - on the 
a(1-6) arm.
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Figure 1.10. Normal-phase HPLC separation of total IgG glycans from (a) normal and (b) 
RA serum (Guile et al, 1996). All glycans, released from IgG by hydrazinolysis, are 
biantennary. G = galactose (0, 1 or 2 per glycan); F =fucose; S = sialic acid (0, 1 or 2 per 
glycan); B = bisecting GlcNAc. Peaks were assigned glucose unit values (gu) by 
comparison with a standard dextran ladder. The percentage GO sugars, calculated from 
the peak areas, was 51.8% in RA IgG compared with 15.2 % in normal serum IgG
surface, as well as making the glycans more accessible (Wormald et al, 1997).
c. IgG Heterogeneity
Human IgG contains an average o f 2.4 glycans per molecule (Youings et al, 1996), 
with 2 conserved glycans in the Fc, while Fab glycans are present 40% o f the time 
(Wormald et al, 1995). Thus a variety o f  glycoforms are possible. HPLC analysis o f  IgG
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has shown at least 24 different glycan structures, although three varieties on Fc, and two 
on Fab, predominate (Wormald et al, 1997). While variable heterogeneity has been found 
in IgG paraproteins (Farook et al, 1997) with overall increased sialylation (Fleming et al, 
1998), the pattern o f  heterogeneity in serum IgG is surprisingly constant from one 
normal person to anodier (Mizuochi et al, 1982). For instance, HPLC o f  serum IgG 
from normal samples consistently gives a similar trace, as shown in Figure 1.10a, while 
IgG from rheumatoid arthritis patients gives a pattern as shown in Figure 1.10b, with 
larger galactose deficient (GO) peaks (Guile et al, 1996).
Remission o f  RA temporarily occurs during pregnancy, with a decrease in the 
proportion o f  IgG Gal 0. This is thought to be related to suppression o f  the mother’s 
immune system so that the growing fetus is not rejected. Remission o f  MS during 
pregnancy also occurs. This phenomenon provides evidence that these diseases have an 
autoimmune basis. The percentage o f  IgG Gal 0 also distinctly increases with age 
(Shikata et al, 1998; Yamada et al, 1997) with the quantity o f  agalactosyl glycoforms being 
lower in females than in males.
1.3.4.3. Non-Adaptive Defence Mechanisms
The adaptive immune system is not sufficient to protect mammals at all stages o f  
development. Innate, non-adaptive mechanisms are vital in the first 18 months o f human 
life and as a first line o f  defence where there are low levels o f  antibody present (Gabius et 
al, 1997). Body fluids contain a variety o f  proteins which have non-specific anti-bacterial, 
anti-viral or anti-parasite activities. These include the complement proteins, lysozyme, 
acute phase proteins, cytokines and other regulatory proteins. Lectins are also an 
important group o f animal defence molecules, and they may function as agglutinins to 
enhance phagocytosis, as opsonins, complement activators, cell recognition molecules and 
as initiators o f  mediator release.
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Homologous mechanisms o f  innate immunity have been found in invertebrates 
and vertebrates (Marchalonis and Schluter, 1990). For example, die mammalian acute- 
phase reactants, pentraxins, and certain tunicate or horseshoe crab lectins are considered 
to belong to an ancient group o f  recognition molecules. In plants, also, some lectins, 
owing for instance to their toxicity, appear to serve as defence mechanisms. Some 
members o f  the lectin family in humans will be briefly looked at here.
The pentraxins, C-reactive protein (CRP) and serum amyloid P component share 
significant sequence homology indicating a common reactivity during die acute-phase 
response, although often only one o f  the pentraxins behaves as a reactant for die targeted 
species (Ballou and Kushner 1992). CRP acts as an opsonin for bacteria, witii calcium- 
dependent binding to galactosyl residues, rendering them susceptible to phagocytosis 
(Kottgen et al, 1992). Amyloid P component, in die presence o f  physiological levels o f 
calcium, binds to various ligands including chromatin, histones, heparan sulphate, 
mannose-6-phosphate, 3’-sulphated derivatives o f  glucuronic acid, galactose, and GalNAc 
(Tennant and Pepys, 1994). This binding activity aids in the clearance o f  nuclear and 
lysosomal material from necrotic areas during inflammation.
The collectins are a group o f  calcium-dependent (C-type) lectins which contain 
collagen-like domains. In serum collectins, the recognition domain (lectin) is linked to a 
potential effector mechanism resembling die organization o f  die first complement 
component, C lq  (Malhotra et al, 1992). To fulfil tiieir role o f  binding avidly to sugar 
epitopes on die surface o f  patiiogens, serum mannose-binding proteins cluster their 
recognition domains. They form a triple helix with their collagenous tails, widi furdier 
aggregation o f  three to six trimers, each tail holding a lectin, so tiiat the arrangement 
resembles a bunch o f  flowers witii the collagen tails as stalks and die lectins as flower 
heads. Each carbohydrate-binding domain in a trimer is separated from the others by 53 
A, which is optimum for binding to the widely spaced sugars on die surface o f  bacteria,
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yeasts and other parasites (Weis and Drickamer, 1994), and also possibly to tumour cells 
diat have aberrant glycosylation patterns (Ohta and Kawasaki, 1994).
Selectins are C-type lectins involved in the rolling o f  leukocytes and the targeting, 
homing and activation o f  lymphocytes (Zanetta, 1997). Each selectin, as well as a lectin­
like domain, comprises an epidermal growth-factor-like domain, a number o f  
complement-regulatory domains and a trans-membrane polypeptide. They exist on the 
surface o f  endothelial cells (i.e. E-selectins), on platelets (P-selectins) and on leukocytes 
(L-selectins) and recognize ligands on target cells by means o f  carbohydrate groups, 
notably sialyl Lex and sialyl Lea (Phillips et al, 1990). Other proteins involved in leukocyte 
adhesion and extravasation include the integrins and cell adhesion molecules which are 
members o f  the immunoglobulin superfamily — principally ICAM-1, ICAM-2, and V- 
CAM (Springer, 1990), and the neural cell adhesion molecule (N-CAM).
The cerebellar soluble lectins (CSL) are calcium-independent mannose-binding 
lectins o f  varying sizes, depending on the brain cell type. They recognize preferentially 
Man6GlcNAc2 N-glycans, but also hybrid type N-glycans sulphated and fucosylated on the 
core GlcNAc, and heparin. These lectins are important for both cell adhesion, by 
forming bridges between surface glycans on neighbouring cells, and for signal generation, 
by causing clustering o f ligands at the surface o f  a cell.
Apart from lectins, there are other regulatory proteins involved in host defence 
through carbohydrate recognition, which themselves may be glycosylated. Cytokines are 
locally produced hormones that alert the innate and specific immune systems, and include 
the interleukins, interferons and cell colony stimulating factors. They are low molecular 
weight proteins (15-20 kDa) produced by leukocytes and other cells in low concentrations 
(10'15 M). They are highly potent and have multiple effects on the growth and 
differentiation o f  a number o f  cell types, combining with small numbers o f  high affinity 
cell surface receptors and producing changes in the pattern o f  RNA and protein synthesis
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(Roitt, 1994a). Thus they are mediators in cell growth and differentiation, immunity and 
inflammation.
Most cytokines are glycosylated, with one or more glycosylation sites, and hence 
occur as populations o f glycoforms. It is thought that glycosylation acts as a further 
control mechanism on their interactions with various proteins, such as the proteases, 
targeting them to specific cellular receptors and matrix binding sites (Van den Steen et al,
1998). In the matrix protease cascade (see next section) glycosylation is thought to be an 
additional level o f control o f  amplification. N-linked sugars always have a down- 
modulating effect on enzymes and cytokines; O-linked sugars may be up- or down- 
modulating (Opdenakker et al, 1995). In stress situations o f  the host, in which N-linked 
glycosylation is less efficient, the activities o f  the cytokines and enzymes are increased 
which results in an increased metabolism and substrate turnover.
1.3.5. Autoimmune Disease
Most chronic inflammatory diseases have an autoimmune basis; therefore 
glycosylation plays a key role in these diseases since it is fundamental to die operations o f  
molecules involved in die inflammatory response. These include the selectins; collectins 
and other lectins already described, as well as complement and various control proteins 
including cytokines. A  number o f  inflammatory diseases are associated with a deficiency 
o f terminal galactose on the oligosaccharides present on the Fc part o f  IgG in serum (Gal 
0 or agalactosyl IgG). These include rheumatoid arthritis (RA), osteoarthritis, systemic 
lupus erythematosus, Crohn’s disease and tuberculosis (Roitt et al, 1988; Tomana et al, 
1988; Rook et al, 1989; Furukawa and Kobata, 1991). The reduction in terminal galactose 
appears to be due to reduced galactosyltransferase activity towards asialo-agalacto-IgG 
during synthesis in the B-cells (Axford at al, 1987), which might be due to a lowered 
affinity for UDP-galactose.
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The lack o f  terminal galactose residues on IgG could itself be the cause o f  
inflammation in RA and other diseases, through activation o f  the complement system, as 
follows. The absence o f  terminal sugars results in decreased protein-oligosaccharide 
interaction in the Fc, and the sugars are displaced out o f  the CFb domains. Thus 
exposed, they are prone to binding by endogenous lectins such as mannose binding lectin 
(MBL), which will then activate complement (Malhotra et al, 1995). This provides an 
additional route to complement activation to the classical pathways involving IgG antigen- 
antibody complexes or IgG rheumatoid factor (RF) complexes (Rudd et al, 1999).
In autoimmune diseases there is a breakdown in the mechanisms that control self­
tolerance (Roitt, 1994b). In essence, the body produces antibodies against ‘self antigens, 
as opposed to ‘non-self, e.g. an invasive pathogen. It is usually thought that this occurs 
after a foreign organism, such as a virus or bacteria, has invoked an immune response in a 
host which produces polyclonal antibodies against the organism. The antibodies are 
directed against a particular sequence o f  molecules, the antigen, which may be amino 
acids or carbohydrates. Subsequently, these antibodies recognize this same, or similar, 
antigen in the host, even though it is ‘self and poses no threat. Continuous immune 
response against ‘self antigens causes a chronic inflammatory response and chronic 
disease.
The role o f autoimmunity in many disorders is not clearly defined, but a general 
model o f  the mechanism has been suggested, termed the Remnant Epitopes Generate 
Autoimmunity (REGA) model (Opdenakker and Van Damme, 1994), in which the 
cytokine production o f  matrix proteases is the basis o f  the disease (Figure 1.11). The 
regulation o f  extracellular proteolysis is controlled by a balance o f  inflammation- 
producing cytokines, which induce production o f  proteolytic glycoprotein enzymes 
(proteases) and disease-limiting cytokines, which induce protease inhibitors, in a cascade
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system similar to the enzyme cascade in blood clotting. The system is triggered by an 
aedological agent which could be viral or bacterial.
Figure 1.11. Cytokines and proteases in autoimmunity (Dubois et ai, 1999). IL = Interleukin; 
TNF = Tumour necrosis factor; IFN = Interferon; TGF = Transforming growth factor; MCPs = 
Monocyte chemotactic proteins; GCP = Granulocyte chemotactic protein; MBP = myelin basic 
protein; PLP = Proteolipid protein; MAG = Myelin-associated glycoprotein; MOG = Myelin 
oligodendrocyte glycoprotein; PAIs = Plasminogen activator inhibitors; TIMPs = Tissue inhibitors 
of metalloproteases. DP = Degradation products.
One o f  the effects o f  die cytokine network and the matrix proteolytic enzymes is 
the degradation o f matrix components such as collagen in connective tissue or myelin in
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nerve tissue, so as to allow chemoattracted leukocytes to reach the inflammatory focus. In 
the case o f  chronic inflammation or autoimmune disease, matrix components are 
constantly degraded into small peptides (with the same sequence but perhaps another 
conformation), which contain epitopes that stimulate autoreactive T-cells (Dubois et al,
1999). In multiple sclerosis, the destruction is directed towards myelin components such 
as myelin basic protein (MBP), proteoHpid protein (PLP), myelin-associated glycoprotein 
(MAG) and myelin oligodendrocyte glycoprotein (MOG) and results in different 
degradation products (DP). Autoreactive T-cells produce y-interferon (IFN-y) which 
further activates the inflammatory reaction. Oligoclonal immunoglobulins might assist in 
the elimination o f  specific antigens and, when complexed with antigens in the central 
nervous system (CNS) activate complement-mediated inflammation (Opdenakker and 
Van Damme, 1994).
1.4. Multiple Sclerosis
1.4.1. Occurrence
Multiple sclerosis (MS) is a debilitating autoimmune disease o f  the central nervous 
system (CNS) with demyelination — i.e. destruction o f  the myelin sheath that surrounds 
the axons — being the major pathological feature (Bannister, 1992). It is predominantly a 
disease o f young adults, with a peak age o f onset around 30 years, and is more common 
in women dian men. It is most prevalent in Northern Europe, the Northern states o f  the 
USA, New Zealand and Tasmania, with an incidence o f about 1 in 1000 (Figure 1.12). It 
is rare in tropical and sub-tropical countries and never seen in gypsies, Eskimos, Bantus, 
or native North and South Americans. There is a low incidence in Asia, but when it 
occurs the disease is often exceptionally severe. (Matthews, 1978).
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The geographical distribution is thought to result as much from genetic as from 
environmental factors (Ebers and Sadovnick, 1993). There is a strong association with the 
HLA-DR2 histocompatibility antigen and a slightly less obvious one with HLA-A3, -B7, 
-DW2 and -D Q w l. In japan the HLA-DR4 antigen is also common (Fukuzawa et al,
1.4.2. Genetic factors
Figure 1.12. World incidence of multiple sclerosis. Pink areas denote no data available.
1998). It has been suggested that the HLA types associated with MS are characteristically
Scandinavian, that the disease originated in this area and has been carried around the
world by emigrants such as the Vikings (Adams, 1989).
1.4.3. Aetiological Agent
While it is generally accepted today that MS is an autoimmune disease, with a 
strong genetic influence, there have been many suggestions o f  the causative agent. It has 
been proposed that sunlight, especially in the winter, protects against the disease (Acheson
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et al, 1960). Dietary deficiency has been suspected, particularly o f  polyunsaturated fatty 
acids (PUFA), which is required for synthesis o f  myelin. But a high polyunsaturated diet 
has been explored in MS and does not influence the rate o f  clinical deterioration (Bates et 
al, 1978). Coeliac disease has also been suspected, but studies on MS patients show 
normal histology o f  the small intestine (Bateson et al, 1979).
A  number o f  infective agents have been implicated. Emigrants from cold to 
tropical climates have a higher incidence o f  MS than native born, unless they emigrated as 
children. Individuals born in a cold country from parents who emigrated from tropical 
parts have the same high incidence as the indigenous population. Hence it has been 
proposed that MS is a disease contracted in late childhood, manifesting itself some 10 
years later (Elian and Dean, 1987). The low incidence o f  MS in hotter climates has been 
explained by supposing that children become exposed early to a variety o f  infective 
conditions (particularly enteric viruses) in hot climates and develop immunity to them at 
an early age before the critical age at which MS begins. There is little substantial evidence 
for these theories.
MS patients exhibit raised antibody levels to a wide range o f  viruses, including 
measles, rubella and herpes zoster (Reiber et al, 1998), Borna disease virus (Deuschle et al, 
1998) and Epstein-Barr virus (Rand et al, 1998). Most investigators in the MS field 
surmise that viral infection (not necessarily a specific virus) or injury triggers the initial 
events in MS. Subsequently, an autoimmune response amplifies the process into a major 
relapsing disease. Possible mechanisms for tins process will be discussed later.
1.4.4. Symptoms and Course of Disease
There are several patterns o f  presentation o f MS and subsequent course (Walton, 
1993; Bannister, 1992). Most commonly, MS presents as the relapsing-remitting (RR) 
form. There may be a single focal lesion, or several different lesions. Often the first
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symptom is unilateral optic neuritis; other symptoms may be double vision, or numbness 
or weakness in some part o f  the body such as a limb or both lower limbs, or one side o f  
the face. The initial symptoms then diminish over a period o f  weeks or months and then 
either disappear or leave behind a residual disability, but return later after a period o f  
stability. Twenty percent o f  the MS population have a benign form o f  the disease in 
which symptoms show litde or no progression after the initial attack. Primary-progressive 
(PP) MS is characterised by an insidious and gradual clinical decline with no distinct 
remissions. The symptoms are usually predominantly spinal, with progressive weakness o f 
one or both lower limbs. Secondary-progressive (SP) MS begins with a RR course 
followed later by a PP course (Jongen et al, 1997), while a progressive-relapsing (PR) form 
takes a progressive padi punctuated by acute attacks. In a typical advanced case, die 
patient becomes bedridden with severe paraplegia, staccato speech with slurring o f  
syllables. There is likely to be incontinence, and possibly loss o f  emotional control.
1.4.5. Myelin Structure and Myelination
Myelin is a complex membranous structure around axons in the central nervous 
system (CNS) and peripheral nervous system (PNS) (Figure 1.13). It is made by the 
wrapping o f  processes o f  oligodendrocytes (in the CNS) or Schwann cells (in the PNS) 
(Adams, 1989). Its essential molecular structure is a lipid bilayer with protein connecting 
struts. The myelin sheath is essential for effective propagation o f  nerve impulses, and 
myelin abnormalities cause severe disorders in man, as seen in multiple sclerosis and 
Guillain-Barre syndrome.The protein and glycoprotein composition o f  myelin in the CNS 
and PNS is fairly well known. The most abundant myelin proteins o f  the CNS are myelin 
basic protein (MBP), the proteolipid proteins PLP and DM-20 and the Wolfgram proteins. 
The major glycoprotein o f the CNS is myelin-associated glycoprotein (MAG). It is a 
member o f the immunoglobulin superfamily endowed with 8 or 9 N-glycosylation sites.
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Some o f  the N-linked chains have the epitope 
HNK-1, which is glucuronic acid-3-sulphate 
(Burger et al, 1992).
Minor glycoproteins have been 
detected in the CNS myelin, but not 
characterised, which interact with an 
endogenous lectin, cerebellar soluble lectin 
(CSL). This mannose-binding, calcium- 
independent lectin stabilises protein structure 
by serving as a bridging molecule between 
glycoprotein glycans on the surface o f  the 
processes o f  myelin forming cells. Another 
minor glycoprotein is myelin-oligodendrocyte 
glycoprotein (MOG), which belongs to the 
immunoglobulin superfamily and has a single 
N-glycosylation site with an HNK-1 reacting 
glycan.
Figure 1.13. A neurone (Smith, 1992)
The metabolic stability (or speed o f 
turnover) o f  myelin has been studied. Myelin lipids have a slow turnover characterised by
metabolic stability, although some constituents, such as phosphatidyl choline and
phosphatidyl inositide, turn over faster (Benjamins and Smith, 1984). Myelin proteins 
turn over much more rapidly (20-40 days) than the ‘slow-turnover’ myelin lipids (Smith 
and Hasinoff, 1971).
The oligodendrocyte is responsible for myelination in the CNS. Whereas the 
PNS is largely myelinated by birth in most species, the brain is slowly myelinated in the
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months and years following birth (Adams, 1989). An oligodendrocyte is thought to 
myelinate 30 to 40 CNS internodes by a complex series o f extrusions around the axon. 
The mature myelin sheath is maintained by these cells, and damage to the cells causes 
myelin degeneration. Myelination is controlled by thyroxine. Myelin development is at 
risk when malnutrition occurs in earlv life, and myelin defects may persist even though 
nutrition is restored.
1.4.6. Demyelination
Although an illness resembling MS was described in the Middle Ages, the disease 
was not formally recognized until the nineteenth century, when it was seen that selective 
damage to the myelin sheath occurs (Charcot, 1868). The myelin-oligodendrocyte system 
only is damaged; the axon and nerve cell remain intact (although the axon may be 
damaged at a later stage).
Demyelination o f  areas o f  the brain occurs as ‘plaques’ (Adams, 1989). These can 
be visualized by magnetic resonance imaging (MRI), where the demyelination appears as 
lightened regions o f high signal (Figure 1.14). Gadolinium, a paramagnetic contrast agent, 
can be given intravenously, which will cross the non-intact blood-brain barrier, and 
enhance the image o f  some plaques in MS. Over 95% o f patients with clinically definite
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Figure 1.14. MRI brain scans of clinically definite progressive MS, showing (A) multiple 
‘high-signal’ lesions in hemispherical white matter and (B) abnormal periventricular changes.
MS show white matter lesions, but similar lesions also occur in acute disseminated 
encephalomyelitis, cerebral vasculitis and sarcoidosis. Demyelination plaques seem to 
arise in the vicinity o f  the ventricles, around periventricular veins, widi further plaques 
spreading into the brain. This seems to suggest that the early lesion is caused by 
something originating in the blood rather than the CSF. It is thought that the formation 
o f  plaques starts with the infiltration o f  T  cells, B cells and immunoglobulins through the 
wall o f  small draining subependymal veins near the ventricular surface. Demyelination 
appears to spread outward from here, perhaps relayed by immunoglobulins from the 
ventricles (Zanetta, 1996). In the plaques, myelin is decompacted and phagocytosed by 
macrophages and the space filled with reactive astrocytes. Oligodendrocytes are relatively 
well preserved, but do not proliferate nor remyelinate significantly.
1.4.7. Causes of Demyelination in MS
There is still a lot o f  controversy over the causes o f MS and the autoimmune 
mechanism. Venous damage is thought to be an important factor in die pathogenesis o f 
MS, resulting from inflammatory (including immune) agents coming from the blood 
(Adams, 1989). It is generally thought that a viral infection is die underlying trigger for 
die autoimmune reaction though, as already discussed, this may not be a specific virus.
Identification o f the immunological target has always been a problem. Use o f
phage displayed random peptide libraries to identify phagotopes binding to IgG in the
CSF o f  MS patients has shown tiiat CSF antibodies from different MS patients display
different specificities. When serum was screened, anti-phagotope antibodies were equally
frequent in the serum o f  healthy individuals and MS patients (Cortese et al, 1998). In
another study using a phage peptide library, CSF from 5 out o f  14 MS patients and 1 out
o f  14 controls selected an amino acid sequence motif that is found in the Epstein-Barr
virus nuclear antigen (EBNA-1) and a heat shock protein alphaB crystallin (Rand et al,
1998). Nearly all MS patients’ sera were positive for EBV antigen, with raised antibody to
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EBNA in their CSE Using antigen-specific immunoblotting, the antibodies to the 
EBNA-1 motif in CSF corresponded to a subset o f  oligoclonal bands.
In another study, Kaiser et al (1997) screened 185 patients with MS, 130 patients 
with other inflammatory diseases o f  the CNS (OID) and 50 patients with spinal disc 
syndrome (controls). IgG antibodies in serum to CNS proteins were found in 10% o f  MS 
samples, 22% o f OID and 8% o f  controls. In the CSF, IgG antibodies to CNS proteins 
were found in 6% o f MS samples, 28% o f OID and 0% o f  controls. Although as much 
as 97% o f  MS patients showed oligoclonal IgG bands in the CSF, specificity o f  the bands 
for CNS proteins was demonstrated in only 1% o f  these.
A number o f CNS constituents have been proposed as the immunological target. 
Myelin basic protein (MBP) has been implicated, since high levels o f  anti-MBP have been 
found in the CSF o f  MS patients (Warren and Catz, 1993) and a region o f  peptide o f 
MBP has been found to be associated with HLA-DR2 (Zang et al, 1998). But although 
injection o f  myelin from one animal into the brain o f  another o f  the same species causes 
experimental allergic encephalomyelitis (EAE) - an inflammatory disorder similar to MS - 
it produces only minimal demyelination. In contrast, strong demyelination is observed 
with injection o f  whole brain extracts, suggesting that the demyelination agent is not a 
localized component o f myelin, (i.e. MBP, PLP or MAG), or diat several auto-antigens are 
involved (Zanetta, 1996).
Another putative target for the demyelinating autoimmune response is MOG, 
although anti-MOG antibodies are not especially found in the CSF or blood o f  MS 
patients. Anti-MOG monoclonal antibodies cause demyelination in cultures in the 
presence o f  complement. (Xiao et al, 1991). Furthermore it has been shown that 
antibodies to M OG and galactocerebroside (GalC) induce MBP degradation and 
destabilisation o f  myelin, mediated by neutral proteases (Menon et al, 1997). Another
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study showed that the autoimmune response towards M OG predominates over that 
towards MBP, and identified reactivity directed to three epitopes in M OG (Kerlero tie 
Rosbo et al, 1997).
CSL has been proposed as an immunological target in MS. It is found not only in 
oligodendrocytes and Schwann cells but also in neurones and astrocytes, at the surface o f 
cilia and in the tight junctions o f  ependymal cells lining cerebral ventricles (Perraud et al,
1988). Moreover CSL is not specific for nervous tissue but is widely distributed in the 
mammalian body (Zanetta et al, 1990). Anti-CSL antibodies have been shown to cause 
demyelination in vivo and large amounts o f  such antibodies have been found in the blood 
and CSF o f MS patients. It is conjectured that CSL antibodies, produced in the blood 
against systemic CSL, affect the ependymal barrier, eidier alone or with a complement 
component, and allow macrophages and lymphocytes to infiltrate the brain and produce 
multiple sclerosis plaques (Zanetta et al, 1990). The triggering o f  the autoimmune disease 
may not be directed at CNS tissue, but odier tissues — for example the PNS, liver, lddney 
or intestine. Or it is possible that CSL itself may not be the trigger, but an exogenous 
mannose specific lectin o f  bacteria, protozoa or plant origin. Measurement o f  CSF anti- 
CSL antibodies has been proposed as a diagnostic test for MS, with 85% specificity and 
93.5% sensitivity (Zanetta et al, 1994).
Another line o f  inquiry into die cause o f  MS is the effect o f  free radicals on CNS 
tissue. Production o f  the free radical nitric oxide (.NO), which can be induced by 
interferon-y in an inflammatory response, has been correlated with clinical signs o f  EAE 
in rats (Hooper et al, 1998). It is unproven yet whether .NO, which has a short half-life in 
vivo, exerts a toxic effect on the CNS cells direcdy or reacts with superoxide (.O2), in an 
inflammatory response, to form the more toxic peroxynitrite (ONOO'). This can cause 
lipid peroxidation and tyrosine nitration, and plaques in die brains o f  MS patients have
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been shown to contain nitrotyrosine residues. Uric acid, a strong deactivator o f  
peroxynitrite, was found to diminish clinical signs o f  a disease resembling EAE in mice. 
The findings that patients with MS have significantly lower levels o f  serum uric acid than 
controls, and that gout is rarely found in combination with MS, suggest that 
hyperuricaemia may protect against MS.
Finally, there is the REGA model o f  autoimmunity discussed in Section 3.5. This 
takes into account the possibility that any or all o f  the components o f  myelin, or 
degradation products o f them, may be autoimmune targets and could explain the role o f  
oligoclonal IgG. Certainly no single component as target exacdy fits the picture presented 
by MS, and with many aspects o f  the disease unclear, a broad view o f the disease process 
should be taken.
1.4.8. Remyelination and Treatment
Provided that the axon is intact, CNS myelin may be repaired by oligodendroglia, 
although repair and remyelination in MS is controversial (Adams, 1989). Thinly 
myelinated areas, often referred to as “ shadow plaques” , are thought to be areas o f 
remyelination (Ludwin, 1987). Repair o f myelin in the CNS is slower than in the PNS, 
and is thought to be impeded by growth o f  glial fibres from astrocytes that form in MS 
plaques. Clinical recovery is not necessarily an index o f  remyelination, as nerve 
conduction can improve after the formation o f  only a few myelin lamellae.
There is no specific treatment for MS. Steroids, such as high dose intravenously 
administered methylprednisolone, may be given for their anti-inflammatory effect 
(Frequin et al, 1992; Wandiger et al, 1998). A  recent therapy - repeated doses o f  
intravenous immunoglobulin G, thought to suppress T  cell reactivity and promote 
remyelination - has had mixed success (Francis et al, 1999; Pashov et al, 1998; Lisak, 
1998). Currently on trial is interferon-P, which induces disease-limiting cytokines.
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Oestriol, suggested to be the cause o f  the amelioration o f MS during late pregnancy, has 
been shown to reduce the severity o f  EAE in mice (Kim et al, 1999), and may provide the 
basis o f  a novel therapy for MS. Another therapeutic approach, the complete renewal o f  
the immune system by removing stem cells by plasmaphoresis, has given positive results 
so far.
1.4.9. Diagnosis and Disease markers
Diagnosis o f  MS is made on clinical signs including evoked potentials, with 
additional information from brain scans and laboratory investigations o f  CSE MRI 
scanning, described earlier, is superior to computerised tomography (CT). The laboratory 
tests include measurement o f  CSF total protein and IgG, usually expressed as a 
percentage o f  the total protein, and cell count: lymphocytes are typically slightly increased. 
The IgG index, calculated from IgG and albumin concentrations in CSF and serum, 
purports to give an indication o f  the integrity o f  the blood-brain barrier (Andersson et al, 
1994). The presence o f oligoclonal IgG in CSF is highly indicative o f  MS, although it is 
also found in other diseases o f  the CNS. Detection is usually by isoelectric focusing o f  
paired samples o f  CSF and serum from the same patient with detection rates o f  about 
95%. (Cowdrey et al, 1990). More will be said about oligoclonal IgG in the next 
section.One o f  the problems with MS, both with the treatment o f  an individual and with 
clinical trial o f  a treatment, is the lack o f  a suitable and specific marker to monitor the 
activity and course o f  the disease. The reference marker is the Expanded Disability Status 
Scale (EDSS) based on several units o f  disability (Kurtzke, 1983). However it is not an 
ordinate scale, one point in the scale is not a unit o f  disability and there is poor 
understanding o f  its relationship to pathogenesis. The MRI scan is expensive and 
moreover its interpretation does not agree well with clinical situation and pathology. 
There are a number o f  possible markers in CSF, for instance anti-CSL antibodies (Zanetta 
et al, 1994), anti-MBP, immunoglobulins or C3/C4 complement factors. However none
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is satisfactory in all situations, and also would entail performing undesired lumbar 
punctures. Various blood markers have been suggested, such as cytokines, but there is 
poor correlation with disease activity. Urine markers include MBP derivatives, neopterin, 
and free light chains, but again there is poor correlation with disease.
1.4.10. Oligoclonal IgG
As already mentioned, the CSF o f MS patients on isoelectric focusing, typically 
displays a distinctive pattern o f banding o f  oligoclonal IgG (Figure 1.15). These bands 
occur in conjunction with the diffuse polyclonal IgG, also found in normal CSF. They are 
thought to represent the restricted clones that can be produced from the relatively small
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Figure 1.15. PVDF blot of routine IEF of paired samples of 
CSF (C) and serum (S) run on acrylamide gel with im­
mobilized 7 to 10 pH gradient. Detection was with sheep anti­
human IgG/anti-sheep labelled with alkaline phosphatase/5- 
bromo-4-chloroindoxyl phosphate and nitroblue tetrazolium. 
Pairs 1, 3 and 4 are positive for oligoclonal IgG; pairs 2, 5 and 
6 are negative; pair 7 shows non-intrathecal IgG (similar 
bands in CSF and serum). Courtesy of Dr G. Cowdrey, 
Biochemistry Dept., Princess Royal Hospital.
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number o f  CSF lymphocytes in MS and may even be specific for each plaque (Adams,
1989).
Oligoclonal IgG is not known to play any part in MS disease per se. It is detected 
in about 95% o f cases o f  MS in Western patients, but in Japanese MS patients only a 56% 
positive rate was found (Fukuzawa et al, 1998), with the negative oligoclonal bands in MS 
associated with the HLA-DR4 antigen. Although some o f  the CSF oligoclonal IgG 
contains antiviral antibodies (Rand et al, 1998; Reiber et al, 1998; Frederiksen and Sindic,
1998), it is not certain to which antigens or epitopes the bulk o f  these antibodies are 
directed. It has been suggested that oligoclonal immunoglobulins might assist in the 
elimination o f  specific antigens (Opdenakker and Damme, 1994). Thus in the REGA 
model o f  autoimmunity, peptide fragments from myelin might be combining with the 
immunoglobulin. These would include fragments o f  MBP, PLP, MAG and M OG (Figure 
1 .11).
One characteristic o f  the oligoclonal bands is their high pi compared to the broad 
p i range o f  polyclonal IgG. Hence a pFI gradient from about 6 to 12 is used with IEF to 
gain better resolution from polyclonal IgG. The high pi could be for several reasons: (1) 
There could be simply a difference in amino acids, with more basic amino acids occurring 
in oligoclonal IgG. (2) There could be a difference in the glycosylation. Negatively 
charged sialic acid is the only N-linked glycan that can confer a charge difference to the 
IgG molecule. So it has been suggested that there is a deficiency o f  sialic acid in 
oligoclonal IgG. (3) Oligoclonal IgG may be combining with peptides or fragments o f 
peptides which are basic in nature, and confer a positive charge to the antigen-antibody 
complex. This fits with the REGA system o f  autoimmunity, which proposes the release 
o f  immunogenic peptides by proteases. Degradation products o f  MBP would be 
positively charged. One o f  the objectives o f  this project will be to investigate these 
possibilities.
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MS is a debilitating disease whose cause is not well understood and for which 
there is no satisfactory treatment. Any research that would help in the understanding o f  
the mechanism o f  the disease would be justified. The two major questions concerning 
MS are: -
• What is die cause - i.e. what is the aetiological agent? For example is there a 
virus, or range o f  viruses, triggering the disease?
• What is the mechanism o f the autoimmune reaction? What is the autoantigen, 
or range o f  autoantigens?
This project has not attempted to answer direcdy eitiier o f  these questions. 
Plowever IgG is very involved in the immunology o f  MS, and recent research (Rudd et al, 
1998; Dubois et al, 1999) shows that glycosylation plays a major role in the immune 
system. Therefore, the finding o f  any glycosylation changes that occur in IgG with MS 
might induce a better understanding o f  the role o f  that molecule in the disease. For 
instance, with rheumatoid arthritis (RA), the finding that agalactosyl IgG is prevalent has 
opened up research into that disease and increased greatiy our understanding o f  its 
pathogenesis.
Rather dian starting witii a question to be answered, or a direct line o f 
investigation, realization o f problems concerning MS has unfolded as die project has 
progressed, and diis has shaped die order o f  die experimental work. Experimental work 
is necessarily bound by the constraints o f  available equipment, expertise and samples, as 
will be seen. The problems addressed in this project can be arranged as follows: -
1) Does glycosylation o f  CSF IgG change in MS compared witii normal? This 
would be in line with other autoimmune diseases, notably rheumatoid arthritis.
1.5. Aims of the Project
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2) If there are changes, what are they in terms o f  the glycans or the 
monosaccharides o f  IgG? Incidental to this would be die determination o f  
the glycosylation pattern o f  IgG in CSF from normal patients and those with 
MS. This has not yet been published. Is the glycosylation pattern o f  IgG in 
CSF the same as that in serum?
3) D o the changes (if any) contribute to the pathogenesis o f  MS and, if so, how? 
For example would lack o f  a particular glycan 01* residue o f a glycan affect die 
structure and function o f  IgG? Could it thus be either a symptom or a cause 
o f die disease? There would probably not be enough time to address diis 
problem experimentally in this project, but conjectures could be made from 
the studies o f  glycosylation.
4) What is the character o f  the oligoclonal IgG bands? Could their alkaline 
isoelectric points be due to changes in IgG’s amino acids, or to changes in die 
saccharides (such as a lack o f  sialic acid), or to IgG’s complexing witii peptide 
fragments such as degradation products o f myelin?
61
Chap te r  Two
Techn ique s  in G ly c o a n a l y s i s
2.1. Methods of Glycocotijugate Analysis
This section will look at the methods available for die analysis o f  carbohydrates in 
glycoconjugates. A  more detailed study o f  metiiods used in diis project will be given in 
section 2.2.
The analysis o f  glycoconjugates ranges from die identification o f mono­
saccharides to characterization o f  the oligosaccharide chains with determination o f 
monosaccharide sequences and linkages (Hounsell, 1997). Analysis o f  die oligo­
saccharides may be performed while tiiey are in situ on the protein, or after diey are 
released and separated.
2.1.1. Chemical Methods
2.1.1.1. Penodation
One o f  die oldest metiiods for analyzing carbohydrates involves the use o f 
periodic acid, which has particular relevance to die analysis o f  oligosaccharides as will be 
seen. Malaprade in 1928, in his chemical estimation o f  glycols, showed that die oxidation 
o f  substances with vicinal hydroxyl groups could be shown by the equation
CH,OH
I “
(CH2OH)„ + 0  + 1)H I04 2HCHO + nHCOOH +  H20  + (n + 1) H I0 3 
CH2OH
whereby the secondary hydroxyl groups yield formic acid and die primary alcoholic 
groups formaldehyde (Marshall and Neuberger, 1972). Glucose is oxidized thus by 
periodic acid, die anomeric carbon yielding formic acid. Quantitation is achieved by
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measurement o f  periodate, formaldehyde or formic acid (Furth, 1988). This reaction is 
also die first reaction in die histological stain used to detect carbohydrate in tissue: the 
periodate, under die correct conditions does not further oxidize the aldehydes, and these 
combine with Scliiffs reagent, fuchsin-sulpliurous acid, to give a substituted dye (Pearse, 
1968). The periodate oxidation reaction has been much studied, and some points worth 
noting are (Marshall and Neuberger, 1972): 1) secondary reactions occur as well as the 
oxidation o f glycols, depending on reaction conditions; 2) low temperature, i.e. between 0 
and 4°C, produces less secondary reaction; 3) optimal periodic acid concentration is 
between 0.005 and 0.1 M; 4) optimum pH is between 3 and 4.5; 5) light decomposes 
metaperiodate solutions, producing ozone which accelerates the periodate oxidation o f 
non-glycol compounds; 6) amino acids may interfere in the reaction by being oxidized by 
periodate.
Various uses for periodate oxidation have been found in glycoanalysis. It has been 
successfully used in this project to deglycosylate antibody. It can be used to sequentially 
release monosaccharides from die non-reducing end o f  a glycan chain, with intermediate 
mild hydrolysis steps (Hounsell, 1997). In combination with methylation, it has been used 
for oligosaccharide analysis witii mass spectrometry. (Angel and Nilsson, 1988). Reaction 
conditions can be adjusted to specifically cleave die glycerol side chain at C6 o f sialic 
acids, or to oxidize the reduced end o f  oligosaccharide alditols, enabling labeling o f  
sialylated oligosaccharides or reductively aminating and sequencing O-linked chains (Stoll 
and Hounsell, 1988). Periodate oxidized carbohydrates o f  N - and O-linked glycans will 
react widi biotin-hydrazide. The incorporated biotin can dien be bound by streptavidin- 
alkaline phosphatase which will act on a substrate to produce a colour change. This is die 
basis o f  at least two kits on the market for detection o f  glycosylation.
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2.1.1.2. Hydrazinolysis
Anhydrous hydrazine, since its introduction in the 1960s, has often been used to 
release bodi N - and O-linked chains from peptides (Yosizawa et al, 1966). Under 
controlled conditions, it will give a high yield (>85%) o f  intact IV- and O-linked glycans in 
true molar proportions (Patel et al, 1993). The glycans are released with a free reducing 
terminus, rendering them available for labeling. Reaction conditions can be varied to 
selectively release only O-linked oligosaccharides (60°C for 5 h) or both N - and O-linked 
(95°C for 4 h). Excess hydrazine is removed by evaporation at 25°C. Primary amino 
groups generated during the reaction are removed by addition o f  excess acetic anhydride 
in saturated sodium carbonate. Sodium ions and peptide material can be removed by 
column chromatography.
This method has been automated by Oxford GlycoSystems for the release o f  both 
IV- and O-glycans, or only O-glycans, using the GlycoPrep 1000. The intact glycans 
produced are ready for labeling and analysis.
2.1.1.3. Other Chemical Methods.
Methylation has been a useful technique in structural carbohydrate chemistry for 
some time, often used in conjunction with hydrazinolysis or peiiodation to release the 
sugars (Marshall and Neuberger, 1972). P elimination under mild alkaline conditions has 
been used to release O-linked oligosaccharides (Fukuda, 1989). Very strong alkali (Lee and 
Scocca, 1972) or lithium aluminium borohydride (Likosherstov et al, 1990) have been used 
for both N - and O-linked glycans. These reagents cause extensive degradation o f  alkali- 
labile glycosidic linkages unless performed in the presence o f  excess reducing agent, 
which leads to die recovery o f  oligosaccharides as die reduced alditol derivatives.
2.1.2. Biochemical Reagents
Anti-carbohydrate antibodies, lectins and carbohydrate-processing enzymes may
recognize not only monosaccharide types, but also their linkage positions, anomeric
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configurations and sequence (Hounsell, 1997). Monoclonal antibodies are now available 
and with plant, marine and microbial lectins, a wide range o f  specificities is offered. 
Mammalian carbohydrate-binding proteins, such as selectins, collectins, galectins and 
sialoadliesins, are becoming available as recombinant proteins, and tend to recognize more 
complex conformational motifs (tri- to octo-saccharide sequences) tiian enzymes or 
lectins. Glycosyltransferases and glycosidases are also now available from recombinant 
technology.
2.I.2.I. Enzymes
a. Proteases and E  ndoglyeosidases
Several methods o f  oligosaccharide analysis, such as Mass Spectrometry (MS) 
High Performance Liquid Chromatography (HPLC), Nuclear Magnetic Resonance (NMR) 
and Capillary Zone Electrophoresis (CZE) require that glycans be released from peptides. 
This can be accomplished by hydrazinolysis, as described above, 01* by using one o f  a 
variety o f  endoglycosidases or proteases (Table 2.1). These are derived from bacterial or 
recombinant sources, and can be obtained from several suppliers o f  glycoanalysis 
reagents. Purity o f  the enzyme and absence o f  otiier proteases is important. 
Denaturation o f  the glycoprotein is usually recommended to achieve complete cleavage o f 
glycans with minimal amounts o f  enzyme.
b. Sequential Exogjycosidase Digestion
Exoglycosidases cleave non-reducing terminal monosaccharides from glycan 
chains, and can be used step-by-step to determine die sequence o f  monosaccharides. This 
is usually performed after release o f  die glycan from die peptide by hydrazinolysis or 
endoglycosidase digestion. After each digestion, the remaining oligosaccharides, 
appropriately labeled, can be analyzed by polyacrylamide gel electrophoresis (PAGE) or
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Table 2.1. Some examples of enzymes used to release oligosaccharides (Hounsell, 1997)
Enzyme Specificity (the arrow signifies the cleavage point)
Endoglycosidase H (Man)nGlcNAcp1-4GlcNAcp1-Asn (protein)
(Endo-H) t
Peptide A/-glycanase (-glycosidase) F NeuAc ±Fuc ±Gai (GlcNAc)n (Man)3 GlcNAcp 1-4
(PNG-ase F) [±Fuca1 -6lGlcNAcp1 -Asn (protein) 
T
Endo-a-A/-acetylgalactosaminidase Gaipl -3GalNAca1 -Ser/Thrt
Endo-p-galactosidase [-3Gaipi-4GlcNAcpi-]„ ±6SO„
I
HPLC. For example, in the fluorophore-assisted carbohydrate electrophoresis (FACE) 
system, produced by Glyko Inc., aliquots o f  labeled oligosaccharide sample are incubated 
witii different combinations o f  mixtures o f  up to five different glycosidases before 
running on PAGE. Alternatively, the released monosaccharides may be analyzed by high 
pH anion-exchange chromatography witii pulsed amperometric detection (HPAEC-PAD), 
as in the Dionex Ltd. system (Weitzhandler et al, 1994).
With computerized data analysis, an array o f enzymes can be used to determine 
the oligosaccharide profile o f  a glycoconjugate. This is the basis o f  the Reagent Analysis 
Array Metiiod (RAAM) analyzer marketed by Oxford GlycoSystems. N - and O-glycans 
are automatically released by hydrazinolysis and labeled witii die fluorophore 2- 
aminobenzamide (2-AB) or with tritium. Automated sequential digestion is followed by 
chromatography o f  oligosaccharides and then data analysis.
2.I.2.2. Lectins
The biological properties o f  some lectins have been described in Chapter One. 
Lectins can be found in many organisms and are involved in numerous cellular processes 
that depend on specific recognition and binding o f  complex carbohydrates. As such, 
many lectins are available as analytical tools, and offer a wide variety o f carbohydrate
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targets. A  general overview o f  lectin methods will be shown here, with a more detailed 
description o f lectins relevant to this project given in the next section.
a. Classification
Carbohydrate-binding proteins can be divided into two major groups (Rim, 1995). 
Group I consists o f  proteins and enzymes, such as bacterial periplasmic transport 
proteins, which have a buried binding site and engulf the ligand fully upon binding. 
Group II has a shallow binding site, mostly in the form o f  a depression on die protein 
surface. This allows for a loose ’ fit in binding, and binding to several ligands may be 
possible, with a range o f avidity. In this group are the legume lectins, c-type lectins and 
galectins, as well as other plant lectins, viral proteins, toxins, anti-carbohydrate antibodies 
and pentraxins (Weis and Drickamer, 1996).
b. Sources
Lectins derived from plants are usually multimeric and soluble proteins (some 
lectins are themselves glycoproteins) with multiple binding sites for carbohydrates 
(Cummings, 1997). The multivalent nature o f  plant lectins allows them to agglutinate 
cells to which they bind, and a number in plants were identified historically as agglutinins.
Many lectins have been characterized from leguminous plants, and often have 
shared primary structures. These include pea lectin (PSA) from the common garden pea 
(Pisum sativum), concanavalin A  (Con A) from the jack bean (Canavalia cnsiformis), RJcinius 
communis agglutinin (RCA) from the castor bean, and Phaseolus vulgaris agglutinin (PHA) 
from the red kidney bean. The non-leguminous plant lectins comprise a large list. For 
example lectins from the nightshade family include tomato lectin, lycopersicon esculentum 
(LEL), potato lectin, Solatium tuberosum (STL), and jimsonweed (Datura stramoniunt) lectin 
(DSL). These are closely related in term o f  structure and carbohydrate-binding specificity 
and have no similarity to legume lectins in their primary structure.
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Animal lectins have not been as available as those from plants, largely due to the 
higher cost o f  their preparation, but more are appearing on the market. They include the 
eel lectin (Anguilla anguilla), snail lectin (Helix pomatid) and horseshoe crab lectin (Umulus 
polyphemus).
An extensive range o f  affinity-purified lectins is available from several different 
companies. Many are available as conjugates o f  various reagents such as biotin, peroxid­
ase, digoxigenin, fluorescein isothiocyanate or other fluorescent tag, as well as alcohol de­
hydrogenase, ferritin and colloidal gold, or they may be immobilized on agarose, acrylic 
beads or Evans Blue.
c. Binding
Carbohydrates interact with lectins through hydrogen bonds, metal coordination, 
van der Waals forces and other hydrophobic interactions (Elgavish and Shaanan, 1997). 
The availability o f large numbers o f  hydroxyl groups on sugars makes them ready 
partners in complex networks o f  hydrogen bonds. Divalent cations, such as Ca2+ and 
Mn2+ are involved in carbohydrate recognition either indirectly by shaping the combining 
site, as in die legume lectins, or through the direct binding o f  the carbohydrate to Ca2+ as 
in die c-type lectins. For this reason, when using lectins in analysis, it is often necessary to 
incorporate these cations in the assay buffer. Similarly, buffers containing phosphate ions 
should be avoided, as tiiese may bind die cations and render them unavailable to die 
lectin.
Most lectins have a primary specificity, with low affinity, for a particular 
monosaccharide. The selectivity towards a particular target is augmented by several orders 
o f  magnitude through multiple binding (Weis and Drickamer, 1996). This can be ‘sub­
site’ binding where one monosaccharide binds at die primary site, and additional 
monosaccharides in the glycan bind at secondary ‘sub-sites’ . Or ‘subunit’ multivalency
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occurs when several subunits o f  the same lectin bind to different extensions o f  a 
branched carbohydrate. The anomeric linkage o f  the sugars involved is also a factor in 
lectin binding. Some lectins may prefer a particular linkage on a sugar, and binding with 
other linkages may be reduced or absent. However some lectins will recognize and bind 
target sugars tiiat have a range o f  linkages.
A  range o f  substances will bind to a particular lectin with varying degrees o f 
avidity. The more avid substances, which may not be a natural target, will then inhibit the 
lectin from its usual binding to other sugars. This property can help characterize lectin- 
carbohydrate interactions. Tables are available showing die relative inhibitory potency o f 
various saccharides towards particular glycoproteins (Goldstein and Poretz, 1986)
d. Uses in Analysis
The agglutination properties o f  lectins have been studied and utilized for many 
years (Sumner and Howell, 1936), notably in blood grouping (Boyd and Shapleigh, 1954) 
and histopatiiology (Ahoy et al, 1984). They are very much in use today as histochemical 
techniques, and various optimized systems are available from several companies to detect 
specific carbohydrates in tissue sections. Biotinylated lectins are often used which can be 
coupled witii an avidin-enzyme complex, and reacted with a colour-producing substrate 
(Riley and Elhay, 1996).
In a similar way, lectins may be used to detect specific carbohydrates in dot-blot 
techniques (Sumar et al, 1990) or on membranes Western blotted from electrophoresis 
gels (Lundy and Wisdom, 1992; 0rntoft et al, 1997).
Affinity chromatography, witii one or more lectins immobilized within a column, 
has been extensively used to differentiate die various glycoforms o f particular 
glycoproteins (Candiano et al, 1983; Sumi et al, 1999) or glycopeptide hormones (Kobata
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and Takeuchi, 1999). Elution may be with a simple buffer or with a lectin inhibitor, to 
enable collection o f fractions containing the different glycoforms.
In lectin affinity electrophoresis, one or several lectins are incorporated into the 
electrophoresis gel. The separation o f  glycoproteins, or more exactly their relative 
migration distance, is dependent on the differences in dissociation constants o f the lectin- 
glycoprotein complexes: the glycoproteins with sugar chains that have higher affinities for 
a lectin are retarded, revealing microheterogeneity (Taketa, 1991). Crossed affinity 
immunoelectrophoresis is a modification o f  die technique, whereby an antibody to the 
ligand is incorporated into the gel with the lectin in two-dimensional electrophoresis (Bog- 
Hansen, 1973). Increased sensitivity can also be gained by blotting onto antibody-coated 
or lectin-coated membranes. These techniques have been extensively used in the 
characterization o f the chain structures o f  a-fetoprotein in different liver cancers using 
Con A, Tens culinaris agglutinin (LCA), Phaseolus vulgaris agglutinin (E-PHA) and Allomytina 
dichotoma lectin (Allo-A) (Taketa, 1998; Yamamoto et al, 1998; Zaninotto et al, 1996). 
Alkaline phosphatase isoforms have also been studied in liver and bone disease, using 
wheat germ lectin (WGA) (Crofton, 1992).
Lectins may be used in quantitative glycoprotein assays either as a detector system, 
where the target glycoprotein is attached to the solid phase (Goodarzi and Turner, 1997) 
or as a capture system where the lectin is attached to the solid phase, with an antibody, or 
some other recognition system, used for the detection o f  the captured glycoprotein 
(Parker et al, 1992). The concept may be taken a stage further, as in glycoprotein-lectin 
immunosorbent assay (GLIA) where an antibody attached to die solid phase captures the 
target glycoprotein, which can then be probed with a lectin (Kondo et al, 1995; 
Madiyalakan et al, 1996). There are many possible variations: assays may be competitive 
or non-competitive; markers may be enzyme systems, radioactive labels, chemiluminescent 
labels or digoxigenin, and detection may involve avidin/biotin systems (Rhodes et al,
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1993). A  number o f  lectins o f  varying specificities may be used to probe the glycoprotein 
and obtain a picture o f  the glycosylation pattern (Kottgen et al, 1993; Rafferty et al, 1995), 
which is a technique used in this project.
2.1.3. Biophysical Methods
2.L3.1. Mass Spectrometry (MS)
Early use o f  MS in die glycosciences was as a discriminatory device on-line to GC 
(GC-MS) for die large number o f  possible derivatives obtained by methylation analysis 
(Hounsell, 1997). The problem o f  this - an inability to distinguish witiiin die groups o f 
monosaccharide - was improved with the detection methods o f  electron-impact MS 
(EIMS) and chemical ionization MS (CIMS), aldiough these techniques are restricted by 
the size o f  the molecule that can be ionized and hence detected (<m /z 1000). Fast atom 
bombardment (FAB) and liquid secondary ion (LSIMS) became ionization methods o f  
choice for oligosaccharide analysis in die 1980s (Dell, 1987), while in the 1990s, matrix- 
assisted laser desorption ionization (MALDI) has extended the molecular weight range to 
several hundred kDa, particularly with time o f  flight (TOF) analysis. MALDI-TOF is 
particularly simple and quick to use, giving molecular weight o f  oligosaccharides without 
derivitization, with easy-to interpret spectra (Whittal et al, 1995). But there are problems 
witii tiiis metiiod from matrix-dependent deposition o f  excess internal energies, 
producing extensive metastable fragmentation (Burlingame, 1996). Also, electrospray 
ionization (ES), using a straightforward interface witii microbore or capillary FIPLC, is a 
reliable method for structural characterization o f protein glycosylation by MS, at the 
picomole level. This approach requires that the oligosaccharides are derivatized, for 
instance with 2-aminoacridone (Charlwood et al, 1999), 4-aminobenzoic acid (Mo et al,
1999) or l-aminopyrene-3,6,8-tiisulphonate (Monsarrat et al, 1999).
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This technique is valuable for studies o f  ohgosacchaiide-to-protein and 
oligosacchaiide-to-oligosaccharide interactions. The method is viable as long as die 
oligosaccharides are complexed to protein (Hounsell, 1997). The 3-D models o f  proteins 
are very eye-catching, but X-ray crystallography provides more information tiian just 
graphic images.
Lectins and immunoglobulins particularly lend themselves to study by this 
technique. The carbohydrate-binding sites o f  these two types o f  molecules exhibit similar 
features o f protein-carbohydrate interaction (Bundle, 1997). Antibodies possess sites 
generally deeper tiian those found in lectins, but the number o f  monosaccharide residues 
usually required to fill diem - 3 to 4 hexose units - is the same in each case.
Briefly, die procedure for crystal structure determination is as follows (Bundle, 
1997). Firsdy, die glycoconjugate needs to be purified. This can be accomplished by 
affinity chromatography using antibodies, or in the case o f  IgG, protein A  or protein G  
columns. A  concentrated solution o f  the glycoconjugate is prepared and usually water is 
slowly evaporated. Then by one o f  a variety o f  techniques, crystal formation is initiated. 
A  single crystal is tiien held in die patii o f  a narrow beam o f  X-rays. Deflected beams faE 
on to a detector surface, often X-ray film which displays dark spots where beams impinge 
on the film. Or better, electronic area detectors digitize the direction and intensity o f  
reflections. Diffraction data is then converted into electron density maps, which aEows a 
correlation with most amino acid main chain and side chain elements o f  the protein, until 
the protein chain can be traced.
The 3-D structures o f  more than 1000 different proteins o f  various classes are 
coEected in the Brookhaven protein data bank, but less than 100 entries deal witii proteins 
diat bind carbohydrates (Bernstein, 1977). The Cambridge structural database (AEen et al, 
1991) contains structures o f  smaE organic molecules, but there are less than 1000 entries
2.1.3.2. X-ray Crystallography
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for mono and oligosaccharides, reflecting the difficulties in crystallizing complex 
carbohydrates (Siebert et al, 1997).
2.I.3.3. NMR Spectroscopy
NMR spectroscopy is firmly established in the structural analysis o f  biomolecules 
in solution. It is often used in conjunction with X-ray crystallography and computerized 
calculations o f  molecular dynamics simulations for the structural analysis o f  oligo- and 
polysaccharides (Siebert et al, 1997).
One advantage o f  NMR is that it is a non-destructive technique, and die sample 
remains available for analysis by other metiiods. However, a large sample is initially 
required: normally at least 50 jag o f  a purified oligosaccharide to give details o f  the 
monosaccharides present and tiieir positional and anomeric linkages (Hounsell, 1997). 
Structure is determined by comparison with data in die literature (Hounsell and Wright,
1990) o f  die chemical shifts o f  signals from protons in solution in D 20 , where hydroxyl 
ions have been replaced by D O  by exchange. More sample material is needed to carry out 
proton NMR in H20 , or to detect natural abundance o f  I3C.
Information about structural conformation is based on measurement o f the 
Nuclear Overhauser Effect (NOE). This originates from dipole-dipole interactions 
between molecules less than 3.5 A  apart for carbohydrates. The NOE intensity is 
proportional to minus die sixth power o f  the distance between die two protons involved. 
However in flexible molecules like oligosaccharides, the NOE-derived distances must be 
considered as time-averaged data, not necessarily leading to true conformations (Siebert et 
al, 1997).
2.1.4. Chromatography
Chromatography, with its many variations, may be used to study monosaccharides 
or glycans, or the different glycoforms o f  glycoconjugates.
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2.1.4.1. Gel Permeation Chromatography (GPC)
Gel permeation column chromatography separates on the basis o f  hydrodynamic 
volume. This is a function o f  the size (molecular weight) and three-dimensional shape 
(tertiary structure) o f  a given molecule in a given solution (Yamashita et al, 1982). The 
method is suitable for neutral glycans, after enzymic or chemical release from peptide, and 
labeling with a fluorescent or a radioactive marker. It is die basis o f  the automated 
GlycoSequencer (from Oxford GlycoSystems), which gives carbohydrate composition in 
terms o f glucose units (GU), by reference to an internal standard o f  partially hydrolyzed 
dextran. The hydrodynamic volume o f  an individual glycan is determined by inter­
polation and can be used to deduce the approximate number and types o f 
monosaccharides it contains (Table 2.2).
2.1.4.2. Anion Exchange Chromatography (AEC)
In anion exchange chromatography, acidic glycans are eluted sequentially from a 
resin column by increasing the concentration o f  a counter ion. Separation is based on net 
charge, although there may be additional interaction between the uncharged body o f  the 
glycans and die resin material. The most common acidic substituents are sialic acid, 
phosphate and sulphate. The presence o f  these can be demonstrated by comparing 
charge profiles before and after treatment to remove diem (Oxford GlycoSystems, 1994b).
Table 2.2. GU contribution of monosaccharides to hydrodynamic 
volume (Oxford GlvcoSvstems, 1994)
Monosaccharide Hydrodynamic 
Volume (GU)
Galactose 1.1
Mannose 0.9
Fucose - outer arm 0.5
Fucose - core substituted a1-6 1.0
Gal N Ac 2.0
GlcNAc 2.0
Xylose 1.0
GlcNAc 2.0
74
A  development o f  this method is high pH anion exchange chromatography 
(HPAEC) with electrochemical detection by pulsed amperometry (PAD) which has been 
used for analysis o f  sialic acids (Hounsell, 1994) and the carbohydrates o f IgG 
preparations (Weitzhandler et al, 1994).
2.I.4.3. Polyacrylamide gel electrophoresis (PAGE)
There are several gel electrophoresis systems available for analysis o f  mono- or 
oligosaccharides (Hu, 1995). The carbohydrates are released from the peptide by enzymic 
or chemical means and then labeled with a fluorophore such as 2-aminobenzoic acid (2- 
AB), or in the case o f  Glyko’s fluorophore assisted carbohydrate electrophoresis (FACE) 
system, with 8-aminonaphthalene-l,3,6 trisulphonic acid (ANTS). After electrophoresis 
the resultant fluorescent bands can be quantitated using a specialized UV imager. 
Alternatively, derivatization can be omitted and the bands blotted from die gel onto a 
nitrocellulose or PVDF membrane, and then visualized on the membrane by means o f  
lectins or antibodies coupled, possibly via biotin and avidin, with an enzyme such as 
horseradish peroxidase (HRP) or alkaline phosphatase (AP). In the BioRad Immun-Blot 
kit, terminal non-reducing monosaccharides are oxidized with periodate, labeled with 
biotin, then detected with a streptavidin-alkaline phosphatase system.
With analysis o f  glycoproteins, sodium dodecyl sulphate (SDS) can be 
incorporated into polyacrylamide gel (i.e. SDS PAGE), and this will eliminate charge 
differences between the proteins, causing electrophoretic separation to be dependant on 
molecular weight (Laemmli, 1970). Plence different glycoforms o f  the same glycoprotein 
may be resolved (Weitzhandler et al, 1994). Proteins o f  known molecular weight can be 
run as internal standards to determine the molecular weights o f  the analyzed 
glycoproteins.
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2.1.4.4. Isoelectric Focusing (IEF)
Isoelectric focusing is a development o f  PAGE in which a pH gradient is 
introduced into the gel to enable greater resolution on the basis o f  charge. The technique 
has not been extensively used for analysis o f  glycoproteins, because monosaccharide 
residues, apart from sialic acids, have a neutral charge. However, IEF has been used in the 
diagnosis o f die carbohydrate-deficient glycoprotein syndromes, by studying the 
sialylation o f  glycoforms o f  a suitable marker protein such as transferrin in CSF (Keir et 
al, 1999; Schachter and Jaeken, 1999; Krasnewich et al, 1995). The technique has also 
been used to look at transferrin sialylation forms in screening for alcohol abuse (De Jong 
et al, 1995). It has been used also in studies o f  various glycoproteins to establish whether 
observed microheterogeneity is due to variability in sialic acid content or to rearrangement 
o f  amino acid composition (Larrea et al, 1995; Gianazza, 1995; Baudin et al, 1997). It is 
often the first separation step in glycoconjugate analysis, followed by lectin-affino 
chromatography (Hachulla et al, 1992); lectin-affinoblotting (Hansel* et al, 1995) or 
HPAEC-PAD (Anderson et al, 1994).
2.1.4.5. Gas Chromatography (GC)
GC is die method o f  choice for die analysis o f monosaccharides because o f  its 
robustness and ability to separate a large number o f  closely related molecules (Hounsell, 
1997). The sugars need to be converted to methyl glycosides or to partially mediylated 
alditol acetates, using metiianolic hydrochloric acid, before analysis (Tomana et al, 1988; 
Patel et al, 1993). Quantitation o f  the monosaccharides, by GC or GC-MS, is best 
achieved after deiivatization to trimethylsilyl ethers o f  methyl glycosides (Hounsell, 1994).
2.1.4.6. High Performance Liquid Chromatography (HPLC)
HPLC is generally a very sensitive technique adaptable to analysis o f both 
monosaccharides and oligosaccharides. Derivatization o f monosaccharides is often with 
2-aminopyridine (Hounsell, 1994). Oligosaccharides are usually derivatized with
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2-aminobenazamide (2AB), which labels all glycans non-selectively and allows sub- 
picomolar levels o f  sugars to be detected in their correct molar proportions (Guile et al, 
1996; Routier et al, 1998). Neutral oligosaccharides can be analyzed with a reverse phase 
Cl 8 column, or with a normal phase column. Acidic glycans, i.e. sialylated, may be 
analyzed by normal phase chromatography. Usually acetonitrile-water gradients are used 
for both types o f  chromatography (Hounsell, 1997). HPLC may be coupled with MS 
(Charlwood et al, 1999) or with NMR (Sidelmann et al, 1995). More will be said about die 
HPLC used in die project in section 2.2.5.
2.1.4.7. Capillary Electrophoresis (CE)
The high resolving power o f  CE makes it particularly suitable for the separation 
o f  oligosaccharides. It also has an advantage over HPLC in that it can resolve die 
glycoforms o f  intact glycoproteins (Kakehi and Honda, 1996; Hounsell, 1997),
Where charged species are being studied, such as glycosaminoglycans or sialylated 
glycoconjugates, no pretreatment is required for die separation o f glycoforms (Iourin et 
al, 1996). Otiierwise oligosaccharides or glycoproteins can be given a charge by 
complexation with metal ions or with borate (Rudd et al, 1992; Honda et al, 1991), or by 
dedvatization with ANTS or 2-AB.
As mentioned in section 2.1.3.1, increased sensitivity can be achieved by linking 
the outflow from CE direcdy into electrospray mass spectrometry (Monsarrat et al, 1999).
2.1.5. Glycoprotein Analysis Strategy
Several companies producing reagents for glycobiology research suggest different 
ways o f  characterizing glycoprotein glycans, depending on die kits and reagents they have 
to offer, or vatious researchers suggest protocols. One strategy is given in Figure 2.1. 
The basic steps are essentially similar in all the strategies:
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Glycoprotein Analysis Strategy
Protein(s) of interest
m
is the protein 
glycosylated?
Carbohydrate 
Detection (total)
Preliminary
Identification
TMe.g. Giycotrack
Lectin, antibody 
binding
Sialic acid 
characterisation
Monosaccharide
composition
I I
Mild hydrolysis or 
desialylation
i
Derivatization 
Reverse-phase C18
Acid hydrolysis
2-AA derivatization 
Reverse-phase C18
Glycan release 
Enzymic (PNGase)
Chemical (hydrazinolysis)
/  ^„ A . y  , 2-Aminobenzoic
2-Aminobenzamide acicj (2-AA)
(2-AB) derivatization
derivatization
HPLC analysis
Charge weak 
anion exchange
A  I
Neutral reverse- 
phase C18
Gel electrophoresis
Size-based
hydrophilic
interaction
FURTHER STRUCTURAL 
CHARACTERIZATION
Enzymic sequencing 
Mass spectrometry 
e.g. LC-ESMS, MALDI-TOF, FAB-MS. 
High-field NMR
Figure 2.1. A strategy for protein glycosylation identification and analysis (Merry and 
Steventon, 1997). C18; carbon 18 column chromatography; GlycoTrack™: gel electro­
phoresis kit (Oxford GlycoSystems); LC-ESMS: liquid chromatography electrospray mass 
spectrometry; MALDI-TOF: matrix-associated laser desorbtion time of flight mass 
spectrometry; FAB-MS: Fast atom bombardment mass spectrometry; high-field NMR: 
generally 600 MHz or higher nuclear magnetic resonance.
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1. Is die protein glycosylated? This is generally answered by means o f  
electrophoresis with specific labeling, or membrane blotting. Or it may be a 
chemical assay.
2. Preliminary characterization o f  oligosaccharides may be achieved by lectin or 
antibody assays. Glycans can be released by enzymic or chemical means and 
identified as 0 - or IV-glycans, for example by SDS-PAGE.
3. Monosaccharide analysis after hydrolysis can be performed by GC or GPC.
4. Oligosaccharide analysis can be performed after glycan release by chemical or 
enzymic means. Glycans can be labeled and analyzed by HPLC, GC, CE, 
PAGE, IEF, MS or NMR
5. Studies o f  intact glycoconjugates can be carried out by CE or MS, or by 
structural analysis such as X-ray crystallography.
The actual strategy used may well deviate from the classical plan depending on available 
sample, equipment, expertise or other factors. This is die case with tiiis project, as will be 
seen in die section 2.2.
2.2. Techniques used in this project
2.2.1. Plan of experimental work
The basic strategy for tiiis project can be divided into the five stages described in
2.1.5:
1. It is known diat IgG in serum is AT-glycosylated, and this is likely to be die 
case in CSF. So tests for protein glycosylation have been omitted.
2. For preliminary detection and identification o f  oligosaccharides in CSF IgG, a 
series o f  glycoprotein-lectin immunosorbent assays (GLIAs) using different 
lectins were developed and used to examine differences in glycosylation 
pattern between samples for MS patients and ‘normal’ controls. As a
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necessary preliminary step, a simple immunoassay for IgG was developed, as 
described in Chapter Three. Chapter Four then deals with GLIA methods.
3. Monosaccharide analysis, per se, was not performed. The monosaccharides o f 
IgG and their sequence are well known.
4. Oligosaccharide analysis is described in Chapter Five. Glycans were released 
by hydrazinolysis, labeled with 2-AB and analyzed by HPLC. A  group o f CSF 
samples from MS patients was compared with a group o f  ‘normal’ controls.
5. Further analysis o f  intact IgG was carried out in Chapter VI using IEF, then 
blotting and detecting with anti-IgG or lectin binding systems. Enzymic 
deglycosylation was used to characterize the carbohydrate nature o f 
oligoclonal IgG.
2.2.2. Immunoassay
Studies o f  die immune system and recognition o f  antigen:antibody binding began 
in the nineteenth century, and the first quantitative immunoassay - die Precipitin Test - 
was developed by Heidelberger and Kendall in the 1920s (Edwards, 1985). Oudin further 
exploited the technique in 1948, when he demonstrated that overlayered solutions o f 
antibody and antigen diffuse to form a visible precipitin line. Feinberg, in 1957, and 
Ouchterlony, in 1958, carried out the technique in a more precise way in agarose gels.
The conceptual advance made by Ekins (1960) in Britain and by Yalow and 
Berson (1960) in the USA was that o f  labeling the molecules involved in die immune 
reaction. Initially it was the analyte that was labeled with a radioisotope, but subsequentiy 
Miles and Hales (1968) labeled die antibody reagent. The radioisotope could be detected 
in minute amounts, with minimal and simple compensation for background interference. 
This radioimmunoassay (RIA) was seen to offer, over previous technology, increased 
sensitivity, specificity, simplicity, and - in tiiat antibodies could be produced against almost
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any analyte — virtually universal application. The detection limits were extended by 10J- 
fold, into the pmol range (Edwards, 1985).
Antibody binds antigen by a reversible, non-covalent association:
K
Ab + Ag ^  ^  Ab:Ag
kd
where ka is the constant for die rate o f  association and kd is the dissociation constant. 
The Law o f  mass action states that the rate o f  a reaction is proportional to die 
concentration o f the reactants. At equilibrium the rates are equal: 
kJAbMAg] = kd[Ab:Ag]
or ka = [Ab:Ag] -  IC,
K  [Ab].[Ag]
K, is known as the equilibrium or affinity constant. Its values may vary from 106 
to 1012 1 mol"1: the higher the value o f  an antibody, die larger the proportion o f  
antibody that will be complexed to antigen (Edwards, 1985).
RIA has played a major role in medicine and biosciences over the years, however 
many alternatives to radioactive labels and many variations in immunoassay design have 
now been introduced, as will be described in section 2.2.2.3.
2.2.2.I. Separation Methods
One o f  the requirements o f  RIA and most o f  other types o f  immunoassays is a 
means to separate bound label from free. Either may be measured. Yalow and Berson 
(1960) originally used electrophoresis. Other methods include gel filtration, adsorption, 
affinity chromatography, fractional precipitation, immunoprecipitation using second 
antibody in solution or antibody bound to a solid phase. Although the rate o f  the 
antigen:antibody reaction is reduced with solid phase antibodies, it can eliminate the need 
for centrifugation, reduce analysis time and enable automation (Woodhead, 1995).
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One convenient and effective use o f solid phase is to attach the antibody to die 
inside o f  reaction tubes, or wells o f  a microtitre plate. Various materials, including nylon, 
cellulose, silanized glass and silica, have been used for adsorption o f  antibodies and 
proteins or carbohydrate antigens (Cantero et al, 1980; Frey et al, 1993). Antibodies such 
as IgG can be strongly adsorbed non-covalentiy onto die inside o f  polystyrene plastic 
tubes, as is die case in this project, by using a coating buffer o f  suitable pH (Lam et al,
1993).
In many immunoassays, and especially in immunometric assays, most background 
noise stems from non-specific binding o f  the labeled antibody to the solid phase. This 
can be improved by suitable choice o f  solid phase, by using effective washing procedure 
(Woodhead, 1995), and by using a reagent to block areas o f  the solid phase unoccupied by 
capture antibody. The blocking reagent may be serum from the same species providing 
the indicator antibody (Gould, 1988), or small molecular weight proteins such as casein, 
bovine serum albumin (BSA), or human serum albumin, often used in combination with 
Tween (Lam et al, 1993). In immunoassays where glycosylation is being determined, a 
blocking reagent containing minimal carbohydrate is essential.
2.2.2.2. Immunoassay Design
RIA is an example o f  saturation analysis, where a limited amount o f  antibody 
gives rise to competition between the antigen analyte and the labeled analyte to saturate 
die antibody binding sites. In two-site immunometric assays (variously known as capture, 
sandwich or non-competitive assays), an excess o f  capture antibody is used, so tiiat as the 
concentration o f  analyte increases, so too does the amount o f  complexed labeled 
antibody. Since the two antibodies recognize two separate binding sites on die antigen, 
greater specificity is given by these assays, and diey also show lower detection limits and 
greater sensitivity (Jackson and Ekins, 1986; Gould, 1988). The affinity o f  die capture 
antibody is less crucial in die competitive assay since excess antibody is used. Single step
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assays - where sample and labeled antibody are added together - are quicker, but two-step 
assays with a washing step between the addition o f  sample and o f  labeled antibody have 
less interference from matrix effects.
Many other assay formats are possible. With small molecules such as steroids 
two-site methods are inappropriate. It is difficult to label such molecules because the 
relative size or physical properties o f  the label may interfere in the immune reaction. A 
solution is to use labeled antibodies in a competitive reaction between the analyte and a 
solid phase analogue o f  the analyte (Wood et al, 1982).
In tins project the glycoprotein-lectin immunoassay requires that the IgG in the 
CSF sample is immobilized by a capture antibody so tiiat it can be probed by labeled 
lectins, therefore a two-site, two-step immunomefcdc assay was adopted.
2.2.2.3. Types o f Labels in Immunoassay
a. Radioisotopes
Since the nineteen-seventies alternatives to radioactive labels have been used 
(Woodhead 1995). Although labeling witii radioisotopes uses a simple technology, and 
radioactive decay is unaffected by physical or chemical environment, there are a number o f 
disadvantages. There is the safety aspect, with regulation o f  use and monitoring o f  waste 
disposal. Most types o f  radioisotopes used in analysis, such as !25I have short half-lives, 
which limits their shelf life. There is always a step to separate bound label from free. 
Also the signal detected in the space o f  two seconds witii radioactive labels such as 125I is 
1 to 2 orders o f  magnitude smaller tiian over the same time with enzyme or luminescent 
labels (Woodhead, 1995). Thus speed o f  detection witii alternative labels is increased, 
maintaining comparable accuracy, and also background due to the measuring device is 
reduced to a minimum.
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b. Enzymes
Several enzymes have found a use as labels especially in enzyme-linked 
immunosorbent assays (ELISAs) (Edwards, 1985). Substrates with coloured or with 
fluorescent endpoints can be used. Disadvantages are that an extra step is usually needed 
in adding the substrate o f  the enzyme after die Ag:Ab reaction has occurred, and also 
there may be varying interference o f enzyme activity from different matrices.
c. Fluorescence.
Fluoroimmunoassay, often using fluorescein as a label can be a very sensitive 
technique. However, background fluorescence is often very high in biological samples, 
and also quenching may be a problem (Edwards, 1985).
d. Luminescence
Luminescence, and notably chemiluminescence, offers the sensitivity o f  
fluorescence or enzymic detection without the problems o f  interferences from analytical 
samples, and can be as sensitive as radiolabels without the problems o f reagent stability or 
safety aspects. It can be divided into two general types: bioluminescence, derived from a 
living organism, and chemiluminescence which is produced by simple chemical reactions. 
Both may be applied to immunoassays.
A. Bioluminescence
In bioluminescence an enzyme, such as luciferase, catalyzes the oxidation o f  
luciferin to oxyluciferin with a concomitant flash o f  blue light (Edwards, 1985). This 
involves the conversion o f  adenosine triphosphate (ATP) to adenosine diphosphate 
(ADP) or, in some other systems, the oxidation o f  reduced nicotinamide adenine 
dinucleotide (NADH) or reduced nicotinamide adenine dinucleotide phosphate 
(NADPH). The luciferase enzyme can be derived from the firefly (Photinus pyralis), from 
marine bacteria or from recombinant microorganisms (Blum and Coulet, 1994). The
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different luciferases produce slightiy different light flashes widi die kmax ranging from 560 
mn for firefly to 495 nm for bacterial luciferase. An alternative enzyme is aequorin 
isolated from die jellyfish Aequorea victoria. In die presence o f  free Ca2+ this catalyzes the 
oxidation o f  luciferin widi a blue flash (Xmax“  469 mn) which persists for about 10 s. 
Recombinant aequorin has also been obtained from Escherichia coli (Stults et al, 1992).
The disadvantages with bioluminescence immunoassays are tiiat the enzymes are 
expensive, unstable and there have been batch to batch variations in quality (Rongen et al,
1994). Although bioluminescence is potentially more sensitive as a label than chemi­
luminescence because the photon efficiency is higher, cheiniluminescent labels are more 
commonly used.
B. Chemiluminescence
i. The Energetics of Chemiluminescence
Chemilmninescence, as the name suggests, refers to die emission o f  light by a 
substance as a result o f  a chemical reaction. As such, it belongs to a class o f  light- 
emitting phenomena which include fluorescence and phosphorescence. A picture o f  die 
processes involved is provided by the Jablonski diagram (Figure 2.2). Molecules in the 
ground electronic state, S0 absorb enthalpic energy which elevates tiiem to higher 
electronic states, St or S2. Dissipation o f  diis excess energy can occur in a variety o f ways. 
Internal conversion from S2 to can occur, as can deactivation from higher to lower 
vibrational levels within each singlet state. Electron spins can become unpaired and die 
excited molecules undergo intersystem crossing to the triplet state, T t. If molecules lose 
sufficient energy to occupy die lowest vibrational level o f  S, (or T t), they may return to 
ground state witiiout light emission, and the decay takes die form o f  heat exchange to 
surrounding molecules or solvent molecules. Or, die excess energy may be dissipated in 
die form o f  light emission. Decay from die singlet states occurs in die nanosecond time 
scale and is referred to as fluorescence or chemiluminescence, depending on the original
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source o f  excitation energy. Decay from triplet states occurs in the micro- to millisecond 
timescale and is known as phosphorescence (Pringle 1993).
Only a fraction o f  the energy supplied to ground state reactant molecules will 
finally be converted into photon emission. Thus the efficiency o f  a chemiluminescent 
reaction is reflected in the quantum yield, Q. It is generally accepted that Q is the product 
o f  three components:
Q “  T ■ flex • fiem >
where qr is the fraction o f  reacting molecules yielding an excitable molecule, qcx is the 
fraction o f  tiiose molecules that are elevated to the excited singlet state, and qcm is diat 
fraction o f  molecules in excited states that actually emit light. The quantum yield is often 
very low, typically less dian 1% (Rongen et al, 1994).
Ground
State
Figure 2.2. Jablonski diagram showing how the absorption of electromagnetic or chemical 
energy by a molecule can lead to electronically excited states and showing that the 
dissipation of such energy can result in luminescence emission. Maximal 
fluorescence/chemiluminescence emission will occur from the lowest vibrational level of 
the first excited singlet state, S1t to the same vibrational level in the ground state, S0. 
Intersystem crossing to the triplet state, T1t can give rise to long-lived emission or 
phosphorescence (Pringle, 1993).
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Most o f  this section will be devoted to the aminophthallic hydrazides, i.e. luminol, 
isoluminol and their derivatives, since they have most relevance to this project. The other 
compounds mentioned below are widely used, and may well have been suitable as labels in 
the glycoprotein-lectin immunoassays. However, isoluminol had previously been used 
with the luminescence analyzer available, and was adopted for the project and found to be 
satisfactory.
Acridinium esters are often used in luminescence immunoassays (LIA) and 
immunoluminomettic assays (ILMA). Structurally they are similar to lucigenin. They are 
some one hundred times more luminescent than luminol, witii Q  values often above 7%. 
While luminol and isoluminol require an oxidant and catalyst for initiation o f 
chemiluminescence, N-metiiyl acridinium carboxylic acid esters require only hydrogen 
peroxide. The main problem with their use is tiiat tiiey produce an instantaneous 
emission o f light (Rongen et al, 1994; Pringle, 1993).
Dioxetanes are stable compounds which produce prolonged luminescence and can 
be used in simple immunoassay systems witii a wide linear range, high sensitivity and low 
background. They are best used as substrates in enzyme-amplified systems: for example 
as meta-phenyl phosphate dioxetane with alkaline phosphatase-labeled antibody in a 
sandwich immunoassay (Rongen et al, 1994; Pringle, 1993).
Oxalate esters are the most efficient o f  all chemiluminescent compounds, and 
produce quantum yields o f  over 20%. However tiiey are poorly soluble in water and 
prone to hydrolysis so that in aqueous systems the yield may be lower. They are not 
luminescent themselves but need a fluorescer to which they can transfer energy (Rongen 
et al, 1994).
ii. Chemiluminescent Compounds
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The oxidations o f  the aminophtiiallic hydrazides luminol and isoluminol (Figure 
2.3) are among die earliest chemihirninescent reactions to have been studied (Pringle, 
1993). In aqueous solutions die quantum yield o f  luminol is much higher tiian isoluminol, 
however derivatization o f  die heterocyclic ring o f  luminol, or conjugation widi large 
molecules dramatically reduces luminescence. But with isoluminol, derivatization o f  the 
amino group by alkylation is beneficial. Thus several compounds have been developed, 
such as die popular aminobutylethyl isoluminol (ABEI) (Figure 2.4), which can be 
conjugated to haptens or antibodies and still produce a high degree o f  luminescence 
(Table 2.3). Luminol can actually be used in immunoassays as a substrate, witii peroxidase 
as a label (Arakawa et al, 1979).
In aqueous solution die light-emitting reactions o f  luminol and isoluminol require
5-Aminophthalazine dione 6-Aminophthalazine dione 
(Luminol) (Isoluminol)
Figure 2.3. Chemical structures of the chemiluminescent cyclic hydrazides luminol and 
isoluminol (Pringle 1993).
O
Ri = Aminobutyl; R2 = Ethyl
Figure 2.4. Chemical structure of the isoluminol label ABEI (A/-aminobuty!-/V- 
ethylisoluminoi (Pringle, 1993).
Table 2.3. Effect on chemiluminescence of amino-substitution of isoluminol (Rongen et al, 
1994)
Ri r2 Relative
Quantum
yield
Detection 
Limit (pMol)
Isoluminol H- -H 5 30
AEI H2N-(CH2)2- -H - -
AEEI H2N-(CH2)2- -c 2H5 100 1
ABI H2N-(CH2)4- -H 14 20
ABEI H2N-(CH2)4- -c2h5 84 2
APEI h2n-(ch2)5- -c2h5 - -
AHI h2n-(ch2)6- -H 17 2
AHEI H2N-(CH2)6- -C2H5 44 5
AOMI H2N-(CH2)8- COX01 - -
AOEl H2N-(CH2)8- -c2h5 - -
Ri and R2 are defined in the structure in Figure 2.4.
Relative quantum yield is relative to luminol.
ABEI = aminobutylethylisoluminol; ABI = aminobutylisoiuminol; AEEI = aminoethylethyl- 
isoluminol; AEI = aminoethyiisoluminol; AHEI = aminohexylethylisoluminoi; AHI = 
aminohexylisoluminol; AOEl = aminooctylethylisoluminol; AOMI = aminooctylmethyliso- 
luminol; APEI = aminopentylethylisoluminol.
a high pH, a strong oxidant and a catalyst or initiator. Typical oxidizing agents are 
hypochlorite, transition metal complex ions such as Fe(CN)63" and a variety o f  iron- 
containing compound such as porphyrins (Motsenbocker et al, 1993; Jones and Scowen, 
1987), haemoglobin, peroxidases (Kiicka et al, 1996) and catalase. Peroxidase may be 
horseradish peroxidase (HRP), or derived from bacteria (microperoxidase). Oxygen- 
containing species include molecular oxygen, singlet oxygen, ozone and hydrogen 
peroxide (Arnhold et al, 1991). Isoluminol has been used in sensitive assays to detect the 
release o f  oxygen from neutrophils (Lundqvist and Dahlgren, 1996). Horseradish 
peroxidase-catalyzed reactions can be enhanced by luciferin or its derivatives (Whitehead 
et al, 1983) or compounds such as 4-iodophenylboronic acid (Kricka et al, 1996). The 
amino-substituted derivatives o f  isoluminol, such as ABEI, may be used in competitive 
immunoassays, or non-competitive, sandwich-type immunometric assays (Pringle, 1993;
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Rongen et al, 1994). These may be homogeneous assays, i.e. without a separation step, or 
heterogeneous, where bound label is separated from free.
For preparation o f  labels, the isoluminol derivatives are usually modified using 
succinic anhydride and IV-hydroxysuccinamide to produce hydroxysuccinamide esters 
which can be covalently coupled to an antibody or antigen via its terminal amino groups 
(Van Dyke and Van Dyke, 1985). The active esters may be stored at low temperatures (i.e. 
-70°C for over nine mondis), but lyophilization is unsuitable. The conjugated steroids or 
proteins, however, may be stored at -20°C for at least 6 months (Messeri et al, 1989). 
Compounds such as ABEI can be conjugated to a variety o f  substances, ranging in size 
and complexity from steroid hormones to immunoglobulins. Witii steroids especially, die 
length o f  the spacer on Rt between die steroid and die isoluminol (Table 2.3) is a factor in 
die luminescent properties o f  die conjugate (Pringle, 1993).
2.2.2.4. Immunoassays in this Project
a. habel
As mentioned earlier, isoluminol was chosen as the label in die immunoassays for 
die project, and as will be seen, die detector antibody was conjugated witii ABEI. The 
trigger reagents previously used with the analyzer were also adopted: these were (1) 
NaOH (0.01 M) containing PI20 2 and (2) Microperoxidase diluted in water. The 
chemiluminescent reaction can be summarized as follows:
O H ' H20 2
Isoluminol --------------------------------------- ► Oxidized isoluminol + N2 + Light.
Microperoxidase
b. Assay Format
As a preliminary step to probing IgG from CSF with different lectins, a 
heterogeneous immunometric assay was developed for measuring CSF [IgG], dien
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adapted to a lectin immunometdc assay (Figure 2.5). Details o f  the actual lectins used will 
be given in section 2.2.2.5.
c. Choice of Antibody
Monoclonal or polyclonal antibodies may be used in immunoassays for either the 
capture antibody or die detector antibody. Although monoclonal antibodies can confer
(a) Scheme 1.
IgG assay
Step 1
Anti-IgG
capture
antibody
A
/
Solid phase 
(Polystyrene /  
tube)
/
/
<
<
Step 2
CSF IgG
Step 3
Anti-lgG-ABEI
conjugate
>— &
(b) Scheme 2.
Intermediate IgG 
assay
Solid phase 
(Polystyrene 
tube)
Step 1
Anti-IgG
capture
antibody
<
<
Step 2
CSF IgG
Step 3
Biotinylated
Anti-IgG
Step 4
Streptavidin-
isoluminol
5)—
(c) Scheme 3.
Lectin assay
Solid phase
(Polystyrene
tube)
Step 1
Anti-IgG
capture
antibody
<
<
Step 2
CSF IgG
Step 3
Biotinylated
lectin
Step 4
Streptavidin-
isoluminol
5)-
Figure 2.5. Format of immunoassays in the project. The lectin assays 
(Scheme 3) were developed from the IgG assay (Scheme 1) via an 
intermediate assay (Scheme 2). Washing was performed after each step 
shown.
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more specificity, they have low affinity constants when compared to their polyclonal 
counterparts. Also monoclonal antibodies are less stable and may be prone to loss o f 
activity with labeling or immobilization on a solid phase (Van Dyke and Van Dyke, 1989). 
A  polyclonal antibody was chosen for this project, namely goat anti-human IgG y-chain. 
This was used, for convenience, as both the capture antibody, attached to the inside o f  
polystyrene tubes, and the detector antibody in the IgG assay, conjugated with ABEI.
d. Avidin-Biotin
The (strept)avidin-biotin interaction is well known and can be applied in several 
ways to enable binding o f  two reactants and/or multiply the binding potential o f  two 
reagents.
Biotin is a small molecule (244 Da) tiiat can be covalentiy linked to several types o f 
side chains, including those found in antibodies, lectins, enzymes and other proteins. A  
wide range o f biotinylated compounds is commercially available. Avidin (70 kDa) is a 
glycoprotein o f  egg white and has four very high affinity sites for biotin. As it has 
carbohydrate residues, care must be taken in glycoconjugate analyses that non-specific 
binding does not occur (Danguy et al, 1997). Streptavidin, from Streptomyces avidinii, has a 
similar affinity for biotin, but a lower isoelectric point (pH 6 rather than pH 10) and has 
no carbohydrate (Gould, 1988).
In this project, in the immunoassays, biotin is used to link the lectins, via 
streptavidin, widi isoluminol. Thus streptavidin-isoluminol becomes a ‘universal’ reagent 
for use widi a range o f  different lectins. Multiple binding o f biotin to die lectins leads to 
enhancement o f  the chemiluminescent signal.
Biotinylated lectins are also used in this project for detection o f  sugars on IgG 
blotted on PVDF membranes after isoelectric focusing (IEF). In diis case, the label
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conjugated witii avidin is horseradish peroxidase (HRP), with 3,3’-diaminobenzidinetetra- 
hydrochloride (DAB) as chromogen.
2.2.2.5. Glycoprotein Lectin Immunoassays (GLIA)
In die 1970s lectins bound to cells had been measured or visualized cytochemically 
using enzymes, such as HRP, bearing carbohydrate chains (Bernhard and Avrameas, 1971). 
It was then postulated tiiat lectin-antibody or lectin-antigen conjugates might be a useful 
tool in immuno-enzymic techniques (Guesdon and Avrameas, 1980). In general, three 
different approaches are possible for using lectins in immunoassays to eitiier quantitate a 
glycoprotein or investigate the carbohydrate content o f  a glycoprotein. Firstiy, the capture 
antibody is bound to a solid phase, sample antigen is added, followed by labeled lectin 
(Pekelharing et al, 1987; Rafferty et al, 1995; Tsucliiya et al, 1993; Madiyalakan et al, 1996; 
Casburn-Budd et al, 1992; Kottgen et al, 1993). This is the approach used in tiiis project. 
Secondly, the lectin may be bound to the solid phase, sample antigen added, followed by 
labeled antibody (Parkinnen and Oksanen, 1989; Cullina and GreaEy, 1993). Thirdly, die 
sample analyte, after purification, is bound to die solid phase, and the lectin is added 
which may be biotin or digoxigenin labeled (Goodarzi and Turner, 1997) or enzyme 
labeled (Sumar et al, 1993; Milton and Rhodes, 1998). This method is not actually an 
immunoassay, and usually termed an enzyme-linked lectin assay (ELLA). In another assay, 
the sample antigen is complexed with fluorescein-lectin and biotinylated antibody and 
dien streptavidin added and the whole complex captured on a biotinylated nitrocellulose 
membrane (Dill and Bearden, 1996). ELISA systems are most common, though other 
labels include 125I labeled lectin (Madiyalakan et al, 1996) and europium labeled antibody 
(Parkinnen and Oksanen, 1989).
In lectin immunoassays o f  IgG, some workers have found that heat denaturation 
o f  IgG is necessary to open the tertiary structure o f the molecule to expose die 
carbohydrate and enable access by some lectins such as Bandeimea simplicifolia II (BSII) and
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RJcinus communis agglutinin (R.CA1) (Sumar et al, 1993). However, others have probed IgG 
with the same lectins (Parkkinen and Oksanen, 1989; Casburn-Budd et al, 1992), and 
other lectins (Parkinnen, 1989; Tsuchiya et al, 1993), without denaturation o f  the protein.
Purification o f  IgG and other analytes prior to immunoassay has been found 
necessary by some workers. This is usually achieved by ion-exchange chromatography 
(Sumar et al, 1993; Parkinnen, 1989) or affinity chromatography with protein A 
(Parkinnen, 1989) or protein G  (Goodarzi and Turner, 1997; Tsuchiya et al, 1993). It has 
been found that the method o f  purification, i.e. ion-exchange or protein G, influences the 
glycosylation profile o f  the isolated IgG (Bond et al, 1993). Some workers have used 
serum in lectin assays, without prior purification o f CSF IgG, relying on the capture 
antibody to isolate the sample IgG before probing with lectins (Casburn-Budd et al, 1992; 
Keusch et al, 1996; Kottgen et al, 1993).
In this project, the simplest procedure for lectin immunoassay was tried, at least 
initially, i.e. without prior purification or denaturation o f IgG, as shown in Figure 2.5, 
scheme 2. Some properties o f  the lectins used in this project are given in Table 2.4.
2.2.3. Isoelectric Focusing
2.2.3.I. Theory
Isoelectric focusing (IEF) enables the fractionation o f  molecular species differing 
in net charge. Essentially, IEF is electrophoresis within a pH gradient: macromolecules 
migrate through die gradient until they reach the point where the pH o f  the gradient 
equals their pi. (The isoelectric point, or pi, o f  a molecule is the pH at which the 
molecule is in an electrically neutral form. The pi is a constant o f  a particular compound 
at specific conditions o f  ionic strength and temperature). Optimum resolution is obtained 
when concentration o f  the gel is lowest; therefore separation is performed in media such 
as polyacrylamide gels with high porosity. The method is capable o f  very high resolution 
and macromolecules differing in only 0.001 pH units can be separated (Andrews, 1995).
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2.2.3.2. Gel Media
There are two ways in which a pH gradient can be introduced into a gel plate. The 
first to be developed was the use o f  carrier ampholytes. These are mixtures o f  low 
molecular weight molecules widi a range o f  pis, each o f  which in a current will migrate to 
die point in the gel where die pH o f  die media is equal to its pi (Vesteberg and Svensson, 
1966). A  problem with this mediod is that gradient drift can occur, and a way o f  creating 
an immobilized pH gradient was introduced using Immobilities™ (Bjellqvist et al, 1982). 
The pH gradient in die gel is usually produced by preparing two solutions o f  different 
densities and o f  each extreme o f  the pH range to be used. These are dien 
layered and mixed using a gradient mixer: die bottom solution (usually the more acidic) is 
often made denser widi glycerol (25% w /v). Advantages o f  Immobiline gels are tiiat 
gradient drift cannot take place, they are less sensitive to salts in die sample, and ultraflat 
pH gradients can be prepared (Laas, 1998).
Aldiough agarose gel can be used, polyacrylamide gels are more common. These 
can be bought pre-cast and ready to use, or pre-cast and dried, requiring rehydration 
before use. Broad or narrow pH ranges may be used, depending on die pi values o f  the 
analytes. The shallower the pH gradient, die further apart two different species will be. 
Once cast, gels need to be washed to remove residual salts (Laas, 1998).
For routine analysis o f  oligoclonal IgG bands a pH gradient o f  7 to 10 is normally 
used as diese bands are most prevalent in die alkaline region. However, oligoclonal IgG 
bands are also found as low as pH 3, so it was decided to use a broad range, i.e. pFI 3 to 
10, for the project. Pre-cast, dried gel strips were purchased.
2.2.3.3. Experimental Techniques
Aldiough whole samples, or crude extracts, can be used, samples should have as 
low an ionic strengtii as possible. Too high a salt content will produce curved bands, or 
worse, overheating and possibly burning at die point where the salt is focused. The
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amount o f sample to apply is a balance between the minimum intensity o f  the bands that 
may be detected and maximum intensity before bands overlap (Laas, 1998).
The sharpest bands and best resolution are obtained with maximum voltage. The 
limits are set by die ability o f die system to control die heat produced. Manufacturers o f 
pre-cast gels will give die preferred running conditions for their gels (Pharmacia, 1993). 
If the voltage needs to be reduced, running time should be extended, but this leads to 
reduced resolution.
To check die regularity o f  the pH gradient in a gel and/or identify the pi o f  
analytes, marker proteins may be run. These can be bought as sets, ready to use, or any 
suitable protein, with an established pi for the same system may be used. Lists o f  
isoelectric points for many proteins are available (Malamud and Drysdale, 1978). Table 
2.4a shows the isoelectric points o f  some proteins commonly used as markers in IEF 
(Andrews, 1995).
2.2.3.4. Blotting
Blotting is the transfer o f  large molecules from an electrophoresis gel, or other 
medium, onto the surface an immobilizing membrane. The proteins adsorbed are thus 
fixed and, retaining dieir biological activities, are available for further analysis or detection 
techniques. Transfer methods include blotting by simple diffusion, by capillary action, 
using a vacuum and by electrophoresis (Westermeier, 1998). In this project, diffusion 
blotting is employed, simply placing die membrane on the polyacrylamide gel, followed by 
a glass plate and a weight. By this method, up to 90% o f  the proteins (Westermeier, 1998) 
are pressed out o f  the gel onto die surface o f  die membrane.
Polyvinylidenedifluoride (PVDF) blotting membrane (on a Teflon base) is used in 
this project. Compared to the commonly used nitrocellulose membrane it has a higher 
binding capacity and greater mechanical stability (Westermeier, 1998).
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Table 2,4a. Isoelectric points and molecular weights of some proteins suitable as markers in 
IEF (Adapted from Andrews, 1995 and Pharmacia Biotech pi calibration kit instruction manual). 
Protein pi at Molecular
25°C weight
(kDa)
Pepsin (porcine) 2.9 33
Amyloglucosidase (Aspergillus niger) 3.8 97
Glucose oxidase 4.2 186
Soya bean trypsin inhibitor 4.6 20
Ovalbumin (hen’s egg) 4.7 45
Serum albumin (bovine) 4.9 67
p-Lactoglobulin A (bovine milk) 5.2 36
p-Lactoglobulin B (bovine milk) 5.3 36
Carbonic anhydrase (bovine erythrocyte) 5.9 28
Conalbumin (hen’s egg) 5.9 86
Carbonic anhydrase (human) 6.6 28
Haemoglobin A (bovine) 6.8 64
Myoglobin (equine), minor component 6.9 17.5
major component 7.4 17.5
Myoglobin (sperm whale) minor component 7.0 17.5
major component 7.4 17.5
Lentil lectin acidic band 8.2 -
middle band 8.5 -
basic band 8.7 -
Trypsinogen (bovine pancreas) 9.3 24.5
Chymotrypsinogen A (bovine pancreas) 9.0 23.6
Ribonuclease (bovine pancreas) 9.3 13.5
Cytochrome C (equine heart) 10.2 12.5
Lysozyme (hen’s egg) 10.0 14.4
2.2.3.5. Detection
Several methods for detection o f  the blotted proteins are used in the project. 
Colloidal gold is used as a non-specific stain for proteins (and other macromolecules). 
For specific staining, lectins are used to identify bands containing relevant carbohydrates. 
The lectins are biotinylated and complex with added avidiii-horseradish peroxidase (HRP). 
Hydrogen peroxide is then added together with die chromogen 3,3’-diaminobenzidine- 
tetrahydrochloride (DAB) which forms an insoluble coloured product. The avidin-biotin 
system, as well as enabling HRP to be used as a ‘universal’ reagent, aids to amplify 
detection. For specific detection o f IgG, two systems are used: biotinylated anti-IgG with 
die avidin-HRP-DAB technique as for the lectins, and a system involving sheep anti­
human IgG, widi anti-sheep-alkaline phosphatase complex. For this latter method only,
the membrane is first treated widi skimmed milk to block free binding sites.
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CSF is less complicated to analyze than many other raw materials. Compared to 
blood, for instance, it is less viscous, and contains fewer components and normally few 
cells. Whole, untreated CSF is used in die project in some IEF and immunoassay 
methods. In other methods, IgG must be separated from other, possibly glycosylated, 
components o f  CSF, and in addition, for example for HPLC, die IgG sample must also be 
salt-free. Several methods o f purification o f  IgG are used.
2.2.4.I. Salt Fractionation
Mineral salts have been used for many years for the precipitation or fractionation 
o f  proteins. Agents include magnesium sulphate, sodium sulphate and sodium chloride, 
but most commonly used is ammonium sulphate [(NH4)2S 0 4] for precipitation o f  
immunoglobulins (Heide and Schwick, 1973). Disadvantages are tiiat pure 
immunoglobulin is not obtained witiiout additional treatment, and die salt has to be 
removed by dialysis. Ethanol and acetone are also used as precipitating agents, but are 
more damaging to the protein. Odier agents are polyetiiylene glycol, which is difficult to 
remove from fractionated protein, and Rivanol (2-edioxy-6,9-diamiiioacridine lactate). All 
diese decrease the solubility o f  proteins by increasing their hydrophobicity and promoting 
aggregation by bringing togedier hydrophobic surfaces (Ersson et al, 1998).
Rivanol has been used to fractionate serum into its constituent proteins. With the 
correct conditions, Rivanol will precipitate nearly all serum proteins apart from IgG, 
transferrin, and a r acid glycoprotein. It has been used in analysis o f  transferrin 
glycoforms (Iourin et al, 1996), and to obtain relatively pure IgG by fractionation in 
combination with ammonium sulphate (Heide and Schwick, 1973).
2.2.4. Protein Purification
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a. Ultrafiltration
Ultrafiltration membranes are available for separation o f  molecules, with cut-off 
limits ranging from 1 to 300 kDa. The sample needs to be fairly pure to start widi to 
avoid clogging die pores widi debris or cells (a pre-filter may be used). The method is 
suited for separation o f  salts and other small molecules from a protein fraction with a 
higher molecular weight, and at the same time can effect a concentration o f proteins 
(Ersson et al, 1998).
b. Gel Filtration Chromatography
The use o f  de-salting columns is a rapid way o f removing low molecular weight 
molecules. The gel used is cross-linked dextran, e.g. Sephadex, or porous polyacrylamide 
beads. Proteins and otiier high molecular weight substances (>6 ltDa) elute at the void 
volume, whereas small molecules are retarded by the gel (Ersson et al, 1998). Ready­
made, disposable columns are available.
c. Dialysis
Dialysis is a simple, but usually lengtiiy, metiiod o f  removing salts and small 
molecular weight molecules from sample solutions witiiout significant loss o f 
macromolecules (Ersson et al, 1998). Dialysis membranes o f  various materials, such as 
cellophane, acrylic and polypropylene, are available with a range o f  molecular weight cut­
offs. (It should be remembered that linear molecules such as DNA or RNA might pass 
tiirough membranes that exclude globular proteins with die same molecular weights). 
Systems range from simple bags immersed in die solvent, to electrodialysis apparatus that 
process several samples simultaneously efficientiy and rapidly (Heide and Schwick, 1973). 
For the project, dialysis cassettes are used tiiat are convenient for small samples. The
2.2.4.2. Desalting
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sample is injected by syringe into a mini dialysis bag held in a cassette, which is then 
suspended under the surface o f  the solvent by attachment to a buoy and after dialysis 
sample is removed by syringe.
Salt removal depends on equilibrium being reached o f distribution o f 
contaminants between the sample phase and die solvent. The solvent is tiien changed a 
number o f times with new equilibria being reached, so diat contaminants in die sample 
phase are gradually reduced. The solvent used for simple salt removal is usually water. 
Trifluoracetic acid (TFA) (0.1% v/ v) may be added which helps to keep macromolecules 
in solution.
2.2.4.3. Chromatography
There are many forms o f  liquid chromatography diat can be applied to protein 
purification, based on several different separation principles. In die preparation o f  IgG 
for glycosylation analysis, ion-exchange chromatography and affinity chromatography have 
both been used. As has been mentioned already, human IgG prepared by ion-exchange 
chromatography has a different glycosylation profile to that prepared by affinity 
chromatography (Bond et al, 1993).
a. Ion-exchange chromatography
Ion-exchange chromatography (IEC) offers high resolution, high protein binding 
capacity and ease o f  use. Separation is based on competition between die ions o f  interest 
and other mobile ions for oppositely charged groups on the ion-exchanger. In proteins 
many amino acids are weak acids or bases: it is die overall charge diat counts (Kadsson et 
al, 1998). IgG, like other proteins, has a broad range o f  isoelectric points, from about pH 
6 to pH 10, due to its composite microheterogeneity. Some o f die heteroforms will not 
bind to the ion-exchanger as well as odiers, so there is a possibility diat die purified IgG 
will not have the same composition as die native IgG.
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Nevertheless, diethylaminoethyl (DEAE) chromatography, after precipitation o f  
immunoglobulins with ammonium sulphate, has been used by a number o f workers to 
isolate IgG from serum samples (Pareldi et al, 1985; Tomana et al, 1987; Sumar et al, 1993; 
Shikata et al, 1998).
I?. Affinity Chromatography
Historically, affinity chromatographic techniques have exploited specific 
interactions found in nature. Probably the most widely used are antibody/antigen 
reactions, aldiough immunoglobulin Fc receptors from bacteria have found a wide 
application as immobilized adsorbents. These are cell surface proteins and are classified 
according to their reactivity with IgG subclasses (Godfrey, 1996). Some affinity receptors 
relevant to IgG purification are given below.
i. Antibodies
Generally, antibody-antigen interactions have dissociation constants (IQ in the 
region o f  10'3 to 10'14 M at 25°C. Immunosorbent separations require that antibodies 
have binding affinities for their antigens, in terms o f  Kd values, o f  10"6 to 10'10 M. 
Antibodies with lower IQ values (high affinities) require harsh conditions to elute die 
antigen, which can result in diminished recovery o f  active product and reduced life o f  die 
immunosorbent. Conversely, antibodies widi high IQ values (low affinities) when 
immobilized would offer poor removal o f  antigen from the sample matrix. Another 
factor which is a drawback in the use o f  immunosorbents is the size o f  the antibody 
molecule which may limit accessibility o f  die adsorbate, while rendering immunosorbents 
susceptible to denaturation and/or fouling (Godfrey, 1996).
ii. Protein A.
Protein A (SpA) is a type I Fc receptor found in die cell wall o f  Staphylococcus aureus 
from which it may be isolated, or produced as a recombinant protein in genetically
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modified E. coli. It is a globular protein with a single polypeptide chain and littie or no 
carbohydrate. The molecular weight is 42 kDa, pi 4.85 to 5.15, and A mns is 275 nm. It is 
very resistant to denaturing agents such as 6 M guanidine HC1, 70%(v/ v) ethanol and 0.01 
M HC1 (Godfrey, 1996).
The SpA molecule has five homologous regions, each containing about 50 amino 
acids residues. Four o f  tiiese (regions A, B, C and D) contain a single receptor site 
capable o f  binding to an immunoglobulin Fc region witii high affinity. The fifth region 
(E), which is the site o f  attachment to the bacterial cell wall, has a low affinity for Fc 
binding, but will bind to the Fab region o f IgG. It shares tiiis property witii protein G, 
and two otiier bacterial proteins - L and Fv (Bouvet, 1994).
The nature o f  the SpA-Fc interaction, as revealed by crystallography, is the 
formation o f  a major hydrophobic link between the residues o f  SpA’s active site and the 
antibody’s CH2 and CH3 domains in die Fc region (Sauer-Eriksson et al, 1995; Stone et al, 
1989). There is also a minor polar link in which CH3 residues are involved in a sulphate 
ion link.
iii. Protein G
Protein G  (StpG) is a type III Fc receptor o f  group C streptococci. It has affinity 
for a wider ranger o f IgG subclasses than SpA, especially human IgG3, but is more 
expensive. Its molecular weight is 35 to 40 kDa and its A max is 271 nm. It has two 
locations at which immunoglobulins are bound, along witii four sites for albumin and cell 
surface binding. Like protein A, binding to immunoglobulin is in the CH2-CH3 region o f  
the Fc fraction. Recombinant Protein G  has been created witii the albumin and cell 
binding sites removed, reducing non-specific binding during immunoglobulin purification 
(Godfrey, 1996; Sauer-Eriksson et al, 1995).
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i v .  P r o t e i n  A / P r o t e i n  G
This is a recombinant fusion protein derived from a hybrid gene comprising S. 
aureus Cowan I strain Protein A and die binding domains o f  Streptococcus sp. Lancefield 
group G  Protein G strain. More expensive tiian die above, it is reputed to offer a wider 
range o f  immunoglobulin sub-class specificity, widi increased adsorbent capacity (Godfrey 
1996).
v .  P r o t e i n  H
Protein H (StpH) is a type II Fc receptor protein from group A  Streptococci, 
which may be expressed in recombinant E. co/i. It selectively binds human IgG and rabbit 
immunoglobulins only (Godfrey, 1996).
2.2.4.4. The use o f protein A
In the isolation o f IgG from serum, some workers have used protein A  (Tsuchiya 
et al, 1988; Parkinnen, 1989; Newkirk et al, 1990) while others, more recendy, have 
preferred protein G (Tsuchiya et al, 1993; Goodarzi and Turner, 1997; Wormald et al, 
1997; Fleming et al 1998).
Table 2.5 shows die relative affinities o f  protein A  and protein G  for human IgG 
subclasses. For purification o f  human IgG, protein G would normally be die adsorbent 
o f choice since it binds strongly all die IgG subclasses. However, Prosep-A, produced by 
Bioprocessing (no. 1 Industrial Estate, Consett, Durham, England, DH8 6TJ) was the 
solid phase used in die project, kindly donated by Dr P Kwasowski o f  Surrey University.
Table 2.5. The affinity of Protein A and Protein G for human immunoglobulins. Adapted from
Subclass Affinity of SpA Affinity of StpG
IgGi strong Strong
lgG2 strong Strong
IgGs weak Strong
I9G4 strong Strong
igA2 weak None
IgM weak None
SpA: Staphylococcus aureus Protein A; StpG: Streptococcus Protein G.
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It is said by the company that the affinity o f  Pi*osep-A for IgG3 is maximized if 
the column is used below its immunoglobulin capacity. Although protein A  also binds 
weakly human IgA and IgM, these are present in CSF in very small amounts, if  at all. 
Table 2.6 gives the characteristics o f Prosep-A and some other commercially available 
protein A  adsorbents. Glass beads, although unstable in alkaline conditions, have 
otherwise excellent mechanical stability with rigid intra-particle porosity preventing 
compaction or fouling and increasing longevity (Godfrey et al, 1993). In carbohydrate 
analysis, glass is preferred to agarose from which leakage o f sugars into the IgG eluate 
may occur, producing false readings.
High concentrations o f  inorganic salt (e.g. NaCl > 1 M) may be added to the 
adsorption buffer to promote binding o f  the weaker-binding subclasses (i.e. IgG3). 
However this also increases the level o f  contaminating proteins (e.g. albumin, transferrin) 
in the eluate.
Table 2.6. Characteristics of some commercial SpA solid phases (adapted from Godfrey et al, 
1993) _____________ __________
Solid phase Matrix composition SpA Capacity monoclonal 
Ab (mg)
ACL 4% cross-linked 
agarose
‘Unknown’ 5.3
Bio-Rad ‘Polymer’ Native 3.5
NYGene Cellulose Recombinant 5.1
Pharmacia fast flow 4% cross-linked 
agarose
Native 5.0
Prosep A ‘high 
capacity’
Controlled pore glass Native 15.0
Repligen 6% cross-linked 
agarose
Recombinant 2.2
Sepharose CL-4B 4% cross-linked 
agarose
Native 4.3
Sigma fast flow 4% cross-linked 
agarose
Native 5.6
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The efficiency o f  the column may be increased by adding glycine (up to 2 M) to 
the adsorption and wash buffers (Godfrey, 1996).
Elution o f  immunoglobulin from the adsorbent is usually achieved by causing a 
reversible shift in the tertiary structure o f  the immunoglobulin such that the receptor- 
antibody binding is disturbed. Some examples o f  non-specific desorption buffers are 
given in Table 2.7.
Table 2.7. Examples of non-specific eluants (adapted from Godfrey, 1996; Ruoslahti, 1976).
Technique Elution conditions
Altering solvent pH Acid range (pH 1.5 - 4): proprionic acid (0.01- 
0.1 M); glycine-HCI buffer (0.01-0.1 M, pH 
1.5-3)
Alkaline conditions (pH 11-13.5): KCI (0.055 
M); NaOH (0.145 M).
Reversible protein denaturation Urea (<8 M).
Guanidine hydrochloride (<6 M).
Polarity-reducing agents Dioxane (<10% v/v). 
Ethylene glycol (<50% v/v)
Chaotropic agents Anions (from best to worst): CCi3COO' > 
SCN~ > CF3COO" > CICV > I' > CI04' > NOT
> Br > Cf >CH3COO' > S042' >P042'.
Cations (from best to worst): NH4+ > Rb+ > K+
> Na+ > Cs+ > Li+ > Mg2+ > Ca2+ > Ba2+.
These salts are used at concentrations of
1.5-8 M.
Harsh denaturing conditions can irreversibly denature antibodies, so contact time 
witii eluants should be minimized by using small elution volumes or high flow rates 
(Godfrey, 1996). Proteins are easily split at peptide bonds involving the aspartyl residues, 
and sialic acid is cleaved o ff  under relatively mild conditions (Ruoslahti, 1976).
2.2.5. HPLC
HPLC as a method for oligosaccharide analysis has already been mentioned in 
Section 2.1.4.6. The HPLC assays used in the project, with preliminary IV-glycan cleavage 
by hydrazinolysis and labeling with 2-AB, are methods set up at the Oxford Glycobiology 
Institute. Preparation o f  the samples, at the Princess Royal Hospital, consisted o f
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isolation o f  IgG from CSF by Protein A  chromatography followed by dialysis to remove 
salts and otiier low molecular weight material.
Normal phase HPLC is an established technique for separating mixtures o f 
oligosaccharides (Guile et al, 1996). The earliest mediods used columns with 
diethylaminoethyl functional groups to separate neutral and acidic oligosaccharides. More 
recently, columns with imide and amide functional groups have been used (Townsend et 
al, 1996). Two HPLC systems are used for die project to examine die CSF IgG 
oligosaccharides as follows.
2.2.5.1. System 1: GlycoSep-N™ column
A normal phase system using a GlycoSep-N™ column comprises a polymeric 
silica matrix widi bonded amide functional groups. Oligosaccharides are adsorbed by 
hydrogen bonding and are sequentially eluted by increasing the polarity o f  die mobile 
phase. Separation is due mainly to the hydrodynamic volume (size) o f  the 
oligosaccharide, which is due to monosaccharide composition, but is also affected by arm 
specificity and linkage o f the units (Guile et al, 1996).
In conjunction with the IgG glycans, a series o f  dextran hydrolysates is run to 
calibrate die peak retention times in terms o f  glucose units (gu values). Gu values can 
then be assigned to die peaks for the oligosaccharides and used to identify tiieir structures. 
The Oxford Glycobiology Institute have compiled an extensive table o f  gu values, both 
measured and calculated, for IV-glycans for this particular HPLC system (see Appendix ).
2.2.5.2. System 2: Wax column
This is a reverse phase system using a weak anion-exchange stationary phase. 
Oligosaccharides are separated according to overall charge, which is due to the number o f  
attached sialic acids. Degree o f  sialylation is determined by comparison with sialylated 
oligosaccharides released from fetuin and run in conjunction as calibrators.
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Deglycosylation o f  glycoproteins is used in the project in two instances: a) 
removal o f carbohydrate from anti-lgG used as capture antibody in the glycoprotein lectin 
immunoassays, to obviate non-specific binding by the lectins; b) removal o f  carbohydrate 
from a CSF sample with oligoclonal IgG and comparing bands after isoelectric focusing 
with bands in the untreated sample, to ascertain if oligoclonal banding can be attributed 
to carbohydrate differences. For each o f  these it is desirable to remove as much 
carbohydrate as possible, with minimal destruction o f  peptide. A  number o f 
deglycosylation methods are available, as follows.
2.2.6.1. Chemical methods.
The use o f  sodium periodate to oxidize sugar chains has been described in section
2.1.1.1. Conditions can be chosen so that damage to the peptide is minimized: use o f  low 
temperature (0 to 4°C) so that secondary reactions are reduced; protection from light to 
prevent ozone production, and using minimum concentration o f periodate and incubation 
time (Marshall and Neubauer, 1972). Concentration o f  periodate used varies between
0.005 and 0.1 M. The method would appear to be suitable for deglycosylation o f  capture 
antibody since intact saccharides are not required. A  method is described using 0.1 M 
N aI04 at 4°C for 3 days for an antibody-lectin immunoassay o f  a-fetoprotein (Kinoshita 
et al, 1989).
Hydrazinolysis has been described in section 2.1.1.2 as a means o f releasing N - 
glycans for analysis. However, peptide is denatured and not suitable for use in analysis.
Trifluoromethanesulphonic acid (TFMS) can be used as a deglycosylation agent 
for both IV- and O-linked oligosaccharides (Sojar and Balil, 1987). However, recovery o f  
peptide may be as litde as 70% in some glycoproteins (quoted by Oxford GlycoSystems 
for tiieir product) and TFMS has been found not to remove the terminal GlcNAc o f
2.2.6. Deglycosylation
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some glycoproteins (Tams and Welinder, 1994) or sialylated chains o f  others (Raju and 
Davidson, 1994).
2.2.6.2. Enzymic methods
The use o f  enzymes to release oligosaccharides from glycoproteins is described in 
section 2.1.2.1. The most suitable enzyme to use for removal o f  IV-glycans from 
glycoproteins is peptide-IV-glycosidase F, which cleaves IV-glycans at their link to 
asparagine. Thus, as long as steiic hindrance does not prevent the enzyme from accessing 
die oligosaccharides, complete removal o f  intact glycans should be possible. The enzyme 
has no adverse effect on the peptide, so the method is highly suitable for deglycosylation 
o f capture antibody (Kottgen et al, 1993) as well as studying protein glycosylation, and is 
used in die project to deglycosylate oligoclonal IgG prior to isoelectric focusing.
For complete deglycosylation o f  most glycoproteins, prior denaturation is 
recommended in order to allow die enzyme access to the oligosaccharides (Mann et al, 
1994; Hirani et al, 1987; see also Oxford GlycoSystems application sheet for peptide-IV- 
glycosidase F). This normally involves heating die glycoprotein at 100°C in the presence 
o f up to l% (w/v) sodium dodecyl sulphate. However there is littie information 
specifically on the treatment o f  human IgG.
2.3. Samples for Project
Cerebrospinal fluid used in the project was leftover specimen after routine analysis 
o f  samples from patients who had undergone a lumbar puncture at Hurstwood Park 
Neurological Center. Permission to use this waste material was obtained from the 
Princess Royal Hospital Research Ethics Committee. Permission to review patients’ notes 
was also obtained from die committee, and from the consultant neurologists concerned.
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Generally the CSF samples were stored for up to one week at 4°C before research 
analysis. However treatment, storage and selection o f  samples varied at different stages o f 
die project, and will be described in die relevant methods sections.
2.4. Statistical Methods and Computer Programs
The statistics in this diesis, paired and unpaired Student’s t-tests and Pearson 
correlation analysis, were produced using Prism (version 3.00) from GraphPad Software 
Inc., San Diego, CA, USA. Graphs were produced also using Prism as well as Excel 97 
from Microsoft Corp., USA. Word-processing was performed using Word 97 from 
Microsoft Corp.
Ill
Chap te r  Three
D e v e l o p m e n t  of  an IgG 
I m m u n o a s s a y
The primary aim o f  producing an assay for IgG was to provide a basis for the 
development o f  the glycoprotein lectin immunosorbent assays to probe the 
oligosaccharides o f  CSF IgG. However, creation o f  a reliable, highly sensitive assay for 
IgG would also be useful for quantitation o f the low levels o f  IgG diat are found in CSF 
samples.
The first step was to conjugate anti-lgG antibody witii the isoluminol derivative, ABEI, 
which was then used, along with assay tubes coated witii anti-lgG as capture antibody, to 
set up a sandwich-type chemiluminescent immunoassay. This was then optimised and 
evaluated, ready for die modification with biotinylated lectins.
3.1. ABEI-Conjugation of Anti-lgG
3.1.1. Introduction
After the conjugation reaction between anti-lgG and ABEI, the reaction mixture was 
subjected to ion-exchange chromatography to separate viable conjugate from unbound 
components. The eluate was collected as fractions, whose viability was tested by 
incubation in IgG-coated tubes to enable selection o f  fractions for pooling.
3.1.2. Reagents and Equipment
1. Water used tiiroughout was deionized by reverse osmosis and ion exchange 
chromatography.
2. Affinity purified anti-human IgG, y-chain specific, 1 mg/mL, developed in
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goat (product no. 1-3382); human IgG (supplied as 5.7 mg/mL) (1-2511); 
“high avidity”  BSA (300 g /L  solution) (A3424) and phosphate buffered saline 
(PBS) tablets: obtained from Sigma Chemical Co., Poole, Dorset, BH12 4QH. 
PBS was prepared by dissolving one tablet in 200 mL deionized water to 
produce a solution o f  0.01 M phosphate buffer, pH 7.4.
3. LIAMAT 300 himinescence immunoassay analyser (die ‘LIA’) made by Byk- 
Sangtec Diagnostica GmbH Sc Co., KG Von-Hevesy-Strasse, 63128, 
Dietzenbach, Germany. Supplied by Cambridge Life Sciences pic, Ely, 
Cambs. CB7 4DT.
4. ‘Star’ assay tubes, polystyrene, 5 mL, 12 x 75 mm, (code 115075). Greiner 
Labortechnik Ltd., Brunei Way, Stroudwater Business Park, Stonehouse, 
Glos., GL10 3SX.
5. Aminobutylediyhsohiminol-ethylene glycol-bis-(succinic acid)-IV-hy droxy suc- 
cinamide ester (ABEI-EGS), HPLC purified, was supplied courtesy o f 
Cambridge Life Sciences pic, stored at -20°C in acetonitrile in 10 pL aliquots, 
widi an effective ABEI concentration o f 3.4 nmol/pL.
6. Sephacryl S-300 Superfine ion-exchange resin (40-105 pm wet bead diameter:), 
obtained from Pharmacia Fine Chemicals AB, Uppsala, Sweden, packed in a 
30 cm x 2 cm column.
7. Fraction Collector 270 (Chemlab U.K.), used widi a Varioperpex II pump 
(LKB/Pharmacia, Uppsala, Sweden).
8. Luminescence ‘Starter’ reagents. Reagent 1: one Perhydrit tablet (500 mg 
peroxide) (Merck Cat N o 7201, 0100) in 50 mL M NaOH. Reagent 2: 1.0 mg 
microperoxidase (sodium salt from equine heart cytochrome c) (Sigma 
M6756) in 50 mL deionized water.
9. Teleostean fish gelatine 45% solid. Product no. G7765, Sigma Co.
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10. Marvel™. Milk powder, food item
11. Sucrose. Granulated sugar, food item.
12. Blocking solution: Marvel (0.2 g) + granulated sugar (0.5 g) in 10 mL coating 
buffer.
13. Coating buffer (0.1 M): prepared by dissolving 4.2 g N aH C03 in 500 mL 
deionized water (solution A), 1.06 g Na2C 0 3 in 100 mL deionized water 
(solution B) and adding B to 500 mL o f  A  to produce pH 9.2.
14. Conjugate buffer: PBS containing 100 g/1 BSA (Sigma A3424) and 10 g /L  
NaN3.
15. Wash buffer: phosphate buffered saline with gelatine (PBS-G). To 1.0 litre 
PBS was added 200 mg sodium azide and 0.2 mL fish gelatine
16. All other chemicals not specified above were o f  Analar grade and obtained 
from Merck Ltd. Poole, Dorset.
3.1.3. Methods
3.1.3.1. Addition o f ABEI-EGS to Anti-lgG
The effective molar reaction ratio o f  ABEI-EGS to anti-lgG is 30:1. The solvent:water 
ratio o f  the mixture should be between 1:4 and 1:10 (recommendations from Cambridge 
l i fe  Sciences).
Concentration o f  anti-lgG = 1 mg/mL. This is 6.67 nmol/mL, assuming molecular 
weight o f  anti-lgG to be 150 kDa. Supplied ABEI-EGS is 34 nmol per 10 pL aliquot, 
therefore anti-lgG required for reaction is 1.13 nmol, i.e. 169 pL. This would give a 
solvenfcwater ratio o f  10:169, i.e. 1:17. Therefore add 30 pL acetonitrile to give a ratio o f  
40:169, Le. 1:4.2.
169 pL o f anti-lgG was placed in a plastic cuvette. To this was added 30 pL acetonitrile 
and mixed, then 10 pL o f  ABEI-EGS and mixed. This was incubated for 2 h at RT.
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3.1.3.2. Column Separation
The Sephacryl S-300 column was flushed witii 0.01 M PBS and die flow-rate set to 0.6 
mL/min. The fraction cutter was set to 100 s per fraction, giving a volume o f  1.0 mL per 
fraction. The reaction mixture was introduced to die top o f  die column and, using 0.01 M 
PBS for elution, 50 fractions o f  1.0 mL were collected.
3.1.3.3. Assay o f Fractions.
a. Total mints
10 pL from every fraction from numbers 6 to 50 was diluted witii 990 pL o f  PBS. Then 
10 pL aliquots o f  diese dilutions were pipetted to die bottom o f LIA assay tubes in 
duplicate and die RLUs measured.
b. Bound Counts
42 pL o f human IgG (1.0 mg/mL) was mixed witii 22 mL coating buffer and 0.2 fnL o f  
tiiis was placed into each o f  100 assay tubes and incubated overnight at RT. After 
washing each tube diree times witii 1.5 mL PBS-G and aspirating, tubes were incubated 
witii 0.3 mL blocking solution for 2 h, tiien washed.
Each fraction was diluted with PBS-G to produce a count (see 3.1.3.4. RLU measurement) 
o f  approximately 100 000 per 10 pL.
In triplicate, 10 pL o f  each diluted fraction was placed in an IgG-coated tube witii 200 pL 
o f  PBS-G. Tubes were incubated for 1.5 h at RT, then washed and aspirated as above, 
and the RLU measured as below. Pooled fractions o f viable conjugate were mixed 9:1 
witii conjugate buffer and stored at -70°C in 20 pL aliquots.
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3.1.3.4. RLUMeasurement
The LIA was used in luminometei* mode only. After final washing, tubes loaded in racks 
were passed into the luminometer, where, for each tube, 300 pL o f  each starter reagent 
was automatically injected, forcibly to mix thoroughly, and the luminescence reading was 
taken in a 0.2 s window (RLU reading).
3.1.4. Results for ABEI-Conjugation of Anti-IgG
Measurement o f  the column fractions is shown in Fig 3.1. The plot o f  the total RLU o f 
each fraction (left-hand y axis) shows ABEI to be eluted as two peaks: ABEI-anti-IgG 
conjugate, and free ABEI. The % Bound plot (right-hand axis) shows binding o f  the 
viable conjugate to the IgG o f  the coated tube, expressed as a percentage o f  die activity 
(100 000 RLU) o f  die diluted fraction added to die tube. The viable conjugate is seen to 
be eluted as the first peak. Based on these results, fractions 10, 11 and 12 were pooled 
and stored in 20 pL aliquots at -70°C.
Fraction Number
Figure 3.1. Measurement of fractions from the Sephacryl column after the conjugation 
reaction between ABEl-EGS and anti-IgG.
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This is a straightforward procedure for conjugating anti-IgG with isoluminol. However, 
this was the second attempt at ABEI-anti-IgG conjugation. With the first attempt the 
peak for die bound fraction was not well defined and it was difficult to select fractions to 
pool, producing a conjugate that gave low binding in the assays. This time, however, the 
bound and free peaks were well defined. Fractions 6 to 9, aldiough showing high 
%binding, have total RLUs that are not part o f  the total RLU peak and these fractions 
were not included in the pool. The frozen conjugate remained effective for at least 1 year, 
producing over 40% maximum binding in the assays.
3.2. Optimization of IgG Immunoassay
3.2.1. Introduction
Using the prepared ABEI-anti-IgG conjugate, a basic immunoassay was set up which was 
then optimised by varying the conditions and reagent preparation.
Unless stated otherwise, all washing steps consisted o f three additions o f  1.5 mL o f  wash 
solution witii aspiration after each, and all incubations were at room temperature.
3.2.2. Reagents
1. Reagents and equipment were as described previously, with the following 
additions.
2. Dynagel: hydrolysed pig gelatine: kindly donated by Dr Hans Hager, 
Cambridge Life Sciences.
3. Dextran: Average m.w. 10 kDa. Prod. No. 9260, Sigma Co.
4. Tween 20. Prod. No. 66368, Merck Ltd.
5. Saline-Tween wash solution. 9 g NaCl in 1 L deionized water containing 0.5 
mL Tween 20.
3.1.5. Discussion
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3.2.3.1. Preparation o f a Calibration Curve
Anti-lgG was diluted 1:200 with coating buffer (30 pL in 6 mL buffer). 200 pL was 
pipetted into each o f  30 assay tubes and incubated for 8 h at RT then washed x3 with 1.5 
mL PBS-G and aspirated. Tubes were blocked for 2 h with 1 g /L  BSA in PBS, 300 pL 
per tube, and washed and aspirated as before. As controls, three anti-lgG coated tubes 
were not blocked.
Calibration solutions were prepared by diluting the supplied IgG to produce a solution o f 
100 m g/L  (0.1 mL with 5.6 mL PBS-G). This was then further diluted as shown in Table
3.1. Then 200 pL o f  PBS-G was pipetted into die assay tubes, followed by 10 pL o f 
calibration solution to labelled tubes in triplicate and incubated for 1 h at RT. The 1.0 
m g/L  calibrator was added to the non-blocked control tubes. Tubes were washed and 
aspirated as above, tiien conjugate diluted 1:900 (4 pL + 3.6 mL PBS-G) was added to the 
tubes (including ‘total’ tubes which were not subsequentiy aspirated) and incubated for 1 h 
at RT. Blank tubes were prepared with PBS-G instead o f conjugate. After further 
washing as above, the RLU o f  each tube was determined as described in section 3.1.3.4.
3.2.3. Methods
Table 3.1. Preparation of calibration solutions.
Volume ‘stock’ 100 mg/L Volume PBS-G (pL) [IgG] (mg/L)
IgG (pL)
4 0 1 6 0 2 0
2 0 1 8 0 1 0
1 0 1 9 0 5
1 0 4 0 0 2
8 0 2 0 0 .8
6 0 4 0 0 .6
4 0 6 0 0 .4
2 0 8 0 0 .2
1 0 9 0 0.1
1 0 1 9 0 0 .0 5
1 0 4 9 0 0 .0 2
0 2 0 0 0
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3.2.3.2. Variation o f Coating Antibody Dilution
Anti-IgG was diluted 1:200 with coating buffer (100 pL in 20 mL buffer). Then taking 3 
mL o f tiiis and double diluting with 3 mL additions o f  coating buffer, solutions o f  1:400, 
1:800 and 1:1600 were prepared. Tubes were coated witii each o f  these solutions, 
incubating 200 pL per tube for 12 h, then washing and aspirating x3.
Standards o f  0, 0.05, 1.0 and 20.0 m g/L  IgG were prepared from a stock 100 m g/L IgG 
solution as described in section 3.2.3.1. 10 pL o f  these with 200 pL o f  PBS-G were 
pipetted into sets o f  coated tubes in triplicate and incubated for 1 h at RT. After washing 
and aspirating, 200 pL o f  conjugate diluted 1:900 was added to each tube and incubated 
for a further 1 h at RT. Tubes were again washed and aspirated and RLUs measured. 
Blank and ‘total’ tubes were prepared as described in 3.2.3.1.
3.2.3.3. Trial o f Different Blocking Agents
a. Uncoated tubes
Fish gelatine, Dynagel, Dextran and BSA were diluted in PBS to produce 10 g /L  and 1 
g /L  solutions. 1.0 mL volumes o f these solutions were placed in plain polystyrene assay 
tubes in triplicate and incubated for 4 h at RT. After washing x3 witii 1.5 mL PBS-G and 
aspirating, 0.2 mL o f  conjugate diluted 1:500 with PBS was pipetted into each tube and 
incubated for 16 h at RT. Tubes were washed and aspirated as above and the RLUs 
obtained as described in section 3.1.3.4.
b. Coated Tubes
Anti-IgG was diluted 1:200 witii coating buffer and 0.2 mL pipetted into each o f  30 assay 
tubes to coat for 8 h at RT, then washed and aspirated. A range o f  blocking agents in PBS 
was prepared: lg /L  BSA (0.3 mL o f  300 g /L  BSA in 100 ml PBS); 5 g /L  BSA; 10 g /L  
BSA; 1 g /L  BSA with 1 m L/L  Tween; 1 g /L  BSA with 5 m L/L Tween; 1 g /L  BSA with 
10 m L/L  Tween; PBS containing 20 g /L  Marvel with 50 g /L  sucrose. For each blocker,
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0.3 mL was added to coated tubes in triplicate. N o blocker was added to 3 coated tubes. 
Tubes were incubated for 1 h at RT then washed and aspirated.
ABEI-anti-IgG conjugate was diluted 1:1000 with PBS and 200 pL was added to each 
tube, also to 3 uncoated tubes and 3 tubes which were not further treated (‘totals’). Tubes 
were incubated for 16 h at RT then washed and aspirated and RLU measured.
3.2.3.4. Variation o f Sample Incubation Time
Tubes were coated with 200 pL o f  anti-IgG diluted 1:200 with coating buffer, incubated 
for 2 h, washed, aspirated and blocked with 200 pL o f  PBS containing 1 g /L  BSA and 1 
m L/L  Tween. IgG standards solutions o f  0, 0.5, 1.0, 3.0 and 5.0 m g/L  were prepared 
from a stock 100 m g/L  IgG solution as described in 3.2.3.1 and 200 pL PBS-G and 10 pL 
o f  standard solutions were pipetted into duplicate assay tubes. Tubes were incubated for
0.5, 1, 2, 4 or 6 h, then washed and aspirated. Conjugate was diluted 1:1500 and 200 pL 
was added to each tube, incubated for 1 h at RT, washed and aspirated and the RLU 
measured. Blank and ‘total’ tubes were prepared as before.
3.2.3.5. Variation o f Conjugate Incubation Time
Tubes were coated for 12 h with anti-IgG diluted 1:200 with coating buffer, washed and 
aspirated then blocked for 2 h with 200 pL o f  1 g /L  BSA and 1 m L/L  Tween in PBS, 
washed and aspirated. IgG standards o f  0, 0.5, 1, 3 and 5 m g/L  were prepared as 
described in section 3.2.3.1. Then 200 pL o f  PBS-G was added to each coated tube 
followed by 10 pL standard solution in duplicate in six sets. Tubes were mixed, incubated 
for 2 h at RT, then washed and aspirated.
Conjugate was diluted 1:1500 and 200 pL added to each tube and to ‘total’ tubes which 
were not further diluted. PBS-G was added to ‘blank’ tubes. Sets o f  tubes were incubated 
for 0.5,1, 2, 4 or 6 h.
One-step assays were also tried. 200 pL o f  diluted conjugate was added to two sets o f
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coated tubes immediately followed by 10 pL o f  IgG standards. One set was incubated for 
2 h and die other for 4 h.
After die designated incubation times, all sets o f  tubes were washed x3 witii PBS-G (one 
set, incubated for 6 h, was washed witii saline-Tween) and, along witii ‘total5 and blank 
tubes, RLUs were measured.
3.2.3.6. Variation o f Anti-lgG Coating Incubation Time
Anti-lgG was diluted 1:200 with coating buffer and used, 200 pL per tube, to coat tubes 
for 2 h, 4 h and 16 h. Tubes were washed with PBS-G, except one set incubated for 16 h 
was washed with saline-Tween.
IgG standard solutions o f  0, 0.5, 1.0, 3.0 and 5.0 m g/L were prepared as described in
3.2.3.1. Into coated tubes was pipetted 200 pL o f  PBS-G followed by 10 pL o f  standards 
in duplicate. Tubes were incubated for 1 h, tiien washed witii PBS-G, or one set witii 
saline-Tween. Conjugate was diluted 1:1800 in PBS-G and 200 pL added to each tube 
and incubated for 2 h. Tubes were washed in PBS-G (saline-Tween for one set) and RLU 
measured.
3.2.3.7. Comparison o f Saline-Tween and PBS-G Washes
30 tubes were coated with 0.2 mL o f  anti-lgG diluted 1:200 witii PBS for 16 h then 
washed with PBS-G and aspirated. IgG standard solutions o f  0, 0.2, 0.6, 1.0, 2.0, 3.0, 4.0 
and 5.0 m g/L  were prepared as described in 3.2.3.1. To coated tubes was added 200 pL 
PBS-G then 10 pL o f standards in two sets in duplicate. Tubes were incubated for 1.5 h, 
tiien one standard set was washed x3 with PBS-G and one standard set washed x3 with 
saline-Tween. 200 pL o f  conjugate diluted 1:1800 was added to tubes (plus ‘totals’) and 
incubated for 2 h, tiien tubes were again washed witii PBS-G or saline-Tween, and RLU 
measured.
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IgG standard solutions from 0 to 5 m g/L  were prepared from stock 100 m g/L  IgG 
standard as described in section 3.2.3.1. From these, 0.5 mL aliquots were stored a) at - 
20°C for 1 month, b) at 4°C for 2 weeks in polystyrene analyser cups, c) at 4°C for 2 
weeks in glass botdes. Before use the aliquots were diawed and/or mixed and, togetiier 
with a set o f  standards freshly prepared from stock 100 m g/L  IgG, were assayed as 
described in 3.2.3.7, using saline-Tween washing.
3.2.4. Results
3.2.4.1. Results for Preparation o f a Calibration Curve
Figure 3.2 shows a plot o f  the IgG calibrators after subtraction o f  the baseline (mean o f 
RLUs, i.e. 3733, for 0 m g/L  IgG calibrator). Mean count for ‘totals’ was 111179; mean 
for blanks was 507.
The assay appears to be viable, witii a projected working range for IgG in the region o f
0.1 to 5.0 mg/L.
3.2.3.8. Storage o f IgG Standards
[IgG] mg/L
Figure 3.2. Preliminary plot of IgG standards after baseline subtraction.
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3.2.4.2. Results for Variation o f Coating Antibody Dilution
Figure 3.3 shows RLUs plotted for the different coating antibody dilutions after 
subtraction o f the baselines (i.e. mean RLUs for die 0 m g/L IgG solutions). At the 20 
m g/L  IgG level there is a decrease in binding with increase in coating antibody dilution. 
However, at the 1.0 m g/L  level, die binding for the 1:200 dilution is reduced and highest 
binding is shown by the 1:400 dilution. As the working range o f  the assay will probably be 
in the region o f 0.1 to 5.0 mg/L, a 1:400 dilution o f coating antibody might be most 
suitable.
3.2.4.3. Results for Trial o f Different Blocking Agents
a. Uncoated tubes
Binding o f  die anti-IgG conjugate to uncoated tubes is shown in Figure 3.4. BSA, 
at either dilution, is shown to be the most effective blocker.
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Figure 3.3. IgG binding with different dilutions of coating antibody.
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Non-specific binding o f  the conjugate with different blocking agents is shown in Figure
3.5. Marvel/sucrose is shown to be the most effective blocker, followed by 1 g /L  BSA 
with 1 m L/L  Tween. BSA without Tween, however, increases rather than blocks non­
specific binding and is therefore unsuitable as a blocking agent.
3.2A.4. Results for Variation o f Sample Incubation Time
Figure 3.6 shows IgG binding with different incubation times for the sample. Binding is 
virtually complete by 2 h.
3.2.4.5. Results for Variation o f Conjugate Incubation Time
Figure 3.7 shows that binding o f  conjugate is almost complete by 4 h. With 5 m g/L  IgG, 
at 4 h incubation o f  conjugate, the mean RLU was 44381 compared to 115146 for the 
‘totals’ i.e. 38% o f  the added conjugate was bound to captured sample IgG. The binding 
o f  conjugate at 2 h incubation was still high, with an RLU o f 34564 at the 5 m g/L  level,
i.e. 30% o f conjugate bound.
With the 4 h assay saline-Tween washing gave very similar results to PBS-G washing, 
suggesting that it might be possible to replace PBS-G with saline-Tween washing in the 
IgG assay, which would be more convenient and cheaper. The one-step assays show 
flattened curves compared to the two-step assays, with higher binding up to 2 m g/L  IgG 
sample, but reduced binding above this. It is possible that when increased levels o f  sample 
IgG is added it forms a complex with the conjugate but this is not binding to the capture 
anti-lgG o f the tube coating. It is possible that a one-step assay could be developed, but it 
might have a reduced linear range.
b. Coated Tubes
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Figure 3.4. Anti-lgG-ABEI conjugate binding to uncoated tubes. All blockers made up in
0.01 M PBS. Error bars show standard error of the mean of triplicate tubes.
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Figure 3.5. Non-specific binding by anti-lgG-ABEI conjugate to antibody-coated tubes with 
different blocking agents. Error bars show standard error of the mean of triplicate tubes. All 
blockers made ud in 0.01 M PBS. Marvel/Sucrose: 20 a/L Marvel + 50 a/L sucrose.
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Figure 3.6. Binding of IgG standard solutions with different sample incubation times.
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Figure 3.7. Measurement of IgG with different incubation times of anti-lgG-ABEI conjugate, 
and with trials of one-step assays and of using a saline-Tween wash.
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3.2.4.6. Results for Variation o f Anti-lgG Coating Incubation Time
Figure 3.8 shows that anti-lgG coating is achieved witii an incubation time as short as 2 h. 
For the times tested, percentage binding witii the 5 m g/L IgG standard ranged from 20% 
to 22%. Results for die 4 h incubation are lowest: for reasons unknown the non-specific 
binding (i.e. binding for 0 m g/L  IgG) was higher than for the other times. Washing with 
saline-Tween does not appear to have an adverse effect.
3.2.4.7. Results for Comparison o f Saline-Tween and PBS-G Washes
It can be seen from Figure 3.9 tiiat washing with saline-Tween or PBS-G makes very littie 
difference to eitiier the binding potential or the precision o f  the assay.
3.2.4.8. Results for Storage o f IgG Standards
Fig 3.10 shows that highest IgG binding is obtained if standards are freshly prepared from 
stock 100 m g/L IgG solution. Standards prediluted and stored at 4°C for 2 weeks show a 
loss o f  IgG in die low concentrations, presumably through adhesion o f  IgG to the sides 
o f  the container. Storage in polystyrene shows even greater loss, whetiier stored at 4°C or 
-20°C.
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Figure 3.8. Variation of anti-lgG coating time. Apart from one 16 h incubation, washing was 
with PBS-G.
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Figure 3.9. Comparison of washing with saline-Tween (9 g/L NaCI containing 0.5 ml/L 
Tween 20) and PBS-G (0.01 M phosphate buffered saline, pH 7.4, containing 0.1 g/L fish 
gelatine).
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Figure 3.10. Storage of IgG standards.
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The results show that an IgG assay can be produced with a working range from less dian 
1 m g/L  to about 5 m g/L  IgG. Sensitivity is particularly high for low levels o f  IgG and it 
should be possible to have die range as low as 0.02 mg/L. At die upper end o f  die range, 
widi the flatter calibration curve greater imprecision was found, and in later assays wider 
differences were found between replicates for standards and patients’ samples. Therefore 
an upper limit o f  4 m g/L  IgG was chosen for the assay. With levels o f  IgG ranging from 
20 to 40 m g/L in normal CSF, and up to 1000 m g/L  in disease states, samples will need 
to be diluted 40 fold or more, if die sample volume remains at 10 pL.
IgG standard solutions will be prepared freshly before use from stock 100 m g/L IgG 
solution. Storage, whether at 4°C or -20°C leads to loss o f IgG, probably to the sides o f 
die containers, but should be minimised if IgG is stored as a stock solution witii high IgG 
concentration.
The preparation o f  anti-IgG coated tubes is straightforward and sufficient coating can be 
achieved with an incubation time as short as 2 h. The antibody can be used at a 1:400 
dilution, but diluting more tiian this gives less binding o f  IgG. Experiments witii different 
blocking agents show that Marvel/sucrose is most effective, however it was decided not 
to use this as the sugars would probably interfere in die lectin assays. BSA (1 g/L) with 
Tween (1 mL/L), found to be the next most effective blocker, will be used. BSA is not 
highly glycosylated and should not interfere in the lectin assays.
Sample incubation time can be reduced to 1 or 2 h without significant loss o f  IgG binding. 
Incubation o f anti-IgG-ABEI conjugate should be for a minimum o f 2 h.
Saline-Tween can be used as washing solution throughout tube coating and assay 
procedures in place o f PBS-G, thus reducing expense and preparation time, important in 
view o f  the large volumes o f  wash solution tiiat are used.
Initial trial o f  a one-step assay showed potential, but tiiis will not be pursued further, as a
3.2.5. Discussion
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3.3. Evaluation of the Assay
3.3.1. Introduction
The working range for the assay was decided at 0.02 m g/L to 4 m g/L  IgG. CSF samples 
would be diluted 1:40 to bring the IgG into this range, widi further dilution for die 
occasional sample diat exceeded this range. A  number o f assays were performed to 
evaluate die method.
3.3.2. Reagents
• Unless mentioned below, reagents were as previously described.
• Coating buffer, 0.1 M. Prepared by dissolving 4.2 g N aH C03 in 500 mL 
deionized water (solution A), 1.06 g Na2C 0 3 in 100 mL water (solution B) and 
adding B to 500 mL o f A  until pH was 9.2.
• Assay buffer: Tween 20 (0.5 mL/L) in 0.01 M PBS.
• Wash solution (“ Saline-Tween”): 9 g /L  NaCl containing 0.5 m L/L  Tween 20.
• Blocker: 1 g /L  BSA with 1 m L/L  Tween 20 in 0.01 M PBS.
• Immunoturbidimetric assay o f  CSF IgG was performed using the method o f
Cowdrey (1990) using the Cobas-Bio centrifugal analyser (Roche Diagnostica, 
Welwyn Garden City, Herts, AL7 3AY.
3.3.3. Methods
Washing at all stages consisted o f  3 additions o f  1.5 mL saline-Tween with aspiration after 
each addition.
3.3.3.1. The Working IgG Method
Tubes were coated overnight (16 h) with 200 pL anti-lgG (diluted 1:400 with coating 
buffer). After washing, they were incubated for 2 h witii 300 pL blocker, tiien rewashed.
two-step procedure is needed for development o f the lectin-binding assays.
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Assay buffer (200 pL) was added, followed by 10 pL o f freshly prepared IgG calibrators 
in duplicate, or 10 pL in duplicate o f  CSF samples diluted 1:40 with PBS immediately 
beforehand, and the tubes were incubated for 1.5 h at RT. The tubes were further washed 
before adding 200 pL ABEI-anti-IgG conjugate (2 pL in 30 mL assay buffer), and 
incubating at RT, in die dark, for 2 h. After final washing, the tubes were loaded in racks 
and fed into die luminometer, where automatically, 300 pL o f  each starter reagent was 
injected into each tube, and die luminescence reading taken in a 2 s window (RLU 
reading).
Patients’ CSF samples were stored for up to 4 weeks at 4°C, and had already been assayed 
routinely by the laboratory, including IgG measurement by IT.
3.3.3.2. Imprecision and Recovery Studies.
Three CSF samples, with low, medium and high levels o f IgG, were measured 15 times 
each in a batch. Thirty random CSF samples were measured after 0, 5 or 15 pL additions 
o f  1 g /L  IgG to 200 pL aliquots o f  CSF, to produce spiking o f  0, 24.4 and 69.8 m g/L  
IgG.
3.3.3.3. Correlation Study
Seventy CSF samples, chosen at random, were assayed by the described chemiluminescent 
immunoassay, and results compared with those obtained by routine IT IgG measurement.
3.3.4. Results
3.3.4.1. Results for the Working IgG Method
A typical non-linear calibration curve is shown in Figure 3.11. The limit o f  detection, 
calculated as 2 SDs from zero o f  results for 0 m g/L IgG (n =  10), was 0.02 mg/L. This is 
equivalent to 0.8 m g/L  IgG in CSF after multiplication by die dilution factor (x40).
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3.3.4.2. Results for Imprecision and Recovery Studies
Table 3.2 shows data for within batch imprecision and recovery studies. The CVs were 
between 4.3% and 6.6% for the imprecision, and the recoveries were close to 100%.
3.3.4.3. Results for Correlation Study
Correlation o f  the method with immunoturbidimetry (IT) was good (r = 0.88) as shown 
by measurement o f 68 samples (Figure 3.12). Another two samples, with IgG values o f 
440 m g/L  and 489 m g/L  obtained by IT (after dilution), were diluted 1:200 before 
measuring by LIA, producing results o f  500 and 620 m g/L respectively. These results 
have not been plotted, but if included in the correlation, would increase r to 0.99.
IgG (mg/L)
Figure 3.11. A typical calibration curve for the IgG chemiluminescence immunoassay, 
y = -1,7x2 + 15.38x + 0.85; r = 0.99.
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Table 3.2. Imprecision and recovery studies for CSF IgG immunoassay.
Sample Mean ± SD n CV%
Imprecision
Low IgG CSF 6.3 mg/L ± 0.27 15 4.3
Medium IgG CSF 18.5 mg/L ± 1.22 15 6.6
High IgG CSF 64.5 mg/L ± 3.80 15 5.9
%Recovery
Addition of 24.4 mg/L IgG 106% ± 10.7 30 10.1
Addition of 69.8 mg/L IgG 97% ± 11.7 30 12.1
Figure 3.12. IgG measured in 68 CSF samples by both chemiluminescence immunoassay and 
immunoturbidimetry. y = 1,26x -  4.35; r = 0.88.
A  useful method for measurement o f  IgG in CSF has been developed, with a working 
range o f 0 to 4 m g/L  IgG. Pre-dilution o f  CSF is required. The feature o f  the assay is its 
sensitivity, witii limit o f  detection as low as 0.8 mg/L, after correction for dilution, and 
potentially as low as 0.02 m g/L  if samples are not pre-diluted.
The assay is robust and shown to be precise, with true measurement o f  IgG in CSF. The 
method correlated well witii an IT method using not only different calibration material, 
but also a different antibody. The IgG o f  the calibrators was derived from human serum, 
CSF IgG not being commercially available, but results suggest commutability o f  the 
method.
3.4. Development of an IgG Immunoassay: Overall Discussion
Using the working method described, it takes about 4 hours to measure a batch o f  40 CSF 
samples. This is more rapid than RID or electrophoretic techniques, but witii sample pre­
dilution and two pipetting stages, it is not as rapid as an automated one-step IT assay. 
Attempts were made to automate the assay using the LIA analyser, but problems were 
encountered with carryover, probably stemming from the LIA’s main use o f  routine 
analysis o f  serum samples. Despite thorough washing through o f  the analyser before 
research use, contamination persisted and this line o f development was eventually 
abandoned. Frequent mechanical failures o f the LIA were also a hindrance, as well as 
difficulties in fitting in research work around routine use o f  the analyser.
The calibration range o f  this sensitive method, with 1:40 pre-dilution o f  CSF samples is 8 
to 160 m g/L  - wider than with IT (10 to 100 mg/L: Cowdrey, 1991). The detection limit, 
o f  0.8 m g/L IgG witii pre-dilution o f  sample, is lower than other methods. The detection 
limit o f  RID is 30 mg/L, which is the upper margin o f the normal range for CSF. Rate
3.3.5. Discussion
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The anti-IgG-ABEI conjugate was easy to prepare and stable for 1 year, and probably 
longer, at -20°C. Storage in small aliquots, e.g. 20 pL, ensured that fresh, active conjugate 
was available for every assay.
Although a metiiod for measurement o f  IgG in CSF is presented here, tiiere is potential 
for measuring IgG in other body fluids. For measuring IgG in serum, where a less 
sensitive assay is required, it should be feasible to construct a one-step competitive- 
binding immunoassay. The same anti-IgG-coated tubes would be used, but the anti-IgG- 
ABEI conjugate would be added at die same time as diluted serum (or undiluted CSF). 
This would produce a more rapid method. There is die capability o f  full automation in 
either format.
Widi die high sensitivity o f  this method, there is die capacity, using die same coated tubes, 
to measure IgG subclasses, by substitution o f anti-IgG-ABEI conjugate witii anti-IgG 
subclass-ABEI conjugate. It might also be possible to develop assays for specific IgG 
antibodies e.g. serological tests for viral antibodies. The next chapter will describe 
incorporation o f  lectins into die assay, to enable detection o f carbohydrate variants o f 
IgG.
nephelometry, like IT, measures down to 10 mg/L (Christenson et al, 1998).
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Cha p te r  Four
D e v e l o p m e n t  of  Lec t in  
Binding  Assays  for  CSF IgG
4.1. Introduction
Most o f the development o f  the lectin binding assays was carried out using Con A  
and then extended to die other lectins. The conversion o f die IgG immunoassay to 
incorporate lectins was not as straightforward as anticipated and, as will be seen, a number 
o f  problems were encountered and various ways o f  overcoming them were tried. Finally, 
a range o f  lectin binding assays was used to probe the oligosaccharides o f  IgG in CSF 
samples from a group o f MS patients and a group o f control patients.
For the formats o f  the immunoassays described in this chapter please refer to 
Figure 2.5 in Chapter 2 (section 2.2.2.6). The lectin immunoassays all follow scheme 3 
[Figure 2.5(c)]. The IgG immunoassays follow scheme 1 [Figure 2.5(a)], apart from die 
intermediate IgG assay described in the first experiment (4.2.3.1. Use of Biotin-Streptavidin 
in the IgG immunoassay) which follows scheme 2 [Figure 2.5(b)].
4.2. Incorporation of Con A in Immunoassay
4.2.1. Introduction
This section will show how die IgG immunoassay was modified witii a biotin- 
streptavidin system, and then extended to using biotinylated Con A. Different incubation 
times for Con A  were tried and various blocking agents were tested.
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4.2.2. Reagents
Reagents are as described previously, with the following additions.
1. Anti-human IgG, biotinylated; y-chain specific; raised in goat, affinity purified, and 
lyophilised. Product no. BA-3080, Vector Laboratories Ltd., 16 Wulfiic Square, 
Bretton, Peterborough, PE3 8RF, U.K.
2. Isoluminol-streptavidin: 3.5 moles o f  isoluminol per 1 mole o f  streptavidin. 
Contains 0.1 mg protein (by Biuret). Product no. S8532, from Sigma Chemical 
Co., Poole, Dorset, BH12 4QH. Made up with 1 mL PBSG and stored at -70°C 
in 50 pL aliquots.
3. Concanavalin A, biotinylated, 5 mg. B-1005, Vector Laboratories. Reconstituted 
in 1.0 mL water, to give 10 mM HEPES buffer, 0.15 M NaCl. Stored at -70°C in 
50 pL aliquots.
4. D-xylose. Analar reagent, product no. 10372, Merck Ltd, Hunter Boulevard, 
Magna Park, Lutterworth, Leics., LE 17 4XN.
4.2.3. Methods
Washing at all stages consisted o f 3 additions o f  1.5 mL o f  saline-Tween, with 
aspiration after each addition. All incubations were at room temperature.
4.2.3.I. Use o f Biodn-Streptavidin in the IgG Immunoassay
The usual IgG immunoassay [scheme 1, Figure 2.5(a)] was compared to a 
modified IgG immunoassay using biotinylated anti-IgG and streptavidin-isoluminol 
[scheme 2, Figure 2.5(b)] as follows.
Anti-IgG capture antibody was diluted 1:200 in coating buffer, and 200 pL was 
added to assay tubes and incubated for 9 hours, dien washed. IgG solutions were 
prepared as described in section 3.2.3.1. 200 pL o f  PBSG was pipetted into die antibody-
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coated tubes, followed by 10 pL o f  IgG standards in duplicate tubes. Two series o f 
standards were prepared. All tubes were incubated for 1 h then washed.
Following scheme 1, anti-IgG-ABEI conjugate was diluted 1:1000 with PBSG and 
200 p,L was added to one series o f  tubes, incubated for 1 h, washed and the RLU 
measured for each tube.
Following scheme 2, biotinylated anti-lgG was diluted 1:1000 with PBSG and 200 
pL was added to the other series o f  tubes, incubated for 1 h then washed. Streptavidin- 
isoluminol was diluted 1:2000 with PBSG, 200 pL was added to each tube, incubated for 1 
h, washed, then the RLU measured.
4.2.3.2. Blockers o f Non-Specific Binding with Con A
The following solutions were prepared in carbonate buffer: 10 g /L  and 1 g /L  
BSA, 10 g /L  fish gelatine, 10 g /L  dextran, 10 g /L  pig gelatine, 10 g /L  D-xylose, 10 g /L  
and 1 g /L  human serum albumin (HSA), 10 m l/L  Tween and 10 g /L  BSA containing 10 
m l/L  Tween. Also 10 g /L  BSA was prepared in PBS.
400 pL o f each solution (made fleshly in glass botdes) was pipetted into assay 
tubes in duplicate. Duplicate tubes were also prepared with PBS only, carbonate buffer 
only and with no solution. All tubes were incubated for 1 h, then washed.
Biotinylated Con A  was diluted 1:5000 with PBS, 200 pL was added to each tube 
and incubated for 1 h then washed. Streptavidin-isoluminol was diluted 1:10 000 with 
PBS, 200 pL was added to each tube, incubated for 30 min, washed and RLUs measured.
4.2.3.3. Con A Incubation Times
Replicate assays (scheme 3) o f  IgG standard solutions were performed, with a 
different incubation time o f  Con A  for each.
Tubes were coated overnight witii 300 pL o f  anti-lgG diluted 1:400, washed, then 
blocked overnight with 400 pL o f  10 g /L  BSA in PBS and washed.
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IgG standard solutions o f  0 m g/L, 1 m g/L, 5 m g/L  and 100 m g/L  were prepared 
according to the protocol in section 3.2.3.1. A  CSF sample was diluted 1:40 and 1:200 
with PBS. 200 pL o f  PBS containing 0.2 g /L  BSA was pipetted in the assay tubes. This 
was followed by 10 pL o f  0 m g/L  or 5 m g/L  IgG solutions in duplicate tubes, or 10 pL 
o f  CSF or CSF dilutions in duplicate tubes. Also included were, in duplicate, plain tubes, 
anti-IgG coated tubes without blocker and blocked tubes without anti-IgG coat, which 
had no sample added.
All tubes were incubated for 2 h and washed. 200 pL o f  biotinylated Con A  
diluted 1:5000 in PBS containing 0.2 g /L  BSA was pipetted into tubes and incubated for 5 
min, 15 min, 30 min, 1 h, 2 h, 3 h or 4 h. The CSF samples and unblocked or uncoated 
tubes were incubated for 30 min.
After washing, 200 pL o f  isoluminol-streptavidin diluted 1:20000 in PBS 
containing 0.2 g /L  BSA was pipetted into all tubes, incubated for 20 min, washed and 
RLUs measured.
4.2.4. Results
4.2.4.1. Results o f Use o f Biotin-Streptavidin in the IgG Immunoassay
Figure 4.1 compares the IgG assay using biotin-streptavidin with the assay using 
anti-lgG-ABEI. Use o f  biotin-streptavidin appears viable and adaptation with 
biotinylated lectin looks feasible.
4.2.4.2. Results for Blockers o f Non-Specific Binding with Con A
Figure 4.2 shows that the most effective blocking agent with Con A  was BSA with 
litde difference between the 10 g /L  and 1 g /L  solutions. However use o f  Tween with the 
BSA reduced blocking ability.
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° Biotin-Streptavidin 
• Anti-IgG-ABEI
IgG mg/L
Figure 4.1. Comparison of an IgG assay using biotinylated anti-IgG and isoluminol- 
streptavidin with one using anti-IgG-ABEI. Duplicate points are shown for the standards for 
each assay. See 4.2.3.1 for details of method.
100000-1
75000-
z>
C£ 50000J
25000-
^  'Jy
Figure 4.2. Solutions blocking Con A binding to assay tubes. Prepared in carbonate buffer, 
pH 9.4, unless specified as PBS. Error bars represent SEM of duplicate samples. See 
4.2.3.2 for details of method.
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Figure 4.3 shows that binding o f  Con A  at the 5 m g/L  IgG level increases widi 
incubation time up to a maximum at 3 or 4 h. However, binding o f  Con A  without 
addition o f sample IgG (i.e. 0 m g/L  IgG) is as high as binding with 5 m g/L  IgG at all 
incubation times. It appears that Con A  is binding to the capture anti-lgG coated to the 
tube as well as to bound sample IgG. There is also high binding to the cno anti-lgG’ tube 
(i.e. no antibody coating, but blocked), which is undesirable.
Figure 4.4 compares the binding at several levels o f  sample IgG with 30 min 
incubation o f  Con A. Although the binding increases from 0 to 1 and to 5 mg/L, non­
specific binding at 0 m g/L  is relatively high and presents a problem. Also the RLU 
reading for the 1:200 dilution o f  CSF is similar to the 1:40 dilution and the neat samples, 
again indicating non-specific binding.
i 10 mg/L IgG 
M  5 mg/L IgG
4.2.4.3. Results for Con A Incubation Times
Figure 4.3. RLUs measured with 0 and 5 mg/L IgG samples with a range of Con A incubation 
times. Error bars represent SEM of duplicate samples. See 4.2.3.3 for details of method.
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Figure 4.4. Measured RLU with different IgG solutions, CSF and diluted CSF with 30 min 
incubation of Con A. Error bars represent SEM of duplicate samples. See 4.2.3.3 for details 
of method.
4.2.5. Discussion for Incorporation of Con A
A relatively large amount o f  non-specific binding by Con A was found, which is 
probably due to binding to carbohydrate on the anti-IgG capture antibody. Therefore, 
either an aglycosylated form o f  antibody could be used, if available, or the existing 
antibody could be deglycosylated.
4.3. Deglycosylation of Capture Antibody
4.3.1. Introduction
It was decided to deglycosylate the capture antibody in use, and to do this after 
binding the antibody to the assay tube, using a chemical method - i.e. oxidation with 
sodium periodate - rather than an enzymic method. It will be shown how, after an initial 
trial assay using periodate, reaction conditions were varied to obtain as complete 
deglycosylation as possible with least damage to antibody activity. The method was 
compared to two recendy published protocols for the deglycosylation o f  capture antibody 
using stronger concentrations o f  periodate (Baharaki et al, 1996; Keusch et al, 1996).
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Despite deglycosylation o f  capture antibody, high blank readings persisted. It was 
suspected that periodate oxidation might be producing active groups such as aldehydes 
which were binding to a sample constituent or to a reagent, and ethanolamine was 
introduced to neutralise such groups. The Con A  inhibitor, a-methylpyramioside was 
used to ascertain if the lectin was binding specifically or non-specifically to carbohydrates.
Finally a range o f  lectins was used to assess the glycosylation o f  IgG in four CSF 
samples.
4.3.2. Reagents
As described previously, widi the following additions
1. Citric acid (C6H80 7.H20 ). Product no. 10081, Merck Ltd.
2. Disodium hydrogen phosphate (Na2H P 04). Product no. 10248, Merck Ltd.
3. Citrate/phosphate buffer, 50 mM, pH 4.0.
Reagent A: dissolve 1.05 g citric add in 100 mL water.
Reagent B: dissolve 1.79 g Na2H P 04 in 100 mL water.
Add A  (approximately 31 mL) to B (approximately 24 mL) to give pH 4.0.
4. Sodium m-periodate (N aI04). Product no. S-1147, Sigma Co. To prepare 
0.1M N aI04, dissolve 0.214 g in 10 mL citrate/phosphate buffer, pH 4.0, 
immediately before use.
5. Ethanolamine. CH2(OH)CH2NH2. Merck, 10325. Mw 61.08. Supplied as 
10% (v/v ) solution in water. A 0.1 M solution was prepared by diluting 1.5 
mL in 25 mL PBS.
6. Tris buffered saline (TBS). Dissolve one tablet (T-5030, Sigma Co.) in 15 mL 
water to produce a 0.05 M Tris buffer, pH 7.6, containing 0.15 M sodium 
chloride.
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7. Coating buffer. Now prepared from capsules from Sigma (product no C- 
3041). Contents o f  one capsule are dissolved in 100 mL water to produce a 
0.05 M carbonate-bicarbonate buffer, pH 9.6.
8. Lectins, biotinylated. From Vector Laboratories. Kit I (product no. BK-1000) 
containing 1 mg quantities o f  biotinylated Con A, DBA, PNA, RCA120, SBA, 
UEA 1 and WGA. Kit III (BK-3000) containing 0.5 mg quantities o f  
biotinylated DSL, ECL, GSL II, Jacalin, LEL, STL and W L . Also 
biotinylated SNA, 2 mg (B-1305). All lectins reconstituted witii 0.5 mL water. 
CAUTION: RCA120 is mildly toxic.
9. Lectin assay buffer, containing 1 mM MgCl2 and 1 mM CaCl2. Dissolve 10.15 
g o f  MgCl2.6H20  (29096, Merck), 7.35 g o f  CaCl2.2H20  (10070, Merck) and 
25 mg NaN3 in 50 mL water. Add 45 pL o f  this solution, plus 23 pL Tween 
20, to 45 mL TBS.
10. PBS-T. PBS containing 0.5 m L/L  Tween 20.
11. a-Mediylpyrannoside (methyl-a-D-glucopyrannoside). C7H14Oe. Mw 194.2. 
M-9376, Sigma Co.
4.3.3. Methods
All washing steps are with 3 additions o f 1.5 mL o f  Saline-Tween, with aspiration 
after each.
4.3.3.I. Initial Trial o f Periodate-Treated Tubes.
20 tubes were coated overnight with 200 pL o f  anti-IgG, diluted 1:400 in coating 
buffer, dien washed. The tubes were blocked with 300 pL o f  BSA (10 g/L ) for 1 h, then 
washed. To all tubes, apart from 4, was added 400 pL Of 0.1 M sodium periodate, 
followed by incubation overnight at 4°C in die dark (i.e. in a refrigerator), then washed.
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Solutions containing 100 mg/L, 5 mg/L, 1 m g/L and 0 m g/L  o f  IgG were 
prepared as described in section 3.2.3.1. 200 pL o f  PBSG was pipetted into the coated 
tubes followed by 10 pL o f  IgG solution (0, 1, 5 and 100 m g/L  IgG solutions in 
periodate-treated, tubes, in duplicate; 0 and 100 m g/L  solutions in untreated tubes, in 
duplicate) and incubated for 90 mill. After washing, 200 pL biotinylated Con A, diluted 
1:1000 with lectin assay buffer, was added to each tube, with further 90 min incubation. 
After washing tubes were incubated for 60 min with 200 pL isoluminol-streptavidin 
diluted 1:1000 in PBS-T, then washed and RLUs measured.
4.3.3.2. Effect o f Temperature and Concentration o f Periodate
80 tubes were coated overnight with 200 pL o f  anti-lgG diluted 1:400, then 
blocked with 300 pL o f  10 g /L  BSA for 1 h. Solutions o f periodate o f  0.1 M (0.214 g 
sodium periodate/10 mL citrate/phosphate buffer pH 4.0) and 0.01 M (0.021 g/10 mL 
citrate/phosphate buffer pH 4.0) were made freshly and kept at 4°C. 400 pL amounts o f  
either periodate solution were added to tubes, in duplicate, at different times, incubated at 
25°C or 4°C, for between 1 h and 18 h, then all tubes were washed together.
A  CSF sample containing 80 m g/L  IgG (CSF T35) was diluted with PBS (25 pL in 
20 mL), and 200 pL o f  this was added to all tubes and incubated for 90 min. After 
washing, to half the tubes 200 pL o f  biotinylated Con A  (diluted 1:1000) was added and 
incubated for 90 min, washed and 200 pL o f  isoluminol-streptavidin was then added, 
incubated for 60 min, washed and RLUs measured. To the other tubes, 200 pL o f  anti- 
lgG-ABEI (diluted 1:15000) was added, incubated for 2 h, washed and RLUs measured.
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4.3.3.3. Increasing Incubation Time with 0.01 M  Periodate.
50 tubes were coated and blocked as in section 4.3.3.2. 0.01 M periodate was 
prepared freshly (42 m g/ 20 mL citrate buffer) and 0.4 mL was added to a l tubes at the 
same time which were incubated at 4°C and washed at varying times.
A CSF sample containing 41 m g/L  IgG (CSF ‘C’) was diluted with PBS (40 pL in 
8 mL) and 0.2 mL was added to coated tubes which were incubated for 90 min and 
washed. Tubes were assayed for [IgG] or for Con A  binding as in section 4.3.3.2.
4.3.3.4. Comparison o f Periodate Treatments
100 tubes were antibody coated and blocked as in 4.3.3.2. Also 60 tubes were
treated with blocker only (300 pL o f  10 g /L  BSA for 1 h).
Immediately before use, 0.1 M periodate solution was prepared by diluting 428 mg 
o f  sodium periodate in 20 mL citrate/phosphate buffer. 5 mL o f  this was diluted with 5 
mL citrate/phosphate buffer to produce 0.05 M periodate solution. 4 mL o f  0.1 M 
periodate was diluted widi 36 mL citrate/phosphate buffer to produce 0.01 M periodate.
20 coated tubes were incubated with 0.3 mL 0.1 M periodate for 3 min.
20 coated tubes were incubated with 0.3 mL 0.05 M periodate for 10 min.
20 coated tubes and 20 ‘blocked only’ tubes were treated with 0.01 M for 20 h at
4°C.
20 coated tubes were not periodate treated.
A CSF sample (CSF CVR’) with an IgG concentration o f 27 m g/L  was diluted to 
give a solution o f  5 m g/L  IgG (200 pL CSF + 880 pL PBS). Then dilutions were made
from this to give solutions containing 1 m g/L  and 3 m g/L o f  IgG.
a. IgG Assay
200 pL o f  PBS-T and then 10 pL o f  0 mg/L, 1 mg/L, 3 m g/L  or 5 m g/L  CSF 
IgG solutions was pipetted in duplicate into labelled periodate untreated tubes. This was
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repeated with 3 min periodate treated tubes, 10 min treated tubes and 20 h treated tubes. 
All tubes were incubated for 2 h, washed and 300 pL o f  anti-lgG-ABEI (diluted 1:10 000) 
was added. After 2 h incubation, tubes were washed and RLUs measured.
b. lectin Binding
200 pL o f  PBS-T was pipetted into 9 periodate untreated tubes and into 9 tubes 
each o f  the three periodate treatments. Into 6 tubes o f  each treatment set was also 
pipetted 10 pL o f  5 m g/L  CSF IgG. All tubes were incubated for 1.5 h then washed.
0,2 mL o f  Con A, diluted 4 pL in 10 ml lectin assay buffer, was pipetted into 
triplicate tubes o f  each treatment set without the CSF addition and into triplicate tubes 
with the CSF IgG addition. 0.2 mL o f  RCA, diluted 10 pL in 10 mL o f  lectin assay 
buffer, was pipetted into triplicate tubes o f  each sample set with the CSF IgG addition. 
Tubes were incubated for 1,5 h and washed.
0.2 mL o f  isoluminol-streptavidin, diluted 2 jliL  in 20 m L  PBS-T, was pipetted into 
all tubes, incubated for 1 h, washed and RLUs measured.
4.3.3.S. Dilution o f Capture Antibody
Although a 1:400 dilution o f  the capture antibody was found to be optimum for 
tube coating for the IgG assay, the dilution for the lectin assay, where the coating is 
subject to periodate treatment, was now tested.
A  1:100 dilution o f  anti-IgG was made by adding 60 pL to 6 mL o f coating buffer, 
then by doubling dilutions, using 3 mL amounts o f  coating buffer, 1:200, 1:400 and 1:800 
solutions were prepared. Tubes were coated overnight with 0.2 mL o f  each solution, then 
blocked witii 0.3 mL o f  10 g /L  BSA for 1 h, and treated witii 0.01 M sodium periodate 
for 20 h at 4°C.
IgG standard solutions were prepared and IgG assays performed as described in
3.3.3.1. using the different sets o f  coated tubes.
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4.3.3.6. Use o f Ethanolamine and a Con A Inhibitor
20 tubes were coated with 200 pL anti-lgG at 1:400 for 21 h and washed. 300 pL 
o f  0.01 M periodate (0.21 g in 10 mL citrate buffer) was added to the tubes and incubated 
for 21 h and washed. 400 pL o f  0.1 M ethanolamine solution was added to 14 coated 
tubes; 0.4 mL o f  PBS was added to other tubes and incubated for 21 h then washed. 300 
pL BSA (0.45 mL o f  300 g /L  BSA in 15 mL coating buffer) was added to coated tubes 
and to 20 untreated tubes and incubated for 1 h then washed.
200 pL o f  PBS was added to all tubes, then 10 pL CSF sample in duplicate (no 
CSF was added to one series o f  tubes), and incubated for 1.5 h and washed. Con A  was 
diluted with lectin assay buffer (2 pL in 20 mL) without BSA. To 10 mL o f  this was 
added 0.4 g a-methylpyrannoside (to give a 200 mM solution). 200 pL o f  diluted Con A  
or 200 pL o f  diluted Con A with inhibitor was added to tubes and incubated for 1 h then 
washed. 200 pL isoluminol-streptavidin diluted 1 pL in 10 mL lectin assay buffer (no 
BSA) was added to each tube and incubated for 30 min then washed and RLUs were 
measured.
4.3.3.7. Analysis o f IgG Glycosylation Using a Panel o f Lectins
200 tubes were coated overnight with 200 pL o f  anti-lgG diluted 1:400 (105 pL in 
42 mL coating buffer) then washed. To each tube and to 170 additional plain tubes was 
added 0.3 mL o f  blocker (3.6 mL o f  300 g /L  BSA in 120 mL PBS). All tubes were 
incubated for 2 h and washed. 400 pL o f  0.01 M periodate was then added to all tubes 
and incubated for 20 h at 4°C then washed.
a. Total IgG Assay
IgG calibration solutions o f  5, 3, 2, 1, 0.6, 0.2 and 0 m g/L  were prepared as 
described in section 3.2.3.I. Four CSF samples, A, B, C, and D  were all diluted 1:40 (10
p.L CSF + 390 pL PBS). They were also diluted to give an IgG concentration o f  10
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mg/L, according to Table 4.1. To labelled coated tubes was added 200 pL o f  PBS-T tiien 
10 pL o f  diluted CSF or calibrator and incubated for 2 h and washed. 200 pL o f  anti- 
IgG-ABEI was added to the tubes, incubated for 2 h, washed and RLUs measured.
b. Lectin Immunoassay
For die lectin assays, the CSF dilutions containing 10 m g/L  IgG (Table 4.1) were 
sampled. At this level o f  IgG, die capture antibody would be virtually saturated by IgG, 
ensuring that die same amount o f IgG for all samples is available for lectin binding. 200 
pL o f  each diluted CSF (or 200 pL o f  PBS for ‘no CSF’ tubes) was added to 32 coated 
tubes each and 32 blocked only tubes each and incubated for 2 h tiien washed. Different 
biotinylated lectins were diluted 1:1000 (5 pL in 5 mL lectin assay buffer) and 200 pL o f  
tiiis (or 200 pL o f  lectin assay buffer only for ‘no lectin’ tubes) was added in duplicate to 
tubes for CSFs A to D  and ‘no CSF’ tubes. After incubating for 2 h and washing, 200 pL 
o f diluted isoluminol-streptavidin (8 pL in 80 mL PBS-T) was added to all tubes, 
incubated for 40 min, washed and RLUs measured.
4.3.4. Results
4.3.4.I. Results for Initial Trial o f Periodate-Treated Tubes
Figure 4.5 shows tiiat there is an improvement in background binding widi 
periodate treated tubes, although it is still higher than would be liked. Differentiation 
between sample IgG concentrations also needs to be increased.
Table 4.1. Details of CSF samples used in total IgG and lectin assays.
CSF Oligoclonal
Bands
IgG mg/L by IT Dilution to produce 10 mg/L IgG. 
mL CSF mL PBS
A Positive 22 0.33 0.40
B Positive 72 0.10 0.62
C Negative 25 0.33 0.50
D Negative 17 0.50 0.35
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Figures 4.6(A) and 4.6(B) show the effect o f 0.1 M and 0.01 M periodate re­
spectively on the activity o f  the capture antibody (i.e. ‘IgG’ in the legend) and on the 
glycosylation o f  the antibody (i.e. ‘Con A ’ in the legend). Figure 4.6(A) shows that 0.1 M 
periodate effectively destroys most carbohydrate on the antibody after about 3 h, however 
deterioration in the activity o f  the antibody also begins after a few hours even at 4°C. 
Destruction o f  the anti-IgG activity at room temperature is considerable. On the other 
hand, 0.01 M periodate [Figure 4.6(B)] shows a gender reaction and there is only a small 
reduction in anti-IgG binding up to 18 h incubation, by which time most o f  the 
carbohydrate appears to be eliminated.
4.3.4.2. Results for Effect o f Temperature and Concentration o f Periodate
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13 30000- 
- J
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10000-
periodate treated 
no periodate
\<P \<?
*  J ' J t  A ' J ' J '
Figure 4.5. Initial trial of 0.1 M periodate treated tubes. Error bars 
represent SEM for duplicate samples. See 4.3.3.1 for details of method.
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Figure 4.7 shows that the integrity o f  the capture antibody is maintained with up 
to 27 h incubation with 0.01 M periodate at 4°C. Deglycosylation, shown by Con A 
binding, is almost complete by about 9 h. Binding o f  Con A to carbohydrate in the 
sample IgG can be clearly seen (i.e. the legend ‘Con A + CSF’) after the pretreatment with 
periodate has deglycosylated the capture antibody.
4.3.4.3. Results for Increasing Incubation Time with 0.01 M  Periodate
A. 0.1 M PERIODATE
60000 — ♦ —  IgG refrigerated
INCUBATION (h)
B. 0.01 M PERIODATE
-♦—  IgG fridge 
■*—  Con A fridge
60000
50000
40000
3 30000 oc
20000 
10000 
0
0 2 4 6 8 10 12 14 16 18
INCUBATION (h)
Figure 4.6. The effect on IgG measurement and Con A binding after treating capture 
antibody with (A) 0.1 M periodate and (B) 0.01 M periodate for different incubation periods. 
Incubation with periodate was at 4°C and also at room temperature with (A) 0.1 M periodate. 
Each point represents the mean of duplicate treatments. See 4.3.3.2 for method details.
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Figure 4.7. The effect of 0.01 M periodate at 4°C on capture antibody. Each point 
represents the mean of duplicate treatments. See 4.3.3.3 for method details.
Therefore to remove most carbohydrate on the capture antibody, whilst leaving 
the antibody still viable, 0.01 M periodate could be incubated with the coated tube at 4°C 
from 9 h to 27 h. For convenience, a 20 h incubation will be consistendy used.
4.3.4.4. Results for Comparison o f Periodate Treatments
Figure 4.8 compares the RLUs measured for a series o f  IgG calibration solutions 
assayed in antibody coated tubes treated by the three periodate protocols or not treated 
with periodate. As would be expected, antibody coated tubes not treated with periodate 
show highest binding o f  IgG. The different treatment protocols give similar results, 
although the 20 h treatment gives the lowest results. However removal o f  sugars is most 
effective using the 20 h treatment, as shown by Figure 4.9(C) which shows Con A binding 
direcdy to the capture antibody without addition o f  sample IgG. This is also seen in 
Figure 4.9(A), where CSF IgG is added and the RLU readings are a result o f  the CSF IgG 
sugars as well as those o f  the capture antibody. Figure 4.9(B) shows similar reductions in
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Figure 4.8. Assay of IgG standard solutions using antibody coated tubes deglycosylated by 
different periodate protocols or not treated with periodate. Duplicate points are shown for 
the standards in each assay. See 4.3.3.4 for method details.
RCA binding for the 3 periodate methods, suggesting that RCA-binding sugars in IgG are 
more easily oxidised than Con A  binding sugars.
4.3.4.5. Results for Dilution o f Capture Antibody
Figure 4.10 shows that the 1:100 dilution o f  capture antibody gives the highest 
binding o f  IgG. The shape o f  the curve is similar to that with 1:400 dilution o f antibody 
without periodate treatment (Figure 4.1), while the other dilutions show plateauing o f  die 
curve at much lower levels.
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Figure 4.9. Comparison of 3 protocols for deglycosylation of capture antibody by treatment 
with periodate. (A) and (B) show binding of Con A and RCA respectively to capture antibody 
and CSF IgG after addition of CSF. (C) shows Con A binding with no addition of CSF. Error 
bars represent SEM of triplicate samples. See 4.3.3.4 for method details.
154
50000-
30000-
40000-
d 1:100 Dilution
* 1:200 Dilution
° 1:400 Dilution
x 1:800 Dilution
OH
20000 -
10000-
0
0 2 3 4 5
IgG mg/L
Figure 4.10. IgG binding with varying dilutions of capture antibody treated with 0.01 M 
periodate for 20 h. IgG standards were sampled in triplicate in each assay. See 4.3.3.5 for 
method details.
4.3.4.6. Results for Use o f Ethanolamine and a Con A Inhibitor
Figure 4.11 shows the Con A  binding assays o f  two CSF samples when the assay 
tubes are prepared in different ways. Antibody coated and blocked tubes (i.e. 
‘Coat/block/ethanolamine’ and ‘coat/block/no ethanolamine’) give high RLUs for assay 
o f  both CSFs, and are similar whether or not the tubes were incubated with ethanolamine. 
However, tubes that were blocked without an antibody coat (i.e. ‘no coat/block’) show a 
substantial amount o f  Con A  binding. The tubes without sample added (i.e. ‘N o sample’) 
have low counts compared to tubes with CSF, showing that the Con A  is itself not 
binding to the tube, antibody coat, nor blocker. Therefore there must be some substance 
(or substances) in CSF which is glycosylated and which binds avidly to the tube, coating 
antibody, blocker, or captured IgG (all or any o f  these) to which Con A  is then binding. 
The inhibitor drastically reduces the binding o f  Con A  in the assay, indicating that the 
lectin is not binding non-specifically to any great extent, but is binding to carbohydrates in 
this substance. The only slightly lower counts obtained for uncoated tubes with inhibitor 
suggest there is negligible Con A  binding to the coating antibody.
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Figure 4.11. Comparison of assay tubes prepared in various ways, incubating with CSFs B,
C or with no CSF and binding to Con A. Error bars represent SEM of duplicate samples. 
See 4.3.3.6 for method details.
4.3.4.7. Results for Analysis o f IgG Glycosylation Using a Panel o f Lectins.
a. IgG Assay
The results for the IgG concentrations o f  the four CSFs agreed fairly well with the 
results by IT (Table 4.2). The mean RLUs for the CSFs diluted to contain 10 m g/L o f 
IgG (the dilution used for the lectin assays) are also shown. These are well above the 
mean RLU o f the highest IgG calibrator (5 mg/L), indicating that, in the lectin assays, the 
capture antibody, with each CSF, should be fully - or almost fully - saturated with sample 
IgG.
b. Lectin Immunoassay
Figure 4.12 shows the RLUs obtained for each CSF for all 15 lectin assays. The 
chart ‘No CSF’ shows the lectins’ binding to the capture antibody without sample IgG.
Table 4.2. Results of the IgG assay of the four CSFs used for the immunoassays with a 
)anel of lectins.
CSF IgG mg/L by IT IgG mg/L by LIA Mean RLU (n=2) for dilution 
containing 10 mg/L IgG.
A 22 16 51674
B 72 91 51140
C 25 26 52588
D 17 19 54797
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On each chart is shown the results using antibody coated, blocked tubes (gi'ey columns) 
and results using blocked only tubes, without an antibody coat (black columns). For each 
o f  the four CSFs it can be seen diat lectin binding to die blocked-only tubes is 
considerable for most o f  the lectins. The lectins are not binding direcdy to the blocker, as 
can be seen in the chart ‘N o CSF’ in Figure 4.12, where binding for ‘no coat’ tubes (black 
columns) is relatively small. Again it would appear that there are glycosylated substances 
in CSF which bind to the blocking agent and coating antibody, to which the lectins are 
binding.
The ‘N o CSF’ chart in Figure 4.12 also shows that binding to the capture antibody 
is minimal for most lectins, with some exceptions. These will be discussed in the next 
section.
Figure 4.13 shows the same data as Figure 4.12, but the RLUs for the uncoated 
tubes have been subtracted from the antibody coated tubes. This is an attempt to correct 
for the binding due to the interfering substance, but is probably grossly inaccurate, as will 
be discussed in the next section.
4.3.5. Discussion for Deglycosylation of Capture Antibody
Incubation with 0.01 M periodate at 4° C for up to 27 h was shown to 
deglycosylate the capture antibody so that subsequent binding to Con A was minimal 
while the activity o f  the antibody was largely preserved. This method was found to 
deglycosylate the antibody more thoroughly, as shown by Con A  binding, than the two 
other methods o f  periodate treatment. The 3 minute method is thought not to be 
suitable, as timing would be too critical when treating a large number o f  tubes. The 10 
minute method (with 0.05 M periodate) could be used, however, according to the 
literature (Marshall and Neuberger, 1972), the lower the periodate concentration, the less 
problems there are from secondary oxidation damaging the peptide, so the 20 h 
incubation method (witii 0.01 M periodate) will be used henceforth.
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Figure 4.12. Binding of CSFs A, B, C and D in immunoassays using a range of lectins. The 
‘No CSF’ chart shows lectin binding without addition of CSF sample. Columns are the mean 
of duplicate samples. Grey columns show results using antibody-coated and blocked assay 
tubes; black columns show results using blocked-only tubes. See 4.3.3.7(b) for further 
method details.
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Figure 4.13. Subtraction of RLUs for blocked-only tubes from RLUs for antibody-coated tubes 
for the four CSFs and No CSF assay (Figure 4.12). Each column is the mean of duplicate 
samples. See 4.3.3.7(b) for method details.
It was eventually concluded that 1:100 dilution o f  the capture antibody was better 
than 1:400 with the 20 h periodate treatment, and although 1:400 was used in most o f  the 
studies described here, for the final lectin assays, described in section 4.6, 1:100 dilution 
was used.
Binding o f  most lectins to the deglycosylated capture antibody is shown to be 
minimal (Figure 4.12: ‘N o CSF’) with some exceptions, notably WGA, DSL, jacalin, LEL 
and STL. This is probably due to incomplete glycosylation o f  the antibody. WGA, DSL, 
LEL and STL are known to bind to GlcNAc monomers or dimers. The first two sugars 
in an iV-linked glycan are both GlcNAcs, and it is probable that the first one, or possibly 
both, are not completely destroyed by the periodate treatment. Jacalin, however, does not 
have an affinity for GlcNAc, but preferentially binds Gaip 1-3GalNAc, GalJT, and 
NeuAc2- linked to -3Gal and 3GalNAc, which are not found in IgG. The only human 
immunoglobulin that jacalin is said to bind to is IgA, so this suggests that IgA might be a 
component o f  the anti-lgG antibody.
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Despite deglycosylation o f  the capture antibody, there is still a large and variable 
amount o f  background binding by the lectins in the immunoassays. This was effectively 
abolished for Con A  by incubation with the inhibitor a-methylpyrannoside, indicating that 
the lectin is binding in a specific way to carbohydrate. Also it had been thought that the 
periodate oxidation o f the antibody carbohydrates was producing reactive groups such as 
aldehydes which could be binding biotin, or the isoluminol-streptavidin and thus 
producing die high background binding. However, incubation o f  the periodate-treated 
antibody with ethanolamine, a primary amine which would neutralise such active groups, 
did not lead to a reduction in the background binding o f  Con A.
So it would appear that diere is a substance (or substances) in CSF which is 
glycosylated and which binds avidly to the antibody coated tube and the blocking agent, 
and the lectins are binding to the sugars present in this. The same thing occurs with 
serum in lectin immunoassays, as found by Dr G. Firdi while working on lectin 
immunoassays for serum transferrin (data not published). The phenomenon is not 
reported in several papers describing lectin immunoassays o f  IgG without pt'ior 
purification o f  die IgG (Casbum-Budd et al, 1992; Keusch et al, 1996; Kottgen et al,
1993). None o f  these give any data for non-antibody-coated control tubes, so it is 
assumed tiiat control tubes were not run.
With most lectin immunoassays, however, the analyte is purified before the 
immunoassay stage by affinity or ion-exchange chromatography. Similarly, with this 
project, some means must be found o f  removing, or possibly compensating for, diis 
interfering substance. The feasibility o f  subtracting die measured RLUs from blocked- 
only control tubes from coated tube for every sample assayed has been considered (Figure 
4.13). However, the amount o f  lectin binding to the control tubes is not necessarily die 
same as, or even in proportion to, the background binding o f  the lectin to the antibody- 
coated tubes. For example, the amount o f  IgG in die sample CSF would reduce
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interferant binding by blocldng sites on die capture antibody. So using blocked-only 
control tubes as sample blanks is not really viable. The nature o f the interferent and the 
ways o f  removing it will be investigated in the next section. It would be expedient to 
actually identify the substance(s), but tiiis is probably beyond the scope o f  this project.
4.4. Investigation of the Interferent
4.4.1. Introduction
The nature o f  the interferent was investigated and various ways o f  removing it, or 
compensating for it, were tried. These included dilution o f  CSF so that the IgG added to 
the assay tube was just saturating the capture antibody, but die interferent was so dilute as 
to be ineffective. Also polypropylene tubes were antibody coated for the assay, as it was 
thought the interferent might bind less to this material. Storage o f  CSF in glass containers 
was investigated as it was thought the interferent bound more to this material and so it 
might be a means o f  removing it. Extraction o f IgG from CSF was tried using ion- 
exchange particles (DEAE), salt fractionation (with Rivanol), and Protein A. (The use o f  
Protein A  will be given in section 4.5.) Not all the data obtained will be presented here, as 
much was inconclusive and because o f  die need to reduce the size o f  the thesis. Similarly, 
attempts to automate the tube coating, and other assay steps, on the LLA analyser will not 
be shown.
4.4.2. Reagents
Reagents were as already given witii the following substitutions or additions:
1. Coating buffer. Carbonate-bicarbonate buffer capsule: Sigma C-3041. The 
contents o f one capsule were dissolved in 100 mL deionized water to produce 
a 0.05 M carbonate-bicarbonate buffer, pH 9.6.
2. Ethanolamine. From Merck as a 10% (v/v ) aqueous solution. 1% (v/v ) (0.16 
M) and 0.2% (v/v ) (0.03 M) solutions in PBS were prepared.
161
3. DEAE. Sephacel, wet particle size 40 to 150 pm, product no. 17-0500-01, 
Pharmacia Fine Chemicals AB, Uppsala, Sweden.
4. Equilibration/elution buffer, 0.02 M, pH 7.2.
A  = Na2H P 0 4 (0.1 M; 14.2 g/L ); B = KH2P 0 4 (0.1 M; 13.6 g/L)
7 mL o f  A  was mixed with 3 mL o f  B, diluted with 40 mL o f water and 
adjusted to pH 7.2.
5. Final buffer. 1 M KC1 in equilibration/elution buffer.
6. Coomassie blue CSF total protein assay was performed by the method o f  
Cowdrey (1991) using a Cobas-Bio centrifugal analyser (Roche Diagnostics).
4.4.3. Methods
All washing steps consisted o f  3 additions o f  1.5 mL o f  saline-Tween, witii 
aspiration after each addition. All incubations were at room temperature.
4A.3.1. Serial Dilution o f CSFs: Assay with Con A, RCA and anti-lgG
200 assay tubes were coated overnight with 0.2 mL anti-lgG diluted 1:400, washed 
then blocked with 0.3 mL o f  10 g /L  BSA for 1 h. 100 plain tubes were also blocked in a 
similar way. 0.4 mL o f  0.01 M periodate in citrate buffer was added to all tubes apart 
from 50 coated and 50 uncoated and incubated at 4°C for 20 h. 0.4 mL o f  1% (v/v ) 
etlianolamine and 0.4 mL o f 0.2% (v/ v) ethanolamine was added to 64 coated and 64 
uncoated tubes each and incubated for 2 h.
CSF A, oligoclonal IgG negative, and CSF B, oligoclonal IgG positive, both 
coincidentally with an IgG o f  46 m g/L  by IT, were each diluted with PBS-Tween to 10 
m g/L  IgG. Human IgG (from Sigma) was diluted to 10 mg/L. The three solutions were 
then diluted with PBS-Tween to give a range o f  IgG concentrations for each as described 
in section 3.2.3.1.
0.4 mL o f all IgG solutions was diluted with 8 mL PBS-Tween and immediately 
0.2 mL o f  this was added to labelled assay tubes in duplicate and incubated for 2 h, then
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washed. Biotinylated lectins were diluted 1 in 1000 with lectin assay buffer, and 0.3 mL 
added to relevant tubes and incubated for 1.5 h, then washed. 0.2 mL o f  strep tavidin- 
isoluminol diluted 1:1000 with PBS-Tween was added to each tube, incubated for 45 min 
and washed and tubes counted. For the IgG assay, 0.2 mL o f  anti-IgG-ABEI diluted 
1:1000 with PBS-Tween was added to the relevant tubes, incubated for 1.5 h, washed and 
counted.
4.4.3.2, DEAE Column Fractionation o f CSF
The DEAE resin was prepared by equilibration over 4 h periods in 3 changes o f  
Tris-saline. A  column o f  5 cm length was prepared, with a capacity o f  1.2 mL.
a. First Fractionation
200 pL o f  a CSF sample (‘BM’ - with [IgG] o f  78 mg/L) was applied to the top o f 
die column and 200 pL amounts o f  Tris-saline were applied to the column and the eluate 
collected in a glass vial after each application. Nine fractions were collected. The 
fractions were assayed for (i) total protein using Coomassie blue and (ii) IgG by IT, botii 
metiiods following Cowdrey, 1991.
As described in section 4.3.3.6, 20 assay tubes were anti-IgG coated and periodate 
treated, then blocked along widi 20 plain tubes. CSF BM was diluted 1:20, 1:40, 1:80 and 
1:160 with saline. 200 pL o f  assay buffer, followed by 10 pL o f  CSF, diluted CSF or 
column fraction was pipetted into labelled tubes in duplicate and incubated for 1.5 h. 
After washing, 200 pL o f  Con A-biotin, diluted 1:10000 with lectin assay buffer was added 
and incubated for 1.5 h. After washing, 200 pL o f isoluminol-streptavidin diluted 1:10 
000 was added and incubated for 1 h, washed and RLUs measured.
b. Second Fractionations
Two samples, CSF H (total protein = 451 mg/L; IgG = 56 mg/L; oligoclonal IgG 
bands positive) and CSF W  (total protein = 188 mg/L; IgG = 13 m g/L; oligoclonal IgG
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negative) were processed as follows. 200 pL o f  CSF was applied to the column, followed 
by 200 pL amounts o f  equilibration/elution buffer, with collection o f  eluted fraction. Ten 
such fractions were collected. Then 200 pL amounts o f  final buffer were applied to the 
column, and 8 more fractions were collected. The fractions were assayed for total protein 
by Coomassie blue and IgG by IT.
Fractions 3, 4 and 5, containing IgG, were pooled and along with the untreated 
CSFs, portions were diluted to contain 5 m g/L  o f  IgG, and then assayed with Con A  as 
described in (a) above, but with sampling in triplicate rather than duplicate. Fractions 6 to 
18 were also pooled and, with the IgG pools and the untreated CSF, were assayed for IgG 
according to the protocol in section 3.3.3.1 after suitable dilution (1:13 for pools 3 to 5; 
neat for pools 6 to 18 and 1:40 for untreated CSFs).
4.4.3.3. Effect o f Storage at 4°C on IgG and Interferent
For the IgG assay, 50 tubes were coated overnight with 200 pL o f  anti-IgG 
diluted 1:400, washed and blocked with 300 pL o f  10 g /L  BSA. IgG calibrators were 
prepared as described in section 3.2.3.I. For Con A  assays, 100 tubes were antibody 
coated, blocked and treated with periodate, and 100 tubes were blocked only, as described 
in section 4.3.3.6.
Tubes were coated witii different amounts o f  human IgG (from Sigma), to 
compare with die tubes in which the CSF had been stored. Thus, 10 pL o f  IgG was 
diluted with 4 mL PBS; o f  this, aliquots o f  50, 100, 150 or 200 pL, containing respectively
0.7, 1.4, 2.1 and 2.8 pg o f  IgG, were placed into four assay tubes each and incubated 
overnight, tiien washed.
Three CSF samples, Y, W  and E, with IgG levels by IT o f  60, 50 and 43 m g/L  
respectively, were obtained on die day o f  the lumbar puncture. 100 pL aliquots o f  each 
CSF were placed into glass botties and stored at -70°C, while 100 pL aliquots were placed
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into 4 polystyrene tubes for each CSF and placed at 4°C along with the remaining samples 
in the collection tubes. For CSF Y, 100 pL was placed in four additional polystyrene 
tubes and stored at -70°C. Thereafter, at weekly intervals for 4 weeks, 100 pL from each 
CSF collection tube was placed into glass botdes and stored at -70°C.
All frozen samples were thawed at room temperature just before use. For the IgG 
assay, all samples were diluted 1:40 and assayed as described in section 4.3.3.6. For the 
Con A assays, all CSFs were used neat and also diluted to contain 5 m g/L  IgG. 200 pL o f  
PBS-T followed by 10 pL o f  sample was pipetted into periodate-treated coated tubes in 
duplicate and corresponding blocked-only control tubes, incubated for 2 h and washed. 
200 pL o f  biotinylated Con A  diluted 1:1000 witii lectin assay buffer was added to all 
tubes and incubated for 1.5 h then washed. 200 pL o f  isoluminol-streptavidin diluted 
1:1000 was added to all tubes, incubated for 1 h, washed and measured.
The polystyrene tubes used for storing the CSFs at 4°C for 4 weeks, and those 
containing CSF Y  kept at -70°C, were washed x3 and assayed along with the IgG coated 
tubes. For IgG measurement, diluted anti-IgG-ABEI was added directly to the tubes and 
the assay continued as described above for the IgG assay. For the Con A  assay, diluted 
biotinylated Con A was added directly to the tubes, and the assay continued as described 
above for the Con A  assay.
4.4.4. Results
4.4.4.I. Results for Serial Dilution o f CSF: Assay with Anti-lgG, Con A and RCA
Graphs showing anti-lgG binding to dilution curves o f  purified IgG, CSF A  and 
CSF B are shown in Figures 4.14(a), (b) and (c) respectively. The curves are o f  similar 
shape for all three samples, and reach a plateau by 5 m g/L  IgG, indicating near saturation 
o f  the capture antibody at this level. In die lectin assays, dilution o f  samples to 5 m g/L
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IgG would ensure that the capture antibody is saturated and enable comparison o f  results 
o f  different samples for a particular lectin.
In all three graphs, periodate treated tubes show less binding capacity tiian non 
periodate treated tubes, indicating die capture antibody is more damaged by die 
periodation metiiod tiian was previously suspected, when over 95% o f  the activity was 
seen. The damage to the antibody appears to have a variable effect on its binding to the 
IgG in different samples: with CSF A, Figure 4.14(b), tiiere is 55% o f  die original activity; 
with CSF B, Figure 4.14(c), there is 90% activity. Treatment o f  coated tubes with 
ethanolamine reduces IgG binding, with the effect o f 1% (v/v ) solution more than 0.2%
CM-
Figure 4.15 shows binding o f  Con A  and RCA for different dilutions o f  CSF A  
[(a) and (b) respectively] and for CSF B [(c) and (d) respectively]. The effect o f  
ethanolamine on CSF A  with Con A  and RCA is shown in (e) and (f) respectively.
Graphs (a) to (d) for antibody coated tubes (open square symbol) show that there 
is increasing binding o f  both lectins even beyond the point where die capture antibody is 
largely saturated (i.e. 5 m g/L  IgG). The increasing binding must be attributable to 
increasing binding o f  die interferent, as suggested by die non-antibody-coated tubes (filled 
squares). The graphs for coated and uncoated tubes are linear apart from Graph (a) where 
there is a flattening o f  the graph. Unless die interferent is eliminated, the chosen 
saturating concentration o f  the CSF IgG would be critical in the lectin assays. Dilution o f  
CSFs to contain 5 m g/L  IgG has been considered, but a level o f  10 m g/L  might produce 
very different data and a different conclusion.
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Figure 4.14. Serial dilutions of (a) purified IgG, (b) CSF A and (c) CSF B assayed with Anti- 
IgG-ABEI. Legends indicate the following preparations to assay tubes: C = coated with anti- 
IgG; B = blocked with 10 g/L BSA; P = periodate treated; no P = not periodate treated; E = 
treated with 0.2% (v/v) or 1.0% (v/v) ethanolamine. Points for samples assayed in duplicate 
are shown. For further experimental details, see 4.4.3.1.
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• No C/B/P/E(1%)
IgG mg/L IgG mg/L
Figure 4.15. Serial dilutions of CSF A and CSF B assayed with Con A or RCA. Legends 
indicate the following preparations to assay tubes: C = coated with anti-IgG; B = blocked with 
10 g/L BSA; P = periodate treated; no P = not periodate treated; E = treated with 1.0% (v/v) 
ethanolamine. Points for samples assayed in duplicate are shown. For further experimental 
details see 4.4.3.1.
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Graphs (e) and (f) show that ethanolamine does not have an effect on binding o f  
either lectin with coated or uncoated tubes. Generally the patterns o f  the graphs are the 
same as for graphs (a) and (b), although there is some degree o f  imprecision at the low 
IgG levels, and in some cases the RLUs for 0.2 and 0.6 m g/L IgG were lower than RLUs 
for the 0 m g/L IgG, and so the regression lines do not pass through the origin.
4.4.4.2. Results for DEAE Column Fractionation o f CSF
a. Results for First Fractionation
Figure 4.16 shows the IgG and total protein concentrations in the DEAE column 
fractions o f  CSF BM. IgG is seen to elute in fractions 3, 4 and 5. Figure 4.17 shows the 
Con A binding to CSF BM, to a range o f  dilutions o f BM and to the DEAE fractions 3 
and 4 o f  BM with both antibody coated tubes and blocked only control tubes. In the neat 
CSF, interferent binding, reflected by the control tubes, is very large and must contribute 
considerately to the Con A binding with the antibody coated tubes. With 1:20 dilution o f 
the CSF, the interferent as well as the IgG is diluted and overall Con A binding with 
coated tubes is reduced. With further dilution, the interferent binding in the control tubes 
decreases, but binding in the antibody coated tubes remains fairly constant. This indicates 
that more IgG can bind to the antibody after removal o f  the interferent. Fractions 3 and 
4 do not appear to have much advantage in terms o f reduction o f interferent compared to
120
Fraction No.
Figure 4.16. Measured IgG and total protein in DEAE column fractions of CSF BM. For 
further details of method see 4.4.3.2.
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Figure 4.17. Con A immunoassay, using antibody coated tubes and control (blocked only) 
tubes, of CSF BM, a range of dilutions of CSF BM, and DEAE column fractions of CSF BM. 
Error bars represent SEM of duplicate samples in the immunoassay. For further method 
details see 4.4.3.2(a).
the diluted CSF. Unfortunately a ‘no sample’ blank was not run, so the background Con 
A binding cannot be assessed.
b. Results for Second Fractionations
The IgG and total protein measurements, expressed as absorbance changes for the 
DEAE column fractions for CSFs H and W are shown in Figures 4.18(a) and (b) 
respectively. Again there is a definite IgG peak in fractions 3, 4 (and 5), with very litde 
IgG subsequendy eluted even after addition o f  KC1. The Con A binding o f  the pooled 
fractions 3, 4 and 5 compared with the whole CSFs, after dilution to 5 m g/L IgG, is given 
in Figure 4.19. With dilution o f  the CSFs, the interferent binding (shown by the dark 
columns) is fairly small relative to the overall binding in the antibody-coated tubes (light 
columns). The interferent binding in the pooled fractions is slighdy reduced compared to 
that in the whole CSFs.
The IgG measured in the pooled fractions 3 to 5 for CSFs H and W was used to 
calculate the recovery o f  IgG from the column. These were found to be only 34% and 
18% respectively.
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(a) CSF H
-♦  C S F  H IgG
■ - C S F  H Total Protein
(b) CSF W
C S F  W  IgG
- - C S F  W  Total FYotein
Figure 4.18. Absorbances of IgG and total protein assays of DEAE column fractions of (a) 
CSF H and (b) CSF W. KCI buffer was added to the column after collection of fraction 10. For 
further experimental details see 4.4.3.2(b).
4.4.4.3. Results for Effect o f Storage at 4°C on IgG and Interferent
Figure 4.20 shows the IgG measured in (a) CSF Y, (b) CSF W  and (c) CSF E after 
storage at 4°C for up to 4 weeks. There does not appear to be any decrease in IgG over 
this time. An odd result was obtained for CSF Y  after 4 weeks [Graph (a)] where the IgG 
appears to increase compared to the other aliquots. It is possible that this was due to the 
freezing and thawing o f  the other aliquots prior to the assay, whereas the 4 week samples 
were not frozen as the assay was performed at 4 weeks from the beginning o f  the storage. 
However, this effect is not seen in the other two CSFs treated in the same way.
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Figure 4.19. Con A binding to CSFs H and W and their pooled DEAE IgG fractions after 
dilution of all samples to 5 mg/L IgG. Error bars represent SEM of triplicate sampling for the 
immunoassay. For further experimental details see 4.4.3.2(b).
Figure 4.21 shows Con A binding to the three CSFs stored for different lengths o f 
time. The charts for each CSF show the binding for blocked only control tubes as well as 
the standard anti-lgG coated, blocked and periodate treated tubes, and for CSF assayed 
neat and diluted to 5 mg/L. There is no evidence o f  a decrease in Con A binding with 
time due to removal o f  either IgG or interferent from the sample, except possibly for CSF 
E [chart (c)] where the neat CSF shows a downwards trend. However, this is not reflected 
in the controls or the dilution for CSF E and is probably due to assay imprecision.
The assay o f the CSF storage tubes is shown in Figure 4.22. The prepared IgG 
coated tubes show increasing RLU for IgG with increasing IgG coating but a decrease 
with the 200 pg coating. This decrease is possibly due to steric hindrance from excessive 
coating. The Con A binding is similar in all the prepared tubes. In the sample tubes, the 
IgG binding is small, but Con A binding is relatively high, suggesting substantial binding 
o f  the interferent to the tubes.
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Figure 4.20. IgG measured in three CSF samples stored at 4°C for up to 4 weeks. Error 
bars represent SEM of duplicate sampling. See 4.4.3.3 for further experimental details.
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Figure 4.21. Con A binding for 3 CSFs after storage at 4°C for up to 4 weeks. CSFs were 
assayed neat and diluted to 5 mg/L of IgG. Control tubes are blocked only, with no antibody 
coating. Error bars represent SEM of duplicate samples. For further experimental details 
see 4.4.3.3.
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Figure 4.22. IgG and Con A assays of washed tubes used for storage of CSFs Y, W and E 
compared to a range of IgG coated tubes. Error bars represent SEM of duplicate tubes. For 
further experimental details see 4.4.3.3.
4.4.5. Discussion for Investigation of Interferent
The dilution studies have confirmed that using less CSF sample reduces the effect 
from the interferent. When the sample is diluted so that it contains 5 m g/L o f  IgG, the 
capture antibody is almost saturated with IgG, although absolute saturation is not reached 
even at the 10 m g/L level. The interferent causes much less lectin binding at 5 m g/L 
compared to 10 m g/L as judged by the blocked-only control tubes. So it seems expedient 
to dilute all samples to 5 m g/L for the lectin assays.
It is difficult to assess the effect o f  ethanolamine with the data obtained. With the 
IgG assays, ethanolamine added to periodate treated tubes caused a reduction in measured 
RLUs, suggesting that IgG may be binding to periodate-activated groups on the capture 
antibody. However, non periodate treated tubes gave higher binding with similar shaped 
graphs, so it would seem unlikely that non-specific IgG binding is caused by periodation 
[Figures 4.14(a) and (b)]. As the 1% (v/v) ethanolamine treatment produces less binding 
than the 0.2% (v/v), it is possible that ethanolamine treatment damages the antibody. 
Further work could include ethanolamine treatment o f  non-periodate treated tubes, to see
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if it causes deterioration o f  binding. The lectin assays seem unaffected by ethanolamine 
treatment, so it does not appear to be the cause o f  the interference in the lectin assays, 
which was the subject o f  the experiment, so no further work was done.
The reduction o f  IgG binding to periodate treated tubes was greater than had 
been previously found and led to using 1:100 dilution o f  anti-IgG rather than 1:400 for 
tube coating.
With DEAE column fractionation o f  CSF, binding o f  the interferent was reduced, 
although simple dilution o f  the CSF produced almost die same reduction. However, with 
DEAE fractionation the recoveries o f  IgG were low, so more work would need to be 
carried out if DEAE purification were to be used for the lectin assays o f  patients’ samples. 
A  quantity o f  protein A  (Prosep A) was donated, however, and affinity purification o f  
samples with this is described in section 4.5.
The results showed that IgG was not reduced in CSF with storage at 4°C. 
However, assay o f  the storage tubes did show substantial Con A  binding, so there may be 
adhesion o f  the interferent. Further work on storage o f  CSF will be described in the next 
section.
4.5. Protein A Separation of IgG
4.5.1. Introduction
Preliminary work (data not presented here) found that a 0.2 mL Prosep A  column 
retained IgG better than a 0.1 mL column, and that there was litde advantage using a 
stirred mode over a flow-through mode. This section will firstiy describe the initial Con A 
assay o f  CSF fractions, followed by the selection o f adsorption, elution and neutralising 
buffers. Then stepped elution studies are shown, measuring IgG, total protein and Con A  
binding (including blocked only control tubes to indicate interferent binding) witii
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assessment o f  IgG recovery. Finally, studies on die stability o f  IgG in the eluates under 
different storage conditions are described, together with ways to improve it.
4.5.2. Reagents
Reagents are as previously described, widi the following additions.
1. Prosep A. Protein A  immobilised on controlled pore glass. Bioprocessing 
Ltd., N o 1 Industrial Estate, Consett, Durham, DH8 6JT. Kindly donated by 
Dr P. Kwasowski, Surrey University. 0.2 mL used in a 1.4 mL capacity 
polypropylene column.
2. Neutralising/Preserving buffer. 0.5 M phosphate buffer pH 7.4 containing 
azide. Dissolve (a) 15.3 g o f NaH2P 0 4.2H20  and (b) 57.6 g o f  Na2H P 04 in 
about 950 mL o f  water. Add 5 g /L  NaNv Test pH and adjust if necessary 
widi small addition o f  (a) or (b), tiien make the volume up to 1 L with water.
3. Phosphate buffers pH 7.4, 0.5 M, 0.2 M and 0.1 M. Prepared from 0.5 M 
buffer.
4. Adsorption buffers:
• NaCl 2 M. Dissolve 5.8 gNaCl in 50 mL PBS
• Glycine 2 M, pH 7.0. Dissolve 7.5 g glycine in 50 mL PBS.
5. Elution buffers
• HC1 0.03 M, pH 1.5. Dilute 0.14 mL concentrated HC1 to 50 mL with 
water.
• HC1 added to water to give solutions o f  pH 2.0 and pH 2.5.
• HCl/glycine pH 3.0. Dissolve 0.375 g o f  glycine with 0.292 g NaCl in
50 mL water. To 23 mL o f  this add 7 mL o f  0.1 M HC1 and adjust to
pH 3.0.
• Sodium citrate 0.5 M in water (pH 2.15).
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• Disodium hydrogen phosphate (Na2H P 04) 0.5 M in water.
• Citrate/phosphate buffers: sodium citrate (0.5 M) + Na2H P 04 (0.5 M)
mixed to give solutions o f  pH 2.8, 3.9, 4.9, 6.7 and 7.8
• Sodium citrate (0.5 M) + Na2H P 04 (0.5 M) with 2 M glycine (1.5 g/10 
mL). Adjusted to pH 2.8.
• Potassium iodide 2 M (3.32 g/10 mL water)
• Sodium thiocyanate 2 M (5 g/10 mL water).
6. Anti human IgG conjugated with horseradish peroxidase. Product No PP04, 
The Binding Site, Ltd. PO Box 4073, Birmingham B29 6AT.
7. o-Phenylenediamine dihydrochloride (OPD) and urea hydrogen peroxide 
tablets set. Sigma product N o P-9187. The reagent was prepared just before 
use by dissolving one o f  each o f  the tablets in 20 mL water. This produces a 
0.05 M phosphate-citrate buffer solution containing 0.4 pg /L  OPD and 0.4 
pg /L  urea hydrogen peroxide.
8. Peroxidase stopping solution: 3 M HC1. Dilute 28 mL o f  conc. HC1 to 100 
mL widi water.
4.5.3. Methods
4.5.3.1. Preparation o f the Column
a. Initial Con A  Assay o f Protein A  fractions
0.2 mL o f  Prosep A  was placed in the column and, after draining, was re­
suspended in 1.0 mL o f  PBS. After settling out, the buffer was aspirated, thus removing 
any fines, and flushed with 3 ml o f  0.03 M HC1, followed by 3 mL o f  PBS.
0.2 mL o f  CSF P, containing 122 m g/L  IgG, was applied to the column, followed 
by 0.2 mL o f  PBS with collection o f  the breakthrough (fraction P-l). 1.0 mL o f  PBS was 
applied to the column, followed by 0.2 mL o f  0.03 M HC1, then another 0.2 mL o f  0.03 M
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HC1, collecting the eluate onto 0.2 mL o f  0.2 M PBS (fraction P-HC1). After flushing the 
column with 1 mL o f  0.03 M HC1 and 1 mL o f  PBS, 1.0 mL o f  CSF B (containing 20 
m g/L  o f  IgG) was applied to the column and die breakthrough collected (fraction B-l). 
1.0 mL o f  PBS was then applied to the column followed by 0.4 mL o f  0.03 M HC1, 
collecting the eluate onto 0.4 mL o f  0.2 M PBS (fraction B-HC1).
The collected fractions were assayed for IgG by IT and then, witii the CSFs, were 
assayed with Con A  after diluting the HC1 fractions and the CSFs to 5 m g/L  o f  IgG. The 
Con A  assay was as follows:
Tubes were coated overnight with 0.2 mL o f  anti-IgG diluted 1:100, washed, then 
blocked for 1 h witii 0.2 mL 10 g /L  BSA, washed and treated with 0.3 mL o f  0.01 M 
periodate for 20 h at 4°C. Control tubes were blocked only with 0.2 mL 10 g /L  BSA. 
200 pL o f  PBS-Tween was placed into prepared tubes followed by 10 pL o f  sample in 
triplicate and incubated 1.5 h. After washing, 0.2 mL o f  biotinylated lectin (diluted 1 in 
1000 with lectin assay buffer) was added and incubated for 1.5 h. After washing 0.2 mL 
isoluminol-streptavidin was added (diluted 1 in 1000 with lectin assay buffer) and 
incubated for 45 min. After a final wash, RLUs were measured.
b. Adsorption Buffer
Three CSFs were pooled to give sufficient volume. The column was primed with 
0.4 mL o f  the first buffer, then 0.2 mL o f die buffer was mixed with 0.2 mL o f CSF and 
applied to the column. A  further 0.4 mL o f  the buffer was added. Then 0.1 mL o f  0.03 M 
HC1 was added, followed by a further 0.4 mL with collection o f  eluate onto 0.1 mL o f  0.5 
M phosphate buffer. The column was cleaned with a further 0.4 mL o f  0.03 M HC1, then 
die procedure repeated with the next buffer.
c. Elution Buffer
2.5 mL o f  pooled CSF samples was mixed witii 2.5 mL o f  PBS/glycine. 0.4 mL o f  
the mixture was applied to the column, followed by 0.4 mL o f  PBS/glycine. 0.2 mL o f
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the first eluant was applied, followed by another 0.4 mL with collection o f  the eluate. The 
column was cleaned with 0.4 mL o f  0.03 M HC1 then equilibrated with 0.4 mL o f  
PBS/glycine and the procedure repeated with each eluant in turn.
d. Column Capacity
The column was primed with 1.0 mL o f  PBS, then 14 x 100 pL aliquots o f  CSF 
(IgG measured by IT was 76 mg/L) were applied to the column and the breakthrough 
collected after each addition. IgG (IT) was then measured on each breakthrough fraction.
e. Neutralising Buffer
The selected elution buffer was mixed in the ratios 1:1 with 0.01 M PBS pH 7.6, 
0.1 M, 0.2 M, and 0.5 M phosphate buffer pH 7.4, and also in the ratios 2:1, 3:1 and 4:1 
with the 0.5 M phosphate buffer. The pH o f  the mixtures was measured with pH paper 
and confirmed with a pH meter.
4.5.3.2. Stepped Elution Studies
a. Stepped Elution with Buffers of DecreasingpH
0.4 mL o f  pooled CSF ([IgG] = 56 mg/L) was mixed with 0.4 mL o f  adsorption 
buffer (PBS containing 2 M glycine) and applied to the column and the breakthrough 
collected as Fraction 1. Then 0.4 mL o f  adsorption buffer was applied, collecting the 
breakthrough as Fraction 2. Then in turn, 0.4 mL aliquots o f buffers o f  pH 7.8, 6.7, 4.9,
2.8 and 1.6 were applied to the column, collecting the eluates as Fractions 3 to 7. 0.1 mL 
o f  neutralising/preserving buffer was added to each fraction botde prior to collection.
The fractions were then assayed for total protein by Coomassie Blue (Cowdrey, 
1991) and for IgG as described in section 3.3.3.1. The Con A  assay was as described in
4.5.3.1, although the fractions were sampled (10 pL) without dilution.
b. Stepped Elution with Additional Washes
The previous gradient elution was modified: only the pH buffers which had eluted 
protein were used; twice the volume o f  these was applied to ensure all possible IgG was
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eluted with each buffer, and additional washes were applied after die sample application to 
ensure that the protein eluted with pH 7.8 was not simply flow-through o f  the sample.
Fractions were collected into 0.1 mL o f  neutralising/preserving buffer. 0.5 mL o f  
CSF PB (containing 33 m g/L  IgG) was mixed with 0.5 mL adsorption buffer and applied 
to the column with collection o f  the breakthrough (Fractionl). Three washes o f  
adsorption buffer were applied with collection o f  breakthrough after each (Fractions 2 to 
4). Then 0.4 mL o f pH 7.8 was applied (Fraction 5), 0.4 mL o f  wash (Fraction 6), two 
applications o f 0.4 mL o f  pH 2.8 buffer (Fractions 7 and 8), two applications o f pH 2.1 
buffer (Fractions 9 and 10) and two applications o f  pH 1.6 buffer (Fractions 11 and 12). 
Total protein, IgG and Con A  binding were again measured on the fractions as described 
in (a) above.
c. Stepped Elution ivith Small Volumes
0.2 mL o f  CSF was mixed with 0.2 mL adsorption buffer and applied to the 
column and the breakthrough collected (Fraction 1). The column was washed with 1.6 
mL o f  adsorption buffer (Fraction 2) and a further 0.4 mL (Fraction 3). Then 0.4 mL o f  
pH 7.8 buffer containing 2 M glycine was added (Fraction 4) followed by 0.4 mL o f 
adsorption buffer (Fraction 5), 0.4 mL o f  pH 7.8 buffer (no glycine) (Fraction 6), and two 
additions o f  0.4 mL o f  adsorption buffer (Fractions 7 and 8). Then 10 aliquots o f  0.1 mL 
o f  eluate (pH 2.8 buffer) were applied with collection after each (Fractions 9 to 18). 
Finally 0.4 mL o f  pH 1.6 buffer was added (Fraction 19). To fractions 9 to 19 was added 
25 pL o f  neutralising/preserving buffer.
Fractions 3 to 19 were assayed in duplicate for IgG and fractions 3 to 17 were 
assayed in triplicate for Con A  binding, as described in (a) above.
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a. Without BSA
CSF BW (IgG = 172 mg/L) was fractionated with the Prosep column by applying 
39 pL o f  the sample prediluted witii 461 pL o f  adsorption buffer. (The volume applied 
was calculated from the [IgG] so diat it contained 6.7 pg o f  IgG, which would produce an 
eluate containing 5 m g/L  IgG, assuming 67% recovery). After draining, a further 0.8 mL 
o f  adsorption buffer was applied. After draining, 0.1 o f  elution buffer was applied 
followed by a further 0.8 mL o f  elution buffer with collection o f  the eluate into a glass 
botde (z5) containing 0.2 mL o f  neutralising buffer. The column was cleaned with 0.4 mL 
o f pH 1.6 buffer and re-equilibrated with 0.8 mL o f  adsorption buffer.
100 pL o f  the eluate was placed in a glass botde at -70°C (Day 0). The remainder 
o f  the fraction was stored at 4°C and after 29, 40, 57 and 75 days, further 100 pL aliquots 
were placed at -70°C. These were thawed out and immediately diluted 1:5 with PBS and 
assayed for IgG as described in 3.3.3.1.
To test the stability o f  IgG in different solutions, 100 pL o f  100 m g/L  IgG stock 
solution was added to i) PBS, ii) pH 2.8 buffer and iii) pH 2.8 buffer containing 
neutralising/preserving buffer in the ration o f  4+1. The mixtures were incubated for 1 h 
before assaying for IgG.
b. Stability of IgG Fractions in Different Bottles.
Calculated volumes o f  CSF P (containing 31 m g/L IgG), CSF B (366 m g/L IgG) 
and CSF L (66 mg/L) were diluted to 1.5 mL with adsorption buffer so that they 
contained 6.7 m g/L  o f  IgG. (The volumes were 645 pL, 75 pL and 303 pL respectively). 
For each CSF 0.5 mL o f  diluted CSF was applied to the column and fractionated as 
described in a) above. This was repeated three times, pooling the eluates, for each CSF,
4.5.3.3. Stability o f IgG in Eluates
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then adding a further 0.4 mL o f  elution buffer and 0.1 mL neutralising buffer to make up 
the volume to 3.5 mL.
The pooled eluates for each CSF were then aliquoted into containers as follows:
• 0.5 mL into glass, polystyrene or polypropylene bottles.
• 0.5 mL into similar bottles to which had been previously added 5 pL o f  300 
g /L  BSA.
• 0.1 mL into two polypropylene tubes and placed immediately at -70°C.
• After 4 days further 0.1 mL aliquots were placed in polypropylene tubes and 
immediately frozen at -70°C.
The stored fractions were diluted 1 in 5 immediately before the IgG assay, 
however one set o f  the polypropylene-stored eluates was diluted 1:5 at 1 h before the 
assay, to see if IgG bound to the tube at this stage. The ‘parent’ CSFs P, B and L were 
diluted 1 in 31, 1 in 366 and 1 in 66 respectively. For the IgG assay die sample volume 
was 5 pL, with sampling in triplicate, otherwise the assay was performed as described in
3.3.3.I.
To measure IgG bound to the inside o f  the storage tubes, a rudimentary 
calibration curve was prepared by incubating IgG standard solutions (0, 0.2, 0.6, 1.0, 2.0 
and 3.0 m g/L  IgG) overnight in coated tubes, and washing. The tubes containing eluate, 
and those used to make dilutions, were aspirated and washed. Anti-IgG-HRP was diluted 
1 /2000 with PBS-Tween and 400 pL was added to ah washed tubes and incubated for 45 
min. After washing, 400 pL o f  prepared OPD solution was added to the tubes, as well as 
a blank tube, and incubated in the dark at room temperature for 30 min. After addition o f  
100 pL o f  3 M HC1 to each tube and mixing, the absorbance o f  the solutions was 
measured against the blank tube at 492 nm.
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4.5.4. Results
a. Initial Con A  Assay of Protein A  Fractions
Con A binding o f  the CSF fractions is shown in Figure 4.23. CSF P appears to 
have proportionally less interferent binding than CSF B, as shown by the blocked-only 
tubes. In the breakthrough fractions P-l and B-l, the proportion o f  interferent to IgG 
binding is as high or higher than in the untreated CSFs. However, in the HC1 eluted 
fractions, the binding o f  interferent is much reduced. These results are encouraging and 
suggest Protein A may be used to eliminate the interferent.
4.5.4.I. Results for Preparation o f the Column
Anti-IgG coated 
BSA Blocked Only
Figure 4.23. Con A assay of two CSFs and their protein A fractions. Error bars represent 
SEM of triplicate sampling in the assay. For experimental details see 4.5.3.1 (a).
b. Adsorption Buffer
The result o f  the IgG (IT) assays o f  the eluate with different adsorption buffers is 
shown in Figure 4.24. The addition o f  glycine appears to dramatically improve the 
efficiency o f  the column.
c. Elution Buffer
Figure 4.25 shows the results o f  the IgG (IT) assays for different eluates. The pH 
3.9 and 4.9 buffers are not o f  low enough pH to elute IgG at all. The chaotropic agents,
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potassium iodide and sodium thiocyanate, also do not elute IgG. The pH 1.5, 2.15 and
2.8 buffers are equally effective, but the inclusion o f  glycine reduces elution.
d. Column Capacity
The column was loaded with 14 x 100 pL aliquots o f  CSF, but IgG was undetect­
able in each breakthrough volume collected after each 100 pL load. This indicated that 
the 106 pg in total o f  IgG loaded onto the 0.2 mL column did not exceed the column
3 0 -,
Figure 4.24. The effect of different adsorption buffers on IgG elution. For experimental 
details see 4.5.3.1(b).
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Figure 4.25. Elution of IgG with Different Elution Buffers. For experimental details see 
4.5.3.1(c).
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capacity. This is far above the level (6.7 jag) that will in practice be loaded onto the 
column, and far below the manufacturers stated column capacity o f  11 mg o f human IgG 
per 1 mL column (Godfrey, 1996).
4.5.4.2. Results for Stepped Elution Studies
a. Stepped Elution with Buffers of Decreasing pH
Figure 4.26 confirms the findings o f  4.5.4.1(c) that IgG is not eluted until pH 2.8 
is used. However, even though the recovery o f  IgG in the pH 2.8 fraction is 97%, there 
appears to be some IgG remaining which is eluted only with the HC1 at pH 1.6. It is 
possible that this IgG would have been eluted with more pH 2.8 buffer, and this will be 
checked in the next experiment. This fraction also has a high amount o f  Con A binding 
relative to the IgG concentration compared to the pH 2.8 fraction, suggesting the IgG in 
this fraction is glycosylated differendy from that in the pH 2.8 fraction.
Some non-IgG protein material, which binds to a small extent to Con A, is eluted 
with pH 7.8. In the next experiment the volume o f  wash buffer will be increased to try to 
remove this.
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Figure 4.26. Stepped Elution 1. Measurement of fractions of CSF eluted from a protein 
A column using, stepwise, buffers of decreasing pH. For experimental details see
4.5.3.2(a).
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Figure 4.27 shows that the majority o f  IgG is eluted with the two volumes o f  pH
2.8 buffer. Therefore in the first stepped elution experiment the IgG appearing in the 1.6 
pH buffer (Figure 4.24) was due to insufficient volume o f 2.8 buffer to elute all bound 
IgG, and was not a function o f  the lower pH. Interestingly, the Con A binding relative to 
IgG in the second IgG fraction was higher than in the first fraction in both experiments.
Figure 4.27 also shows that protein is still being removed from the column even in 
the fifth wash, although in this wash the interferent binding is minimal. The pH 7.8 
buffer, however does appear to elute some Con A binding material, and may be due to the 
different pH, different molarity or lack o f  glycine, compared to the adsorption buffer.
The IgG recovered in fractions 7 and 8 combined is 91% o f  the IgG applied to 
the column.
b. Stepped Elution with Additional Washes
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Figure 4.28. Stepped Elution 3. Elution of IgG from a protein A column with small volumes 
(0.1 mL) of pH 2.8 buffer, with additional washes before elution. For experimental details
see 4.5.3.2(c).
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Figure 4.28 shows that the majority o f  IgG is eluted with 0.4 mL o f  pH 2.8 buffer, 
after addition o f  the first 0.1 mL when no IgG is eluted. There are small amounts in the 
wash fractions, and notably fraction 5 due to addition o f  pH 7.8 buffer with glycine. 
There is no additional IgG eluted in fractions 6 or 7 from the pH 7.8 buffer with no 
glycine, therefore it appears to be the pH change which elutes IgG with this buffer, rather 
than a change in molarity.
Fraction 19 contains some IgG eluted with the pH 1.6 buffer, but is only 0.4% o f 
the IgG applied to the column, so it should not affect the results o f  the lectin assays. The 
recovery o f  IgG in fractions 10, 11, 12 and 13 combined was 53%.
The Con A binding o f  the control tubes indicates that there is very little 
interferent in this particular CSF. The Con A binding with the antibody coated tubes 
shows high levels with the washes (from non-IgG material) and a peak with the IgG peak.
c. Stepped Elution with Small Volumes
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Figure 4.27. Stepped Elution 2. Measurement of fractions of CSF eluted stepwise from a 
protein A column, with incorporation of additional washes. For experimental details see
4.5.3.2(b).
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However there is no indication o f  a gradient o f  glycosylation o f  IgG as was suspected.
4.5.4.3. Results for Stability o f IgG in Eluates
a. Without BSA
Measurement o f  the fresh eluate gave an IgG level o f  4.23 mg/L. This was 
considerably higher than the levels in die aliquots frozen after storage at 4°C for between 
0 and 75 days, as shown in Figure 4.29. Freezing appears to have an adverse effect on 
IgG, although there is also a loss over time at 4°C. This shows that addition o f 
neutralising buffer to the eluates preserves IgG in the short term.
After storage at 4°C for 1 h, the 10 m g/L  IgG diluted in PBS was 9.97 m g/L, in 
the pH 2.8 buffer it was 6.9 m g/L  and in the pH 2.8 buffer with neutralising buffer, it was 
10.4 mg/L.
b. In Different Containers
Figure 4.30 shows the IgG measured in the different botdes after storage o f  
eluates for 5 days. It is apparent that addition o f  BSA greatiy improves recovery o f  IgG. 
Freezing drastically reduces IgG levels. AN OVA tests (Bonferroni’s Multiple Comparison
Days stored at 4°C
Figure 4.29. Stability of IgG in eluate, without addition of BSA, stored at 4°C. Error bars 
represent SEM of triplicate samples. For experimental details see 4.5.3.3(a).
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Figure 4.30. Measurement of protein A eluates from three CSFs, stored for 5 days at 4°C 
(or frozen) in different containers with and without addition of BSA. Error bars represent 
SEM of triplicate sampling in the IgG assay. For experimental details see 4.5.3.3(b).
Tests) showed no significant difference between the means for samples stored in glass, 
polypropylene and polystyrene without BSA (P=0.6771), or for them stored with BSA 
(P=0.7560). Paired t test comparisons o f ‘glass’ with ‘glass with BSA’, and ‘polypropylene’ 
with ‘polypropylene with BSA’ showed the means to be significandy different (P=:0.0248 
and 0.0256 respectively) although comparison o f  ‘polystyrene’ with ‘polystyrene with BSA’ 
showed no difference (P=0.0608). Paired t tests comparing the frozen samples (day 1) 
with the polypropylene samples showed a difference (P=0.0160), as did comparison o f  the 
prediluted samples with samples (‘glass’) diluted just before assaying (P=0.0153).
Figure 4.31 shows the results o f  the OPD assay o f  IgG bound to the containers. 
The binding to polypropylene without BSA addition was much higher than to the other 
materials. Addition o f  BSA almost completely reduced IgG binding to polypropylene and 
polystyrene, but with glass it remained the same. There was a small amount o f  IgG 
binding to the glass botdes used for the dilutions.
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Figure 4.31. Eluate IgG bound to different containers with and without addition of BSA after 
storage for 5 days. IgG was measured using anti-human IgG-HRP conjugate with 
OPD/peroxide substrate. For experimental details see 4.5.3.3(b).
However the amount o f  IgG bound to the containers, from about 10 ng up to 50 
ng (Figure 4.31), is small compared to the amount o f IgG in solution (Figure 4.30). The 
IgG in solution, for 0.5 mL volumes o f  eluate that were placed in the containers ranged 
from about 1.25 pg for the eluates without BSA to a maximum o f 3.5 pg with BSA. - 
about 100 times more than the IgG measured on the containers. For the highest binding 
tube (polypropylene without BSA), the IgG bound to the tube is about 2.5% o f  the IgG 
measured in solution.
Recoveries o f  IgG applied to the column were 80%, 80% and 67% for eluates o f 
CSFs P, B and L respectively in glass botdes with BSA, compared to 42%, 37% and 35% 
for the same eluates in glass without BSA.
4.5.5. Discussion for Protein A Separation of IgG
A method for affinity purification o f  IgG was developed for the lectin assays, 
using a 0.2 mL column o f  protein A attached to glass beads. For the adsorption buffer, 
addition o f  2 M glycine increased recovery o f  IgG. For elution, citrate-phosphate buffer
o f  pH 2.8 was found to be as effective as lower pH eluants. Chaotropic agents did not 
elute IgG (possibly due to interference by glycine).
The amount o f  IgG applied to the column was far below the column capacity, 
giving optimum chance o f  recovery o f  all IgG subclasses, including IgG3.
Stepped elution studies showed that non-IgG material can be washed through the 
column prior to elution o f  IgG. The majority o f  IgG can be eluted from the 0.2 mL 
column with 0.4 mL o f  eluant, after a 0.1 mL ‘prime5 o f eluant with the breakthrough not 
being collected. Recoveries o f  IgG ranged from 50% to 90%. The eluates were largely 
free o f  lectin-binding interferents, as determined by assays using blocked-only control 
tubes. Con A  binding o f  die elution fractions suggested that IgG eluted as a gradient o f  
glycoforms, but this was not confirmed.
Collection o f  the eluates onto neutralising 0.5 M phosphate buffer reduces loss o f  
IgG owing to the low pH o f  the eluant. Some loss o f  IgG was found to be due to binding 
to the storage container, but most would appear to be from denaturation or aggregation o f  
the IgG. Addition o f  BSA was found to reduce the loss, possibly fulfilling a protective 
role towards the IgG in the same way as proteins would in the body. Freezing o f  the 
eluate has an adverse effect on IgG. Therefore eluates will be stored in glass botdes with 
added BSA at 4°C for up to 2 weeks before lectin assays are performed. For the lectin 
assays, the desired IgG content o f  each eluate is 5 fig per 1.0 mL o f  eluate. Recovery o f 
IgG from the column in earlier studies had averaged 75%, therefore the IgG to load on 
the column is 6.67 pg, and die volume o f  a CSF sample to apply will be:
(6.67 x 1000) pL.
[IgG] o f  sample
Measurement o f  IgG in the eluates will then enable adjustment o f  each sample volume for 
the lectin assays, so that a consistent amount o f  IgG from each sample is available for 
binding by the capture anti-IgG.
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4.6.1. Introduction
The foregoing work has enabled the development o f  a working method for 
probing sugars on CSF IgG using lectins, as will be described. The method was used to 
analyse two groups o f  samples: CSF from patients with confirmed MS, and control CSF 
from neurological patients without demyelinating disease. Four different lectins were 
used, selected by showing binding to CSF IgG in the development work, as well as from 
information from the literature.
4.6.2. Reagents
See previous Reagent sections for full descriptions.
Affinity Chtvmatography:
• Prosep protein A  column, 0.2 mL.
• Phosphate buffered saline 0.01 M (TBS’). Sigma PBS tablets.
• Adsorption/wash buffer. 0.01 M PBS containing 2 M glycine, pH 7.0.
• Elution buffer. 0.05 M solutions o f  cittic acid and Na2H P 04 mixed to 
produce pH 2.8.
• Neutralising/preserving buffer. 0.5 M phosphate buffer containing NaN3 (5 
g/L) and BSA (7.5 g/L).
• HC10.03 M, pH 1.6.
IgG/Lectin Immunoassays:
• Biotinylated lectins. From Vector Labs. Reconstituted as recommended to 
give concentrations o f  5 m g/L  (Con A and RCA120), 2 m g/m L (SNA) and 1 
mg/mL (DSL). Aliquots o f  50 pL were stored at -70°C.
• Lectin assay buffer. Made up freshly before use. TBS (Tris buffered saline 
tablets, Sigma Co.) containing 1 M MgCl2 and 1 M CaCl2.
4.6. Lectin Assays of MS and Control CSF samples
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• IgG assay buffer. PBS containing Tween (0.5 g/L)
• Coating buffer. Carbonate buffer pH 9.2 (Sigma Carbonate buffer tablets) 
containing anti-lgG (Sigma) diluted 1:400 (for the IgG assays) or 1:100 (for the 
lectin assays).
• Wash solution. NaCl (9 g/L ) containing Tween (0.5 mL/L).
• Blocker. 10 g /L  BSA. 32 mL PBS containing 0.96 mL o f  300 g /L  BSA.
• Periodate 0.01 M. 63 mg o f  N aI04 in 30 mL citrate buffer, 0.05 M pH 4.0. 
Prepared freshly before use.
4.6.3. Samples
MS positive samples were selected on the basis o f  having a) intrathecally formed 
oligoclonal IgG bands on IEF, (b) elevated CSF IgG and percentage o f  CSF total protein,
(c) an MRI scan implicating demyelination, (d) clinical diagnosis o f  ‘MS’ or ‘probable MS’.
Control samples were selected as having (a) oligoclonal bands negative, (b) normal 
results for CSF total protein, IgG, glucose and white cell count (<5), (c) no evidence o f  
demyelination on MRI scan, (d) MS excluded from clinical diagnosis.
Using these criteria, 13 samples were selected as MS positives and 14 as controls 
and stored at -70°C for up to 6 months.
4.6.4. Method
4.6.4.I. Affinity Chromatography
1. For each sample, the amount o f CSF (in pL) to load onto the column was 
calculated from the formula (6.67 x 1000)/[IgG]. The calculated volume o f  
CSF was diluted with adsorption/wash buffer to a volume o f  0.5 mL and 
applied to the column.
2. After draining, 0.8 mL o f  adsorption wash buffer was applied to the column.
3. After draining, 0.1 mL o f  elution buffer was applied.
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4. After draining, 0.8 mL o f  elution buffer was applied and the eluate collected 
onto 0.2 mL o f  neutralising/preserving buffer in a 5 mL glass botde.
5. 0.4 mL o f  pH 1.6 buffer was applied to the column and allowed to drain.
6. 0.8 mL o f adsorption/wash buffer was applied to the column and allowed to 
drain.
7. Steps 1 to 6 were repeated for each sample.
4.6.4.2. IgG Immunoassay
The IgG mediod was as described in section 3.3.3.I. CSF samples were diluted 
1:40 and the eluates 1:5 with PBS-T immediately prior to the assay.
4.6.4.3. Lectin Immunoassays
Polystyrene ‘star’ tubes were coated overnight with 0.2 mL o f  anti-IgG diluted 
1:100 with coating buffer, then blocked witii 0.3 mL o f  10 g /L  BSA for 1 h. The 
antibody coating was deglycosylated with 0.3 mL o f  0.01 M sodium periodate in citrate 
buffer (0.05 M, pH 4.0), incubating for 20 h at 4°C.
For each eluate, the sample volume (ranging from 5 to 15 pL) was calculated from 
the result o f  the IgG immunoassay, so that 50 ng o f  IgG was added to each assay tube.
0.2 mL o f  PBS-T was added to die prepared/periodate-treated tubes, followed by the 
prescribed volume o f  eluate, in triplicate tubes. After incubation for 1.5 h, tubes were 
washed and to each was added 0.2 mL o f  biotinylated lectin, diluted to 500 pg /L  with 
lectin assay buffer. After incubation for 1.5 h and washing, 0.2 mL o f  isoluminol- 
streptavidin, 10 pL diluted in 100 mL o f  lectin assay buffer, was added, followed by 
further incubation for 1 h, washing and measurement o f relative luminescence units.
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Figures 4.32 to 4.35 show for each lectin the binding to IgG in the MS samples 
compared to the controls. It can be seen that for both Con A  and RCA, and to a lesser 
extent for SNA, there is a wide scatter o f  results for the MS samples, with a tight 
bunching for the controls. Comparison o f  the means o f  the two groups for each lectin 
gave the results shown in Table 4.3, using an unpaired t test, two-tailed, with Welch’s 
correction (for unequal variances). Although only Con A  showed significant difference 
between the means at the 95% level), the P value for RCA is very low. With DSL and 
SNA there is no difference between the means. Variances o f  die two groups were 
significandy different for Con A  and RCA (P<0.0001) and SNA (P=0.0012), but not for 
DSL (P=0.4011).
4.6.5. Results fot Lectin Assays of MS and Control CSF Samples
Table 4.3. Unpaired t test of MS samples v controls.
Lectin-binding MS: RLU
M eantSEM  (n = 13)
Controls: RLU 
Mean ± SEM (n = 14)
P value
Con A 4275 ± 906 1716 ±244 0.0172*
RCA 1220 ±375 533 ± 87 0.0981
DSL 514 ±95 459 ± 98 0.6922
SNA 6445 ± 896 5701 ± 345 0.4506
Means significantly different (P<0.05) between MS and controls.
The bindings o f  the four lectins for all samples were analysed for correlation with 
each other, and with CSF [IgG], CSF [total protein], and CSF (IgG/total protein)%, as 
shown in Table 4.4. Con A  binding was found to correlate witii %IgG (P=0.0222) and, 
more strongly, RCA binding with SNA binding (P<0.0001).
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To compare the lectin bindings o f  each sample, results for Con A, RCA and SNA 
were normalised by converting the RLUs to percentages: the lowest RLU taken as 0% and 
the highest 100% for each lectin, and die intermediate results calculated accordingly. The 
normalised results are plotted in Figure 4.36, comparing Con A  with RCA, and Figure 
4.37, comparing RCA with SNA. The MS positive samples are indicated by an asterisk. 
Looking at Figure 4.36, the three highest Con A  results are for MS samples and die three 
highest RCA results are for different MS samples, suggesting a negative correlation, but 
otherwise tiiere is no obvious trend. With Figure 4.37, the correlation between RCA and 
SNA (P<0.001) can be distinguished, but no other patterns can be seen.
Table 4.4. Correlations of lectin binding
Groups Compared Correlation 
Coefficient (r)
P-value
Con A v RCA 0.0650 0.7474
Con A v DSL 0.1755 0.3811
Con A v SNA -0.0203 0.9217
Con A v [IgG] 0.2263 0.2564
Con A v [total protein] 0.0010 0.9959
Con A v %lgG 0.3900 0.0443*
RCA v DSL -0.0467 0.8171
RCA v SNA 0.7924 <0.0001*
RCA v [IgG] 0.0882 0.6617
RCA v [total protein] 0.0674 0.7385
RCA v %lgG 0.2034 0.3088
DSL v SNA -0.0532 0.7964
DSL v [IgG] 0.1048 0.6029
DSL v [total protein] -0.0906 0.6533
DSL v % IgG 0.2888 0.1440
SNA v [IgG] -0.1023 0.6194
SNA v [total protein] -0.1506 0.4628
SNA v %lgG 0.1281 0.5329
‘ Pairing significantly effective.
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Figure 4.32. Con A binding of MS samples compared to controls.
Figure 4.33. RCA binding of MS samples compared to controls.
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Figure 4.35. DSL binding of MS samples compared to controls.
199
100—,
’OcM
X)
8
E1m©
Z
x
50-
Hi
I RCA
Con A
m J
6 8 11 15 16 22 23 26 28 29 30 32 34 36 37 38 40 43 44 46 50 51 53 56 58 64 67
*  * * * * * * ★
CSF Number
Figure 4.36. Comparison of results of RCA and Con A binding for each 
sample. * Indicates MS samples.
RCA
SNA
CSF Number
Figure 4.37. Comparison of results of RCA and SNA binding for each 
sample. * Indicates MS samples.
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O f the four lectins, Con A  showed the most significant differences between the 
MS samples and controls. The means are significantly different, with a wide spread o f 
higher binding for the MS samples. There is also a positive correlation with %IgG, not 
seen with RCA, which is probably to be expected if Con A  does distinguish between MS 
and non-MS, because %IgG is known to correlate with MS and is used clinically as a 
marker for the disease.
RCA also shows a wider and higher spread with MS samples, even though the 
means o f  the two groups are not quite significantly different for the numbers o f  samples 
used. The three very high RCA results are MS positives and also have high Con A 
binding, but overall there is no correlation between the two lectins.
SNA and DSL do not distinguish between MS samples and controls. However, 
there is a strong correlation between SNA and RCA binding, which suggests that where 
sialic acid is lacking, galactose is also deficient. The increased SNA binding in a large 
proportion o f  the MS samples (Figure 4.34) does not support the theory that oligoclonal 
IgG is deficient in sialic acid.
Con A generally shows higher RLUs than the other lectins and shows a degree o f  
binding in all samples - i.e. all samples contain mannose. RCA, however, and DSL and 
SNA even more so, have zero or virtually zero binding with some samples. It is feasible 
that some samples contain IgG with little sialic acid or with little galactose, but DSL is 
present in all IgG glycans. This suggests that steric hindrance might affect DSL binding, 
as discussed in section 4.7.
There are several possible reasons for the increased Con A  binding in the MS 
samples: there could be an overall increase in glycans attached to IgG in MS samples, or 
there could be an increase in the branching o f  the glycans in MS. Either o f  these would
4.6.6. Discussion for Lectin Assays of MS and Control CSF Samples
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be consistent with the increases, albeit not significant, in SNA and RCA binding seen with 
MS samples.
4.7. Development of Lectin Binding Assays: Overall Discussion
Reliable lectin immunoassays were eventually developed to probe the oligo­
saccharides o f  CSF IgG. Because o f  the problem o f  glycosylated substances apart from 
IgG binding to the capture antibody, there needed to be a preliminary separation o f  IgG 
from CSF and this was finally achieved by using protein A  affinity chromatography.
The main findings o f  the lectin assays were:
• Con A  showed most significant difference between MS samples and controls.
• Con A  showed a positive correlation with %IgG, which is used clinically as a 
marker for MS.
• The increased Con A  binding in MS samples - i.e. increased mannose - 
suggests either overall increase, or increased branching, o f  IgG glycans in MS.
• The strong correlation between SNA and RCA binding is consistent with die 
understanding that where galactose is deficient, sialic acid must necessarily be 
lacking.
• The increased SNA binding in a large proportion o f  MS samples does not 
support the hypothesis that oligoclonal IgG is deficient in sialic acid.
There are several problems widi using lectins to investigate the glycans o f  a 
protein. One is the range o f  binding specificities that each lectin has, although usually the 
relevant target can be deduced. Another is the possibility o f  steric hindrance to their 
binding by the protein, which can, however, be overcome by denaturation o f  the protein 
(Sumar et al, 1990). The relatively low binding generally o f  DSL, and possibly RCA, might 
be due to steric hindrance. The moieties which are bound by DSL - GlcNAc([31 -
4)G1cNAc]1.3 and Gal(pl-4)GlcNAc - are present in all glycan chains o f  IgG (found to
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date) so binding to them would be thought to be as extensive as the binding to mannose 
by Con A. In the assays o f  four CSF samples witii a panel o f  lectins, in which the CSFs 
were not affinity purified but were diluted to 10 m g/L o f  IgG, DSL certainly showed 
substantial binding in all CSFs (Section 4.3.4.7; Figure 4.12), comparable to the levels with 
SNA. However, there is more binding shown by DSL, compared to Con A, RCA and 
SNA, to the capture antibody (see the ‘N o CSF’ chart, Figure 4.12). This binding, plus die 
interferent binding may explain the substantial binding seen with the capture antibody 
coated tubes for the CSFs in Figure 4.12.
Another possibility that should be considered is tiiat the assay did not work 
properly although there was no reason to suspect this at the time. Although there are 
moves to produce an agalatosyl IgG control for assays for RA, finding controls for Con 
A, SNA and DSL binding is a problem. Running a serum sample would not help, unless 
it were known, from a previous reference assay, what level o f  lectin binding was expected. 
But, for comparison o f  one group o f  samples witii another, in a single assay for each 
lectin, in the case o f  this project, where actual concentrations are not needed, a control 
does not seem essential. In a way, the non-coated tubes are controls, as are the tubes 
assayed with no CSF, and the tubes assayed with no lectin.
Overall, the lectin assays have shown that there is a difference in IgG glycosylation 
in MS CSF compared to controls. This may be due to variant glycosylation o f  oligoclonal 
IgG compared to polyclonal. There will also be polyclonal IgG in the MS samples, which 
will lessen the differences in glycosylation seen between the two groups. Thus it would 
seem that the spread o f  bands found in IEF o f  oligoclonal IgG may be due to differences 
o f  glycosylation, but it is more likely that die differences are in the peptides as well as in 
glycosylation. This should be made clearer by the methods o f  glycosylation analysis in the 
next chapters - namely IEF studies o f  IgG, and the more specific HPLC quantitation o f  
IgG glycans.
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Chap te r  Five
I s o e le c t r i c  Focus ing  o f  CSF and 
D e te c t i o n  o f  G l y c o s y l a t i o n  us ing  
Lect ins
5.1. Introduction
The intention was to use IEF to separate IgG bands and use lectins to detect 
differences in glycosylation o f the bands.
Two IEF methods were used. Firsdy, a routine method for detection o f 
oligoclonal IgG bands using a gel prepared in-house, with a 7 to 10 pH gradient. 
Secondly, a method using bought, pre-cast gel strips with a 3 to 10 pH gradient. Although 
oligoclonal IgG runs mainly in the alkaline pH region, the wider pH range would allow 
examination o f  the total IgG fraction.
Polyvinylidene fluoride (PVDF) blots o f CSF samples run by both methods will 
be shown, with visualisation by different methods. Also with the pH 3 to 10 system, blots 
o f  focused proteins o f  known pi were run, in order to calibrate the system. Finally, two 
samples o f  CSF IgG were deglycosylated, to compare the resultant bands with those o f 
the whole CSF.
5.2. Reagents and Equipment
Reagents are as previously described unless listed below.
1. Polyacrylamide gel strips, pre-cast on plastic support film, with an immobilised 
linear 3 to 10 pH gradient. Size 110 x 3 mm. Immobiline DryStrip, Pharmacia
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Fine Chemicals AB, Uppsala, Sweden, product code 18-1016-61. The strips 
are delivered in a dehydrated form and stored at -20°C. After rehydration, the 
gel diickness o f the strips is 0.5 mm.
2. Reswelling cassette. Pharmacia, 18-1013-74.
3. Electrophoresis unit. Multiphor II, Pharmacia 18-1018-06.
4. Rehydration solution:
• Deionized water
• Pharmalyte pH 3-10 Immobiline solution
(Pharmacia 17-0456-01)
• Urea (Merck 10290)
• Triton x-100 (Merck 30632)
• 2-Mercaptoethanol (Merck 44143).
• Orange G  (G. T. Gurr Ltd., London)
5. Repel-Silane. Pharmacia 80-1129-42.
6. Wick solutions - 0.5 M H2S 0 4 for anode wick.
- 1 M NaOH for cathode wick.
7. PVDF microporous membrane. Immobilon-P from Millipore Corporation, 
Watford, WD1 8YW, U.K. Product No. IPVH 000 10. 26.5 cm x 3.75 m roll; 
0.45 pm pore size.
8. Slide-A-Lyzer dialysis cartridge. 3500 molecular weight cut-off; 0.1 to 0.5 mL 
capacity. Product No. 66335. Pierce Chemical Company: from Pierce and 
Warriner (U.K.) Ltd, Chester CHI 4EF.
9. Extavidin-horseradish peroxidase (Avidin-HRP). From Sigma Chemical Co., 
Poole, Dorset, BH12 4QH. Used at 1:2000 dilution, i.e. 20 pL + 40 mL PBS- 
Tween.
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10 mL
52 pL 
5.4 g
52 pL o f  0.5% (v/v ) 
40 pL 
1 mg
10. Hydrogen peroxide 6% (w/v ) aqueous solution. Thornton and Ross, 
Huddersfield, HD7 5QH, U.K.
11. 3, 3’-Diaminobenzidine (DAB). D-5637 Sigma Co. Caution: possibly 
carcinogenic. For use, 10 mg o f  DAB was dissolved in 20 mL o f  TBS with 
addition o f 50 pL o f  6% (w/v ) hydrogen peroxide.
12. DAB Tablets. 3, 3-cLaminobezidine tetrahydrochloride, 10 mg. Kem-En-Tec 
A /S , Lerso Parkalle 42, DK-2100 Kobenhavn 0 ,  Denmark. Just before use, 
two tablets, after equilibration to room temperature for 15 min, were dissolved 
in 20 mL o f  water {giving a solution o f  pH 7.0 containing 1 mg/mL o f  DAB 
in 20 mM phosphate buffer) with addition o f  100 pL o f  6% (w/v) hydrogen 
peroxide.
13. pi calibration kit pH 3 - 1 0 .  Pharmacia. One vial was reconstituted with 0.5 
mL o f  water, giving concentrations o f  each marker o f  between 40 to 100 ng 
per pL.
14. Peptide-N-glycosidase F. Oxford GlycoSciences (UK) Ltd. From 
Flavobacterium meningosepticum. Supplied as frozen 20 pL aliquots containing 4 
Units.
15. Enzyme incubation buffer. Oxford GlycoSciences. Supplied five times 
concentrated, which when diluted with four volumes o f  water gives 20 mM 
sodium phosphate pH 7.5 containing 50 mM EDTA and 0.02% (w/v ) sodium 
azide.
16. Igepal CA-630 (non-ionic detergent; analogue o f  Nonidet P40). Sigma Co. A  
10% (v/v ) solution was prepared by adding 0.1 mL o f  Igepal to 0.9 mL o f 
working incubation buffer.
17. Sodium dodecyl sulphate (SDS). Electran grade, Merck Ltd.
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18. Wash saline. NaCl (9 g/L) containing Tween (0.5 mL/L).
19. Trypsin inhibitor (soybean). Product no. T-9003, Sigma, pi =4.55
20. (3-Lactoglobulin (bovine milk). L-2506, Sigma, pi = 5.20.
21. Carbonic anhydrase (bovine erythrocyte). C-2273, Sigma, pi = 5.85.
22. Myoglobin (horse heart). M-1882, Sigma, pi =  6.85, 7.35.
23. Lentil lectin (lens culinaris). L-9267, Sigma, pi = 8.15, 8.45, 8.65.
24. Trypsinogen (bovine pancreas). T-9011, Sigma, pi = 9.30.
25. Tetrachloroauric acid trihydrate. Sigma G-4022. A  10 g /L  solution was 
prepared by dissolving 1 g in 100 mL water, stored in a dark container and 
kept cool.
26. Stannous chloride, anhydrous. Sigma S-2752. 10 g /L  solution prepared 
freshly for use by dissolving 0.1 g stannous chloride in 0.4 mL o f  1 M HC1 and 
making up to 10 mL with water.
27. Citric acid, anhydrous. Sigma C-0759.
28. 5-Sulphosalicylic acid. GPR grade. Merck 30314.
29. Colloidal gold stain. Prepared as follows: 370 mL o f water and 7.5 mL o f  10 
g /L  tetrachloroauric acid were place in a dark container and 2.5 mL o f  10 g /L  
stannous chloride solution was added dropwise with gentle stirring. Then, 110 
mL o f  10 g /L  citric acid and 12.5 mL o f  Tween 20 were added, slowly with 
gentle mixing. After standing overnight in the dark, 25 g o f  anhydrous citric 
acid was added slowly with gentle mixing, followed by 2 g o f  sulphosalicylic 
acid with mixing. After 24 h the stain was ready to use, and could be used for 
up to 4 weeks if stored in a cool dark place.
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a. Rehydration of Gel Strips
Following Pharmacia’s instructions, the gel strips, with protective film removed, 
were placed inside the reswelling cassette, which was then filled with rehydration solution. 
The cassette was tilted upwards at an angle o f  about 10°, in a refrigerator, and die strips 
allowed to rehydrate over 48 h.
b. Isoelectric Focusing
The rehydrated strips were aligned on the electrophoresis platform with the 
pointed end (pH 3) at the anode (red) electrode, and lighdy blotted with dampened filter 
paper. CSF sample, from 1 to 4 pL, was usually applied in the middle o f  a strip keeping 
the application spot as small as possible. Paper wicks moistened witii 0.05 M H2S 0 4 
(anode) or 1.0 M NaOH (cathode) were placed across the ends o f  the strips, covering 3 
mm o f the gel. Pieces o f  blotting paper, cut to 10 x 4 cm, were placed at each end o f  die 
platform, just overlapping the each wick. The electrode wires were lowered onto the 
wicks at die points where they covered the gel. Dampened paper towels were placed on 
each side o f  the platform, the lid was dosed and the water cooling turned on.
Several running conditions were tried. In each case 300 V  was initially applied for
1 h, followed by: 1100 V  for 6 h (6900 Volt hours in total); 950 V  for 22 h (21200 Volt 
hours), or 1400 V  for 15 h (21300 Volt hours).
After the run, the power was switched off, and the electrodes, blotters and wicks 
removed. The strips, in situ, were very lighdy blotted with damp blotting paper.
c. Transfer to Membrane
PVDF membrane, cut to size, was immersed in metiianol for 15 s, then water for
2 minutes, and then lighdy blotted. It was laid over the strips, covered witii damp blotting
5.3. Methods
5.3.1. Isoelectric Focusing with pH 3 - 1 0  Gradient
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paper, absorbent towels, then a glass plate, and then a 2 kg weight. After 1 h, the weight, 
blotter etc. were removed. The PVDF membrane was briefly immersed in water to 
remove the strips. The membrane could now be blocked and taken through a protein 
detection procedure. If die membrane was allowed to dry out, it needed to be rehydrated 
prior to blotting and detection by immersion in methanol (15 s) and water (2 minutes).
5.3.2. Isoelectric Focusing with pH 7 - 10  Gradient
All electro focusing using pH 7 to 10 gradient gels described in this chapter was 
kindly performed by Dr Geoffrey Cowdrey in die Biochemistry Department at the 
Princess Royal Hospital. Details o f  the mediod are given in Cowdrey (1990). To 
summarise, the pH 7 to 10 acrylamide gels were prepared in house by mixing together, in 
a gradient former, two gels o f  differing densities and containing different concentrations 
o f  immobilities. Electrofocusing was carried out before sample application for 30 min at 
1750 V, 50 mA and 10 W, and then after placing samples in formed wells, for 2 h at 5000 
V, 10 mA and 10 W. Protein transfer onto PVDF membrane was as described in 5.3.1(c).
5.3.3. Detection Systems
5.3.3.I. Lectin
Each PVDF membrane containing separated proteins was immersed in PBS (20 
mL) containing BSA (0.6 mL) for 1 h, or overnight at 4°C, in order to block remaining 
protein binding sites. Without washing, the membrane was transferred to 20 mL o f  lectin 
buffer containing 40 pL o f  biotinylated Con A  or RCA and incubated for 1.5 h witii 
gentle shaking. After washing three times in 40 mL wash saline for 5 min each with gentle 
shaking, the membrane was transferred into 20 mL o f  lectin assay buffer containing 10 pL 
o f  avidin-HRP and incubated for 1 h with gentle shaking. After washing as before, the 
membrane was immersed in 20 mL o f  DAB containing H20 2 (DAB either in tablet form 
or weighed out, as described in 5.2 Reagents and Equipment) and gently shaken for about 
5 min until bands were seen to develop.
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5.3.3.2. Anti-human IgG (Biotin-Avidin System)
The procedure was the same as 5.3.3.1 except 30 pL o f  biotinylated anti-human 
IgG was used in place o f  biotinylated lectin.
5.3.3.3. Anti-Human IgG (Double Antibody System)
This procedure, where used, was carried out by Dr Cowdrey. For details please 
see Cowdrey, 1990. Briefly, a membrane was blocked by immersion in a solution o f  dried 
skimmed milk, then incubated with anti-human IgG (raised in sheep). After washing, the 
membrane was incubated with donkey anti-sheep alkaline phosphatase conjugate, and 
after washing stained in buffer containing Nitroblue Tetrazolium with 5-bromo-4- 
chloroindoxyl phosphate.
5.3.3.4. Colloidal Gold
To visualise all transferred proteins, a PVDF membrane, without prior blocking 
treatment, was immersed in colloidal gold stain for 30 min with gentie shaking. It was 
dien washed widi water, and allowed to dry for at least 4 h at room temperature before 
viewing.
5.3.4. p i Calibration o f  pH  3 - 1 0  System
A  vial o f  broad pi calibrators was prepared as described in 5.2(13) and run on pH 
3 to 10 strips, according to the method o f  5.3.1. Other proteins, namely carbonic 
anhydrase, myoglobin, lentil lectin, trypsinogen, trypsin inhibitor and (3-lactoglobulin were 
dissolved in water (1 mg in 20 mL) and run with the broad pi calibrators in several assays. 
In all cases, 2 pL samples were applied to the centre o f  the gel strips, which were run at 
300 V  for 1 h, then 1400 V  for 15 h. After blotting onto PVDF membrane, detection was 
with colloidal gold.
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5.3.5. Deglycosylation of CSF IgG
5.3.5.I. First Sample
a. Affinity Chromatography
For the basic method, see 4.6.4. Here, 1.2 mL o f CSF CE (Oligoclonal IgG 
positive; [IgG] =  94 mg/L) was loaded onto a 0.2 mL Prosep column along with 1.2 mL 
o f  adsorption buffer. After draining, the column was washed with 1.0 mL o f  adsorption 
buffer. After draining, 0.1 mL o f  elution buffer was applied to the column and drained. 
Then 0.5 mL o f elution buffer was applied, and the eluate collected onto 0.1 mL o f  0.5 M 
phosphate buffer, pH 7.4.
b. Dialysis
For a fuller description o f  the dialysis materials and method, see 6. . The eluate 
(0.6 mL) from (a) above was injected into a Slide-a-Lyzer dialysis cartridge and dialysed 
against three changes o f  1.0 L o f  deionized water containing 0.7 mL o f  trifluoroacetic acid 
for 24 h each. The dialysate was removed and the cartridge washed with 0.2 mL o f  water, 
which was combined with the dialysate. The absorbance o f  the dialysate at 279 nm was 
measured against water and the IgG concentration calculated.
c. Denaturation
Denaturation o f  a protein is often recommended to afford the deglycosylating 
enzyme access to the glycan core (Hirani et al, 1987; Kottgen et al, 1993; Mann et al,
1994), although specific reference to IgG is not made. Therefore the deglycosylation was 
performed here with denatured and non-denatured (i.e. native) IgG.
0.2 mL o f  enzyme incubation buffer was added to the dialysate, which was then 
divided into 2 portions o f  0.5 mL each.
To portion 1 (for denaturation) was added 10 pL o f SDS (200 mg/mL), giving a 
solution o f  0.4% (w/v ) SDS. After mixing, 10 pL o f  mercaptoethanol was added and
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mixed, to produce 2% (v/v). The mixture was boiled for 2 min then cooled. 82 pL o f  
Igepal was added and mixed. This mixture was divided into two equal aliquots: A and B.
Portion 2 (non-denatured) was divided into two equal aliquots (C and D).
d. Deglycosylation
One vial (4 Units) o f  PNGase F was added to each aliquot A  and C. To B and D 
(controls) was added 20 pL o f  water. All aliquots were incubated for 24 h at 37°C.
e. Isoelectric Focusing
Isoelectric focusing was performed following the method described in 5.3.2 using 
gel with pH 7 to 10 gradient. 2 pL aliquots o f  the untreated CSF in triplicate, and aliquots 
o f  A, B C and D  (C and D  in duplicate) were applied to the gel. Detection was with the 
anti-human IgG double antibody system (5.3.3.3) or with biotinylated Con A  (5.3.3.1).
5.3.5.2. Second Sample
Using a different sample, CSF NP (Oligoclonal IgG positive; [IgG] = 120 mg/L), 
the assay was repeated with some changes, as follows. 1.7 mL o f  the CSF was loaded 
onto the column with 1.7 mL o f  adsorption buffer. Washing o f the dialysis cartridge was 
omitted, and the dialysate was mixed with enzyme incubation buffer to give a volume o f
0.7 mL. Denaturation o f  the IgG was omitted. Double the enzyme as previously was 
used to ensure complete deglycosylation: the dialysate was divided into two equal aliquots, 
A  and B; to A was added two vials (8 Units) o f  PNGase F and to B, 40 pL o f  water. Also 
an enzyme ‘blank’ was prepared by mixing 5 pL o f  buffer concentrate with 20 pL o f  
water, and mixing 9 pL o f  this with 1 pL o f  PNGase F.
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It was found that the gel strips needed the 21000 Vh run time, as recommended 
by Pharmacia, and running at 1400 V  for 15 h overnight, after 300 V  for 1 h, was found to 
be most convenient. It was also found that better results were obtained if dampened 
tissues were placed in die tank to maintain humidity, rather than pouring in water. 
Condensation o f  water onto the gel was a problem, but could be reduced by placing 
blotting paper strips on top o f  each o f  the wicks.
Figure 5.1 shows the PVDF blot o f  pH 3 - 1 0  gel strips, stained with colloidal 
gold. Samples A, B and C are the eluate from the Prosep A  column containing 1500 
mg/L, 150 m g/L  and 0 m g/L  o f  BSA. N o bands attributable to IgG can be seen, so the 
method does not appear to be sensitive enough to detect IgG in the eluate samples. The 
BSA gives a dense cluster o f  bands at around pH 6, clearly seen in strip D, which is BSA 
in buffer only. The broad range calibrators are run as strip E and, widi added BSA, as 
strip F. The a-and P-lactoglobulin bands are clearly seen in strip G, and enable the P- 
lactoglobulin band in the calibrator to be positively identified. The bands for the other 
protein markers in die calibrator were identified by subsequent IEF runs o f  die broad pi 
calibrator alongside the pure proteins. The pi values o f these markers were plotted 
against the distance from the cathode o f  their respective bands (Figure 5.2). The graph 
confirms tiiat the pH 3 to 10 gradient is linear for the running conditions used.
Inability to visualise bands in die Prosep eluates was a problem with the pH 3 - 1 0  
gel strips with lectin detection as well as widi colloidal gold. Increasing the sample 
volume o f  eluate applied to the gel caused overheating due to focusing o f  the buffer salts 
in the sample, and also occurred widiout the incorporation o f  BSA. It would probably be
5.4. Results
5.4.1. Results for Isoelectric Focusing with pH 3-10 Gradient
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possible to ran the eluates if  salts were removed by dialysis, but the easiest solution would 
be to only ran the whole CSF samples.
Figure 5.3 shows the PVDF blots o f  various whole CSF samples run on pH 3 - 1 0  
gel strips. Blot 1 shows the bands for a CSF sample (W) negative for oligoclonal IgG by 
routine IEF, and for an oligoclonal positive sample (S), detected using Con A. The bands 
in sample S are possibly more extensive than in W. There is some faint staining in the 
alkaline region in sample W, which must be due to glycoproteins other than IgG. The 
large number o f well defined bands in this blot show that diis method o f  probing with 
lectins has potential. The bands in S2, with the longer run time, are generally sharper than 
in St.
Blot 2 is also visualised using Con A, although the stain has not ‘taken’ as well. 
However, banding in the alkaline region can be seen in sample B which is positive for 
oligoclonal IgG. The samples were run in duplicate and, in Blot 3, visualised using SNA. 
This lectin, which has a binding preference for sialic acid is seen to bind only in the acidic 
half o f  the gel strips.
Blot 4 shows an oligoclonal positive CSF (O) with two negatives (M and H), with 
Con A  detection. There are very pronounced bands in the alkaline region for CSF O. 
This CSF was run in duplicate and also visualised using SNA (Blot 5), however with this 
lectin, diere is no staining in the alkaline region.
5.4.2. Results for Isoelectric Focusing with pH 7 -10  Gradient
Figure 5.4 shows the PVDF blot o f  an electrofocused CSF witii fractions from a 
Prosep column. The low concentrations o f  IgG in the eluted fractions Et and E2 have 
resulted in attenuated patterns o f  banding. However, die main oligoclonal IgG bands in 
the whole CSF appear to be replicated in the eluates, suggesting that the oligoclonal IgG is 
not affected by the low pH o f  the elution buffer, and that no IgG isoforms are lost in die
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affinity chromatography process. There is no difference between Et and E2, using 
different volumes o f  elution buffer. There is faint staining in W, the wash fraction from 
the column. This may be from traces o f  IgG which are not bound by the protein A, or 
may be carryover from the CSF sample during application o f  samples to the gel.
Figure 5.5 shows the results o f  the first deglycosylation study. In the anti-lgG 
detected blot, oligoclonal IgG bands are clearly seen in the whole CSF (CE). The banding 
pattern is replicated in the non-deglycosylated eluate (D). In the deglycosylated eluate (C), 
again there are well-defined bands, but the pattern o f  banding is altogether different to CE 
and D. In the denatured samples (A and B), there is virtually no staining, indicating the 
treatment has either rendered the IgG so that it is not detected by the stain, or has 
changed the charge o f the IgG so that it has migrated out o f the pH range. In the Con A  
detected blot, bands in the whole CSF (CE) are again replicated, albeit fainter, in the non- 
deglycosylated eluate (D). However, in the deglycosylated sample (C) there is hardly any 
staining visible, indicating, within the detection limits o f the system, that the PNGase F 
treatment successfully removed all Con A  binding glycans from the IgG. As all IgG 
glycans contain mannose, to which Con A  binds, deglycosylation o f  the IgG is complete. 
The results o f  the second deglycosylation study are shown in Figure 5.6. Again, in the 
anti-lgG detected blot, bands in the non-deglycosylated eluate (NPB) correspond to bands 
in the whole CSF (NP), whereas in the enzyme-treated eluate (NPA) the banding pattern 
has changed. In the Con A  detected blot, the non-deglycosylated eluate (NPB) has a 
similar pattern to the CSF (NP), while there is faint banding in the enzyme treated eluate 
(NPA), indicating that there may be some glycans still remaining on the IgG. There is 
similar faint banding in the enzyme blanks (E), corresponding to heavy bands in the CSF, 
and is thought to be due to carryover from other samples, rather than due to the enzyme 
itself.
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Figure 5.1. PVDF blot of gradient pH 3 -10 gel strips, run at 300 V for 1 h then 1400 V for 15 
h. Detection was with colloidal gold stain. Samples applied were 2 pL of:- A: eluate of CSF M 
from a protein A column with 1500 mg/L BSA added; B: the eluate with 150 mg/L BSA; C: the 
eluate with no BSA; D: 0.5 M phosphate buffer with added 1500 mg/L BSA; E: broad pi 
calibrators; F: broad pi calibrators with added 1500 mg/L BSA; G: (3-Lactoglobulin.
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Figure 5.2. Distance from cathode of bands from broad pl calibrators (sample E in Figure 5.1) 
plotted against pH. The identities of the bands were confirmed by additional runs of the broad 
calibrator alongside single purified proteins.
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Figure 5.3. A selection of five PVDF blots of CSF samples run on pH 3 -10 gel strips. Apart 
from W and which were run at 300 V for 1 h then 1400 V for 6 h, all samples were run at 
300 V for 1 h then 1400 V for 15 h. and S2 are the same sample, but with different run 
conditions). 2 pL samples were applied onto the centres of the gel strips. Detection was 
achieved using the biotinylated lectins as shown, with avidin-HRP and DAB.
Blot 1 shows CSF W, which was negative for oligoclonal IgG bands by routine IEF, 
and CSF S, which was positive. Blots 2 and 3 are of four CSFs run in duplicate, with detection 
using Con A and SNA respectively. The CSFs A, C and D were negative for oligoclonal 
bands, while B was positive. Blot 4 is of the oligoclonal positive CSF O and the oligoclonal 
negative CSFs M and H, detected using Con A. Blot 5 is of CSF O, run by IEF simultaneously 
as Blot 4, but detected using SNA.
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Figure 5.4. PVDF blot of a CSF containing oligoclonal IgG bands and fractions from a Prosep 
A column run on pH 7 to 10 IEF gel, with detection using sheep anti-human IgG and donkey 
anti-sheep alkaline phosphatase conjugate. IEF and staining was kindly performed by Dr G. 
Cowdrey, as described in sections 5.3.2 and 5.3.3.3. Affinity chromatography using a 0.2 mL 
Prosep A column was as described in 4.5.3.1(a).
‘CSF’ is the untreated CSF sample; ‘W’ is the breakthrough collected on washing the column; 
‘E / is the eluate collected onto neutralising buffer, and applied to the gel in duplicate. ‘E2’ is 
the eluate collected with modification of the chromatography procedure i.e. using half the 
volume of elution buffer.
218
Cathode 
pH 10
* i
T
Cj£  A  S 
Anti-IgG
Anode 
pH 7
Figure 5.5. PVDF blots of isoelectric focused CSF IgG before and after deglycosylation with 
PNGase F. Samples were run simultaneously on a pH 7 to 10 gel by Dr G. Cowdrey as 
described in 5.3.2. Detection was with sheep anti-human IgG/anti-sheep alkaline phospha­
tase conjugate (see section 5.3.3.3) and with biotinylated Con A/HRP (section 5.3.3.1).
CE is the untreated CSF (containing oligoclonal IgG bands). A, B, C and D are 
portions of the IgG-containing fraction from the same CSF eluted from a Prosep A column. 
A and B were treated with denaturing agents; C and D were not. A and C were treated with 
PNGase F; B and D were not. For method details see 5.3.5.1.
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Figure 5.6. PVDF blots produced as for Figure 5.5 for a different oligoclonal IgG positive 
sample (CSF NP), with some changes in the procedure i.e. denaturation of a portion of the 
sample was omitted, double the quantity of enzyme was used and an enzyme blank was 
run. For full method details see 5.3.5.2.
NP is the untreated CSF; NPA is eluate treated with PNGase F; NPB is untreated 
eluate. E is buffer containing PNGase F only.
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Much work could still be done using IEF to investigate the glycosylation o f  IgG. 
The practical work using the pH 3 - 1 0  gel strips is largely incomplete. The IEF technique 
and detection using lectins was very time-consuming and required a high degree o f 
manipulative skill, which would probably come with practice. But, with time at a 
premium, the pH 7 - 1 0  gel system was used instead for the deglycosylation study. 
Nevertheless, the high resolution o f  the bands on some o f  the PVDF blots o f  the pH 3 - 
10 gel strips illustrate the potential that die method has.
The concentration o f  IgG in the Prosep protein A  eluates prepared for the lectin 
immunoassay was too low for detection with the lectin assays. Increasing the sample 
applied to the gel led to problems with overheating, because o f focusing o f  the salts in the 
eluate into high concentration bands. However, for the deglycosylation studies, the use o f  
dialysis to remove salts from die eluates enabled affinity purified IgG to be run by IEF. 
Also, the BSA hitherto used to stabilise the IgG in the eluates, showed numerous bands 
on the PVDF blots with detection by colloidal gold. It would be preferable then to use 
highly purified BSA or HSA (human serum albumin), or a non-protein product as 
stabiliser, or to perform the affinity chromatography immediately before the IEF.
With die detection using lectins, Con A  - which binds to mannose, present in all 
IV-linked glycans - is seen to bind to oligoclonal bands throughout the pH 3 to 10 range. 
SNA, however, binding only to glycans containing sialic acid, shows binding in the acidic 
and neutral range, but not to oligoclonal IgG bands in the alkaline region. These findings 
are compatible with the hypothesis that oligoclonal IgG bands in the alkaline region are 
lacking sialic acid, although with so few samples it is impossible to be conclusive.
With enzymic deglycosylation, prior denaturation o f  the target protein is often 
performed. However, in this study almost total deglycosylation o f  die IgG was achieved 
without denaturation, as illustrated by die absence o f Con A binding to the deglycosylated
5.5. Discussion
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samples (Figures 5.5 and 5.6). It is feasible that deeply buned glycosylation, for example 
in the Cy2 domains, is not reached by the enzyme nor by Con A. But if glycosylation is 
complete, the altered pattern o f  bands in the deglycosylated sample compared with the 
untreated sample shows that the spread o f  isoelectric points o f  oligoclonal IgG bands is 
not simply due to differences in carbohydrate. Were this the case, the oligoclonal IgG 
bands would coalesce into a single, or only a few, bands. As it is, the resultant bands in 
the deglycosylated sample are as diverse as those in the untreated sample, but with a 
different pattern.
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Chap te r  Six 
Analysis of  IgG Glycans by H PLC
6.1. Introduction
The results o f  the lectin immunoassays suggest there is a difference between MS 
patients and non-MS controls in the glycosylation o f  CSF IgG. To try and show the 
difference, HPLC was used to analyse the N-glycans after cleavage from IgG by 
hydrazinolysis and labelling with 2-aminobenzamide (2AB). A  normal phase HPLC 
system was used for all samples, which separates largely by the hydrodynamic volume 
(size) o f  the glycan and to a lesser extent by the hydrophilicity o f individual sugars and 
antenna linkage. Some samples were also run on a weak anion-exchange column, 
separating by overall negative charge, which would show differences in sialylation.
The purification o f  IgG by protein A  column chromatography and subsequent 
dialysis and spectrophotometry was carried out at the Princess Royal Hospital 
Biochemistry Department. The lyophilisation and glycan release was carried out by Dr 
Louise Royle at the Glycobiology Institute, Oxford University. The labelling and HPLC 
was carried out mostly by myself at the Glycobiology Institute, using the systems set up in 
those laboratories, and relying on help and guidance from the staff there.
6.2. Equipment and Reagents
Reagents for protein A  affinity chromatography are as described in section 4.6.2.
1. Slide-A-Lyzer dialysis cartridge. 3500 molecular weight cut-off; 0.1 to 0.5 mL 
capacity. Product No. 66335. Pierce Chemical Company, Rockford, IL 
61105, USA.
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2. Scanning spectrophotometer. U-2000. Hitachi Ltd., Tokyo, Japan.
3. GlycoPrep 1000 for automated release and purification o f  glycans. Oxford 
GlycoSystems, Blacklands Way, Abingdon, 0X 14  1RG,
4. Centrifugal sample evaporator. Eyela Vapour Mix S-100. Tokyo Rikakikai Co 
Ltd. (Eyela-ex@eyela.co.jp).
5. Speed sample evaporator. GyroVap. V.A. Howe Ltd., Banbury, U.K.
6. Chromatography paper. 3M. Whatman Ltd., Maidstone, England. Prior to 
use this was washed with water by descending chromatography for 24 h.
7. HPLC system. 2690 HPLC Separations Module with column heater; 474 
fluorescent detector; Millennium 32 software. Waters Corp. 34 Maple St., 
Milford, Massachusetts 01757, USA.
8. HPLC columns 1) GlycoSep-N normal phase, size 4.6 x 250 mm (Oxford 
GlycoSystems). 2) Protein WAX: weak anion-exchange, size 7.5 x 50 mm 
(Vydak, Crompack, Middelburg, Netherlands).
9. Trifluoroacetic acid (TFA). Biochemika grade, >99.5% purity. Product No 
91699. Fluka/Sigma Co.
10. 2-Aminobenzamide (2AB). Signal kit. K-404. Oxford GlycoSystems.
11. Acetonitrile, methanol. HPLC grade from Romil Ltd., The Source, Convent 
Drive, Waterbeach, Cambridge, CBS 9QT.
12. Ammonia solution, formic acid. Aristar grade from Merck Ltd.
13. Solutions o f  50 mM ammonium formate, pH 4.4 and 0.5 M, pH 9.9 were 
prepared by adjusting formic acid solution to the required pH using ammonia 
solution and diluting to give the appropriate concentration.
14. HPLC calibrators. System 1: Dextran homopolymer standard, lyophilised 7.5 
mg. Product code 1-4014. System 2: Fetuin (bovine) glycans 1-4015, 
lyophilised 5 mg. Product code 1-4015. Oxford GlycoSystems.
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A  relatively large amount o f  IgG was required in the CSF samples, owing to losses 
that occur during the lengdiy preparation prior to HPLC. The initial recommendation 
from the Oxford Glycobiology Institute was for at least 50 pg o f  IgG in the samples ready 
for labelling, although this was decreased to 20 pg for the second batch o f  samples. This 
meant that only a small proportion o f  the CSFs after routine analysis were suitable, and it 
was not possible to select samples for HPLC by the same criteria as for the lectin 
immunoassays, where a confirmed diagnosis o f  MS was required for the positive group 
(see section 4.6.3). This will have important implications when comparing die results o f  
the two methods.
The samples for HPLC were cohected over a period o f one year. In view o f  the 
lengthy preparation procedure and die high cost o f  reagents, an initial batch o f  4 samples 
was analysed. The encouraging results from this batch led to analysis o f  a further batch o f  
10 samples.
The criteria for selecting Positive samples were:
1. Strong oligoclonal IgG bands on IEF.
2. At least 50 pg o f  IgG in the sample (at least 100 pg for first batch).
The criteria for selecting Negative Control samples were:
1. Absence o f  IgG oligoclonal bands on IEF.
2. At least 50 pg o f  IgG in the sample (at least 100 pg for first batch).
Details o f  the samples assayed by HPLC are given in Table 6.1. To help distinguish the 
samples, the samples containing IgG oligoclonal bands are identified by upper case 
lettering, while the negative controls are in lower case.
6.3. Samples
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6.4.1. Affinity Chromatography
1. The protein A  columns were prepared as described in Section 4.5.
2. The amount o f  each sample applied to the column, and the IgG content, is 
shown in Table 6.1. Each sample was diluted with an equal volume o f  
adsorption/wash buffer before applying to the column. The (RH) serum 
sample was diluted with 1.0 mL o f  buffer.
3. When the sample/buffer mixture had drained through, a further 1.0 mL o f  
adsorption/wash buffer was applied and allowed to drain.
4. 0.1 mL o f  elution buffer was applied and allowed to drain to waste.
5. 0.5 mL o f  elution buffer was applied and the eluate collected onto 0.1 mL o f 
neutralising buffer in a glass bottle.
6. The eluates were immediately dialysed.
6.4.2. Dialysis
1. The Slide-A-Lyzer cassettes were used according to the manufacturer’s 
instructions. Each eluate (volumes o f  eluates were approximately 0.6 mL) was 
injected into a cassette and dialysed against 1.0 L o f  deionized water 
containing 0.7 mL o f  TFA for 24 h, changing the dialysis solution twice.
2. The dialysate was removed from the cassette and placed into a 3 mL 
lyophilisation tube. 0.2 mL o f  water was injected into the cassette, which was 
agitated for 20 s, then removed and added to the dialysate.
3. 100 (ilL o f  the dialysate was placed into a quartz glass cuvette for 
spectrophotometry, as described below, then returned to the lyophilisation 
tube, which was then stored at -70°C.
6.4. Methods
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6.4.3. Spectrophotometry
Purified human IgG was diluted to 5 m g/L  and 100 m g/L  in dialysis fluid (1.0 L 
deionized water containing 0.7 mL TFA). These solutions, with the dialysate for the 
sample AW, were scanned in quartz cuvettes against air between 200 and 360 nm. The 
scans were used to ascertain the best wavelength for measurement o f  the IgG in the 
dialysates.
Calibration solutions were prepared as follows. 50 pL o f  the human IgG was 
diluted in 2.8 mL o f  dialysis fluid to produce a 100 m g/L  solution. This was then further 
diluted in dialysis fluid to give 80, 60, 40, 20,10 and 5 m g/L solutions. The absorbance o f 
these was measured at the selected wavelength against dialysis fluid, using quartz cuvettes, 
and a calibration graph was constructed. Dialysates were measured similarly, and the 
[IgG] determined from the calibration graph. The IgG content o f  the dialysate was then 
calculated.
6.4.4. Lyophilization
The samples were posted, frozen, to Oxford. There they were thawed out, 
centrifuged, then lyophilised over 2 days - this work carried out by Dr Louise Royle.
6.4.5. Glycan Release
The glycans were released from the IgG and purified by Dr Royle, using the 
GlycoPrep 1000 in N* mode for IV-glycans. The GlycoPrep uses hydrazine to release 
glycans in a quantitative manner, followed by column chromatography to remove 
protein/peptide material. Samples were processed in pairs, running each pair overnight.
6.4.6. Labelling with 2-Aminobenzamide (2AB)
Double distilled water was used throughout. The samples from the GlycoPrep 
were dried using the GyroVap (approximately 2 h). The 2AB Signal kit was used 
according to the manufacturer’s instructions: 5 jiL o f  the prepared labelling mix was 
added to the dried samples and to the dextran and fetuin calibrators, followed by vortex
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mixing, centrifuging and incubating for 2 h at 65°C. (The samples were re-vortexed and 
centrifuged after 15 min to ensure that any slow-dissolving material was mixed.).
The labelled samples were cleaned up as follows. Washed chromatography paper 
was cut into strips using a template. After incubation, the samples were spotted onto the 
paper strips and dried for 2 h. The strips were inserted into Teflon holders, stood in 
acetonitrile and subjected to ascending chromatography for 1 hour. Labelled glycans 
remain on the origin: unbound 2AB runs up the paper. Completion was checked by 
visualising under a UV lamp. After drying the paper, the spots containing labelled glycans 
were cut out under the UV lamp.
Elution o f  labelled glycans was performed as follows. The paper cut-outs were 
placed into marked 1 mL polypropylene syringes, with PTFE filters fitted to the nozzle. 
The syringes were positioned over glass Rotovap tubes (previously soaked overnight in 
4M HNOa then washed 10 times in deionized water) and 1 mL o f  water placed inside. 
After 10 min, the liquid was pushed through the syringes. This was repeated 3 more 
times, but adding 0.5 mL o f  water each time.
The labelled glycan solutions were concentrated prior to HPLC as follows. The 
tubes were placed on the Rotovap, with vacuum suctioning and vortexing, and an infrared 
lamp warming the outlet to prevent condensation o f  the evaporated liquid. After 
evaporation to dryness, 1.0 mL o f  water was added to each tube, with vortexing and 
centrifuging, then rotary evaporated again to dryness. This was repeated with 0.5 mL o f  
water. The purpose o f the reduction o f  liquid is to obviate loss o f glycan material on the 
sides o f  the tubes. To each tube was then added 0.25 mL o f  water, followed by vortexing, 
centrifuging, and pipetting o f  the water into a marked polypropylene Eppendorf micro­
tube, and this procedure repeated with 3 more 0.25 mL additions o f  water. Finally, the 
samples were evaporated to dryness (GyroVap) and 100 pL o f water (for first batch) or
200 |iL o f water (for second batch) was added and vortex mixed.
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6.4.7.1. System 1. GlycoSepNColumn
Running conditions are shown in Table 6.2. The injection volume was 95 pL. 
For the first batch, 1 pL o f  each reconstituted labelled sample or calibrator was placed 
into a HPLC vial witii 19 pL o f  double distilled water and 80 pL acetonitrile (i.e. 1% [v/v] 
sample dilution). For the second batch, 4 pL o f  sample pins 16 pL o f  double distilled 
water and 80 pL o f  acetonitrile (i.e. 2% [v/v] sample dilution) was run initially for some 
samples to obtain an idea o f  the dilutions needed to be within the detector range. All 
samples were then diluted appropriately, according to Table 6.3.
6.4.7.2. System 2. Vydac Protein WAX Column
Samples only from the first batch, i.e. ms, ja, GH and DH, were run on this 
system, processed as described in 6.4. The HPLC work was carried out by Dr Royle at 
the Institute o f  Glycobiology, Oxford. 5 pL o f  each reconstituted, labelled sample or 
labelled calibrator was pipetted into an HPLC vial with 95 pL o f  double distilled water. 
The running conditions are shown in Table 6.4.
6.4.7. HPLC
Table 6.2. Running conditions for HPLC System 1.
Time (min) Flow (mL/min) %A %B
Equilibration 180 0.4 20 80
Injection 0 0.4 20 80
152 0.4 58 42
155 0.4 100 0
163 1.0 20 80
178.5 0.4 20 80
A is 50 mM ammonium formate, pH 4.4; B is acetonitrile.
The column was re-equilibrated in 20% A, 80% B before injection of each sample. Total run 
time for a sample was 180 min. The column temperature was set at 30°C. The detector was 
set at 330 nm excitation wavelength, 420 nm emission wavelength. Sample injection volume 
was 95 pL.
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Table 6.3. Dilution of labelled samples for HPLC System 1.
Sample Recon­
stitution
volume
(pL)
Sample
volume
(pL)
Water
volume
(pL)
Acetonitriie
volume
(pL)
Sample 
Dilution 
% (v/v)
ms, ja, GH, DH 100 1 19 80 1
AR, al 200 2 18 80 1
HC 200 4 16 80 2
AW, BP, dg, ib, y 200 20 0 80 10RH(serum), jt 
RH 80 20 0 80 25
6.5. Results
6.5.1. Spectrophotometry
Figure 6.1 shows the spectrophotometric scans o f (A) diluted IgG, (B) dialysis 
buffer and (C) a dialysate from affinity purified CSF sample. From these scans (and other 
scans o f  IgG solutions) an absorbance o f  279 nm was chosen for the quantitation o f  IgG 
in the dialysates. Figure 6.2 gives the calibration plot for measuring IgG in the dialysates. 
The IgG content o f  the dialysates is given in Table 6.5.
Table 6.4. Running conditions for HPLC System 2.
Time (min) Flow (mL/min) %c %D '..
Equilibration 180 1.0 100 0
Injection 0 1.0 100 0
12 1.0 95 5
25 1.0 21 79
50 1.0 20 80
55 1.0 0 100
66 1.0 100 0
80 1.01 100 0
C is 0.5 M ammonium formate, pH 9.0; D is 10 % (v/v) methanol in water.
The column was re-equilibrated in 100% C before injection of each sample. Total run time for 
a sample was 80 min. The column temperature was set at 30°C. The detector was set at 330 
nm excitation wavelength, 420 nm emission wavelength. Sample injection volume was 95 pL.
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A. 100 mg/L IgG
B. Dialysis Fluid
C. Dialysate from CSF DH
Figure 6.1. Spectrophotometric scans of: A: pure human IgG, 100 mg/L in dialysis fluid; B 
dialysis fluid; C: The dialysate from CSF DH.
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Figure 6.2. Calibration plot for measuring the IgG content of dialysates. Solutions 
containing less than 10 mg/L of IgG were also measured, but it was found linearity 
did not extend below this level. The correlation coefficient (r) for the fitted graph is 
0.999 (y = 668.7x + 0.01207). The formula: [lgG]mg/L = (A279nm -  0.012) x 668.7 was 
used to obtain the IgG concentration of the dialysates.
Table 6.5. Details of samples for HPLC showing IgG content of dialysates.
Sample Oligoclonal CSF IgG Dialysate IgG
_______________________________Bands_________ mg/L______  pg_________
DH Positive 69 42
First GH Positive 112 82
Batch ms Negative 39 62
ja Negative 44 68
AW Positive 43 30
HC Positive 177 56
BP Positive 31 30
Second AR Positive 189 82
Batch RH Positive 65 10*
RH (serum; [IgG] = 10.6 g/L 57
dg Negative 25 20
ib Negative 34 42
jt Negative 22 28
al Negative 38 55
*Small volume of dialysate due to spillage during processing.
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a. First Batch
Figure 6.3 shows the chromatograms o f  the first batch o f  samples. The overall 
patterns o f  the chromatograms is similar to patterns for serum IgG found previously (e.g. 
Guile et al, 1996) (Figure 1.10). The calibrator, partially hydrolysed dextran, was used to 
assign GU values to retention times, enabling peaks to be identified by comparing the GU 
values to the examples o f  Guile et al, and by using tables o f GU values compiled by the 
Oxford Glycobiology Institute for the same HPLC system. Figure 6.4 shows the plot o f  
the retention time o f  the dextran polymers against their component glucose units, which is 
seen to be curvilinear. Figure 6.5 shows the structures assigned to the peaks for sample ja: 
the other samples were processed similarly.
The two negative control samples have a very similar pattern and closely resemble 
the pattern (Figure 1.10b) found by Guile et al (1966) for serum IgG from RA patients. 
They have the distinctive large peak containing fucosylated agalactosyl biantennary glycan 
(A2G0F) at 85 min. The triplet o f  peaks, with the retention times o f  92 and 95 min, is 
very similar for both control samples.
The two positive samples, however, differ from each other and from the negative 
samples and generally show wider variations than the controls. The triplet peaks have 
different patterns, and o f  the four samples, DH has the largest agalactosyl (A2G0) peaks, 
between 81 and 89 min, while GH has the largest digalactosyl (A2G2) peaks, between 100 
and 112 min.
6.5.2. HPLC
6.5.2.I. System 1. GlycoSep N  Column
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Figure 6.3. Chromatograms of the first batch of samples, labelled with 2AB, run by normal 
phase HPLC (System 1). For running conditions, see 6.4.7.1.
DH and GH are CSF samples containing oligoclonal IgG; ms and ja are oligoclonal IgG 
negative samples. (In this and the following figures, upper case letters are used to denote 
positive oligoclonal IgG samples, and lower case negative controls).
CAL is the calibrator, containing homopolymers of glucose derived by partial hydrolysis of 
dextran. Thus GU4 contains four glucose units, up to GU12 containing twelve glucose 
units.
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140
60 
50 i
4 5 6 7 8 9 10 11 12
Glucose Units (GU)
Figure 6.4. GU calibration of HPLC System 1. The number of glucose units (i.e. GU value) in 
each dextran polymer is plotted against the retention time. The curve is fitted by 5th order 
polynomial regression. The retention times of the sample peaks can then be assigned GU 
values to enable identification of the glycan structures comprising the peaks.
b. Second Batch
Chromatograms for the second batch o f  CSF samples are shown in Figures 6.6 
(negative controls) and 6.7 (oligoclonal IgG positive samples). Figure 6.7 also shows the 
serum sample o f RH with the matching CSF. The peaks in both sets are not as well 
resolved as those in the first batch, especially noticeable with the triplet o f  peaks at 92 to 
95 minutes. Nevertheless, assignment o f  glycan structures to the peaks as performed for 
the Batch 1 samples was not a problem, although quantitation o f  peak areas was probably 
not as accurate.
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Figure 6.6. Chromatograms of the negative control samples in the second batch run on 
normal phase HPLC (system 1) after labelling with 2AB. For method details see section 
6.4.7.1.
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Figure 6.7. Chromatograms of the oligoclonal IgG positive samples in the second batch run 
on normal phase HPLC (system 1) after labelling with 2AB. ‘RH serum’ is a serum sample 
paired with the CSF ‘RH’.
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Unlike the first batch, there is some dissimilarity between the negative samples. 
However, the size o f  the A2G0F peaks at 85 min and the appearance o f  the triplet peaks 
at 92-95 min are similar in the four samples. Other major peaks at 80 min (A2G0), 89 
min (A2G0FB), 100 min (A2G2F) and 105 min (A2G2FS) vary considerably in peak 
height. The sample jt appears to be highly sialylated with exceptionally large peaks at 102 
min (A2G2S1) and especially 108 min (A2G2S2), which dominates the chromatogram. 
This sample also has some relatively large peaks between 60 and 80 min i.e. GU values 
between 4 and 5.5. The structures with GU values in this region are core products o f  
glycans, i.e. incomplete glycans containing components o f  the trimannosyl core, but no 
antennae.
If BP is ignored, the positive CSFs (Figure 6.7) resemble each other as much as 
the negatives. The A2G0F peaks at 85 min are a similar size and the triplet peaks at 92-95 
min have similar patterns. There are, however, large differences in the major peak heights 
at 80 min (A2G0), 89 min (A2G0FB), 100 min (A2G2F) and 105 min (A2G2FS). 'The 
CSF sample RH, for instance, has relatively smaller asialylated agalactosylated peaks at 80 
and 85 min (A2G0 and A2G0F), but correspondingly larger digalactosylated and 
digalactosylated monosialylated peaks at 100 and 105 min respectively (A2G2F and 
A2G2FS). The sample BP shows a very different pattern o f peaks to other samples, with 
substantial peaks for core products between 60 and 80 minutes. It does not, however, 
have the increased peaks for sialylated glycans, as seen in the negative sample jt.
The overall pattern o f  the serum sample RH resembles its paired CSF, but the 
A2G0F peak at 85 min is larger in the serum, and other peaks between 83 and 92 min 
differ in the two samples.
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c. Data Combinedfrom Both Batches 
Overall Peaks
The percentage peak areas o f  the main peaks in all the CSF samples are shown in 
Table 6.6, giving the GU value o f  each peak and the glycan(s) nominated to that GU 
value. In order to compare the positive samples with the negative controls, the data from 
this table was plotted as Figure 6.8(A). Also the peak areas o f  all CSF samples - rather 
tiian the percentage areas - were plotted, after a correction, as follows. The areas o f the 
peaks (in mV.ms) were divided by die amount o f  IgG (in pg) in the dialysates (as given in 
Table 6.5) and multiplied by the dilution factor for the labelled residues prior to HPLC 
(Table 6.3). After dividing this value by 106 to obtain more manageable numbers, these 
corrected areas are plotted in Figure 6.8(B): thus in this graph die peaks are relative to the 
amount o f  glycan per unit o f  IgG in the sample. In diis graph it appears that the positive 
samples have more peaks on the left-hand side o f  die graph, and the negative samples 
have more on the right-hand. However, this effect is due to the much higher amounts o f 
glycosylation in the positive BP, with large amounts o f  core products, and in the negative 
jt, with large amounts o f sialylated glycans. I f die data for these two samples is removed, 
the result is seen in Figure 6.9. The graph resembles that o f Figure 6.8(A).
It was noted previously tiiat the A2G0F peak height at 85 min appeared similar in 
the batch 2 negative samples. In fact, in the negative samples in both batches, this peak is 
always higher than the triplet Gal 1 peaks. In the positive samples, the peak is generally, 
but not always, smaller than the triplet Gal 1 peaks. Figures 6.8 and 6.9 do not show any 
difference between the positive and negative samples for this peak, but t-tests were carried 
out for these peaks as will be shown later.
Figure 6.8(A) shows possibly larger peaks for die positive samples for die three 
Gal 1 triplet peaks (GU values 6.73, 6.85, and 6.95 in Table 6.6). Also, with the A2G2S
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peaks (GU values between 7.98 and 9.23 in Table 6.6), the negative samples seem to 
predominate. These will be investigated below with graphs and t-tests.
Table 6.6. Percentage areas of the main peaks for ail CSF samples.
Glucose Glycan 
Units
GH DH AW HC AR RH BP ms dg ib jt ai ja
4.24 7.0 4.5
4.33 8.9 3.4
4.43 M3N2 0.5 1.1 0.5 0.5 0.4 0.6 2.0 0.6 2.4 0.1 1.1
4.62 M3N2F 1.1 0.5 1.2 1.0 0.4 0.8 1.8 0.3 2.5 0.4
4.68 1.3 0.5 0.6 1.1 1.0 0.3 2.4 0.6 0.4
Core 4.76 0.9 1.1 0.5 0.3 0.2 0.1
products 5.02 M3N3 0.5 3.4 0.2 1.7 7.7 0.7 0.3 0.7 5.1 1.9 1.4
5.17 0.5 1.2 0.4 0.3 1.6 3.0 0.8 0.4 0.4 1.2
5.28 M3N3F 0.9 2.5 1.1 1.6 4.0 1.6 0.1 2.0
5.38 0.3 0.8 0.6 1.1 1.9 0.4 0.3 0.8
5.50 A2G0 2.2 8.1 4.0 9.6 2.2 1.0 3.3 6.4 3.8 3.5 7.9 4.5
5.72 A2G0B 1.9 3.4 2.4 0.6 1.7 3.8 5.2 2.3 1.3 1.4 1.3 3.0
5.83 1.8 3.0 1.3 0.8 5.6 2.4 2.3 0.4 0.7 0.8 2.1
5.96 A2GOF(a1-6) 12.7 17.4 20.6 23.4 24.4 14.3 7.6 22.6 15.2 18.9 8.1 21.8 25.2
6.20 1.7 1.5 7.3 9.2 3.6 3.6 3.0 1.8 4.0 6.6 2.3 2.2
..6,2.9.....A2G.O.EB.............. ... 6,2......9..4... ... 2,8......2,7... ...3J 40 ...5.8... ...1,7... ... .1,7 . ..5.7 f*6
6.40 A2G1(a1-6) 2.8 2.7 1.5 1.7 2.2 0.9
6.47 A2G1(a1-3) 2.2 0.2 0.6 1.1 0.7 1.5
0 sialic 6.60 A2G1(a1-6)B 2.3 2.2 1.6 1.9 0.7 1.9
aGids 6.73
6.85
6.95
TA2G1(a1-3)B
bA2G1(a1-6)F
rA2G1(a1-3)F
LA2G1(a1-6)FB
A2G1(a1-3)FB
15.7
7.5
7.5
10.0
3.8
6.0
16.8
10.8
3.5
20.9
8.2
4.4
19.6
9.9
4.9
17.4
9.2
7.2
4.5
1.7
5.9
12.9
7.8
4.1
8.4
3.6
1.7
12.6
7.5
2.3
5.7
3.1
2.1
16.4
8.9
5.5
12.6
6.9
4.6
7.10 A2G2 1.7 1.7 1.2 2.5 1.4 0.7 1.3 0.3 1.6
7.22 1.2 1.3 1.4 1.5 0.8 1.8 3.5 0.5
7.35 A2G2B 1.2 1.4 1.9 1.1 0.6 1.0
7.63 r A2G2F 
1 A2G2FB
17.6 5.0 15.7 16.0 11.5 16.3 5.0 13.4 19.8 12.0 6.6 15.8 9.4
7.98 A2G2S1(a1-3) 1.6 1.5 1.4 1.3 1.8 2.1 1.0 2.8 3.7 11.8 1.2 1.1
1 sialic 8.19 A2G2S1(a1-6) 0.1 0.1
acid 8.38 A2G2FS1(a1-3) 7.7 2.5 5.8 7.7 5.9 9.5 4.2 5.9 8.9 7.4 5.2 6.7 3.4
8.58 A2G2FS1(a1-6) 1.2 1.1 0.5 0.8 1.1 4.4 1.7 1.3 1.2
8.78 A2G2S2 0.2 0.6 0.2 5.0 0.7 0.5 18.7 0.6
2 sialic 9.14 A2G2FS2 1.1 1.1 1.9 2.1 0.8 2.4 3.2 4.4 1.5 0.6
acids 9.23 A2G2FBS2 1.6 1.0 1.8 1.7 0.8 0.4 1.2
Samples were run on system 1 normal phase HPLC after labelling with 2AB. For method details 
see section 6.4.7.1. GH to BP are CSF samples containing oligoclonal IgG; ms to ja are control 
CSF samples without oligoclonal IgG. The GU (glucose unit) values for the peaks are shown in 
column 2, and the glycans structures comprising the peaks, where identified, are shown in 
column 3.
A2 indicates biantennary glycans; G (0, 1 or 2) indicates number of galactose residues; S (0, 1 
or 2) indicates number of sialic acids; (a1-3) or (a1-6) indicates type of glycosidic linkage; F 
denotes the presence of fucose, and B denotes a bisecting GlcNAc residue. M and N indicate 
numbers of mannose or GlcNAc residues respectively in core products.
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Figure 6.8. Comparison of peak areas of all CSF samples run on system 1 (normal phase) 
HPLC. For method details see 6.4.7.1. The peaks in (A) are derived from the percentage 
areas of the HPLC peaks and are drawn from the data in Table 6.6. The peaks in (B) are 
derived from the absolute areas of the HPLC peaks, with adjustment for the IgG content of the 
dialysates and dilution of the labelled extract prior to HPLC, as described in 6.5.2.1(c).
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Figure 6.9. Comparison of corrected peak areas for samples on system 1 HPLC: as for 
Figure 6.8(B) but excluding the samples BP and jt.
Sialylation
To see if sialylation o f the glycans could show a difference between the two groups, the 
peaks were divided into total core products, asialylated, monosialylated or disialylated 
sections, as indicated by the first column o f  Table 6.6. For each sample, the peak areas, 
corrected as described above, in each section were added together and plotted in Figure
6.10. However, the graph does not show any trend in amount or relative proportion o f 
sialylation between the positive and negative groups.
Galactosylation
Peaks were divided into total agalactosylated, monogalactosylated or digalactosyl- 
ated referring to the data in Table 6.6 (see hatched lines) and plotted in Figure 6.11. 
However no differences between positives and negatives are revealed.
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Figure 6.10. Combined corrected areas of peaks for core products, asialylated, 
monosialylated and disialylated glycans for all CSF samples on system 1 HPLC. For 
division of peaks into the four sections, please see Table 6.6.
GH DH AW  HC AR RH BP ms dg ib
Figure 6.11. Division of peaks for all CSF samples run on system 1 HPLC into total agal­
actosylated, monogalactosylated or digalactosylated sections (see hatched lines in Table 6.6).
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T-Tests
The results o f  unpaired t-tests, comparing the means o f  the positive and negative 
groups o f  samples, are shown in Table 6.7. Percentage areas o f  peaks, or the sum o f 
percentage peaks areas were tested, but in some cases, where it was thought appropriate, 
the absolute areas or the areas corrected for IgG content (described in 6.5.2.l.c) were 
tested also.
Although the means for the A2G0F peak areas are not different for positives or
Table 6.7. Unpaired t-Tests.
Tested Positives Negatives P values
%Area %Area % Absolute Area
Mean Mean Area Area corrected
(±SEM) (±SEM)
A2G0F peak 17.20 (2.30) 18.63 (2.53) 0.6828 0.6779 0.6713
Ratio A2G0F peak/Gal 1 0.57 (0.05) 0.82 (0.06) 0.0078* 0.0141* 0.0145*
Ratio A2G0F peak/Gal 1+Gal 2 0.31 (0.04) 0.34 (0.05) 0.6674 0.7450
Gal 0 34.21 (3.34) 32.58 (3.87) 0.7542 0.5421 0.4360
Gal 1 30.39 (3.14) 23.02 (3.37) 0.1382 0.4669 0.2647
Gal 2 25.44 (2.82) 32.80 (4.47) 0.1787
Ratio Gal 0/Gal 1 1.20 (0.15) 1.47 (0.13) 0.2063 0.2152
Ratio Gal 0/Gal 2 1.49 0.27) 1.15(0.25) 0.3874
Ratio Gal 1/Gal 2 1.25 (0.17) 0.82 (0.19) 0.1191 0.1304 0.1609
Ratio Gal 0+Gal 1/Gal 2 2.74 (0.41) 1.97 (0.44) 0.2297
Ratio Gal 1 +Gal 2/Gal 0 0.74 (0.07) 0.60 (0.08) 0.2252 0.6638
Ratio first/second triplet peaks. 15.00 (2.19) 10.63 (2.00) 0.1752 0.5483 0.2060
SO 79.46 (6.47) 70.85 (7.47) 0.3997 0.6197 0.4762
S1 7.96 (0.92) 11.61 (2.02) 0.1119 0.5190 0.5156
S2 2.62 (0.83) 5.95 (3.44) 0.3330 0.3836
S1+S2 10.59(1.20) 17.39 (5.11) 0.1902 0.9768
Ratio S1/S0 0.10(0.01) 0.20 (0.06) 0.1489 0.6088
Ratio S2/S0 0.04 (0.03) 0.13(0.09) 0.3556
Ratio S1+S2/S0 0.14 (0.03) 0.33 (0.16) 0.2466
* Means significantly different (P<0.05) between positive (n=7) and negative (n=6) groups.
The P value is calculated on percentage areas of peaks (Table 6.6) and on absolute areas and 
corrected areas (as described in 6.5.2.1c) where thought appropriate. Throughout n=7 for positive 
samples; n=6 for negative samples.
The A2G0F peak is at 85 min (5.96 GU); the first and second A2G1 triplet peaks are at 92 and 93 
min (6.73 and 6.85 GU) respectively.
Gal 0, Gal 1 and Gal 2 refer to total agalactosylated, monogalactosylated or digalactosylated 
peaks respectively. SO, S1 and S2 refer to total asialylated, monosialylated or disialylated peaks 
respectively.
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negatives, when the peak areas are expressed as a ratio o f  the total monogalactosylated 
peak areas there is a very significant difference. The difference is most pronounced when 
die percent areas o f  the peaks is compared (P=0.0078), although is still seen when 
absolute peak areas (P=0.0141) or corrected areas (P=0.0145) are used. If values for BP 
and jt are excluded, the difference is still significant (P=0.0138 for percentage area, 
P=:0.0220 for absolute area and P=0.0225 for corrected area). The difference, however, is 
not revealed when ratios o f  total agalactosylated (Gal 0) peaks rather than the A2G0F 
peak are tested, or if the A2G0F peak is compared to combined Gal 1 and Gal 2 peaks.
Low P values, although they are not statistically significant, are also seen for total 
Gal 1 and total Gal 2 percentage peak areas, and the ratio o f  total Gal 1 to total Gal 2 
percentage peak areas. There are quite large variances with these groups (Figure 6.12), 
and it is possible that with more data, significant differences may be found.
T-tests did not show significant differences in sialylation, but again, low P values 
were obtained for total monosialylated peak areas (S1+S2), and the scatter o f  results
Figure 6.12. Comparison of positive (POS) and negative (NEG) samples for total mono­
galactosylated (Gal 1) percentage peak areas, total digalactosylated (Gal 2) percentage peak 
areas, and the ratio of these - Gal1/Ga!2 (on right y axis).
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Figure 6.13. Comparison of positive (POS) and negative (NEG) samples for total mono- 
sialylated (S1) percentage peak areas, total disialylated (S2) percentage peak areas and 
combined mono- and disialylated (S1+S2) percentage peak areas.
(Figure 6.13) suggests that with more data a difference might be found. Generally, the 
positive oligoclonal IgG samples show less sialylation than die negative samples.
Total corrected area o f  all peaks o f  the positives and negatives were compared, to 
see if there is a difference in total glycosylation per unit o f IgG. The mean total corrected 
area for the positive samples was 19.28 (SEM^ 10.02) compared to 12.12 (SEM+3.50) for 
the negative samples. Although the means are very different, this is due to the extremely 
high total peak areas for samples BP and jt. I f these two samples are excluded for the 
calculation, the means are similar (9.305±1.14 for positives and 8.81+1.37 for the 
negatives).
d. Reassessment of Positive and Negative Groups
Because o f  the difficulty in obtaining CSF samples o f  large enough quantity for these 
HPLC studies, the Positive and Negative groups were based on the presence or absence 
o f  oligoclonal IgG bands as described in section 6.3. Results o f  a brain MRI scan or 
clinical diagnosis o f  MS (shown in Table 6.1) were not taken into account, as they were
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for the lectin assays (see section 4.6.3). I f these two criteria are considered, along with the 
oligoclonal IgG status, the Positive group will consist o f  three samples - DH, GH and RH 
- and die Negative group four samples - ib, al, ma and ja. Graphs were plotted as for 
section 6.5.2.1c, above, for all peaks, sialylated and galactosylated peaks, but no obvious 
differences between positives and negatives were seen (graphs not shown). Statistical 
analysis was not possible for this number o f  samples.
6.5.2.2. System 2. Vydac Protein WAX Column
Chromatograms o f  the samples o f  die first batch run on the W A X column are 
shown in Figure 6.14. (No samples from the second batch were run). Also shown are 
chromatograms o f  the water baseline and the fetuin calibrator. The peaks at 2 min 
contain neutral glycans but also other uncharged material. The broad peak in the CSF 
samples at 22 min has not been identified. The IS and 2S peaks are relevant to IgG.
As was found with system 1 (normal phase HPLC) for the first batch o f  samples, 
the peak patterns o f  die negative controls, ja and ms, resemble each other, while the 
positives show most variability. GH has the largest IS and 2S peaks o f  the four samples, 
while DH has the smallest. This agrees with the quantitation o f  IS and 2S peaks for the 
four samples in systeml, as shown in Table 6.6.
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Figure 6.14. Chromatograms of the first batch of samples run by reverse phase HPLC 
(System 2: WAX column), labelled with 2AB. For running conditions see 6.4.7.2. DH and 
GH are CSF samples containing oligoclonal IgG bands; ms and ja are CSF samples without 
oligoclonal IgG. W is water. CAL is the calibrator: bovine fetuin and peak groups are 
labelled containing monosialylated glycans (1S) and di-, tri-, tetra- and pentasialylated 
glycans (2S, 3S, 4S and 5S). Also shown is further division into peaks for triantennary (A3) 
and biantennary (A2) glycans.
249
The peak patterns for glycans o f  CSF IgG are generally similar to those found 
previously for those o f  serum IgG as shown in Figure 1.10 (Guile et al, 1996). However, a 
wide variation in patterns was seen with both positive oligoclonal IgG and negative 
oligoclonal IgG groups o f samples. The serum (RH) sample analysed here showed a peak 
pattern similar to that found previously for IgG in normal serum (Guile at al, 1996), with 
the corresponding CSF showing moderate differences in some o f  the peaks. CSF RH 
compared to serum RH showed a decrease in the A2G0F peak, but increases in the 
adjacent A2G0FB and A2G0 peaks. Several minor Gal 0 and Gal 1 peaks in the CSF 
between 86 and 92 minutes are missing in the serum, but there is an increase in the small 
S2 peaks in the serum between 106 and 000 minutes. It is possible that these differences 
are due to the oligoclonal IgG in the CSF.
With the wide variation in these samples, consistent differences between the two 
groups are not easily seen. However, the A2G0F peak is consistently larger in die 
oligoclonal IgG negative samples, and a significant quantitative difference is found 
between positives and negatives when the ratio o f  this peak to the combined mono- 
galactosyl peaks is tested. In the oligoclonal IgG positive samples the size o f  the A2G0F 
peak is similar to tiiat seen in normal serum IgG samples (Guile at al, 1996) and to the 
serum (RH) sample analysed here.
Previous studies o f  serum IgG in RA and other autoimmune diseases have found 
an increase in agalactosylated glycans (Roitt et al, 1988; Tomana et al, 1988; Rook et al, 
1989; Furukawa and Kobata, 1991) with a corresponding reduction in mono- and 
digalactosylated glycans. This is in contrast to the findings here, where the agalatosyl 
glycans are decreased, albeit moderately, in the samples representing the disease i.e. the 
oligoclonal IgG positive samples, rather than in the normal controls. Low P values from 
the Student’s t-tests o f  total monogalactosylated and digalactosylated peaks are not
6.6. Discussion
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significant with the small data sets involved here, but do suggest a reduction in 
monogalactosylation, but not digalactosylation, for the oligoclonal IgG negative samples.
Although significant differences o f  sialylation were not found for the small 
numbers o f  positive and negative oligoclonal IgG samples assayed here, generally the 
negative samples show an increase in sialylation. Only the batch 1 samples have been run 
on the system 2 HPLC. The cause o f  the broad peak at 22 min is not known, but 
apparendy occurs also in all serum samples run on this system. The results generally 
agreed witii the quantitation o f  the monosialylated and disialylated peaks for the four 
samples in system 1, with the peak patterns o f  the negative controls resembling each 
other, and the positives showing more variability. If the batch 2 samples, with their wide 
variety o f  sialylation peaks, were run, differences in sialylation may become clearer.
However, there are several problems with the samples used in this study. One 
problem is that the normal controls are not from a healthy population, because o f  the 
difficulty o f  obtaining CSF from healthy subjects for ethical reasons. The samples for this 
project were selected from samples on which routine laboratory CSF analysis had been 
carried out. Most CSF samples arriving in the laboratory do not contain sufficient IgG for 
glycan analysis by this HPLC method, which requires a larger amount o f  IgG than the 
lectin immunoassays. Even though samples prior to injection onto the HPLC column 
were diluted between 1 in 4 and 1 in 100, depending on the labelled glycan content, there 
are many steps during the sample preparation where loss can occur. These include, for 
instance, loss to the dialysis membrane, and to inside o f  reaction vessels, evaporation 
tubes etc. Essentially, the amount o f  IgG lost at each stage is the same for all samples, 
regardless o f  IgG concentration o f  the sample. So for samples with minimal levels o f  
IgG, the overall loss can be substantial.
The few samples that contain enough IgG do not easily fall into die ‘positive MS’ 
or ‘negative control’ groups that were used for the lectin assays o f  IgG described in
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chapter 4 (see section 4.6.3). For this reason it was decided to use the presence or absence 
o f  oligoclonal IgG bands as the investigation criterion, rather than the clinical condition o f  
MS. Therefore, there is the problem (see Table 6.1) that some negative oligoclonal IgG 
samples may be from patients whose MRI scan suggested demyelination and who show 
clinical signs o f  MS. Similarly some oligoclonal IgG positive samples are from patients 
who have normal MRI scans and for whom MS has not been diagnosed.
An attempt was made to reassess the samples according to the same criteria used 
for the lectin assays, but with the small number o f  samples, a difference between the 
groups was not seen.
As well as selection o f  samples, there are other factors which affect the results o f  
this study. It would appear that oligoclonal IgG is lacking in A2G0F compared to 
polyclonal IgG, but because the oligoclonal IgG positive samples as well as the negative 
controls also contain polyclonal IgG, any subde differences in glycosylation o f  oligoclonal 
IgG would be ‘swamped’ by die polyclonal glycosylation.
There are several possible reasons for the wide variation o f  peak patterns, 
especially o f  batch 2 samples compared to batch 1 samples. It could be related to the 
smaller amounts o f IgG in the batch 2 samples. Also the resolution o f  the peaks for batch 
2 was poor compared to batch 1, presumably due to the age o f  the column, and though 
this is not thought to be a factor in the variation in the peak patterns, it may have affected 
the accuracy o f  the quantitation o f  the peaks.
It is possible that some o f  the wide variation seen in the batch 2 samples is due to 
error introduced during the lengthy preparation o f  the samples, despite the great care that 
was taken. It is possible that the protein A  eluate o f  one or more samples contained some 
protein other than IgG, or that during labelling with 2AB there was contamination from 
other glycans. Two samples especially, the positive BP and the negative jt, have very 
unusual glycosylation patterns for IgG and are discussed below.
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The chromatogram for BP showed excessively large amounts o f core products (i.e. 
trimannosyl structures lacking antennary arms). The usual N-glycan pattern appears to be 
present, although it is not clear. The large scale o f  the y-axis o f  the chromatogram shows 
that the glycan structures are generally in much larger quantities than in the other samples. 
The clinical diagnosis is ‘possible 1° progressive MS’, although an MRI brain scan has 
never been performed. It is not known why there should be so many non-antennary 
glycans, unless these occur with deterioration o f  the sample from die action o f  
glycosidases. Contamination o f  the sample should be suspected.
The sample jt contains very large amounts o f mono- and disialylated glycans, the 
peaks o f  which dominate the chromatogram. The usual amounts o f  N-glycan peaks are 
still there, altiiough they are dwarfed on the chromatogram. It also contains a relatively 
large amount o f  core products. There are no clues as to die cause o f  the high sialylation 
from the clinical details. The patient showed ‘upper motor neurone signs’, not diought to 
be MS, but questionably ‘familial spastic paraplegia’. The MRI brain scan was normal. 
Again contamination o f  the sample should be suspected, although this could be ruled out 
if sialic acid could be shown to be increased in the original CSF sample.
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Cha p te r  Seven
Discussion
7.1. The Problem Investigated
Multiple sclerosis (MS) is an autoimmune disease, characterised by the breakdown 
o f  myelin in the brain (Adams, 1989). The disease mechanism is poorly understood and 
the causative agent and the actual autoimmune target are unknown (Bannister, 1992; 
Zanetta, 1996).
IgG is involved in the disease, not simply as an antibody, in common with other 
autoimmune diseases (Roitt et al, 1998), but also because oligoclonal IgG is produced by 
lymphocytes within the CNS (Adams, 1989). The presence o f  oligoclonal IgG in CSF is 
often used as an aid to diagnose MS, but it is not specific to MS, nor does it always occur 
in the disease, and its prevalence is not related to die seventy o f  the disease (Fukuzawa et 
al, 1998). It has not been shown conclusively that oligoclonal IgG an autoantibody 
directed against myelin (Adams, 1989; Rand et al, 1998), but it may possibly assist in the 
elimination o f  antigenic fragments o f  proteins, such a myelin basic protein (MPB), broken 
down from myelin by proteases triggered by cytokines (Opdenakker and Damme, 1994).
A  feature o f  oligoclonal IgG is tiiat a large proportion has a high isoelectric point 
(pi) compared to polyclonal IgG, as seen with isoelectric focusing (IEF) (Cowdrey et al, 
1990). One o f  the aims o f  die project has been to see if this high pi is due to variant 
glycosylation o f  die IgG, such as a deficit o f  sialic acid. Other causes could be an increase 
o f basic amino acids in the IgG, or the complexing o f IgG with fragments o f  basic 
peptides, for instance from the breakdown products o f  myelin (Opdenakker and Damme, 
1994).
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The glycosylation o f  IgG and other proteins and conjugates plays a key role in 
iminunity and likewise in autoimmune disease (Gabius et al, 1997; Rudd et al, 1999). A 
number o f  inflammatory diseases are associated with a deficiency o f  terminal galactose on 
the oligosaccharides o f  the Fc fraction o f  IgG in serum (i.e. Gal 0 or agalactosyl IgG). 
These include rheumatoid arthritis (RA) and osteoarthritis (Parekh et al, 1985; Roitt et al, 
1988), systemic lupus erythematosus, Crohn’s disease and tuberculosis (Tomana et al, 
1988; Furakawa and Kobata, 1991). In other diseases, a variety o f  changes in 
glycosylation has been found. Cancer cells, for instance, often have increased sialylation 
and glycan branching on their surface, and some types also show differences in galactosyl- 
ation and fucosylation (Brockhausen, 1993). Also in cancer there may be an expression o f 
carbohydrate antigens, usually O-linked glycans, that are not normally present in the 
particular tissue (Kim et al, 1996). The fucosylation o f  serum alpha-fetoprotein shows 
differences in liver germ cell tumours compared to hepatomas (Aoyagi et al, 1998). 
Human chorionic gonadotropin (HCG) in urine from women with invasive hydatidiform 
mole has been found with additional triantennary chains compared with urine from 
women in normal pregnancy, and HCG witii abnormal biantennary chains has been found 
in urine from patients with choriocarcinoma or non-invasive mole (Kobata and Takeuchi, 
1999). Asialylation o f  serum transferrin is found in liver disease (Matsumoto et al, 1994), 
alcoholism (Stibler et al, 1980) and in inherited metabolic diseases (Keir et al, 1999).
It is possible, therefore, that the glycosylation o f  IgG might be different in MS 
patients compared to normal controls. In this project the IgG in CSF has been studied 
and as mentioned already, two types o f  IgG can exist in CSF. There is polyclonal IgG, 
which is produced by the pool o f  lymphocytes circulating in the body outside o f  the CNS. 
Levels o f  this may increase in response to disease such as infection, and may also increase 
in the CSF. Additionally, there is oligoclonal IgG produced within the CNS by a relatively 
small numbers o f  CSF lymphocytes. This is found in CSF only in certain neurological
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diseases. The glycosylation o f  each o f  these types o f IgG may be under different control 
mechanisms. For instance, with an inflammatory disease such as MS, serum polyclonal 
IgG, and hence CSF polyclonal IgG, might have an abnormal feature in the same way that 
serum IgG in RA is less galactosylated. However, the glycosylation o f  the oligoclonal IgG 
might be independent o f this. Therefore changes in glycosylation o f  the polyclonal IgG 
might be hidden by the oligoclonal IgG. The reverse might also be true: oligoclonal IgG 
might be glycosylated differendy from polyclonal IgG (e.g. asialylated), but detection o f  
this may be obscured or confused by the presence o f  polyclonal IgG. In this project, die 
lectin binding assays and the HPLC analysis do not distinguish between the two types o f 
IgG. IEF, however, can differentiate between die bands o f  oligoclonal IgG and the 
diffuse pattern o f  polyclonal IgG.
7.2. The Findings
In this section, the findings for each o f  the metiiods (Chapters 3 to 6) will be 
looked at in turn.
7.2.1. Chapter 3: Development of an IgG Immunoassay
Essentially this is a methodological chapter, and does not deal with the problems 
outlined in 7.1, above. Setting up a method to quantitate CSF IgG was a necessary step 
for the development o f  the lectin binding assays. It resulted in a robust, highly sensitive 
mediod for IgG with reasonable precision and good recovery o f  IgG. A  good correlation 
(r=0.88, n=68) was found with an established immunoturbidometric assay for CSF IgG. 
Although attempts were made to automate the assay, they were not successful. The 
outcome was a reliable assay in which CSF IgG was ‘captured’ in a quantitative way, which 
facilitated the next step o f  incorporating lectins into the assay in order to probe the IgG 
carb ohydrates.
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Much o f this chapter was concerned with method development and overcoming 
problems with interfering substances in the CSF samples. Interference was thought to be 
from highly glycosylated substances in the CSF, which bound non-specificaUy to the 
capture antibody as well as to the assay tube, and were then bound by the lectins. These 
were finally eliminated by using protein A  affinity chromatography to isolate the sample 
IgG. Again attempts to automate the assays were unsuccessful.
Four different lectins - Con A, RCA, SNA and DSL - were used to look at the 
carbohydrates in IgG in two groups o f  CSF samples. The MS positive group consisted o f  
13 CSF samples from patients diagnosed as having MS, containing oligoclonal IgG and 
raised [IgG]/[total protein] ratio. The Control group consisted o f  14 CSF samples, from 
patients without the diagnosis o f  MS, containing no oligoclonal IgG and normal 
[IgG]/[total protein] ratio.
A  significant difference between MS samples and controls was found for Con A  
binding to IgG (unpaired t-test: P= 0.0172; n=13 and 14). The mean for the MS samples 
was higher, with a wider spread o f  results. The amount o f IgG added in the immuno­
assays was the same for all samples. Since Con A  primarily binds to mannose, these 
results suggest tiiat die IgG in die MS samples contains more mannose. This could mean 
either that the extent o f  IgG glycosylation in the MS samples is increased, i.e. that there 
are more glycans per IgG molecule, or tiiat the extent o f  glycosylation is the same but that 
the glycans contain more mannose, i.e. have more branching. Serum IgG glycans are 
always described as having a ‘tdmannosyl core’ (see sections 1.2.5.1 and 1.3.4.2) witii up to 
2 antennary chains. It is unlikely that CSF IgG is fundamentally different, so an increase 
in average number o f  glycans per IgG molecule is more likely.
However, anotiier possible reason for increased Con A  binding is tiiat the more 
terminal monosaccharides, i.e. sialic acid and galactose, might be missing from the glycans
7.2.2. Chapter 4: Development of Lectin Binding Assays for CSF IgG
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in the MS samples, causing the mannose residues to be more exposed and more accessible 
to Con A  binding. Glycans lacking antennary chains altogether, exposing the mannose, 
often called ‘core products’, were detected by HPLC o f  CSF samples in this project but 
overall differences between the oligoclonal IgG positive and negative groups were not 
seen. However, as will be made clearer in the discussion o f  the HPLC results, although 
galactosylation might be increased, sialic acid is possibly reduced in oligoclonal IgG so this 
could be a reason for increased Con A  binding rather than an increased number o f  glycans 
per IgG molecule.
Con A  binding to IgG was also found to correlate with the %IgG values o f  the 
samples analysed (Paired t-test: P=0.0443; n= 27). This is to be expected if Con A  does 
distinguish between MS and non-MS conditions, because %IgG is known to correlate 
with MS and is used clinically as one o f  the markers for the disease (see section 1.4.9). 
There may be the potential for Con A  binding to IgG to be used as a disease marker in 
place of, or in addition to, %IgG. For the samples analysed in the project, %IgG and IgG 
concentration gave better differentiation between MS positives and controls than Con A  
binding (Unpaired t-tests: P<0.0001; n=13 and 14 for both %IgG and IgG concentration; 
P=0.172; n=13 and 14 for Con A). But this is not surprising, since increased %IgG and 
IgG concentration were part o f  the criteria used for selecting MS positive samples for the 
study. So the potential o f  using Con A  binding as a marker could be explored by 
analysing new samples selected on the basis o f  diagnosis o f  MS and other criteria apart 
from IgG levels.
RCA binding to galactose was substantially increased in 3 out o f the 13 MS 
samples compared with the controls, but the difference between the two means was not 
quite significant at the 95% confidence level (P=0,0981). There appears, therefore, to be 
increased galactosylation in only some o f  the MS positive samples. A correlation was not
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found between Con A  and RCA (1—0.0650; P=0.7474), although the three high RCA- 
binding samples also had high Con A  binding.
For SNA, no statistical difference was found between the MS samples and 
controls (Unpaired t-tests: P= 0.4506, n= 13 and 13). However, the scatter o f  binding to 
the MS samples was much wider than the controls, with 5 out o f the 13 MS results being 
higher than any o f  the controls. Since SNA binds to sialic acid, the increased binding o f  
SNA in a large proportion o f  the MS samples does not appear to support the theory that 
oligoclonal IgG is deficient in sialic acid. This will be further discussed later.
There was, however, a strong correlation between SNA and RCA binding 
(r::=0.7924; P<0.0001; n=26). This is consistent with the understanding that where 
galactose is deficient, sialic acid must also be lacking.
DSL binding did not distinguish at all between MS samples and controls 
(Unpaired t-test: P=0.6922; n=13 and 14), with similar means and wide variances, but also 
small RLU counts compared to the other lectin assays.
As discussed in section 4.7, one o f  the problems with using lectins to investigate 
the glycans o f  a protein is the possibility o f  steiic hindrance to their binding by the 
protein. This can be overcome by denaturation o f the protein, but for this project it was 
chosen not to do this, to enable isolation o f  the IgG from the samples by immunoassay. 
It is suspected that the relatively low binding generally in the DSL assay is due to steric 
hindrance. The moieties which are bound by DSL - GlcNAc(j3l-4)GlcNAc]1.3 and 
Gal(P 1-4)GlcNAc - are present in all glycan chains o f  IgG (found to date) so DSL binding 
would be expected to be as extensive as Con A  binding to mannose. Although binding o f  
DSL to IgG appeared to be high in the preliminary lectin assays, this binding was 
probably predominantly due to the interferent. A  lectin’s binding to its target 
carbohydrate in a glycoprotein could be influenced to varying degrees by neighbouring
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groups which may be variable or absent, so binding to die target may not be as 
quantitative as one would hope.
Overall, the lectin assays have shown that there is a difference in IgG glycosylation 
in the MS positive samples compared to controls, with generally a higher mean and greater 
spread o f results in die MS samples. This might be due to variant glycosylation o f  
oligoclonal IgG compared to polyclonal IgG or to changes in the glycosylation o f  the 
polyclonal IgG with MS, or a combination o f  both. These points will be looked at further 
later.
7.2.3, Chapter 5: Isoelectric Focusing of CSF and Detection of Glycosylation using 
Lectins
The work using IEF to investigate the glycosylation o f  IgG is o f  a preliminary 
nature and could still be developed further. Use o f  pH 3 tolO gel stnps and detection 
with lectins was found to be difficult, however die high resolution o f  the bands on some 
o f  the PVDF blots illustrates the potential o f  the technique.
Con A  was seen to bind oligoclonal IgG bands throughout the pH 3 to 10 range, 
showing that mannose-containing glycans are present throughout the pi range o f 
oligoclonal IgG. SNA, however, although only a few samples were run, was seen to bind 
oligoclonal IgG in the acidic and neutral regions only, and not in the alkaline region. This 
suggests that alkaline oligoclonal IgG is possibly deficient in sialic acid.
This finding with SNA, however, does not agree witii the findings o f die lectin 
binding assays, where SNA binding was certainly not reduced in the MS samples, and in a 
few MS samples it was higher than all the controls. If the validity o f  botii results is to be 
believed, it could be argued that the alkaline oligoclonal IgG is indeed deficient in sialic 
acid, but neutral or acidic oligoclonal IgG might have increased amounts o f  sialic acid. 
Another explanation is that there may be increased sialic acid in die polyclonal IgG in MS
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samples compared to controls, which may overcome the effect o f  the sialylation o f  the 
oligoclonal IgG. These points will be discussed further later.
Another aspect o f  using IEF was to study the effect o f  deglycosylation o f 
oligoclonal IgG. A CSF sample containing oligoclonal IgG bands was subjected to IEF 
before and after treatment with PNGase F. Confirmation o f  deglycosylation o f  the 
treated sample was made by its absence o f  binding to Con A. But detection using the 
anti-lgG double antibody system showed a pattern o f banding that was different to the 
untreated sample, although it was as extensive. This was interpreted as suggesting that the 
spread o f  isoelectric points o f  oligoclonal IgG bands is not simply due to differences in 
carbohydrate. Were this the case, the oligoclonal IgG bands would coalesce into a single, 
or only a few, bands.
7.2.4. Chapter 6: Analysis of IgG Glycans by HPLC
The selection o f  samples for HPLC analysis was different from the lectin 
immunoassays, and this has important implications when comparing the results from the 
two methods. Because o f  the difficulty o f  finding CSF samples with sufficient IgG for the 
HPLC method, die more stringent selection criteria o f the lectin immunoassays was not 
used. Rather than selecting on the basis o f  the clinical condition o f  MS (accompanied by 
positive oligoclonal IgG bands in the CSF, raised CSF IgG and an MRI scan indicating 
demyelination), the positive samples for HPLC were simply selected on the basis o f  
containing oligoclonal IgG. Similarly the negative ‘controls’ were selected as not 
containing oligoclonal IgG.
As explained in section 7.1, neither the HPLC method nor the lectin 
immunoassays can distinguish between oligoclonal and polyclonal IgG. Therefore 
differences in glycosylation between the positive and negative groups may be due to one, 
or both, kinds o f  IgG. A difference found by the lectin immunoassays can be attributed 
to MS, although it may be due to a characteristic o f the oligoclonal IgG, or to the
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polyclonal IgG, or both. However, a difference found by the HPLC method probably 
cannot be related to disease and again may be a reflection o f oligoclonal or polyclonal 
IgG, or both.
The HPLC samples were analysed in two batches. In the first batch, the two 
negative samples showed similar peak patterns while the positive samples showed wider 
variations. In the second batch there was more variation in the peak patterns for the 
negative as well as the positive sample groups. Several possible reasons for this increased 
variation have been given for this in the Chapter Six discussion (section 6.6). It is difficult 
to tell, especially with few previously published examples o f  HPLC o f IgG glycans, 
whether the variation is due to post-transcriptional heterogeneity, or whether inaccuracy 
has been introduced into the assay.
Two samples especially, BP and jt, show extremes o f  variation. The variation in jt 
cannot be due to oligoclonal IgG because it contains none. Omission o f  the two samples 
from statistical comparison o f  positive and negative groups does not greatly affect the 
results. It is possible that these two samples have been contaminated because o f  their 
atypical peak patterns and because they contain a much larger quantity o f  glycan structures 
than die other samples. However, the peak patterns o f  these two samples do not have the 
characteristics o f  contamination tiiat have been seen at the Glycobiology Institute. It is 
possible that they ate genuine results, and that the patients are suffering from different 
inherited metabolic disorders o f  glycosylation. The result for BP, especially, with an 
excess o f trimannosyl core products with some GlcNAc residues, suggests a defect in a 
GlcNAc transferase or perhaps a galactosyltransferase. The case notes o f  these two 
patients will be re-examined for any evidence o f symptoms o f  inherited disease.
The main finding o f  the HPLC analysis is a difference in the A2G0F peak, which 
is consistendy larger in the negative samples compared to the positives. The difference is 
statistically significant when the A2G0F percentage peak area is expressed as a ratio o f  the
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total monogalactosylated (Gal 1) percentage peak area. In previous studies, increased 
levels o f  agalactosylated glycans o f  serum IgG have been found in patients with RA and 
other autoimmune diseases (Roitt et al, 1998; Tomana et al, 1988; Rook et al, 1989; 
Furukawa and Kobata, 1991). This appears to be in contrast to the case here, where the 
agalactosyl glycans are decreased in die samples representing the disease, i.e. die 
oligoclonal IgG positive samples. However, as previously explained, positive and negative 
sample groups for the HPLC analysis were not selected on the basis o f  MS status, i.e. the 
oligoclonal IgG positive samples are not necessarily MS positive samples. Therefore the 
decrease in A2G0F glycans in the positive samples might well stem from the oligoclonal 
IgG and might not be due to polyclonal IgG. There might be separate changes in the 
polyclonal IgG.
In comparisons o f galactosylation, the Student’s t-test was also applied to total 
monogalactosylated (Gal 1) and total digalactosylated (Gal 2) percentage peak areas and 
the ratio o f  Gal 1 to Gal 2 percentage peak areas for the two sample groups. Aldiough 
not statistically significant, low P values were found and scatter plots suggest that the 
oligoclonal IgG positive samples contain more Gal 1 glycans but less Gal 2, but overall are 
more galactosylated than the negative oligoclonal IgG samples.
As well as percentage peak areas, t-tests were applied to the absolute peak areas, 
and the absolute peak areas corrected according to die amount o f  IgG in the dialysates 
and die dilution o f  the labelled extract prior to column injection. The correction would 
adjust the area to relate to the amount o f  glycan per unit o f  IgG in the CSF sample. 
Although differences between the two sample groups, using tiiese values, were significant 
in some cases, die P values were never lower than the corresponding ones for percentage 
areas.
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Total glycosylation, i.e. the sum o f  all peaks, was also looked at in terms o f  
absolute peak areas and corrected peak areas, but no difference was found between the 
positive and negative groups.
Differences in sialylation between the positive and negative sample groups were 
not significantly different, however low P values were obtained, with small differences in 
the means but a wide scatter o f  results. With more data a significant difference might be 
found. Generally, the positive oligoclonal IgG samples were less sialylated than the 
negatives.
A  single serum sample was analysed along with its paired CSF. Generally the peak 
patterns o f  the two were similar, but some differences are notable. We see in the CSF a 
decrease in the A2G0F peak, although there are small increases in minor GO and G1 
peaks. We also see a decrease in disialylated peaks in the CSF sample, while the 
monosialylated are similar. The differences might be due to the influence o f  oligoclonal 
IgG which is present in the CSF and not in the serum, while the polyclonal IgG in both 
samples is from the same pool. The two differences - a decrease in A2G0F glycans and 
decreased sialylation - correspond to the differences found for oligoclonal positive CSF 
samples compared to the negatives. It could be, therefore, that these are both features o f  
oligoclonal IgG rather than polyclonal IgG, although these tentative conclusions are based 
on only one sample.
There is another point to consider with the HPLC results. One possible reason 
suggested for the alkaline nature o f  the oligoclonal IgG, as well as a possible deficiency o f  
sialic acid, is that IgG might be complexing with degradation products o f  myelin, such as 
myelin basic protein (MBP), resulting from protease activity (Opdenakker and Van 
Damme, 1994). Although MBP itself is not glycosylated, other myelin components are, 
such as myelin-associated glycoprotein (MOG) which contains 8 or 9 IV-glycosylation 
sites. If these IgG-degradation product complexes bind tighdy to oligoclonal IgG, these
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complexes would have been bound by protein A  during affinity purification o f  the CSF 
samples for HPLC. Elution o f  IgG with pH 2.8 phosphate-citrate buffer would release 
the peptides into die eluate witii the IgG. As the molecular weight cut-off o f  die dialysis 
membranes subsequentiy used was 3500 kDa, the peptides would probably not be 
removed from the dialysates, and any glycans attached would go on to be labelled with 
2AB, along widi the IgG glycans, and hence contribute to the HPLC chromatograms. It 
is not certain if this has occurred, or if  so, how much the peptide glycans contribute to die 
HPLC chromatograms. It might explain the diverse peak patterns obtained for the CSF 
samples, although the oligoclonal IgG negative samples should not be affected, and it 
does not account for the unusual peak pattern for sample jt, which is oligoclonal IgG 
negative.
7.3. Have the Questions Been Answered?
The aims o f  the project were set out in Chapter One (section 1.5). In this section 
die combined findings o f  the three methods o f  glycosylation analysis will be discussed in 
relation to the questions asked concerning MS. The interpretation o f  the results is 
complicated by the differences in the selection o f positive and negative samples for the 
lectin immunoassays and HPLC, but also by the occurrence o f  both polyclonal and 
oligoclonal IgG in CSF each o f  which may possibly show different patterns o f  
glycosylation.
7.3.1. Changes in IgG Glycosylation
Does glycosylation of CSF IgG change in MS compared with normal? The results o f  the 
lectin immunoassays, which looked at CSF from MS patients and non-MS patients, 
indicate that there is probably a difference in IgG glycosylation. I f there an changes, what are 
they in terms of the glycans or the monosaccharides of IgG? Is the glycosylation pattern of IgG in CSF the
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same as that in serum? These points will be discussed by looking in turn at each general 
glycosylation change, in the light o f  results o f  the three analytical methods.
7.3.11. Extent o f Glycosylation
A possible difference between normal IgG, and IgG from patients with a disease, 
could be the average number o f  glycans per IgG molecule. A  significant increase in Con 
A  binding to IgG was found in the MS positive samples compared to the negative 
controls. This could be due to increased glycosylation o f  the IgG, although there are 
other possible reasons. The IgG glycans could contain more branched mannose, although 
this would be very unusual, with hitherto only trimannosyl glycans being recorded in IgG. 
Or die increased Con A  binding could be due to a possible lack o f  sialic acid in the 
oligoclonal IgG, giving Con A  more access to the mannose.
The suggestion o f  increased glycosylation o f  IgG glycans in the MS positive 
samples is supported by the increase in RCA binding to galactose. However, total 
absolute areas o f  HPLC peaks, and the absolute areas corrected according to the IgG in 
the dialysate and dilution o f  the labelled extract, were calculated and differences between 
the oligoclonal IgG positive and negative samples were examined. N o differences were 
seen, although tiiey could be masked because die samples after dialysis contained varying 
amounts o f  IgG and variable losses o f  IgG could occur during subsequent sample 
preparation.
In short, the increased Con A  binding in the MS positive samples is not supported 
by die HPLC data. It is possible, diough, tiiat this is because a different category o f 
positive samples was analysed by HPLC. IEF gives 110 information about extent o f 
glycosylation o f the IgG molecule: although Con A  binding to IgG bands in samples 
containing oligoclonal IgG was greater than to the IgG bands in oligoclonal IgG negative 
samples, tiiis was not looked at quantitatively.
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7.3.1.2. Galactosylation
The results o f  the RCA immunoassay suggest an increase in the galactosylation o f 
the MS positive samples compared to the negative controls. With HPLC, a decrease in 
the A2G0F/Gal 1 ratio was noted in the oligoclonal IgG positive samples, suggesting a 
tendency toward monogalactosylation rather tiian agalactosylation although di- 
galactosylation was possibly greater in the negative samples. The results o f  the two 
methods appear to agree with each other. The increase in galactosylation o f the positive 
groups o f samples could be from either the oligoclonal or the polyclonal IgG in the 
samples. Galactosylation was not studied witii IEF.
A  serum sample, with a paired oligoclonal IgG positive CSF was also assayed by 
HPLC. In the serum, the A2G0F peak area was increased compared to that in the CSF, 
and is thus more like the A2G0F peak in the oligoclonal IgG negative CSF samples. 
Assuming that the IgG in serum is polyclonal rather than oligoclonal, this would suggest 
that the increased A2G0F peak is due to polyclonal, rather than oligoclonal, IgG, i.e. there 
are less A2G0F glycans in oligoclonal IgG. It would explain why decreased agalactosyl 
IgG was found in the oligoclonal IgG positive samples in this study, when increased 
agalactosyl IgG is a feature o f  several autoimmune diseases. It is possible that separate 
changes, such as an increase in agalactosyl IgG, occur in the polyclonal IgG o f  CSF and 
serum in MS, but in CSF are confused by oligoclonal IgG glycosylation.
7.3.1.3. Sialylation
SNA binding to IgG in MS positive samples showed a wider and higher spread o f 
results compared to the controls. Although the means were not significantly different 
(impaired t-test: P=0.4506; n=13 and 14), 5 out o f  the 13 MS results were higher than the 
controls, with 2 results lower.
With HPLC, the data suggests that the oligoclonal IgG positive samples were less 
sialylated than the negative samples, although again significant differences between
267
oligoclonal IgG positive and negative samples were not seen (unpaired t-test for S1+S2 
percentage peak areas: P=0.1902; n=6 and 7). This is contrary to the lectin immunoassay 
results. The HPLC chromatogram for the serum sample shows increased peaks o f  
sialylated glycans compared to that o f  the paired CSF, also suggesting that sialylated 
glycans are increased in polyclonal IgG compared to oligoclonal IgG.
SNA detection o f bands was used for only a few samples mn by IEF. However, 
the lectin appeared not to bind the oligoclonal IgG in the alkaline region, although it 
bound IgG in the neutral and acidic regions. This suggests that oligoclonal IgG contains 
less sialic acid than polyclonal IgG. This agrees with the HPLC finding.
The contradictory results o f  the SNA immunoassay are difficult to explain. 
Although the MS positive samples exhibit a wide range o f  sialylation, the picture is 
certainly not o f reduced sialylation. The MS positive samples selected for the lectin 
immunoassays differ from the oligoclonal positive samples selected for HPLC in that diey 
ate all MS cases and perhaps the anomaly is related to this. There might be a tendency for 
increased levels o f  polyclonal IgG to occur in this sample group along witii the oligoclonal 
IgG, and the increased sialylation to result from this. On the other hand, increased 
polyclonal IgG may not be a feature o f  all the samples in the oligoclonal IgG positive 
group selected for HPLC, so increased sialylation is not seen.
7.3.2. Oligoclonal IgG
What is the character of the oligoclonal IgG bands? The IEF studies suggest that, while 
variable glycosylation occurs in die oligoclonal IgG bands, the spread o f  isoelectric points 
o f  the bands is not simply due to differences in carbohydrate. The lectin immunoassays 
and the HPLC assays do not distinguish between oligoclonal and polyclonal IgG, but a 
clue to the features o f  oligoclonal IgG might be given by comparison o f  the serum sample 
with its paired CSF sample, which contains oligoclonal IgG. It is possible that differences 
between the two might be due to the difference between oligoclonal IgG and polyclonal
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IgG. However, assumptions based on the results o f  a single serum/CSF pair are not 
definitive.
Looking at the results from all three methods, it is possible tiiat oligoclonal IgG 
glycans are generally less sialylated than polyclonal IgG glycans, although tiiis inference is 
not backed up by die lectin immunoassay data. The results also suggest that oligoclonal 
IgG glycans are generally more galactosylated. There is a slight anomaly here, for a lack o f 
galactose would perhaps necessitate a lack o f  sialic acid, which is die final residue on IgG 
chains, but the converse does not necessarily apply.
The impression gained from considering all results is that there is a wide variation 
o f  glycosylation in oligoclonal IgG compared to polyclonal, but that die glycans are 
generally more galactosylated and less sialylated. The question o f  whether a deficit o f  
sialic acid is responsible for the alkaline nature o f  the oligoclonal IgG is still not 
completely answered. It seems tiiat sialic acid is reduced in oligoclonal IgG, but is not the 
primary cause o f  its aUcalinity. If it is caused by the complexing o f  IgG with alkaline 
peptides, such as fragments o f  MBP, fragments o f  other myelin components might also be 
forming complexes and possibly contributing glycans to the patterns o f the HPLC 
chromatograms, which would negate many o f  the conclusions drawn in this project. 
Another reason suggested for the alkaline nature o f  IgG was a change in the amino acids 
o f  the IgG. Could the amino acids in the variable region o f  the Fab fraction o f  the 
oligoclonal IgG be different from that o f  polyclonal IgG in that either they are more 
basic, or they have a predilection for glycans which are deficient in sialic acid? IgG 
research in the past has concentrated on the glycans in the Fc fraction, for instance the 
finding o f  agalactosyl IgG in the serum o f  RA patients is due to differences in Fc glycans 
(Pareldi et al, 1985). Perhaps Fab glycans could also show changes in different diseases.
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Do the changes (if any) contribute to the pathogenesis of MS and, if so, how? Specific 
differences in the glycosylation o f  polyclonal IgG between MS samples and controls have 
not been established in this project, but it has been found that oligoclonal IgG compared 
to polyclonal may be less sialylated, and possibly more galactosylated.
One o f  the functions o f  sialic acid in glycoconjugates is to act as a shield to 
prevent recognition by clearing receptors (Powell and Varki, 1995). An important 
receptor is the IgG Fc receptor o f  macrophages which will remove from circulation 
glycoconjugates devoid o f  sialic acid (Paulson, 1989; Wormald et al, 1997). This supports 
the theory that oligoclonal IgG could help in the elimination o f  specific antigens such as 
peptide fragments from myelin (Opdenakker and Damme, 1994). Galactose is also 
important for binding o f  IgG to C lq  and Fc receptors (Tsuchiya et al, 1989).
IgG contains on average 2.4 glycans, so with two conserved glycans in the Fc 
region, about one in two molecules also has a glycan chain in the hypervariable region o f  
the Fab. The Fab glycans contain higher levels o f  galactose than the Fc glycans (Wormald 
et al, 1997). The possible increase in galactose in the oligoclonal IgG could be in either 
the Fc or Fab glycans. An increase in overall glycosylation for the MS positive samples 
was perhaps suggested by the results and could perhaps be due to increased Fab glycans in 
the oligoclonal IgG compared to IgG.
Without speculating, it is not possible to elucidate any further the biochemical or 
clinical significance o f  the glycosylation changes found in this project.
7.4. Future Work
One o f the points to come out o f  this research is the need to look at polyclonal 
IgG separately from oligoclonal IgG when investigating possible glycosylation changes in 
neurological diseases. Therefore two continuing lines o f  research are suggested: firstly, the
7.3.3. The Effect of the Glycosylation Changes
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study o f  possible glycosylation changes in polyclonal IgG in neurological diseases such as 
MS and, secondly, further investigation o f  the character o f  oligoclonal IgG and its role in 
neurological diseases such as MS.
Changes in polyclonal IgG glycosylation have been described, for several 
autoimmune diseases, with serum IgG as the sample (Tomana et al, 1988; Rook et al, 
1989; Furukawa and Kobata, 1991; Rudd and Dwek, 1997; Roitt et al, 1998). In this 
project, using CSF as the sample has made interpretation o f  the data difficult because o f  
the probable different glycosylation o f  oligoclonal IgG, and better results might be 
obtained with future studies o f  neurological diseases by analysing serum IgG samples, 
rather than CSF, when comparing patients with controls.
The glycosylation pattern o f  the polyclonal IgG in CSF probably reflects the 
glycosylation pattern o f  IgG in the serum, unless it undergoes glycosylation changes 
during its passage across the blood-brain barrier. This could be demonstrated by 
analysing paired samples o f  serum and CSF from ‘normal5 control subjects, where IgG in 
both would be polyclonal. If the paired samples from normal subjects have matching 
glycosylation patterns, then analysis o f  paired samples from MS patients, or from patients 
with other neurological diseases where CSF oligoclonal IgG is a feature, might show a 
difference, which would be due to the oligoclonal IgG. Subtraction software has been 
developed at the Oxford Glycobiology Institute, which could reveal the glycosylation 
profile o f  oligoclonal IgG. Comparison o f  oligoclonal IgG in neurological diseases as well 
as MS might show glycosylation features which could lead to a more specific diagnostic 
test for MS.
Various studies have been carried out to identify the antigenic target o f  oligoclonal 
IgG. Activity against different viruses has been found using phage libraries (Cortese et al, 
1996; Rand et al 1998) and against different components o f  myelin, including myelin basic 
protein (MBP), using IEF with immunoblotting techniques (Cruz et al 1987). But no
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single antigen common to more than 50% o f  the MS patients, has been found in any o f 
the studies. Another approach would be to identify the peptide fragments that might be 
bound to the IgG. One technique that would enable analysis o f  peptide fragments in the 
presence o f  a large molecule like IgG is mass spectrometry, such as MALDI, which has 
high sensitivity over a wide range o f molecular weights. The fragment peptides should be 
distinguishable from the IgG, and their mass could also be determined. SDS PAGE might 
be another technique for looking at oligoclonal IgG complexes: under SDS conditions, 
any peptides complexed with IgG would be disassociated, and would migrate according to 
their mass, which could be determined by using calibrators. A  problem with this 
technique might be lack o f  sensitivity and the difficulty o f  detecting a small amount o f  
peptide in the presence o f  a larger amount o f  IgG. But visualisation o f  the bands blotted 
from the gel might be possible with a sensitive stain such as colloidal gold or by using 
monoclonal antibodies specific, for example, for different regions o f  MBP. Use o f  two- 
dimensional electrophoresis might also give added sensitivity to IEF or SDS-PAGE 
techniques.
Aldiough oligoclonal IgG may not be the cause o f  myelin breakdown, its study 
will hopefully lead to a better understanding o f  MS, and might possibly lead to better 
treatment. Detection o f  oligoclonal IgG in the CSF is currendy an important diagnostic 
tool, but further study might also lead to a more specific marker for MS.
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A p p e n d ix
T a b l e  o f  G U  V a l u e s  
The following table shows GU values for IV-linked glycans for the HPLC System 
1 used for this project, taken from tables being prepared by the Oxford Glycobiology 
Institute. GU values were derived at the Institute by comparing the retention times of 
peaks of 2AB labelled standard glycans with a series of glucose homopolymers (dextran 
ladder), derived by partial hydrolysis of dextran, that was run simultaneously. 
Subsequendy, incremental GU values were calculated for additions of monosaccharides to 
the oligosaccharide core, and confirmed by experiment.
Therefore by running a dextran ladder with unknown glycan mixtures under the 
same HPLC conditions, GU values can be determined for the peaks, enabling glycan 
structures to be assigned to the peaks.
In the following table: Man=mannose, Glc=glucose; A=antennary arms, 
G—galactose, F=fucose, B=bisecting N-acetylglucosamine, N=terminal N-acetylglucos- 
amine, S=sialic acid; the columns headed H, N, F and S indicate the number of hexoses 
(i.e. mannose+galactose), N-acetylglucosamine, fucose and sialic acids, respectively, in 
each structure; MW indicates the molecular weight of die 2AB labelled structure; £Gu 
calc.’ is the GU value derived by calculation; cGu meas.’ is the GU value obtained by 
experiment.
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Oligosaccharide Structure: H N F 8 M.W. Gu Gu
(2AB) calc, meas.
Oligomannose-type N-linked Oligosaccharides:
Oligomannose 9 Man-9 9 2 0 0 9.51 9.50
Oligomannose 8 Man-8 8 2 0 0
Oligomannose 8 D1, D3 Man-8 01. D3 8 2 0 0
Oligomannose 8 D1, D2 Man-8 D1.D2 8 2 0 0 8.83 8.81
Oligomannose 8 D2, D3 Man-8 D2,D3 8 2 0 0
Oligomannose 7 Man-7 7 2 0 0
Oligomannose 7 D1 Man-7 D1 7 2 0 0 7.92 7.91
Oliqomannose 7 D2 Man-7 D2 7 2 0 0
Oligomannose 7 D3 Man 7 D3 7 2 0 0
Oligomannose 6 Man-6 6 2 0 0 7.07 7.06
Oligomannose 5 Man-5 5 2 0 0 6.20 8.09
Hybrid-type Native N-linked Oligosaccharides:
Hybrid Hybrid type 0
Gtc3Man9 0
Glc3Man8 0
Glc3Man7 0 10.21
Glc3Man4 0 7.54
Neutral Comptox-type Native N-Linked Oligosaccharides:
Asialo-, agalaclo-, biantennary A2G0 (NGA2) 3 4 0 0 1339.49 5.49 5.42-5.92
A2G0B (NGA2B) 3 5 0 0 1542.57 5.68 5.58
A2G0F(a1,3)(NGA2F) 3 4 1 0 1485.54 6.2B
Astab-, agalacto-, biantennary, core-substituted with fucosi A2G0F(a1,6)(NGA2F) 3 4 1 0 1485.54 5.90 5.92-5.93
A2G0F2 3 4 2 0 6.72
biantennary, core substituted with fucose and with bisectin A2G0FB (NGA2FB) 3 5 1 0 1688.62 6.19 6.23-6.24
A2G1 (1,3) 4 4 0 0 1501.54 6.50 6,50
A2G1(1,3)B 4 5 0 0 1704.64 6.69 6.68
A2G1 (1,3)F 4 4 1 0 1647.60 6.91 6.80-6.82
A2G1(1,3)FB 4 5 1 0 1850.68 7.20 6.88-7.03
A2G1(1,6) 4 4 0 0 1501.54 6.38 6.38
A2G1 (1,6)B 4 5 0 0 1704.64 6.57 6,50
A2G1(1,6)F 4 4 1 0 1647.50 6.79 6.68-6.70
A2G1(1,6)FB 4 5 1 0 1850.68 7.08 6.80
A2G1F2 4 4 2 0 1793.60 7.49
A2G1(1,3)FBF 4 5 2 0 1996.70 7.90 7.50-7.65
A2G1(1,6)FBF 4 5 2 0 1996.70 7.78 7.46-7.50
Asialo-, galactosylated biantennary A2G2 (NA2) 5 4 0 0 1663.40 7.15 7.16
Asialo-, galactosylated biantennary with bisecting GlcNAc A2G2B (NA2B) 5 5 0 0 1866.50 7.30 7.31
Asialo-, galactosylated biantennary, core substituted with ft A2G2F (NA2F) 5 4 1 0 1809.50 7,56 7.57
A2G2F2 5 4 2 0 1955.60 8.26
A2G2F2F 5 4 3 0 2101.70 8.96 8.67
A2G2F3 5 4 3 0 2101.70 9.66
A2G2F4 5 4 4 0 2247.80 10.36
biantennary, core -substituted with fucose and with bisecti A2G2FB (NA2FB) 5 5 1 0 2012.60 7.85 7.67-7.6S
A2G2FBF 5 5 2 0 8.38
A2G2FBF2 5 5 3 0 2304.8 9.25 9.10-9.14
Asialo-, agalacto-, triantennary A3G0 (NGA3) 3 5 0 0 1542.5 5.91 5.91
A3G0B 3 6 0 0 1745.6 6.10 6.15
A3G0F 3 5 1 0 1688.6 6.32 6.36
A3G0FB 3 6 1 0 1891.7 6.61 6.68
A3G1FB 4 6 1 0 2053.7 7.46 7.50
A3G1FBF 4 6 2 0 2199.8 8.16 7.72
A3G2 5 5 0 0 1866.5 7.61 7.90
A3G2B 5 6 0 0 2069.6 7.80
A3G2F 5 5 1 0 2012.6 8.02 7.85
A3G2FB 8.03
A3G2FBF 5 6 2 0 2361.8 8.72 8.52
A3G2F2BF 5 6 3 0 2507.9 9.42 9.12
A3G2FF 5 S 2 0 2158.7 9.01
Asialo-, galactosylated triantennary A3G3 (NA3) 6 5 0 0 2028.5 8.65 8.35
A3G3B 6 6 0 0 2231.6 8.46
A3G3F 6 5 1 0 2174.6 8.87 8.74
A3G3F2 6 5 2 0 2320.7 9.57
A3G3FB 6 6 1 0 2377.7 9.16 8.89-9.14
A3G3FFB 9.32
A3G3F2BF G 6 3 0 2669.9 10.56 10.02
A3G3F3BF 6 6 4 0 2816.0 11.26 10.72
A3G3FF2 6 5 3 0 2466.8 9.86 10.18
Asialo-, agalacto-, tetraantennary A4G0 (NGA4) 3 6 0 0 1745.6 6.54 6.54
A4G0B (NGA4B) 3 7 0 0 1948.7 6.73 6.53
A4G0F 3 6 1 0 1891.7 6,95 6.82
A4G0FB 3 7 1 0 2094.8 7.24 6.90
A4G1 4 6 0 0 1907.6 7.39 7,48
A4G1B 4 7 0 0 2110.7 7.58
A4G1F 4 6 1 0 2053.7 7.80
A4G1FB 4 7 1 0 2256.8 8.09 7.85
A4G1FBF 4 7 2 0 8.79 8.24
A4G2 4 7 0 0 0.24
A4G2B 5 7 0 0 8.43
A4G2F 5 6 1 0 0.65 8.58
A4G2FB 5 8 0 0 8.94
A4G2FBF 5 8 2 0 9.64 9.04
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j Oligosaccharide Structure h t\ F E M.W. Gu Gu
| (2AB) calc. moas.
A4G2FBF2 5 a 3 0 10.34 9.74
A4G3 6 6 0 0 9.09
A4G3B 6 7 0 0 9.50
A4G3F 6 6 1 0 9.28 9.31
A4G3F3 6 6 3 0 11.19 11.36
A4G3FB 6 7 1 0 9.79 9.37/9.9E
A4G3FBF 6 7 2 0 10.49 10.76
A4G3FBF3 6 7 4 0 11.89
Asialo-, galaclosylaled tetraantennary A4G4 (NA4) 7 6 0 0 10.13 9.68
A4G4B 7 7 0 0 9.94
A4G4F 7 6 1 0 10.35 9.96
A4G4FB 7 7 1 0 10.64 10.36
A4G4FBF 7 7 2 0 11.34 10.64
A4G4FBF2 7 7 3 0 12.04 11.66
A4G4FBF3 7 7 4 0 11.34
A4G4FF 7 6 2 0 11.05 10.81
Native N-Linked Oligosaccharide Coro Products: M2N2 2 2 0 0 3.46
M2N2F(a1-6) 2 2 1 0 3.97
M2N2F{a1-3) 2 2 1 0 4.29
M2N2F2 2 2 2 0 4.76
Irimannosyl core M3N2 3 2 0 0 4.42 4.38-4.44
trimannosyl core, 1-6 fucose on reducing end GlcNAc M3N2F{a1-6) 3 2 1 0 4.91 4.86-4.97
trimannosy! core, 1-3 fucose on reducing end GlcNAc M3N2F(a1-3) 3 2 1 0 5.32 5.29-5.32
M3N2F2 3 2 2 0 5.32 5.68-5.74
M3N3 3 3 0 0 5.00
M3N3F(a1-6) 3 3 1 0 5,32
M3N3
6-a-fucosy! chitobiose N2F 0 2 1 0 2.30
N2F2 2.80
6-a-fucosyi GlcNAc NF 0 1 1 0 1.59
Chitobiose NN 0 2 0 0 1.73
4'-b-mannosy! chitobiose MNN 1 2 0 0 2.65 2.66
4'-b-mannosyl 6-a-fucosyl chitobiose MNNF 1 2 1 0 3.17 3.18
Conserved tri-mannosyl core, substituted with fucose and x M3N2FX 3 2 1 0
Sialylated structures:
A2G2S(3) (A1) 5 4 0 1 7.49 7.57
A2G2S(6) (A1) 5 4 0 1 7.89 7.98
A2G2S2<3)2 (A2) 5 4 0 2 7.72
A2G2S2(6)2 (A2) 5 4 0 2 8.65 8.80
A2G2S2(6){3) (A2) S 4 0 2 8.28 8.42
A2G2FS(6) S 4 1 1 8.27 8.32
A2G2FS(3) 5 4 1 1 8.10- 8.26
A2G2FS2 (A2F) 5 4 1 2 8.82
A3G2S(3)
A3G3S(3) 6 5 0 1 8.56 8.64
A3G3S(6) 6 5 0 1 8.94 9.03
A3G3S2(3)2 6 5 0 2 8,86 9.00
A3G3S2(6)2 6 5 0 2 9.61 9.77
A3G3S2(6)(3) 6 5 0 2 9.22 9.37
A3G3S3(6)3 6 5 0 3 10.26
A3G3S3(3)3 (A3) 6 5 0 3 9.16
A3G3S3{6)(3)2 6 5 0 3 9.54 9.78
A3G3S3(6)2(3) 6 5 0 3 9.89 10.15
A3G3S4(6)2(3)2i 6 5 0 4 9.99 10.28
A3G3S4(6)3(3)1 6 5 0 4 10.33 10.63
5 1xS(6) attached to GlcNAc. Antenna on Manb1-4 arm is Gatbl-3GlcNAc
1 1 I I I
: ....... " t t :  r i : .
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